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Abstract 
Introduction 
Neurocardiovascular instability (NCVI) describes a group of disorders characterised by 
orthostatic hypotension (OH), carotid sinus hypersensitivity (CSH) and autonomic 
dysfunction.  
 
In cross-sectional studies, NCVI has been associated with cognitive impairment, 
depression and falls. It is suggested that episodic hypotension causes cerebral 
hypoperfusion, which in turn causes anoxic brain damage. White matter hyperintensities 
(WMH) on MRI are thought to represent ischaemic damage due to hypoperfusion and 
are also associated with cognitive impairment, depression, and falls.   
 
Despite these observations, the long-term clinical significance of NCVI remains 
unclear, particularly in asymptomatic individuals 
 
Aims  
 To examine the associations between NCVI and cognition, depression and falls 
over a ten-year follow-up 
 To examine the association between NCVI and WMH volume on MRI  
 To examine the association between NCVI and ten-year all-cause mortality.  
 
Methods 
Participants were recruited from an established cohort of people aged ≥65 years in 2002. 
Baseline evaluation of neurocardiovascular function in 2002 included heart rate 
variability, autonomic function tests and carotid sinus massage. Neuropsychological 
assessment was performed at baseline and at follow-up. MRI was performed at follow-
up (but not at baseline). WMH volume was calculated using FLAIR MRI. Cox 
regression analysis was used to examine the association between NCVI and mortality.  
 
Results 
In 2002 1000 individuals aged ≥65 years  were selected at random from a single GP 
practice and invited to participate in the study.  353 consented to enrolment in the 
II 
 
baseline study. Of whom 104 individuals [median age 79 years (range 74-92)] 
participated in the year 10 follow-up.  
 
Asymptomatic NCVI was not associated with cognition, depression, falls or WMH 
volume at follow-up. Symptomatic OH was associated with greater decline in 
CAMCOG memory score [B =1.19, P<0.05] and symptomatic CSH  was independently 
associated with increased WMH volume [P<0.01]. 
 
NCVI defined according to standard criteria was not associated with ten-year mortality. 
However, at baseline it had been identified that the  95
th
 percentile for systolic 
vasodepression was 76.6 mmHg and the 95
th
 percentile for RR interval post CSM was 
7.3 seconds. These thresholds were used to define CSH modified criteria. CSH defined 
according to modified criteria, derived from the baseline populations’ response to CSM, 
was associated with increased mortality [HR2.37, P=0.02].  
 
Conclusions 
NCVI is not associated with adverse outcomes at ten years in asymptomatic older 
people but symptomatic NCVI is associated with decline in memory and greater WMH 
volume, suggesting symptoms are of prognostic significance. Modified CSH criteria are 
better predictors of ten-year mortality than current criteria.  
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Rationale for the Study 
Cognitive impairment, gait and balance disorders, falls and depression are common in 
older people (World Health Organization and Life Course, 2008, Luppa et al., 2012, 
Ferri et al., 2005, Axer et al., 2010). Loss of cognitive and physical independence is 
feared by individuals and, in societies with an ageing population, present significant 
social and economic challenges (Luengo-Fernandez et al., 2011, Jeon et al., 2006). This 
combination of cognitive and motor dysfunction is so frequently encountered by 
geriatricians and older patients that it is sometimes referred to as a “geriatric syndrome”. 
Small vessel cerebrovascular disease, seen as white matter hyperintensities on magnetic 
resonance imaging (MRI), has been proposed as one possible underlying pathological 
mechanism for this syndrome (Sonohara et al., 2008, Kuo and Lipsitz, 2004).  
 
White matter hyperintensities are common in older people and have been associated 
with cognitive impairment, gait and balance abnormalities, and late-life depression 
(Sonohara et al., 2008, Kuo and Lipsitz, 2004, The et al., 2011). They occur close to the 
cerebral ventricles, in an arterial “watershed” and are thought to represent ischaemic 
damage resulting from chronic or recurrent hypoperfusion (Pantoni, 2002).  Cerebral 
autoregulation maintains cerebral perfusion over a range of systemic BP, typically 60-
150 mmHg (Panerai, 2008). Falls in systemic blood pressure (BP), below the lower 
limit of cerebral autoregulation, result in cerebral hypoperfusion. The 
neurocardiovascular mechanisms responsible for maintaining systemic BP become 
impaired with age, making older people vulnerable to sporadic hypotensive episodes 
and cerebral hypoperfusion (Kenny et al., 2002). This thesis explores the longitudinal 
association between systemic blood pressure control, white matter hyperintensities on 
MRI and common clinical features of the geriatric syndrome, namely; cognitive 
impairment, depression, gait and balance impairment, and falls.  
 
The overarching hypothesis is that age-related changes in cardiovascular and autonomic 
nervous system function lead to impaired homeostasis of systemic BP, causing recurrent 
hypotensive episodes. These hypotensive episodes in turn result in cerebral 
hypoperfusion and white matter damage, causing cognitive impairment, gait and 
balance disorders, depression and falls. Figure 0-1 displays the proposed mechanism.  
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Figure 0-1 Proposed Mechanism of Association between Neurocardiovascular 
Instability, White Matter Hyperintensities, Cognitive Impairment and Gait 
Disorders  
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Falls 
 
The following introduction describes the epidemiology of cognitive impairment, falls 
and depression in the context of an ageing population and reviews the published 
literature examining the associations between blood pressure control, white matter 
hyperintensities and the clinical correlates of white matter hyperintensities.  
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Chapter 1 Introduction and Summary of Existing Literature  
 Ageing Population  1.1
 Demographic Changes 1.1.1
The worldwide population is ageing. Over the last century, life expectancy in Europe, 
USA and Canada has increased by approximately 30 years (Christensen et al., 2009). 
Figure 1-1 shows the steady increase in life expectancy at birth observed in the UK 
between 1841 and 2010 (ONS, 2012a).   
 
Figure 1-1 Life expectancy at birth in the UK 1841 to 2010 (reproduced from Office 
of National Statistics Report Population Ageing in the United Kingdom its constituent 
countries and the European Union – Permission granted under free use licence) 
 
 
Initial increases in life expectancy were a result of decreases in infant and childhood 
mortality but since the 1970s increases have been due to decreases in old age mortality, 
resulting in an ageing population (Spijker and MacInnes, 2013). Figure 1-2 shows that 
in the UK the percentage of persons aged 65 and over increased from 15% in 1985 to 
17% in 2010, an increase of 1.7 million people. The oldest old (people aged >85) are the 
most rapidly increasing segment of the population. Between 1985-2010 the number of 
people in the UK aged 85 and over more than doubled to 1.4 million (ONS, 2012b). By 
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2035 people aged 65 and over are predicted to account for over 20% of the population 
and people aged 85 years and over for 5%.  
 
Figure 1-2 Percentage of older people in the UK, 1985, 2010 and 2035 (reproduced 
from Office of National Statistics Report Population Ageing in the United Kingdom 
its constituent countries and the European Union – Permission granted under free 
use license)  
 
 
These demographic changes have significant implications for medicine and society. 
Older people, particularly those over 70, are at high risk of disease and disability 
(Christensen et al., 2009). With increasing age, cognitive and physical impairments 
become greater threats to functional independence (Reynish, 2009, Bischkopf et al., 
2002, Wolfson, 2001). Understanding and addressing underlying risk factors for 
cognitive and motor decline in later life is essential in order to ensure increases in 
longevity are not accompanied by unacceptable increases in morbidity and disability.  
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 Cognition, Depression and Physical Function in the Ageing 1.2
Population 
 Cognition and Ageing  1.2.1
1.2.1.1 Dementia and Ageing 
Prevalence of dementia increases significantly with age. In Europe, dementia affects 
1.5% of people aged 65-70 compared to 24.8% of people aged 85 and over (Ferri et al., 
2005). For woman aged 95 and older studies have found prevalence as high as 50% 
(Reynish, 2009).  
 
Incidence studies report a positive association between age and incidence rates of 
dementia. However, the trend of association with age is not clear. A meta-analysis by 
Goa et al indicated that the increase in the incidence rate of dementia slows down with 
increasing age, although the incidence rates themselves do not decline(Gao et al., 1998). 
They reported, for every five-year increase in age, dementia incidence rates triple before 
age 64, double before age 75, and increase 1.5 times around age 85 (Gao et al., 1998). 
In contrast, two meta-analysis have found that the incidence of dementia and AD 
increase with age (Jorm and Jolley, 1998, Launer et al., 1999). Corrada et al found 
incident rates continued to increase even in individuals aged 90 and older, with 
estimates of incidence as high as 41% per year in centenarians (Corrada et al., 2010). 
1.2.1.2 Mild Cognitive Impairment 
It is recognised that milder forms of cognitive impairment, insufficiently severe for the 
diagnosis of dementia, also occur commonly among older people (Morris et al., 2001a, 
Petersen et al., 2001). Several names have been used to describe this state between 
normal cognition and dementia. The term currently most in use is mild cognitive 
impairment (MCI). MCI is considered a pathological entity. Petersen(Petersen et al., 
1997), originally, defined the diagnostic criteria as;  
1. Normal functional abilities with activities of daily living 
2. The absence of dementia 
3. Abnormal cognitive function in  memory domains 
4. Normal function in other cognitive domains.  
5. Self-reported subjective memory loss.  
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The last point, self-reported subjective memory loss, is intended to ensure there has 
been a change in cognitive performance rather than life long cognitive impairment 
(Luck et al., 2010b, Petersen et al., 1997). 
 
More recently, the definition of MCI has broadened. MCI no longer refers to isolated 
memory loss. Where memory and at least one other cognitive domain are impaired, it is 
termed multi-domain amnesic MCI. Non- amnesic forms of MCI are also recognised 
and can be single or multi-domain (Luck et al., 2010b, Petersen, 2004, Bischkopf et al., 
2002) . Reported incidences vary widely. In a thorough meta-analysis of studies 
reporting the prevalence  and incidence of MCI, Ward et al reported an incidence 
ranging from 21.5-71.3 per 1,000 person-years for  MCI – all types and  8.5-25.9 per 
1,000 person years for amnesic MCI (Ward et al., 2012). Reported prevalence for MCI- 
all types ranged from 3%-42% (Ward et al., 2012). Prevalence of MCI increased with 
age after 65 years but appeared to plateau after the age of 85(Bischkopf et al., 2002). 
Variations in reported prevalence and incidence in these studies resulted from variations 
in the operational definitions used to describe MCI variations in the population 
characteristics of study samples.  
 
Identifying risk factors for MCI is important as MCI is associated with increased risk of 
Alzheimer’s disease and vascular dementia. Reported annual rates of conversion from 
MCI to dementia range from five to 65% (Katz et al., 2009, Palmer et al., 2008).  
 Depression and Ageing 1.2.2
Cognitive deterioration among older people is commonly associated with late-life 
depression (Weisenbach et al., 2012). Luppa et al performed a meta-analysis, examining 
the prevalence of depression among older people (Luppa et al., 2012). They grouped 
studies into two categories: (1) studies using classification systems such as ICD-10 and 
DSM, which they called “categorical studies”; and (2) studies using rating scales to 
diagnose clinically significant depression called “dimensional diagnostics.” Meta-
analysis of categorical studies indicated a point prevalence of major depression of 4.6% 
-9.5% for people aged 75 years and over, and 2.1%-11.1% for people aged 85 years and 
over. Analysis of studies using depression rating scales showed prevalence rates 
between 4.5% and 37.4% for people aged 75 years and older (Luppa et al., 2012). Age 
of onset of psychiatric symptoms is important as early and late-life depression are 
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thought to have different aetiology, prognosis and presentation. Over half of older 
people with depression experience their first episode after the age 60 (Fiske et al., 
2009). Depression in late-life has been associated with dementia, cerebrovascular 
disease, and white matter disease. This has led authors to hypothesise that depression in 
later life is secondary to cerebral small vessel disease (Jellinger, 2013).  
 Physical Function and Ageing 1.2.3
1.2.3.1 Mobility and Ageing 
Mobility is impaired in 14% of people aged 65-74 and 50% of people aged 85 years and 
over (Wolfson, 2001). A survey of older people found that half limit their daily activity 
in some way due to concerns about their mobility (Sudarsky, 1990)  
1.2.3.2 Gait, Balance and Walking  
It is estimated that 15% of people aged 60 and 82% of people aged 85 have a gait 
disorder (Axer et al., 2010). Gait speed remains stable up to the seventh decade then 
decreases at a rate of 15% per decade (Wolfson, 2001). Normal gait velocity for a 
person aged 80 is about 1.0 -1.2 m/s. A cohort study of 79 year olds in Goteborg, 
Sweden, found none could comfortably walk at 1.4 m/s, a pace considered by the 
Swedish government to be the norm for pedestrian crossings (Sudarsky, 1990). After 
the seventh decade, sway when standing still increases, and single leg stance time 
decreases. Gait broadens and more time is spent with both feet on the ground. One in 
four people over age 79 walked with a walking aid (Sudarsky, 1990). Ability to 
compensate for trips and pushes becomes impaired with age and older people become 
more reliant on sensory input for multiple modalities to remain stable (Wolfson, 2001). 
These changes are important since impaired gait and balance are major risk factors for 
falls (Voermans et al., 2007).  
1.2.3.3 Ageing and Falls  
Thirty-five to forty per cent of community-dwelling people aged 65 years and older will 
fall once in a year (Blake et al., 1988, Rubenstein, 2006, Campbell et al., 1989). Rates 
increase with age, 50% of adults aged 85 and older, and 60% of adults aged 90 and over 
report falling in a year (Fleming et al., 2008, Iinattiniemi et al., 2009). Falling is 
particularly dangerous in the elderly because of their high susceptibility to injury (Axer 
et al., 2010). Of people aged 65 and older, 1 in 40 will be hospitalised due to a fall 
(Rubenstein, 2006). Accidental injury due to falls is a cause of death in 20% of older 
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Americans (Sudarsky, 1990). Falls also result in decreased confidence, loss of 
independence and isolation (Scheffer et al., 2008).  
 
Cognitive impairment, late-life depression, impaired mobility and falls commonly co-
occur in older people and are sometimes referred to as geriatric syndromes. 
Traditionally the term syndrome is used to describe a collection of symptoms or signs 
resulting from a single pathogenic pathway. In older peoples’ medicine the term 
geriatric syndrome is used to describe a collection of symptoms highly prevalent in the 
older population resulting from multiple disease and risk factors (Rikkert et al., 2003). 
Although the causes of geriatric syndromes are multifactorial, growing attention has 
turned to the association between small vessel cerebrovascular disease common 
geriatric syndromes including cognitive and motor decline in later life. Other terms such 
as “geriatric phenotype” have also been proposed however phenotype is generally 
considered to describe observable characteristics determined by genotype(Inouye et al., 
2007). While genetic and environmental factors both undoubtedly contribute to the 
diseases underlying geriatric syndromes there is limited understanding of the 
association between genotype and frailty. The term Geriatric Syndrome therefore 
appears more appropriate in this context 
 White Matter Hyperintensities and Selected Geriatric Syndromes 1.3
Cerebral white matter hyperintensities (WMH) are thought to represent small vessel 
cerebrovascular disease and are common in older patients. Seen as symmetrical patchy 
or diffuse areas of hyperintensity on  dual echo or FLAIR MRI, white matter 
hyperintensities are found in 27 – 86 % of patients over 65 (Kuo and Lipsitz, 2004). 
Previously dismissed as benign age-related changes, studies have suggested associations 
between WMH and cognitive impairment, depression, reduced mobility and falls 
(Sonohara et al., 2008, Kuo and Lipsitz, 2004, The et al., 2011). Severe WMH have 
been shown to predict global functional decline (Inzitari et al., 2009, Briley et al., 
2000).  
 White Matter Hyperintensities and Cognition 1.3.1
Cross-sectional population-based studies have demonstrated an association between 
greater white matter hyperintensity volume and poorer performance on tests of 
cognitive function (Longstreth et al., 1996, Au et al., 2006, de Groot et al., 2000, 
9 
 
Geerlings et al., 2009). Longitudinal studies show that progression of white matter 
hyperintensities parallels decline in cognitive function (Longstreth et al., 2005, Schmidt 
et al., 2005, Van Den Heuvel et al., 2006). Extensive WMH volume has been associated 
with incident dementia and MCI independent of other vascular risk factors and in 
patients with dementia the presence and severity of white matter hyperintensities 
associates with degree of cognitive impairment and functional status (Debette et al., 
2010).  
 
The impact of lesion location on cognitive function remains controversial. Lesions are 
classified as periventricular white matter lesions (PVWMH) if WMHs adjoin the 
margins of the lateral ventricle and deep white matter lesions (DWMH) if they are 
separate from it (Kim et al., 2008). Two meta-analyses have examined association 
between lesion location and different cognitive outcomes. Gunning-Dixon et al 
concluded that there was insufficient evidence to conclude reliably that lesion location 
affects global functioning, speed, fluid intelligence or executive functioning (Gunning-
Dixon and Raz, 2000). Bolandzadeh et al found that a greater number of studies 
reported an association between periventricular WMHs and executive 
function/processing speed than deep WMHs (Bolandzadeh et al., 2012). However, they 
also concluded that it remains unclear whether WMHs in different brain regions have a 
differential effect on cognitive function (Bolandzadeh et al., 2012). 
 
Studies investigating the association between WMH and performance on specific 
cognitive domains have used different cognitive tests, making direct comparison 
between studies difficult. Gunning-Dixon et al aimed to establish if WMH are 
associated with deficits in specific cognitive domains (Gunning-Dixon and Raz, 2000). 
They concluded greater WMH volume was associated with poorer performance on tests 
of global cognitive functioning, speed of processing, immediate-recent memory, 
delayed memory, and executive functioning. The group went onto assess whether any of 
the cognitive domains related to WMH were differentially sensitive to WMH. Tests of 
executive function and speed of process appeared to be more strongly associated with 
WMH than tests of memory (Gunning-Dixon and Raz, 2000). Subsequently Parks et al 
have suggested that executive function mediates the effect of WMH on memory (Parks 
et al., 2011) 
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 White Matter Hyperintensities and Depression 1.3.2
Evidence also suggests that white matter disease may be associated with depression in 
older people (Chen et al., 2006, de Groot et al., 2000, Firbank et al., 2005, Godin et al., 
2008, Firbank et al., 2004). In the largest studies, patients with severe white matter 
disease were 3-5 times more likely to have depressive symptoms than those with mild 
or no WMH and individuals with greater white matter volumes at baseline were at 
increased risk of developing depression (de Groot et al., 2000). Longitudinal studies 
have shown an association between progression of WMH and incident depression 
(Firbank et al., 2012b).  The underlying mechanism for this association remains unclear. 
Proponents of the vascular depression hypothesis suggest WMH are indicative of 
vascular disease changes to the brain, predisposing individuals to the development of 
depression by disrupting fibre tracts in the frontostriatal cortex (Firbank et al., 2012b) 
(Teodorczuk et al., 2009). Alternatively, the association between white matter 
hyperintensities and depression may reflect the recognised associations between greater 
WMH volume and increased disability as a result of cognitive and motor decline. Some 
studies controlling for functional ability found white matter disease no longer predicted 
depressive symptoms (Steffens et al., 1999).  
 White Matter Hyperintensities, Gait, Balance and Falls 1.3.3
Several studies have shown associations between WMH, lower limb dysfunction and 
falls (Baezner et al., 2008, Soumaré et al., 2009, Blahak et al., 2009, Tell et al., 1998, 
Starr et al., 2003, Baloh et al., 2003, Rosano et al., 2005, Whitman et al., 2001). The 
LADIS study showed that more severe WMH were associated with slower walking 
speed and poorer performance on assessments of gait (Baezner et al., 2008, Soumaré et 
al., 2009). Severity of WMH has been shown to be significantly associated with balance 
(Blahak et al., 2009, Tell et al., 1998, Starr et al., 2003) and greater WMH load has been 
shown to predict future decline in gait and walking speed (Baloh et al., 2003, Soumaré 
et al., 2009). Incident self-reported physical impairment is more common in patients 
with moderate grades of WMH compared to those with minimal WMH  and 
longitudinal studies show decline in gait and balance parallels increases in 
WMH(Rosano et al., 2005, Whitman et al., 2001). Periventricular WMH appear 
particularly associated with gait disturbances and falls, possibly reflecting involvement 
of descending and ascending
 
pathways serving the lower extremities (Longstreth et al., 
1996, Blahak et al., 2009, Soumaré et al., 2009, Onen et al., 2008). Patients with white 
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matter disease report increased falls in retrospective studies and greater WMH  volume 
has been associated with incident falls (Zheng et al., 2012, Srikanth et al., 2009, Blahak 
et al., 2009). 
 Pathophysiology of White Matter Hyperintensities  1.3.4
Given the associations observed between white matter hyperintensities, cognition, 
depression, gait, balance and falls, growing attention has turned to identifying and 
understanding the risk factors associated with the development of WMHs.  
 
The most well studied modifiable risk factor for the development of WMH is 
hypertension (Park et al., 2005, Skoog, 1998, van Dijk et al., 2004, de Leeuw et al., 
2002, Dufouil et al., 2001, Liao et al., 1997).  Studies show that hypertension is a risk 
factor for the development of WMH and that the severity and progression of white 
matter disease is associated with the severity and duration of hypertension (Basile et al., 
2006, de Leeuw et al., 2002, Dufouil et al., 2001, Goldstein et al., 2005, Liao et al., 
1997, Veldink et al., 1998). Similarly, smoking (Basile et al., 2006, Jeerakathil et al., 
2004, Longstreth et al., 2005) dyslipidemia (Bokura et al., 2008, Park et al., 2007) and 
diabetes (Harten et al., 2006) have been identified as risk factors for the development 
and progression of  WMH. Patients with white matter disease are at significantly 
increased risk of stroke, particularly lacunar infarcts, and myocardial infarction (Gerdes 
et al., 2006).  
 
The association between WMH, vascular risk factors and cardiovascular disease has led 
to the widely held belief that WMH represents cerebral small vessel disease. Arteries 
close to WMH show: concentric hyaline thickening, a reduction in the ratio of arterial 
lumen to external diameter and atherosclerosis (O'Sullivan, 2008). Histopathology 
studies of WMH show a range of changes including; myelin pallor, axonal loss, mild 
reactive gliosis and dilated perivascular spaces (Brun and Englund, 1986, Chimowitz et 
al., 1992, Fazekas et al., 1998, Grafton et al., 1991, van Swieten et al., 1991). However, 
as frank infarction is not seen it has been suggested that that these changes represent 
ischaemic damage resulting from hypoperfusion, termed “incomplete 
infarction”(Bowler, 2003).   
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Cerebral white matter is particularly vulnerable to hypoperfusion. Blood supply to the 
periventricular area is via long, penetrating arteries, originating from the pial network 
on the surface of the brain and ending some distance from the ventricular wall (Pantoni 
and Garcia, 1997). The region closest to the ventricle wall is supplied by the 
ventriculofugal
 
vessels arising from subependymal arteries. These systems do not 
anastomose or form collaterals, resulting in an arterial “watershed”, within the 
periventricular white matter (O'Sullivan, 2008, Pantoni and Garcia, 1997). The low 
perfusion pressure in this vulnerable region means that any reduction in cerebral 
perfusion may result in ischaemic damage.  
 
Under normal conditions, cerebral perfusion is maintained by cerebral autoregulation. 
For healthy adults, cerebral autoregulation ensures that stable cerebral blood flow can 
be adequately sustained over a systemic systolic blood pressure ranging from 60 mmHg 
– 150mmHg. Systemic BP below this lower limit is associated with cerebral 
hypoperfusion.  
Older people are at greater risk of cerebral perfusion pressure falling below the lower 
limit of cerebral autoregulation for two reasons: 
1. The limits of cerebral autoregulation are not fixed. Chronic hypertension shifts 
the autoregulation curve to the right (Strandgaard and Paulson, 1984). This 
protects the brain from elevated BP, but raises the lower limit of autoregulation. 
Falls in BP below the lower limit of autoregulation result in precipitous 
reduction in cerebral perfusion. Although studies suggest that cerebral 
autoregulation, itself does not change in healthy older people, conditions 
associated with shifts in the autoregulation curve, particularly hypertension, 
increase in prevalence with age such that the lower limit of cerebral 
autoregulation is elevated in many older people making them vulnerable to 
cerebral hypoperfusion at systemic systolic BP well above 60 mmHg (van Beek 
et al., 2008).  
2. In addition to changes in the lower limits of cerebral autoregulation, increasing 
age and hypertension are associated with impaired autonomic control of 
systemic blood pressure and heart rate, resulting in greater BP variability (Parati 
et al., 2006). Hypotensive syndromes, associated with sudden drops in systemic 
BP, such as orthostatic hypotension, postprandial hypotension and carotid sinus 
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hypersensitivity become more common in older adults (Low, 2008, Humm and 
Mathias, 2006, Luciano et al., 2010)  .   
 
Thus, older people are at risk of episodic hypotension and, as a result of altered cerebral 
autoregulation, may be at greater risk of cerebral hypoperfusion. It is hypothesised that 
episodic hypotension among older people may result in WMH secondary to cerebral 
hypoperfusion and anoxic damage.  
 Blood Pressure Regulation and Ageing  1.4
This section will briefly describe blood pressure control in healthy individuals, the 
changes in blood pressure regulation associated with ageing and some of the common 
clinical syndromes associated abnormal blood pressure control encountered in older 
people. 
 Regulation of Blood Pressure in Healthy Individuals  1.4.1
Blood pressure homeostasis involves multiple interrelated self-regulating mechanisms, 
principally the autonomic nervous system, central nervous system and hormonal 
control. 
1.4.1.1 The autonomic nervous system  
The autonomic nervous system (ANS) controls blood pressure via the sympathetic and 
parasympathetic branches. Baroreceptors and mechano-receptors monitor blood 
pressure, feeding information to the central nervous system, which in turn adjusts heart 
rate and blood pressure via efferent pathways of the ANS. Of all the cardiovascular 
reflexes, the baroreflex is the most important (Sun, 1995). Baroreceptors in the aortic 
arch and carotid sinus respond to stretch in the vessel wall. Rises in blood pressure 
cause increased stretch, triggering baroreceptor discharge. These changes result in 
increased vagal activity and decreased sympathetic activity which in turn causes a 
reduction in heart rate and a decrease in peripheral vascular resistance. 
 
Mechano-receptors are also present in the large veins, pulmonary circulation and atria. 
These primarily detect changes in circulating volume. Reduced venous return results in 
increased sympathetic and decreased vagal activity, in turn causing an increase in  heart 
rate and peripheral vasoconstriction (Izzo and Taylor, 1999). Increases in efferent 
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sympathetic activity also cause renal vasoconstriction, decreased diuresis and increased 
circulating volume.   
1.4.1.2 Endocrine System  
The renin angiotensin aldosterone system (RAAS) regulates blood volume and is 
directly affected by and affects the autonomic nervous system. Renin is produced in 
response to falls in arterial blood pressure, reduced plasma sodium and increased 
sympathetic activity(Sunhaeswaran, 1998). Renin converts angiotensinogen to 
angiotensin1, which in turn is converted to angiotensin II. Angiotensin II causes an 
increase in blood pressure by stimulating the aldosterone secretion from the adrenal 
cortex and, at high concentrations, causing noradrenaline release from sympathetic 
nerve terminals in vascular smooth muscle(Sunhaeswaran, 1998).  
 
Antidiuretic Hormone (ADH) is produced by the hypothalamus by rises in plasma 
osmolality, and to a much lesser extent, by a fall in blood pressure. ADH causes 
increased water retention by the kidney and peripheral vasoconstriction(Sunhaeswaran, 
1998).  
1.4.1.3 The central nervous system  
The central nervous system has a complex role in the processing of signals from the 
peripheral autonomic nervous system and the cerebral cortex. Most studies examining 
the central control of the peripheral autonomic nervous system have been conducted in 
anesthetised animals. Information from the baroreceptors is received by the nucleus 
tractus solitarius and is relayed to the hypothalamus (Sunhaeswaran, 1998, Dampney et 
al., 2002). The rostral ventral lateral medulla and ambiguous nucleus are responsible for 
the sympathetic and parasympathetic outflow respectively. Higher frontal and temporal 
cortical centres are also believed to be able to exert central control over the 
cardiovascular response via the brain stem (Dampney et al., 2002).  
 Blood Pressure Regulation and Ageing  1.4.2
Several age-related changes have been noted in these homeostatic mechanisms (Kaye 
and Esler, 2008, Izzo and Taylor, 1999, Monahan, 2007, Ferrari et al., 2003, Diz, 2008). 
Sympathetic activity increases with age (Kaye and Esler, 2008). Plasma norepinephrine 
levels become elevated, even when blood pressure is raised, resulting in increased 
vascular resistance (Kaye and Esler, 2008, Izzo and Taylor, 1999). Decreased clearance 
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of catecholamines has been demonstrated among older people (Kaye and Esler, 2008, 
Izzo and Taylor, 1999).  
 
Numerous studies have demonstrated an age-related decrease in the success of 
baroreflex to control BP (Monahan, 2007, Ferrari et al., 2003). Alterations in any part of 
the reflex arc may result in a diminished ability to respond to changes in blood pressure. 
Baroreceptors in the aorta and carotid sinus respond to stretch of the arterial wall. With 
age vessels become less compliant, resulting in reduced dispensability. The range of 
stretch of the mechanoreceptors is decreased and baroreflex sensitivity is reduced 
(Monahan, 2007, Ferrari et al., 2003, Izzo and Taylor, 1999). Studies also suggest there 
may be decreased baroreceptor neural discharge in older people(Ferrari et al., 2003).  
 
In animals, electrophysiological studies and pharmacological studies designed to 
increase acetylcholine (ACH) at the sinoatrial node (SA) found that older animals had a 
much greater bradycardic response to increased ACH (Ferrari et al., 2003). It is 
hypothesized that age related impaired parasympathetic drive causes sinus nodal 
muscarinic receptor up regulation (Ferrari et al., 2003).  
 
Hormonal controls of BP also diminish with age. Renin release from the kidney 
decreases with age. This is a result of decreased renin in juxtaglomerular cells, 
decreased renin release in response to challenges and decreased plasma renin and 
angiotensin II (Diz et al., 2008) . 
 Assessment of Autonomic Function and Blood Pressure Control 1.5
and Age-related Changes 
Several techniques have been developed to access cardiovascular autonomic function.  
Two of the most commonly used are heart rate variability and the Ewing and Clark 
battery.  
 Heart Rate Variability 1.5.1
Heart rate variability is a, non-invasive method used to assess sympathovagal balance. 
ECG recordings are made at rest under controlled conditions (5 minute recording) or 
during activity using an ambulatory monitor (24-hour recordings).  
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Time and frequency domain indices of heart rate variability have been developed 
(Camm et al., 1996). Time domain indices measure the variation in successive normal 
RR intervals. Several measures have been developed including: standard deviation of 
successive normal RR intervals (SDRR), standard deviation of the average RR interval 
calculated over 5 minutes (SDARR), the square root of the mean square differences 
between successive intervals (RMSSD), the number of interval differences of 
successive normal RR interval greater than 50ms (NN50) and the proportion derived by 
dividing NN50 by the total number of NN intervals (pNN50) (Camm et al., 1996).  
 
Power spectral analysis (most commonly using a fast Fourier transform) provides the 
basic information of how power (variance) distributes as a function of frequency 
(Camm et al., 1996, Ori et al., 1992). Three main components are present in the 
spectrum recorded from short (5 minute) recordings; high frequency fluctuations (0.15-
0.40 Hz), low frequency fluctuations (0.04-0.15) and very low frequency fluctuations 
(<0.04) (Xhyheri et al., 2012). High frequency (HF) fluctuations are abolished by 
atropine and are thought to represent parasympathetic activity. Low frequency (LF) 
fluctuations are abolished by both beta blockers and atropine suggesting the LF 
fluctuations are under both parasympathetic and sympathetic influences (Kleiger et al., 
2005). The significance of very low frequency (VLF) fluctuations remains poorly 
understood. LF:HF ratio gives some information about the relevant balance of the 
sympathetic and parasysmpathetic branches of ANS.  
 
Ageing is associated with a reduction in heart rate variability; however the pattern of 
change is measure dependent (Umetani et al., 1998, Jensen-Urstad et al., 1997). 
Umetani et al reported a 40% reduction in SDRR between the second and tenth decade 
compared to a 75% reduction in P50NN between the second and sixth decade (Umetani 
et al., 1998). Similarly LF, HF and VLF power are negatively associated with age where 
as HF:LF ratio does not appear to associate with age (Jensen-Urstad et al., 1997).  
 Ewing and Clark Autonomic Function Tests 1.5.2
HRV only allows autonomic control of heart rate to be measured. Other batteries of 
autonomic function tests have been developed that monitor both HR and BP response 
physiological stressors (Ewing and Clarke, 1982). The Ewing and Clark battery consists 
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of six components (three tests of parasympathetic function and three tests of 
sympathetic function) (Table 1-1)(Ewing and Clarke, 1982).  
 
Table 1-1 Components Ewing and Clark Battery 
Test of Parasympathetic Function Tests of Sympathetic Function 
Heart rate response to standing Systolic BP response to Standing 
Heart rate response to deep breathing  Diastolic BP response to hand grip 
Heart rate response to Valsalva 
manoeuvre 
Blood pressure response to Valsalva 
manoeuvre  
 
Cut-offs for normal, borderline and abnormal response to each test have been defined 
(Ewing et al., 1985). Results from this battery of tests are grouped into one of five 
categories;  
 Normal: all tests are normal or borderline 
 Early autonomic dysfunction: one of the three heart rate tests are abnormal or 
two borderline 
 Definite autonomic dysfunction: two or more of the heart rate tests abnormal 
 Severe autonomic dysfunction involvement: two or more of the heart rate tests 
abnormal plus one or both of the blood pressure tests abnormal, or both 
borderline 
 Atypical: any other combination of abnormal tests.  
 
As with HRV, response to these autonomic function tests is associated with age (Ewing 
et al., 1985, Gautschy et al., 1986). Ewing et al examined response to autonomic 
function tests in a cohort of healthy individuals aged 16-69 years and found heart rate 
response to standing deep breathing decreased with increasing ageing but that Valsalva 
ratio, BP response to standing and BP response to hand grip were unaffected by age 
(Ewing et al., 1985). Gautschy et al examined the association between age and response 
to autonomic function tests in an older cohort (aged 22 – 92 years) and found that 
reduced response to all tests except BP response to hand grip was associated with 
increasing age (Gautschy et al., 1986).  The Ewing and Clark battery only uses one 
normal range regardless of age making it vulnerable to generating false positive results 
in older people (Ryder and Hardisty, 1990). Confidence in tests of autonomic function 
may be increased by using age related normal ranges and many centres have developed 
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there own normal ranges for people age 65 years and over (Kenny, 2008). The high 
number of abnormal autnomic function tests found in apparently healthy older people 
has lead some authors to adapted Ewing classification when applying them to older 
populations. Collins et al defined autonomic dysfunction as having ≥ 2 autonomic 
function tests as abnormal (Collins et al., 2012). Where as Kenny et al uses more 
stringent criteria for those over 65, requiring ≥3 abnormal tests before the diagnosis of 
autonomic dysfunction is made (Kenny, 2008). To date no formal assessment has been 
made of the specificity and sensitivity of the modified criteria.  
 Ambulatory Blood Pressure Monitoring and Age-related Blood Pressure 1.5.3
Changes 
Age-related changes in sympathetic / parasympathetic balance as noted on HRV and 
autonomic function testing contribute to increases in blood pressure with advancing age. 
Systolic BP rises from age 20 to 75 before plateauing and then declining in old age (>80 
years) (Bobrie and Potter, 2002, Bots et al., 1991). Diastolic BP rises up to age 50 or 60 
years and then levels off or slightly decreases (Pestana, 2001).  
 
Individual BP readings are affected by time of day, eating, fullness of bladder, 
temperature, and white coat hypertension. Ambulatory BP monitoring (ABPM) allows 
these changes to be recorded. An appropriate blood pressure cuff and recording device 
can be worn for up to 48 hours and BP measurements taken at predefined intervals 
(usually every 15-60 minutes). ABPM allows calculation of mean BP and BP variability 
for the full 24-hour monitoring period and separately for daytime and night-time. 
 
Mean BP is a better predictor of cardiovascular and renal disease than casual office BP, 
particularly among older people in whom white coat hypertension is common (Minutolo 
et al., 2011, O’Brien, 2011). Recent National Institute for Health and Care Excellence 
guidelines define hypertension as a mean daytime BP >135/80 on 24-hour ABPM 
(NICE, 2011). 
 
Blood pressure variability is usually defined as SD of the blood pressure recordings or 
by the variation co-efficient (SD/ mean ambulatory BP) (Floras et al., 1988a, Ramirez et 
al., 1985). BP variability reflects fluctuations in BP caused by sleep, eating, physical 
activity and medication. It provides information on individuals’ ability to maintain BP 
19 
 
homeostasis. Cross-sectional studies, have shown increased blood pressure variability in 
older age groups (Imai et al., 1997, Jaquet et al., 1998, Mancia et al., 1985) and a 
positive correlation between blood pressure variability and age (Imai et al., 1997, 
Pringle et al., 2003).   
 
Increased ambulatory blood pressure variability is associated with decreased baroreflex 
sensitivity both during beat-to-beat monitoring and over longer periods (Mancia et al., 
1985, Mancia et al., 1986, Floras et al., 1988b). In humans, blood pressure variability is 
not affected by either α or β adrenergic receptor blockade. In dogs, atropine increases 
blood pressure variability.  These observations suggest that regulation by the 
parasympathetic nervous system is the principal determinant of blood pressure 
variability (Floras et al., 1988b, Di Rienzo et al., 1985, Mancia et al., 1986, Parati et al., 
1995, Mancia et al., 1995). 
 Neurocardiovascular Instability  1.6
Neurocardiovascular instability (NCVI) describes a group of disorders associated with 
intermittent hypotension and bradycardia resulting from these age-related changes in 
blood pressure and heart rate control (Kenny et al., 2002). The commonest clinical 
manifestations of NCVI in older people are; orthostatic hypotension and carotid sinus 
hypersensitivity. The following section will define these disorders and describe how 
they are diagnosed.  
 Orthostatic Hypotension 1.6.1
On standing, gravity causes 300- 800 ml of blood to pool in the lower limbs and 
splanchnic circulation (Freeman et al., 2011). There is a resulting decrease in venous 
return to the heart and reduction in cardiac output. Under normal conditions, 
neurocardiovascular mechanisms cause increased sympathetic outflow to the heart and 
peripheral circulation and decreased vagal activity. These adjustments increase vascular 
tone, increase heart rate and cardiac contractility, maintaining blood pressure on 
standing (Freeman et al., 2011). As previously described, these mechanisms become 
impaired with advancing age, making older adults vulnerable to sudden drops in blood 
pressure on orthostasis (Gupta and Lipsitz, 2007).  
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Classical orthostatic hypotension (OH) is a marked fall in blood pressure on standing or 
being tilted upright. The American Autonomic Society and the American Academy of 
Neurology (AAN) have defined classical OH as a systolic blood pressure decrease of at 
least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg within three 
minutes of standing or being tilted to 60 degrees (Freeman et al., 2011).  
 
It should be noted that the definition does not state how long individuals should rest 
supine before lying BP is recorded, how BP should be recorded, how often BP readings 
should be taken during the three minute stand, or if the patient should be symptomatic. 
This makes comparison of studies problematic.  
 
There are two approaches used to record BP during active stand. Firstly, and most 
commonly, BP is recorded at predefined intervals throughout the stand using a standard 
sphygmomanometer. Intervals between measurements vary between protocols. 
Alternatively, continuous beat-to-beat BP recordings can be chronicled using digital 
photoplethysmography. Continuous beat-to-beat monitoring allows all drops in BP to be 
captured and a calculation of the true nadir to be made. Intermittent readings potentially 
miss short-lived drops in BP and are unlikely to capture the true nadir.  
 
The reported prevalence for OH varies considerably depending on method used to 
detect change in BP. In a review of studies, using intermittent BP recordings, Low et al,  
reported a prevalence of OH of 5-35%, with prevalence increasing with increasing age 
(Low, 2008).  Newer studies that have used beat-to-beat BP monitoring to record 
postural change in BP report a prevalence of OH ranging from 59% -94%  among adults  
aged ≥65 years (Cooke et al., 2013, Romero-Ortuno et al., 2011a, Kerr, 2009).  
 Carotid Sinus Hypersensitivity  1.6.2
CSH is diagnosed if there is ≥50 mmHg drop in systolic BP or ≥3 seconds asystole or 
both in response to carotid sinus massage (CSM). CSH is an age-related phenomenon. 
Rarely seen below 40 years of age, the prevalence of CSH increases with advancing 
age. Among patients referred to an autonomic centre the reported prevalence ranged 
from 2.4% among adults aged 50-59 years to 40.4% among adults aged ≥ 80 (Humm 
and Mathias, 2006).Kerr et al reported a prevalence of CSH of 39% among community-
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dwelling older people  aged ≥65 years in whom CSM was performed using beat-to-beat 
monitoring (Kerr et al., 2006).  
 
It is clear from these studies, that neurocardiovascular instability (in the form of OH and 
/ or CSH) is common among older people, particularly when beat-to-beat monitoring is 
used to make the diagnosis. Symptomatic patients often present to clinical services with 
falls, dizziness or syncope, but many patients remain asymptomatic despite changes in 
BP or heart rate in keeping with diagnostic criteria for CSH or OH (Kerr et al., 2006, 
Romero-Ortuno et al., 2013). The long-term consequences of recurrent hypotension and 
intermittent bradycardia are not fully understood. As discussed above there is evidence 
to suggest that systemic hypotension may contribute to the formation of white matter 
hyperintensities in older people. The following sections will review the association 
between BP control and white matter hyperintensities and between BP control and the 
clinical associates of white matter hyperintensities namely; cognition, depression, gait, 
balance and falls 
 Blood Pressure Control and White Matter Hyperintensities  1.7
Age aside hypertension is one of the strongest risk factors for the development of white 
matter hyperintensities. But studies also suggest increased variation in blood pressure 
and low blood pressure may be associated with WMH.  
 Blood Pressure Variability and White Matter Hyperintensities 1.7.1
Several approaches have been used to investigate the question of whether there is an 
association between BP variability and WMH volume. Visit-to-visit blood pressure 
variability records the variation in BP recorded in clinic using a sphygmomanometer. 
Intervals between visits vary from days to years depending on study protocol (Rothwell 
et al., 2010).  Short-term BP variability looks at the variation in BP measured with 
either a sphygmomanometer or continuous beat-to-beat monitoring record over a shorter 
period, usually 30 minutes to two hours, at rest under controlled conditions. Ambulatory 
BP monitors usually report BP variability for one of three time periods; 24-hours, 
daytime and / or night-time. A number of indices are commonly recorded;  
 BP variability (the within-subject standard deviation of all readings over a 
defined period),  
 Coefficient of variability (variability of BP/mean BP)  
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 The maximal variation of BP (difference between the maximum and minimum 
BP over a defined period). 
 
A number of studies have investigated the question of whether BP variability is 
associated with WMH volume (Puisieux et al., 2001, Goldstein et al., 2005, Marti-
Fabregas et al., 2001, Gomez-Angelats et al., 2004, Tartaro et al., 1999). Results have 
been mixed. Puisieux retrospectively examined the CT scans and 24-hour ambulatory 
BP recordings of 79 older people (Puisieux et al., 2001). Higher white matter scores 
were associated with higher maximal variation of SBP, greater variability of SBP during 
24-hour, daytime and nocturnal periods and greater coefficient of variability of SBP 
during sleep (Puisieux et al., 2001). Tataro et al compared BP variability among older 
healthy individuals with and without WMH (n=45 and n=21 respectively) (Tartaro et 
al., 1999). Individuals with WMH had significantly greater nocturnal systolic and 
diastolic BP variability. Daytime and 24 hour BP variability did not significantly differ 
between groups. These findings are in contast to those of Marti-Fabregas et al who  
found no association between blood pressure variability and severity of white matter 
disease (Marti-Fabregas et al., 2001). However the latter paper included only 25 
individuals and all were recruited from a tertiary neurology clinic where they were 
being treated for symptomatic small vessel disease (Marti-Fabregas et al., 2001) 
 
Three groups have attempted to examine the longitudinal association between BP 
variability and WMH progression (Goldstein et al., 2005) (White et al., 2011, 
Yamaguchi et al., 2014) Goldstein et al examined if if  BP variability predicts severity 
of white matter disease 5 years later in a cohort of 155 older healthy individuals 
(Goldstein et al., 2005). Greater daytime systolic BP standard deviation at baseline was 
significantly associated with more severe white matter disease at 5 year follow-
up(Goldstein et al., 2005). A more recent study  examined the association between BP 
variability and small vessel cerebrovascular disease in a cohort of 210 Japanese people 
aged 70-72 years. BP variability, MRI and cognitive function were recorded at baseline 
and repeated 4 years later. Systolic and diastolic coefficient of variation but not BP 
standard deviation were associated with progression of small vessel disease independent 
of other risk factors. Similalry, White et al examined 72 subjects aged 75-89 to establish 
if vascular risk factors were associated with white matter disease progression. 
Ambulatory BP monitoring and MRI were performed at baseline and 24 months later. 
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Mean BP but not BP variability (measured as SD) was associated with WMH 
progression.  This group did not measure coefficient of variation.  
 
Gomez et al examined BP variability using both conventional intermittent ambulatory 
24-hour BP monitoring in the community and beat-to-beat monitoring in hospital for 
24-hours (Gomez-Angelats et al., 2004). Data from ABPM showed that 24-hours 
systolic BP variability was greater among people with white matter disease than those 
without. Daytime and night-time BP variability recorded by ABPM did not differ 
between white matter groups. Similarly long-term beat-to-beat monitoring showed that 
systolic BP variability but not diastolic BP variability was greater in the group with 
white matter disease. Shorter-term BP variability (recorded over 30 minutes) was not 
associated with white matter disease. Gunstad et al  have also examined the association 
between resting short-term BP variability and white matter disease. BP was recorded 
with sphygmomanometer every ten minutes for 2 hours (Gunstad et al., 2005). Systolic 
variability and the coefficient of systolic variability were associated with total white 
matter load and neocortical white matter disease. There was no association with 
periventricular disease. Diastolic variability was not associated with white matter 
disease.  
 
Three groups have examined the association between visit-to-visit variation in office BP 
and white matter disease (Havlik et al., 2002) (Liu et al., 2012, Brickman et al., 2010). 
As part of the Honolulu heart study, 575 participants underwent three assessments of 
office BP between 1965 and 1974 and an MRI scan between 1991 and 1993 (Havlik et 
al., 2002). The cohort was divided into quintiles according to BP variability in mid-life 
(1965 -1977). Compared with those in the lowest quintile, those in the upper three 
quintiles of SBP variability were at an elevated risk of WMHs. There was no 
relationship with diastolic BP variability. The Inwood Columbia Ageing Project 
included 686 non demented older adults. BP measurements were recuorded during 3 
study visits over 24. MRI scans were performed at the final visit. WMH volume was 
highest in patients in the highest quartile of mean BP and the highest quartile of BP 
variability (Brickman et al., 2010).In a study of  584 stroke patients, Liu et al recorded 
BP every 30 days for 12 – 18 months and MRI scans were performed at baseline and at 
the end of the study (Liu et al., 2012). BP variability, BP co-efferent and successive 
variation in BP were calculated. Participants with WMH at baseline had significantly 
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greater systolic BP standard deviation but other variables did not differ between groups. 
BP variability was not associated with white matter disease progression.  
 Orthostatic Hypotension and White Matter Hyperintensities   1.7.2
Raiha et al were the first to examine the potential association between orthostatic 
hypotension and white matter hyperintensities (Raiha et al., 1993). A review of the case 
notes of 204 patients who had undergone CT brain scans found that hypotension, 
congestive cardiac failure (CCF) and orthostatic hypotension were more common 
among patients with WMH. Logistic regression showed age, history of CCF and SBP 
<130, but not OH predicted WMH. Four studies have examined the association between 
OH and WMH in community-dwelling populations, all used a standard 
sphygmomanometer to record postural change in BP (Matsubayashi et al., 1997, 
Longstreth et al., 1996, Havlik et al., 2002, Gottesman et al., 2011). Matsubayashi et al 
found that people with postural hypotension (n= 20) had  more advanced
 
white matter 
hyperintensities than those with a normal response to standing (n=285) (Matsubayashi 
et al., 1997). The group also found that postural hypertension (defined as a 20mmHg 
rise in systolic BP or 10 mmHg rise diastolic BP on standing) was associated with more 
advanced WMH. In a population-based study of 3301 people, Longstregth et al found 
higher white matter grade was associated with presence of OH independent of age, sex 
and SBP(Longstreth et al., 1996). The association however was not significant after 
adjusting for presence of silent cerebral infarct. The Honolulu heart study recorded 
postural drop in 3734 men in 1991. OH was defined according to standard criteria. MRI 
scans were performed in a subset of 575 men between1993–1996. OH status was not 
associated with white matter load (Havlik et al., 2002). Finally a recent abstract 
published from the ARIC study found that presence of OH did not predict white matter 
hyperintensity progression but severity of OH (i.e. degree of postural drop) did predict 
WMH progression (Gottesman et al., 2011).  
 
Colloby et al examined the association between white matter volume and BP response 
to standing using beat-to-beat monitoring  in 38 individuals with late-life depression and 
30 age-matched controls (Colloby et al., 2011). An association between systolic 
vasodepression and white matter volume in the temporal and parietal was found for the 
depressed group, but not for the controls.  
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 Carotid Sinus Hypersensitivity and White Matter Hyperintensities  1.7.3
Few studies have examined the association between CSH and WMH. Kenny et al 
examined the association between CSH and white matter disease in 23 patients with 
Lewy body dementia, 22 with Alzheimer’s disease. There was a correlation between 
magnitude of fall in SBP during CSM and severity of deep white matter changes among 
the Lewy body dementia group, but not for the Alzheimer’s disease or control group 
(Kenny et al., 2004). A similar study including 17 patients with Lewy body dementia 
and 13 Alzheimer’s patients found that vasodepression ≥30mmHg in response to CSM 
or active stand was associated with more severe WMH on MRI.  
 Blood Pressure Control and the Clinical Correlates of White 1.8
Matter Hyperintensities  
Section 1.7 shows that there is some evidence to support an association between 
episodic hypotension and increased WMH volume in later life. If hypotensive episodes 
are a risk factor for WMHs it would be anticipated that they are also a risk factor for the 
clinical presentations associated with white matter damage.  The following section will 
review the existing literature examining the association between BP control and the 
clinical correlates of WMH, specifically; cognitive impairment, depression and falls.  
 Blood Pressure Homeostasis and Cognition 1.8.1
1.8.1.1 Hypertension and Cognition 
Alzheimer’s disease and vascular dementia are the most common forms of dementia, 
together accounting for 80% of all dementia cases (Collins and Kenny, 2007). Once 
thought of as two separate diseases it is now acknowledged that there is overlap 
between the condition (Viswanathan and Sudarsky, 2012, Roman and Kalaria, 2006). 
Cerebral infarctions, multiple lacunar infarctions, and ischaemic periventricular WMH 
(typical of vascular dementia) are common in both vascular dementia and Alzheimer’s 
disease  (Langa et al., 2004). 
 
Age aside, hypertesntion is the most commonly recognised risk factor for WMH. There 
has been  extensive research investigating the association between hypertension and 
dementia. Results have been conflicting, but several reviews have tried to summarise 
these data (Daviglus et al., 2011, Purnell et al., 2009, Power et al., 2011, Sharp et al., 
2011). Daviglus et al reported conclusions of  a recent National Institutes of Health 
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State-of-the-Science Conference (Daviglus et al., 2011). An independent panel reviewed 
the evidence for association between multiple vascular risk factors and Alzheimer’s 
disease. The group described ten studies but did not perform a meta- analysis. They 
were unable to identify a consistent relationship between self-reported hypertension or 
recorded hypertension and Alzheimer’s disease. The group concluded that hypertension 
is not a risk factor for Alzheimer’s. Power et al performed a systematic review and 
meta-analysis of 18 prospective studies examining the associations between 
hypertension and Alzheimer’s disease (Power et al., 2011). They concluded there was 
insufficient evidence to prove a causal relationship between hypertension and 
Alzheimer’s disease. Similarly a systematic review by Purnell et al failed to show a 
significant relationship between hypertension and incident AD (Purnell et al., 2009).  
 
In contrast with Alzheimer’s disease, vascular dementia does appear to be associated 
with hypertension. Sharp et al reviewed six longitudinal studies assessing the 
association between hypertension and vascular dementia. A meta-analysis showed that 
hypertension was significantly associated with increased risk of incident vascular 
dementia (odds ratio: 1.59, 95% CI: 1.29-1.95, p < 0.0001) (Sharp et al., 2011). 
 
Results from longitudinal studies examining the association between hypertension and 
cognitive decline have also been conflicting.  Verdlho, Knopman. Reitz and Luck et al 
have shown an association between hypertension and cognitive decline (Luck et al., 
2010c, Knopman et al., 2001, Luck et al., 2010b, Knopman et al., 2009, Verdelho et al., 
2007). However, the cognitive domains affected have differed between studies. Reitz 
found elevated BP was associated with increased risk of all cause MCI and non-amnesic 
MCI, but not amnesic MCI (Reitz et al., 2007), whereas Luck et al found  hypertension 
was associated with increased risk of amnesic MCI in the AgeCoDe study, but  showed 
no association between blood pressure and incident MCI in the Leipzig Longitudinal 
Study of the Aged (Luck et al., 2010c, Luck et al., 2010a). Oveisgharan and Verdelho 
found hypertension to be associated with decline in executive function (although 
Oveisgharan did not find this to be the case when executive dysfunction was impaired 
in combination with memory impairment) (Verdelho et al., 2007, Oveisgharan and 
Hachinski, 2010). A systematic review of 11 longitudinal studies, Birns et al found most 
studies showed  a relationship between hypertension and cognitive decline (Birns and 
Kalra, 2009). Similarly, in an earlier review, Eftekhari concluded long standing 
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sustained hypertension was associated with cognitive dysfunction (Eftekhari et al., 
2007).  
1.8.1.2 Essential Hypotension and Cognition 
Interestingly, in addition to studies demonstrating an association between impaired 
cognitive function and hypertension, there are several studies suggesting a  U or J 
shaped relationship between BP and cognitive function (Power et al., 2011, Guo et al., 
1996, Morris et al., 2000, Hestad et al., 2005, Richmond et al., 2011). Power et al found 
a suggestion of an inverse association between late-life hypertension and Alzheimer 
disease (Power et al., 2011). Cross-sectional studies have shown increased prevalence of 
dementia (both AD and VD) among older people with relatively low systolic or 
diastolic blood pressure (Guo et al., 1996, Morris et al., 2000). Guo et al found 
significantly elevated odds ratio for dementia among older people with systolic pressure 
≤140 mm Hg or diastolic pressure ≤75 mm Hg. The associations were stronger in those 
with a longer duration of disease and those with more severe dementia (Guo et al., 
1996) . Similarly in the CHAP study Morris et al found Alzheimer’s disease to be 
significantly more prevalent among individuals with relatively low systolic blood 
pressure (BP <130) (Morris et al., 2000). In a later cross-sectional study involving 5,816 
participants aged ≥ 65 years, Morris et al found a curvilinear relationship between blood 
pressure and cognitive performance independent of age, sex and race (Morris et al., 
2002). Hestad et al studied 207 community-dwelling older people aged ≥80 
years(Hestad et al., 2005). Blood pressure was significantly lower in participants with 
MMSE <24. Low diastolic pressure was the best predictor of cognitive impairment as 
measured by the MMSE, followed by low systolic BP.  Likewise, an analysis by 
Richmond et al studying the oldest cohort (142 participants, mean age 101.1) found low 
systolic BP was positively associated with MMSE [r=0.37 (P=0.001)] (Richmond et al., 
2011). 
 
Prospective studies also report associations between chronic hypotension and incident 
dementia (Verghese et al., 2003, Guo et al., 1999, Euser et al., 2009). Between 1980 and 
1983, 488 individuals aged 75 and older enrolled in The Bronx Ageing Study (Verghese 
et al., 2003). Subjects were assessed at 12–18 month intervals. Follow-up lasted up to 
21 years, mean follow-up 6.6 years. Four hundred and six individuals attended at least 
one follow-up of which, 122 developed dementia. Increased risk of incident dementia 
was associated with low diastolic pressure. Risk of incident dementia was higher in 
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subjects with persistently low BP. The Kungsholmen study included 1270 participants 
(aged 75 – 101). The authors found that high systolic BP (>180 mmHg) and low 
diastolic BP (<70 mmHg) were associated with increased risk of Alzheimer’s disease 
(Guo et al., 1999). Low systolic BP and high diastolic BP were not associated with 
cognitive impairment. Euser et al. found for persons aged 65 to 74, higher baseline SBP 
and DBP were related to worse cognitive function 11 years later. In contrast, in older 
age (≥75), higher SBP and DBP seemed to be related to better cognitive function at the 
end of follow-up. This effect appeared strongest in the highest age group (aged 85) 
(Euser et al., 2009). 
1.8.1.3 Blood Pressure Variability and Cognition 
Several studies have shown a cross-sectional association between greater 24-hour (or 
daytime) BP variability and poorer cognitive function (Goldstein et al., 1998, Kanemaru 
et al., 2001, Bellelli et al., 2002, Sakakura et al., 2007).  In contrast, studies examining 
the association between short-term BP variability measured over two hours found a 
significant positive relationship between a function of BP variability (standard deviation 
of systolic BP divided by the average diastolic BP) and cognitive function (Keary et al., 
2007). Okonkwo et al examined the long-term association between short-term (two-
hour) BP variability and cognitive decline (Okonkwo et al., 2011). Using random 
effects modelling, the group demonstrated that reduced variability in systolic BP and 
increased variability in diastolic BP were associated with a faster rate of decline in 
Attention-Executive-Psychomotor function (Okonkwo et al., 2011). There are no 
published studies examining the long-term association between 24-hour ambulatory BP 
variability and incident cognitive impairment / dementia or the impact of 24-hour BP 
variability on cognitive decline.  
 
Two studies report the association between long-term BP variability and cognition 
(Nagai et al., 2012, Alperovitch et al., 2013). Nagai et al recorded 12 BP readings at 
one-month interval in 201 older people (Nagai et al., 2012). Exaggerated visit-to-visit 
BP fluctuations were significant indicators for cognitive impairment. In the largest 
study to examine the association between BP variability and cognition, Alperovitch et al 
examined the association between the variation in BP recorded on three occasions over 
three years and incident dementia (Alperovitch et al., 2013). During the 40,151 person-
years of follow-up, 474 participants developed dementia. In the fully adjusted Cox 
model, the hazard ratio of dementia for those in the highest decile of the coefficient of 
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variation of systolic blood pressure was 1.77 (1.17–2.69) compared with the lowest 
decile (Alperovitch et al., 2013). 
 
ABPM also provides information on diurnal variation. Loss of normal, nocturnal, 
dipping pattern also appears to be associated with cognition in cross-sectional studies. 
Non-dipping, extreme-dipping and reverse-dipping have been associated with poorer 
cognitive function in most studies (Guo et al., 2009, Yano et al., 2011, Yamamoto et al., 
2005). Similarly, non-dipping has been associated with incident dementia over a mean 
follow-up of 8.9 years (Yamamoto et al., 2002).  
1.8.1.4 Orthostatic Hypotension and Cognition 
The reported association between chronic hypotension and cognitive impairment/ 
dementia led authors to investigate the relationship between cognitive function and 
episodic low blood pressure associated with NCVI  
 
Two studies have examined the prevalence of OH in dementia compared to controls 
(Andersson et al., 2008, Mehrabian et al., 2010). Mehrabian performed sitting and 
standing BP on 495 patients attending a memory clinic (Mehrabian et al., 2010). 
Orthostatic hypotension was significantly more common among patients with dementia 
compared with non-demented patients (OH was present in 22% of vascular dementia 
patients, 15% of AD, 4% normal controls; P<0.001) (Mehrabian et al., 2010). Similarly, 
Anderson et al investigated 235 Alzheimer’s dementia patients, 52 with patients with 
Lewy body dementia and 60 controls. OH was more common among individuals with 
Alzheimer’s disease or Lewy body dementia than age-matched controls (Andersson et 
al., 2008).  
 
Mehrabian et al also found OH was more common among individuals with MCI than 
controls  and that after adjustment for age, education level, systolic BP, diastolic BP, 
weight, and antihypertensive drugs, subjects with OH performed significantly more 
poorly on the Cognitive Efficacy Profile than those without OH (Mehrabian et al., 
2010). In keeping with these findings, Collins et al demonstrated that  people with MCI 
show greater changes in SBP on orthostasis, compared to controls, and patients with 
MCI have poorer BP recovery (Collins et al., 2010). Failure of BP to return to baseline 
by 40 seconds was associated with impaired executive function (Collins et al., 2010). 
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In a large community study Yap et al examined 2,321 community-living older adults, in 
China (Yap et al., 2008). OH was not associated with cognitive impairment overall. 
However, among hypotensive participants, OH was associated with increased risk of 
cognitive impairment while hypertensive participants with OH showed reduced risk of 
cognitive impairment (Yap et al., 2008).  
 
In a smaller community-dwelling cohort, Matsubayashi et al found patients with 
postural dysregulation (participants with >20mmHg drop in systolic BP or >20mmHg 
rise in systolic BP on standing) performed more poorly on cognitive tests compared to 
participants with normal BP regulation (Matsubayashi et al., 1997). Similarly, among 
participants recruited from primary care and hospital general medical wards,  
Czarjkowska found both orthostatic hypotension and orthostatic hypertension to be 
associated with poorer cognitive function (Czajkowska et al., 2010).  
 
Four studies have examined the association between OH and cognitive decline (Rose et 
al., 2010, Yap et al., 2008 Viramo et al., 1999 Elmstahl and Rosen, 1997). Rose et al 
examined 12702 individuals. At baseline, participants with OH were more likely to be 
in the lowest quartile of cognitive tests scores than were those without OH. Similarly, at 
follow-up, OH was associated with increased odds of being in the greatest quintile of 
decline in cognitive test scores. After adjustment for socio-demographic and 
cardiovascular risk factors, these associations were no longer significant (Rose et al., 
2010). It should be noted that this group defined BP change as the difference between 
the average of the standing and supine BP measurements rather than the difference 
between the lying BP and standing nadir and that they excluded the first standing 
measurement. This potentially will have resulted in an underestimation of the 
prevalence of OH and will have missed initial OH.  In keeping with the findings of Rose 
et al, and in contrast to their cross-sectional findings,  Yap et al did not find any 
association between OH and cognitive decline among (Yap et al., 2008). Viramo et al 
followed-up 651 community-dwelling people aged ≥70 years and found neither systolic 
or diastolic OH predicted cognitive decline at a 2.5 year follow-up (Viramo et al., 
1999). Similarly, despite finding a cross-sectional association between OH and 
cognitive impairment Yap et al  found no association between OH and cognitive decline 
over a one year follow-up period among a large cohort of Chinese older people (Yap et 
al., 2008). Only one longitudinal study has found an association OH and cognition.  The 
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study was small with just 33 healthy woman, but with a longer follow-up period (5 
years). Women who developed cognitive decline had significantly greater orthostatic 
fall in BP at baseline (Elmstahl and Rosen, 1997).  
 
1.8.1.5 Carotid Sinus Hypersensitivity and Cognition 
Carotid sinus hypersensitivity is more common in people with dementia. Kenny et al 
showed that prevalence of cardioinhibitory CSH was significantly higher among 
patients with Lewy body dementia than controls (Kenny et al., 2004). Kerr et al 
compared CAMCOG scores and performance on computerised drug research battery 
among community dwelling older people with and without CSH and found there were 
no differences in cognitive function.  
 Blood Pressure Homeostasis and Depression  1.8.2
In addition to the concept of vascular cognitive impairment, the model of vascular 
depression has been developed (Sneed and Culang-Reinlieb, 2011). It has long been 
recognised that there is a bidirectional association between vascular disease and 
depression, particularly depression starting in later life (Newberg et al., 2006). 
Depression is more common among patients with myocardial infarction and stroke than 
matched controls and has been found to be more strongly associated with vascular 
dementia than Alzheimer’s disease (Frasure-Smith and Lespérance, 2010, Diniz et al., 
2013, Newberg et al., 2006). Conversely depression has been identified as a risk factor 
for stroke (Dong et al., 2012).  
1.8.2.1 Hypertension and Depression 
These observations and the previously described associations between depression and 
white matter hyperintensities led to researchers to examine the association between 
vascular risk factors as depression in late-life. A recent meta-analysis aimed to quantify 
the extent to which hypertension might be associated with depression in late-life 
(Valkanova and Ebmeier, 2013). The study reviewed 14 papers examining the 
prevalence or incidence of late-life depression among people with and without 
hypertension. In total 20197 participants were included in the studies. After pooling the 
14 studies the OR of depression was > 1 but statistically non-significant (OR: 1.14; 95% 
CI: 0 .94–1.40; P=0.19). The authors suggested that the failure to identify an association 
between hypertension and late-life depression may be because only individuals who 
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develop the most severe cerebrovascular disease develop clinical disease, i.e. that there 
is a threshold effect rather than a linear association between blood pressure and risk of 
developing depression. Other authors have argued that the failure to show an association 
between late-life depression and conventional cardiovascular risk factors in community 
cohorts, despite histopathological evidence of ischaemia in WMH, suggests non-
conventional risk factors, associated with cerebral hypoperfusion, may be important in 
the pathogenesis of late-life depression (Vasudev et al., 2012). If this were true, aspects 
of cardiovascular autonomic control such as neurocardiovascular instability and BP and 
heart rate variability may be of importance.   A small number of studies have 
investigated if depression is associated with NCVI .  
1.8.2.2 Blood Pressure Variability and Depression 
Kayano et al recently examined the association between anxiety (defined as a score >10 
on the Hospital Anxiety and Depression Scale (HADS)) and diurnal variation among 
120 hypertensive Japanese patients, mean age 67 years (Kayano et al., 2012). The group 
found that nocturnal and early morning BP were significantly higher in the anxiety 
group than in the control group. Odds of an existing anxiety disorder were significantly 
higher in the nocturnal risers than in the dippers. Furthermore, daytime and night-time 
BP variability were significantly greater in the anxiety group. Sunbul et al also found an 
association between dipping status and anxiety / depression scores (Sunbul et al., 2013). 
Hypertensive patients with a normal nocturnal BP dipping pattern had significantly 
lower HADS scores than non- dippers.  
 
Kario examined the association between depression, anxiety and ABPM recordings in 
men and woman of working age (Kario et al., 2001). Depression was associated with a 
diminished diurnal variation in BP in men, but not in women. Interestingly this finding 
was independent of daytime activity or nocturnal sleep quality. In an older cohort, 
Scuteri et al found that after controlling for age, sex, and traditional cardiovascular risk 
factors, subjects with depressive symptoms  (diagnosed on the Geriatric Depression 
Scale) had a significantly lower night-time SBP fall than non-depressed ones with a 
significantly higher occurrence of non-dipper status (Scuteri et al., 2009). 
 
As all these studies are cross-sectional, it is currently impossible to establish 
conclusively the direction of association. Altered BP control may contribute to 
subsequent depression through cerebral small vessel disease, as hypothesised. 
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Alternatively, depression may result in altered mood, disturbed sleep and altered 
behaviour in turn causing changes in BP control.  
1.8.2.3 Neurocardiovascular Instability and Depression 
Two small cross-sectional studies have examined the association between orthostatic 
hypotension and depression (Vasudev et al., 2012, Colloby et al., 2011). Both studies 
showed greater systolic vasodepression on standing in older people diagnosed with 
depression than in age and sex matched controls. The depressed groups in both cases 
were recruited from a secondary care psychiatric service and had a history of current or 
previous major depressive episode.  
 
It should be noted that cross-sectional studies examining the association between OH 
and depression are complicated by the use of medication. Anti-depressants, particularly 
tricyclic medication and selective serotonin reuptake inhibitors (SSRI) are recognised as 
having effects on the autonomic nervous system. Tricyclic anti-depressants have been 
associated with increased prevalence of OH and SSRIs are used as a treatment for 
disorders of the autonomic nervous system including OH.  
 
A more recent population-based study compared Centre for Epidemiology Depression 
Scores (CED-S) among participants with symptomatic OH, asymptomatic OH and no 
OH. Participants with symptomatic OH had significantly higher CED-S than 
participants with asymptomatic OH or no OH (Regan et al., 2013). Participants in this 
study were not taking antidepressant medication. These findings suggest that symptoms 
suggestive of cerebral hypoperfusion are associated with depression.  
 
Fewer studies have examined the association between carotid sinus hypersensitivity 
(CSH) and depression. In one study of 315 CSH patients, total Cornell score was 
significantly higher in participants with CSH than controls (Pearce, 2007). Similarly, 
the proportion of participants scoring 10 or more on the Cornell score (indicative of 
probable depression) was significantly greater in the CSH group.  
 
To my knowledge there are no longitudinal studies examining the association between 
depression and OH or CSH.  
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1.8.2.4 Measures of Autonomic Function and Depression  
Heart rate variability has been the most commonly used measure of autonomic function 
in studies examining the association between depression and cardiovascular autonomic 
nervous system function. Several studies have shown that heart rate variability is 
reduced in patients with depression, particularly low frequency heart rate variability, 
indicating withdrawal of parasympathetic control (Carney et al., 2001, Dauphinot et al., 
2012, Koschke et al., 2009, Robinson et al., 2008, Vasudev et al., 2011).  
 
Studies examining the association between HRV and depression are often complicated 
by confounding factors such as use of medications known to affect mood and the 
autonomic nervous system e.g. beta-blockers, SSRIs and the inclusion of participants 
with medical conditions associated with altered cardiovascular autonomic function and 
depression, e.g. myocardial infarction. Rotenberg et al performed a meta-analysis to 
establish the effect of depression on cardiovagal control (Rottenberg, 2007). Studies 
included in the primary analysis excluded patients who had health conditions that 
compromise vagal control or who took medications known to or likely to affect the 
autonomic nervous system, including antidepressants. The group concluded that 
depression is associated with reduced cardiovagal control, but that the effect is small. A 
more recent meta-analysis reviewing 19 studies including 673 depressed participants 
and 407 healthy comparison found that participants with depression had lower HRV 
than healthy control subjects, and depression severity was negatively correlated with 
HRV(Kemp et al., 2010).  
 
Despite cross-sectional evidence for association between HRV and depression there is 
an absence of studies examining the longitudinal associations between cardiovascular 
autonomic function and mood. It is currently impossible to know if depression causes 
changes in HRV or alternatively if impaired HRV predates depression.  
 Blood Pressure Homeostasis and Gait, Balance and Falls  1.8.3
Impaired blood pressure control and NCVI are a frequently cited in guidelines as risk 
factors for falls in older people (NICE, 2013, Panel on Prevention of Falls in Older 
Persons and British Geriatrics, 2011, Beauchet et al., 2011). There are a number of 
plausible physiological mechanisms that may explain this association; 
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1. Sudden reduction in systemic BP may result in sufficient drops in cerebral 
hypoperfusion to induce syncope. It is recognised that over 20% of non-
demented older people with syncope are amnesic to loss of consciousness 
(Shaw and Kenny, 1997). If no eyewitness history is available, these cases 
may be attributed incorrectly to falls rather than syncope.   
2. Cerebral hypoperfusion insufficient to impair consciousness may be enough to 
result in a transient loss of coordination. In individuals with multiple risk 
factors for fall this may be sufficient to result in loss of balance.  
3. As previously discussed, repetitive episodes of hypoperfusion are thought to 
contribute to the development of WMH (Pantoni and Garcia, 1997). Greater 
WMH volume is associated with impaired gait, balance and cognition (Willey 
et al., 2013, Kreisel et al., 2013, Callisaya et al., 2013, Soumaré et al., 2009, 
DeCarli, 2013). Impairment of gait and cognition are among the strongest risk 
factors for falls (Frith and Davison, 2013).   
 
 This final section of the introduction will review the association between blood 
pressure homeostasis, gait, balance and falls.  
1.8.3.1 Blood Pressure Variability, Gait, Balance and Falls 
Ambulatory blood pressure monitoring is often used in clinical practice to identify 
people whose fall may have been a result of chronic hypotension or recurrent drops in 
BP. Surprisingly, only a few studies have examined the association between ABPM 
profile and falls (Puisieux et al., 2000, Jonsson et al., 1990). Puisieux compared ABPM 
records in three groups; older patients with syncope, older patients with falls and an 
age-mated control group (Puisieux et al., 2000). There were no significant differences in 
BP variability or diurnal variation between groups. This is interesting as greater BP 
variability in response to common daily activities such as eating and standing has been 
associated with falls among nursing home residents (Jonsson et al., 1990). It should be 
noted that Jonsson et al included response to nitro-glycerine in their analysis.  
1.8.3.2 Neurocardiovascular Instability, Gait, Balance and Falls 
More attention has been paid to the association between NCVI and falls. Several 
prospective studies have examined the association between OH and falls. Results have 
been inconsistent (Tromp et al., 2001, Ooi et al., 2000, Campbell et al., 1989, Gangavati 
et al., 2011). Campbell et al found that OH was more common in female fallers than 
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non-fallers, but, after adjusting for age the association between OH and falls was no 
longer statistically significant (Campbell et al., 1989). Similarly, Tromp et al failed 
show an association between OH and falls in 1285 community-dwelling older people 
(Tromp et al., 2001). In a study of 844 nursing home residents, OH was not associated 
with falls among the total cohort. However, among individuals who had fallen in the 
prior 6 months, OH was associated with increased risk of falling (Ooi et al., 2000). The 
Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of 
Boston Study examined the association between OH and recurrent falls (>2 falls in 12 
months). The study showed that OH by itself was not an independent risk factor for 
recurrent falls. However, OH at one minute in uncontrolled hypertensive people was a 
risk factor for falling (Gangavati et al., 2011). 
 
A number of literature reviews have aimed to summarise risk factors for falls. Not 
surprisingly results have been inconsistent with some concluding OH is a risk factor for 
falls while others have not (Rubenstein, 2006, Ganz et al., 2007). McCarthy et al 
reviewed 16 studies examining the association between OH and falls in older people 
(McCarthy et al., 2010). Only four of the studies showed an association. The authors 
concluded the evidence for OH as a risk factor for falls is weak.  
 
The discrepancies in these results in part reflect the vagaries of the current definition of 
OH. Studies have not consistently used the same methods of recording BP or recorded 
BP at the same intervals during the active stand. Studies using beat-to-beat monitoring 
instead of a sphygmomanometer find OH to be highly prevalent among the general 
population and have not shown an association between OH defined according to 
conventional criteria and falls (Romero-Ortuno et al., 2011a, Kerr, 2009). Romero-
Ortuno et al did however show an association between initial OH (defined as a transient 
BP decrease, within 15 seconds after standing, of more than 40mmHg in SBP or more 
than 20mmHg in DBP, with symptoms of cerebral hypoperfusion) and falls(Romero-
Ortuno et al., 2011a). Van Der Velde et al examined which time average of continuous-
finger-blood-pressure measurement showed the best association between orthostatic 
hypotension and falls (Van Der Velde et al., 2007). Drops averaged over 5 seconds 
showed the strongest association. In their study, the odds ratio of a fall according to 
orthostatic hypotension using the 5 second average was 2.54 (95% CI: 1.37 - 4.71).  
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Symptoms may also be of clinical importance in defining the association between OH 
and falls. Graafmans et al showed that a history of dizziness on standing was associated 
with increased risk of falls (OR 2.1, 95% CI: 1.2 – 3.7) and recurrent falls (OR 2.1, 95% 
CI: 1.1 -4.2) even though orthostatic hypotension itself was not associated with falling 
(Graafmans et al., 1996). It should be noted that the definition of initial OH (found to be 
associated with falls) used by Romero-Ortuno included a requirement that participants 
had symptoms of cerebral hypoperfusion (Romero-Ortuno et al., 2011a). Similarly 
symptoms of cerebral hypoperfusion during active, stand rather than degree of 
vasodepression, have been shown to be associated with fall in cross sectional studies  
(McDonald, 2013).  
 
Fewer studies have examined the association between carotid sinus hypersensitivity and 
falls. CSH and CSS are more common among individuals presenting to A&E with non-
accidental falls than controls (Davies et al., 2001). Sachpekidis et al compared 
prevalence of CSH among controls, accidental fallers and individuals with unexplained 
falls presenting with fractured neck of femur and reported rates of 18.2%, 17.6% and 
66.7% respectively (Sachpekidis et al., 2009). Ward et al reported a prevalence of CSH 
of 36% among individuals presenting with fractured neck of femur compared to 13% 
among individuals admitted for elective hip replacement (Ward et al., 1999).  To date 
there have been no prospective studies examining the incidence of falls in people with 
CSH compared to controls. Studies examining the role of permanent pacing as a 
treatment to reduce falls in patients of carotid sinus syndrome have shown mixed results 
(Parry and Matthews, 2013). Un-blinded studies in younger cohorts suggest a possible 
benefit to pacing. However the only double blinded study in older individuals failed to 
show any benefit in the paced group, although this was underpowered(Parry et al., 
2009).  
 
The association between neurocardiovascular instability and gait and balance is poorly 
understood. Cross-sectional studies have shown that older fallers with OH spend more 
time in the stance phase than controls, but that gait variability does not differ between 
groups (Barrett et al., 2008). OH has been associated with poor performance on the 
Berg balance scale in diabetic individuals, and increased postural sway in patients with 
Parkinson’s disease (Matinolli et al., 2009, Cordeiro et al., 2009). These studies are 
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small and there are no longitudinal studies examining the association between NCVI 
and future gait and balance problems.  
 
 Summary and Aims 1.9
In summary, impaired blood pressure and heart rate control have been associated with 
cognitive impairment, depression and falls in older adults. These clinical presentations 
have in turn also been associated with greater white matter hyperintensity volume in 
older people. There is histopathological evidence suggesting that these WMH may 
result from cerebral hypoperfusion. Most studies have been cross-sectional and there is 
an absence of comprehensive prospective studies simultaneously examining the long-
term clinical and radiological associations of NCVI. Furthermore, beat-to-beat 
monitoring of BP and heart rate changes during tests of neurocardiovascular function 
are now routinely used in clinical practice. However, as most studies examining the 
long-term consequences of NCVI have used a sphygmomanometere the long-term 
consequences of disorders diagnosed using beat-to-beat techniques is not known.  
 
The aim of this study is to establish the long-term relationship between 
neurocardiovascular function in later life and cognition, depression, falls and white 
matter damage. The thesis reports data from the ten year follow-up of a community 
cohort in whom cardiovascular autonomic function and the prevalence of NCVI was 
well characterised in 2002, using beat-to-beat monitoring. The cohort has undergone 
comprehensive follow-up in terms of repeat cognitive testing, assessment of mood, gait 
and balance and documentation of falls. Brain MRI has been used to quantify WMH 
volume. The association between baseline autonomic and neurocardiovascular function 
and each of these variables is discussed in separate chapters. A brief description of key 
methodological points is summarised at the beginning of each results chapter and 
supplements the methods described in chapter two. At the end of each chapter the key 
results are discussed and interpreted in the context of existing literature. In order to 
examine if loss to follow-up due to mortality has been associated with autonomic 
function and NCVI at baseline, a final section examines the association between 
cardiovascular autonomic function, and ten-year all-cause mortality in the entire 
baseline cohort.  
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Chapter 2 Methods  
This is a longitudinal follow-up of a cohort initially recruited in 2002. The description 
of  baseline methods is as described in Dr Simon Kerr’s Thesis (Kerr, 2009).  
 Recruitment  2.1
Participants were first recruited in April 2002 from a single General Practice (GP) in the 
North East of England. Details of all patients registered with the practice are held on the 
GP electronic database. In order to participate in the study, individuals had to be aged 
65 years or over at time of sampling and living independently in the community. 
Individuals living in nursing or residential care were excluded prior to sampling. At 
sampling 1517 individuals met these criteria. The sample population was sub-stratified 
by age and sex into four groups.  
 
 Male aged <75 
 Female aged <75 
 Male aged ≥ 75 
 Female aged ≥75 
 
Computer generated random samples of 250 individuals were drawn from each group. 
Selected participants were sent a letter outlining the purpose of the study. Included with 
the letter was a response card and a prepaid envelope. Participants were given three 
options: 1) indication of interest in the study, 2) unwillingness to take part in the study, 
but consent to review of their G.P notes, 3) unwillingness to participate in the study. 
Where subjects failed to respond to the initial letter, a second invitation was sent. 
Subjects failing to respond to the second invitation were not re-contacted.  
 
Three hundred and fifty two individuals participated in the study at baseline in 2002 / 
2003 (35% of those invited). Between the initial assessment and the current study 
participants were invited to take part in two further assessments at two and five years 
follow-up. Participants who did not take part in these assessments were considered to 
have withdrawn from the study. Two hundred and nine individuals took part in the 2008 
follow-up and were eligible participate in this study.   
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 Baseline Clinical Assessment 2.2
 History of Falls, Dizziness or Syncope 2.2.1
The number of falls, and/or episodes loss of consciousness in the preceding 12 months 
were recorded. Information regarding the cause of a fall or episode of loss of 
consciousness was sought and whether it had resulted in injury, attendance at an 
Accident and Emergency department or hospital admission.  
 Past Medical History 2.2.2
Past medical history was obtained by direct interview of the subject or subject and 
friend or relative if the participant was accompanied when they attended the assessment. 
Particular attention was paid to the presence or absence of cardiovascular and 
cerebrovascular disease and risk factors. Where possible, participants’ answers were 
recorded as categorical “yes” or “no” responses. If participants were unsure of their past 
medical history, GP medical notes were reviewed.  
 
Ischaemic heart disease was defined as a clinical history of angina or myocardial 
infarction. Participants were designated as having “cardiac disease” if they had any 
ischaemic heart disease, cardiac failure, an arrhythmia or previous rheumatic fever.  
 Social History 2.2.3
Smoking and alcohol history were recorded. For smokers and ex-smokers, pack years 
were recorded. A pack year is calculated by multiplying the number of packs of 20 
cigarettes smoked per day by the number of years the person has smoked. For ex-
smokers, the number of years since cessation was also recorded. The number of units of 
alcohol consumed per week was recorded. Age on leaving education and the number of 
years in education were noted.  
 Medication Use 2.2.4
Participants were asked to bring a list of all of their prescribed and over-the-counter 
medications with them to the baseline assessment. Medication history was recorded. 
Three composite variables were derived.  
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 Cardioactive Medication:  participants were defined as taking a cardioactive 
medication if they were taking  any antihypertensive medication, diuretic 
medication, antianginal, antiarrythmic, fludrocortiosone or midodrine 
 
 Anti-hypertensive medication: participants were defined as taking an anti-
hypertensive medication if they were taking any angiotensin converting enzyme 
(ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, 
angiotensin type 2 receptor blockers and thiazides  
 
 Psychoactive medication: participants were defined as taking a psychoactive 
medication if they were taking any typical neuroleptic, atypical neuroleptic, anti-
cholinergic, cholinesterase inhibitor, tricyclic antidepressant, selective serotonin 
reuptake inhibitor, other antidepressant, anti-Parkinson’s or other psychotropic 
medication.  
 Physical Examination 2.2.5
Height and weight were recorded and body mass index calculated. Pulse rate, rhythm 
and character were recorded. Heart sounds were auscultated and presence or absence of 
signs of peripheral or pulmonary oedema noted. Blood pressure was recorded in the 
semi-supine position after a period of rest using a standard sphygmomanometer.  
 Gait and Balance Assessment 2.2.6
Gait and balance were assessed using the Tinetti Performance Orientated Mobility 
Assessment (POMA) (Tinetti, 1986). Gait and balance are assessed separately. Subjects 
are asked to perform manoeuvres frequently encountered in normal day-to-day 
activities. There are several versions of the instrument reported in the literature with 
variation in items and scoring (Kopke and Meyer, 2006).  The gait assessment used in 
this study was made up of nine manoeuvres. Each component was scored one point if it 
was “normal” and zero if it was abnormal or the subject was unable to complete the 
manoeuvre.   
 
The balance scale was made up of 13 manoeuvres that assessed balance in the sitting 
and standing positions. The subjects’ performance on each task was scored zero, one or 
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two depending on whether their ability was considered abnormal, adaptive or normal 
respectively.  
 Baseline Neurocardiovascular Assessment 2.3
All tests were carried out between 09.00 and 13.00 at a local day hospital. Participants 
were asked to refrain from coffee or nicotine from the previous evening and to have 
only a light breakfast prior to attending for the tests.  
 
Autonomic function tests were carried out in a single bed treatment room to ensure a 
quiet environment. A three lead electrocardiogram (ECG) was used to monitor cardiac 
response to the test. Continuous beat-to-beat blood pressure was recorded from the hand 
using digital photoplethysmography (Portapress, TNO- Biomedical, Amsterdam). The 
subject’s hand was supported at heart level during throughout all measurements.  
 
Standard tests of autonomic function followed on directly from tests of heart rate 
variability.  A minimum of two minutes rest occurred between each test to allow for 
recovery and explanation of the next test. 
 Short-term (five minute) Heart Rate Variability 2.3.1
Blood pressure and ECG data were recorded continuously while participants rested 
supine for ten minutes. The first five minutes of the data were discarded. The remaining 
data was digitised and stored on a laptop computer.  
 
Two locally developed software packages were used to examine the recordings (CRISP 
1.1 and Alpha 1.0). The programs identified a fixed point on the R wave, the fiducial 
point. Where there was unexpected variation in the R wave interval (>30%) the program 
automatically inserts an interpolated R wave based on the variation recorded in the 
preceding four R waves. Recordings were manually reviewed and any incorrectly 
identified R waves or incorrectly interpolated beats removed. The total number of beats 
was calculated and only recordings where ≤ 10% of the beats were interpolated or 
ectopic were included in the analysis.  
 
Once recordings were reviewed and cleaned, mean RR interval and standard deviation 
of RR intervals were calculated for each recording. Power spectral analysis using a fast 
43 
 
Fourier transform calculated total power and divided RR intervals into characteristic 
frequencies; high frequency fluctuations (0.15-0.40 Hz), low frequency fluctuations 
(0.04-0.15 Hz) and very low frequency fluctuations (<0.04 Hz). The HF:LF ratio was 
also calculated.  
 Heart Rate and Blood Pressure Response to Standing (Active Stand) 2.3.2
After resting in the supine position subjects were asked to assume a standing position as 
quickly as possible and without assistance and maintain this position for 3 minutes or as 
long as possible. The recorded heart rate and blood pressure response to standing 
included the time assuming the upright position.  
 
The heart rate response was defined as the 30:15 ratio (the ratio of the longest RR 
interval around the thirtieth beat to the shortest RR interval around the fifteenth beat 
after standing) 
 
The blood pressure response was defined as the earliest sustained drop in systolic and 
diastolic pressure. The time to reach the nadir and time to recover to baseline were 
recorded for each blood pressure response.  
 Isometric Exercise  2.3.3
Participants rose to a sitting position (with legs supported on the bed) from a supine 
position. They were instructed to maintain the positions for three minutes or as long as 
they could manage. Blood pressure response was taken as the difference between the 
average diastolic BP in the 20 beats before the procedure and the average diastolic BP 
in the 20 beats after the procedure  
 Valsalva Manoeuvre  2.3.4
Participants sat quietly on the edge of the bed then blow into a disposable mouthpiece to 
a pressure of 40mmHg for 15 seconds. A bar scale and digital clock, shown on the 
laptop screen, gave visual feedback and helped aid participants to maintain the 
necessary pressure for the required duration. After the test, participants were instructed 
to sit quietly for the next 30 seconds to avoid contaminating the reflex. The manoeuvre 
was repeated three times.  
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Figure 2-1 Systolic Blood Pressure Response to Valsalva Manoeuvre (adapted 
from data provided Dr James Frith (Frith, 2011))  
 
The Valsalva manoeuvre has 4 phases: 
 Phase I: Blood is expelled from the thoracic vessels by the increase in 
intrathoracic pressure (a). 
 Phase II:  
o Early: The increase in intrathoracic pressure causes a reduction of 
venous return, lowering the preload and BP (b).  
o Late: The baroreceptor reflex is activated, causing vasoconstriction and a 
tachycardia, raising BP towards normal (c). 
 Phase III: As intrathoracic pressure suddenly drops there is pooling of blood in 
the pulmonary vessels, causing a further drop in BP (d). 
 Phase IV: With venous return restored there is an overshoot, as compensatory 
mechanisms continue to operate (e). 
 
The ratio of the longest RR interval in the first 30 seconds after the manoeuvre (phase 
IV) to the shortest RR interval during the manoeuvre (phase III) was then measured. 
 
Blood pressure response was the difference between the phase II trough and the phase 
IV overshoot. The best BP response and largest Valsalva ratio were used for the 
analysis.  
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 Cold Pressor 2.3.5
While seated, participants were instructed to fully submerge their hand in a bowl 
containing a mixture of ice and water. They were asked to keep their hand submerged 
for a maximum of one minute, or as long as they could tolerate. They were asked to 
keep their hand still with the palm open.  
 
Blood pressure response was the difference the mean DBP in the 20 beats before 
placing their hand in water and the mean DBP in 20 beats immediately afterwards.  
 Heart Rate Response to Deep Breathing 2.3.6
Subjects lay supine on the couch and were instructed to breathe deeply and evenly at a 
rate of six breaths per minute. To help the subject maintain the correct breathing rate, 
the researcher counted the five seconds inspiration and expiration for each cycle.  
 
The maximum and minimum heart rates during each breathing cycle were measured. 
The mean of the differences for six breathing cycles was calculated 
 Defining Normal Ranges for Autonomic Function Tests  2.3.7
Autonomic function for each participant was categorised according to Ewing criteria. 
Two modifications were made to these criteria. Firstly, blood pressure response to 
isometric exercise was measured using the active sit as a stimulus rather than sustained 
handgrip as described by Ewing and Clark. Secondly age-appropriate normal ranges 
were used to define abnormal, borderline and normal  response.  
 
The normal ranges for response to autonomic function tests defined by Ewing and Clark 
were developed in individuals aged 16 -65 years. As previously discussed, response to 
autonomic function tests are highly correlated with age (Ewing et al., 1985). As 
participants in this study were aged 65 years and over at baseline, age-appropriate 
normal ranges were defined at baseline based on response to autonomic function tests 
observed in a normal subsample. The normal subgroup was defined by excluding all 
subjects with a documented history of cardiovascular disease, diabetes, cerebrovascular 
disease, Parkinson’s disease, dementia, or using cardiac or psychoactive medication. 
The fifth and ninety-fifth percentiles from the normal subgroup were used to quantify 
abnormal, borderline, and normal responses for each autonomic tests.  
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Overall function was then categorised in accordance with Ewing Criteria. Autonomic 
function was considered normal if all tests were normal or abnormal if one or more tests 
were abnormal. 
 Carotid Sinus Massage 2.3.8
Carotid sinus massage (CSM) was performed in consenting participants without 
contraindication. Contraindications included myocardial infarction, stroke or transient 
ischaemic attack in the preceding three months, history of significant carotid stenosis, 
carotid bruit or clinical suspicion of carotid stenosis.  
 
Participants underwent CSM at the end of the neurocardiovascular assessment. Subjects 
rested supine for five minutes before CSM. CSM was performed by the same doctor in 
every case. The point of maximum pulsation over the carotid artery, between the angle 
of the mandible and thyroid cartilage was identified. Firm longitudinal massage was 
applied for five seconds. Heart rate and BP were recorded continuously as described 
above. CSM was stopped before five seconds if >3 seconds asystole was recorded. CSM 
was first performed on the right hand side in the supine position, followed by the left 
hand side in a 70 degree head-up tilt, then right standing and finally left head-up tilt 
position. One minute rest was allowed between each period of massage.  
 
After each episode, participants were asked to report dizziness, light-headedness, or 
symptoms suggestive of pre syncope and the examiner noted any syncopal episodes. A 
maximum of 4 periods of CSM were performed. However, if syncope was observed in 
conjunction with a hypersensitive response, further CSM was not performed.  
 
Carotid sinus hypersensitivity was defined according to standard criteria 
- Cardio inhibitory: ≥ 3 seconds asystole 
- Vasodepressive : ≥ 50 mmHg drop in systolic BP 
- Mixed: both of the above 
 Twenty-four Hour Ambulatory Blood Pressure Monitoring 2.4
Consenting participants were fitted with a twenty-four hour blood pressure monitor 
(Spacelabs 90207 – Spacelabs Medical Inc, Redmond, Washington USA). An 
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appropriate sized cuff was fitted to the non-dominant arm. Subjects were instructed to 
relax their arm where possible when the cuff was inflating and during the one-two 
minutes while the reading was calculated. A test reading was taken at the time of 
monitor reading. Monitors were programmed to take a BP recording every 30 minutes 
during the day (7 am to 10 pm) and every hour overnight (10 pm to 7 am). If the 
monitor failed to obtain a BP recording on the first attempt, it would automatically retry 
the measurement 1-2 minutes later. 
 
Three time periods were examined: daytime (10 am -8 pm), night-time (midnight – 6 
am) and the full 24-hour period. Only studies with at least 16 recordings within 24-
hours were included in the analysis. Studies with 10 or more daytime recordings were 
deemed suitable for daytime analysis and studies with five or more night-time 
recordings were deemed suitable for nocturnal analysis.  
 
Minimum, mean and maximum (with standard deviations) systolic and diastolic blood 
pressure were calculated for each time period as were mean arterial pressure and heart 
rate. Blood pressure variability was calculated using the standard deviation of the mean 
systolic and diastolic blood pressures for each time period. Diurnal variation was 
calculated by the difference between day and night-time mean BP (i.e. day mean BP 
minus night mean BP) expressed as a percentage of the day mean.  
 
Hypertension was defined according to NICE guidelines as mean daytime BP >135/58 
mmHg. In some studies, participants taking antihypertensive medication or who report a 
past medical history of hypertension are also classed as hypertensive. We chose not 
apply these methods in this study because self reported history of hypertension may be 
inaccurate in older people and many medications with antihypertensive properties are 
frequently prescribed to normotensive patients for other indications for example 
diuretics and beta blockers(Bush et al., 1989). 
 Assessment of Activities of Daily Living 2.5
 Nottingham Activities of Daily Living Scale  2.5.1
The Nottingham Activities of Daily Living Scale is a widely used self-assessment of 
functional independence. It includes 22 activities relevant to daily living divided across 
48 
 
four sections: kitchen, mobility, domestic and leisure activities. Subjects are asked 
which activities they have “actually” done over the preceding week (not which activities 
they think they could do). Four possible responses can be given; “on my own”, “on my 
own with difficulty”, “help”, “not done”. A score of one is assigned if they have done 
the activity on their own or on their own but with difficulty. A score of 0 is assigned if 
they have needed help or not done the activity (Nouri and Lincoln, 1987, Lincoln and 
Gladman, 1992). Scores can be derived for subsections or summed to give an overall 
score.  
 Bristol Activities of Daily Living Scale 2.5.2
The Bristol activity of daily living scale has been validated for use in patients with 
cognitive impairment. The assessment is an informant rated questionnaire covering 20 
daily activities. Items are rated on a four-point scale from totally independent (0) to 
totally dependent (3), with an additional “not applicable” option. The scale has a 
minimum score of 0 indicating total independence and a maximum score of 60, 
indicating total dependence (Bucks et al., 1996).  
 Baseline Assessment of Cognitive Function 2.6
Baseline cognitive assessment was performed in participants’ homes by a trained nurse.  
 MMSE 2.6.1
The Mini Mental State Examination is a 17 item cognitive assessment covering various 
cognitive domains (including orientation, memory, attention and language) (Tombaugh 
and McIntyre, 1992, Folstein et al.). Maximum score achievable is 30. Higher scores 
indicate better cognitive function. Deterioration in cognitive function is indicated by 
decreasing scores over repeated tests (Folstein et al.). A score of 23 or less is generally 
thought to indicate cognitive impairment although cut offs are influenced by age and 
education (Tombaugh and McIntyre, 1992).  
 CAMCOG-R 2.6.2
The CAMCOG-R is part of the Cambridge Mental Disorders of the Elderly 
Examination (CAMDEX) (Roth et al., 1999). It comprises 67 items of which 59 
contribute to the total score.  Items contribute between one and six points to the total 
score. The maximum potential total score is 105. The test assesses orientation, 
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language, memory, attention, praxis, abstract thinking, perception and calculation. Two 
composite subscores can be obtained: the memory subscore (the combined remote, 
recent and learning memory scores) and an executive subscore (which includes two 
additional questions added when the CAMCOG was revised to form the CAMCOG-R). 
The maximum, attainable memory and executive subscores are 27 and 28 respectively.  
 Computerised Drug Research Battery (CDR) 2.6.3
The Cognitive Drug Research (CDR) Battery is a computerised test designed to test 
components of executive function including cognitive process speed, attention and 
concentration. Each test was carried out using a laptop computer and response pad with 
two buttons “yes” and “no”. Instructions were given to participants in a standard 
manner and each session was preceded by a standardised training period. Participants 
completed three tests;  
 Simple reaction time 
Subjects were instructed to place their finger over the “yes” button and 
instructed to press the button as quickly as possible every time the word yes 
appeared on the screen. There were 30 stimuli. 
 Digit vigilance  
A fixed number was presented on the right hand side of the screen. A series of 
numbers appeared one after another on the left of the screen. Participants were 
instructed to press the “yes” button as quickly as possible each time the two 
numbers on the screen matched.  
 Choice reaction time. 
The words “yes” or “no” appeared individually on the screen at random 
intervals. Subjects were instructed to press the matching word on the response 
pad as quickly as possible each time “yes” or “no” appeared on the screen.  
 
All data was processed centrally by CDR, Reading, Berkshire, England. 
In addition to the raw scores, two derived measures were calculated 
 Cognitive reaction time: the choice reaction time minus the simple reaction time 
 Power of attention: the sum of the simple reaction time, choice reaction time and 
the digit vigilance reaction time.  
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 Cornell Depression Scale 2.6.4
The Cornell depression scale was designed to assess depression in people with cognitive 
impairment. A semi-structured interview is conducted with the study participants and 
separately with a relative or friend who has regular contact with the participant. The 
scale enquires about symptoms in the two weeks preceding the interview. Nineteen 
symptoms are reviewed. Each item is scored for its severity (zero if not a problem, one 
if it is a mild or intermittent problem, two if it is a severe or constant problem). The 
final score on the scale represents the interviewer’s clinical impression rather than the 
response of the informant or the participants. A score of 10 indicates probable 
depression. Scores of less than six are unlikely to be associated with depression. 
 Recruitment of 2011 Follow-up Cohort  2.7
To examine the long-term associations of neurocardiovascular instability, participants 
were reviewed in 2011 /2012. The general practice computer database was reviewed to 
identify if participants were alive and still registered with the participating GP. If a 
study participant had died, the date of their death, as documented in the GP notes, was 
recorded. All surviving individuals, who had participated in year 5 follow-up and were 
still registered with the participating General Practice, were invited to participate in this 
phase of the study. Participants who had previously withdrawn from the study were not 
contacted.  
 
Potential participants were sent a letter outlining the purpose of this phase of the study. 
The letter included a patient information sheet describing the study and a copy of the 
consent form they would be asked to sign. The letter explained that a member of the 
research team would contact them in the next few weeks to answer any questions the 
participant may have and to establish if they would be interested in taking part in this 
follow-up.  
 
Letters were sent out in a staggered fashion. Forty participants were contacted at a time, 
grouped by postcode. Two weeks after the letters had been posted a member of the team 
contacted potential participants by phone, explained the study, answered questions and 
booked an appointment to meet with individuals who wished to take part. 
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 Consent to Participation in Follow-up Study 2.8
To obtain participants’ consent the researcher visited all potential participants in their 
own home. The interviewer confirmed that the participant had received and read the 
participant information sheet and consent form. The researcher repeated the explanation 
of the study that had been given over the phone and individuals were given a further 
opportunity to ask questions about the study.   
 
In order to ensure participants had capacity to consent to the study a, “consent pathway" 
was followed. Potential participants were first asked if they were happy to take part in 
the study. If they agreed to take part they were asked three further questions 
 “In a few words, can you tell me what the study is about?” 
 “Can you tell me what would happen to you if you agreed to take part in this 
study?” 
 “What will you do if you change your mind and decide you no longer wish to 
participate in the study” 
Patients who had understood the study were asked to give written informed consent.  
 
If the researcher felt the participant had not fully understood the study, the researcher 
explained it again, offered the participant an opportunity to ask further questions and 
rechecked their understanding. Where the researcher remained concerned that the 
participant did not fully understand the study and lacked capacity, a personal consultee 
was consulted. A personal consultee could be a relative or close friend of the 
participant. In order to act as a personal consultee they needed to be able to advise the 
researcher about the participants likely wishes and feelings in relation to the study.  
 
If a personal consultee was required, an additional information sheet explaining the role 
of a personal consultee was provided. Personal consultees were asked to sign a 
declaration stating that, as far as they were aware, the participant would not object to 
participating in the study.    
 Follow-up Clinical Assessment  2.9
The follow-up study consisted of two home visits. At the first visit a clinical history and 
examination were carried out in accordance with baseline protocol (section 2.2, page 
40). Neurocardiovascular assessment was not carried out at follow-up with the 
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exception of ambulatory blood pressure monitoring which was carried out as described 
in section 2.4, page 46.  
 Follow-up Cognitive Assessment  2.10
The second visit was conducted in participant’s homes. Where possible, friends and 
family members were asked to leave the room during testing to avoid distractions. In 
accordance with baseline assessments, MMSE, CAMCOG, and Cornell Depression 
Score were repeated (see section 2.6 Assessment of Cognitive Function, Page 48). 
 
The Cognitive Drug Research Battery was unavailable at ten year follow-up as the 
manufacturer was no longer supporting analysis of the data. Simple reaction time, 
choice reaction time and digit vigilance reaction time were assessed using The 
Computerised Mental Performance Assessment System (COMPASS) (Northumbria 
University, Newcastle, UK). Data using the two programs are not directly comparable. 
The Cognitive Drug Research Battery cleans long responses (≥2.5 standard deviation 
away from the mean for an individual participant). As a result, reaction times, obtained 
using COMPASS, generally show wider variability than those obtained using CDR. 
Consequently, change in reaction times over the follow-up period, could not be 
accessed in this study.  
 
Participants’ ability with activities of daily living at ten years were assessed using the 
Nottingham and Bristol ADL scales (2.5 Assessment of Activities of Daily Living, page 
47).  
 Magnetic Resonance Imaging  2.11
At the 2011/ 2012 examination all participants without contraindications were invited to 
undergo magnetic resonance scan of the brain. Participants who agreed to MRI were 
asked if they had any of the following; cardiac pacemaker, aneurysm clips, stents, heart 
valve replacement, cochlear implant, shunts, spinal stimulation wire or other implants. 
Where a participant answered yes, their relevant medical notes were reviewed to find 
the make and model of the device. MRI compatibility of the device was checked with 
the manufacturer. If T3 MRI compatibility could not be confirmed, or if it was found to 
be unsafe the participant was excluded from the MRI portion of the study. Participants 
were also excluded from this phase of the study if they reported previous injury with 
metal fragments such as shrapnel or shot. Relevant contraindication to inclusion in the 
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MRI portion of the study included claustrophobia and inability to lie flat for 40 minutes 
due to either pain or breathing difficulties. Participants were required to complete a 
safety questionnaire immediately before the MRI scan to ensure there had been no 
changes to their health.  
 
All scans were performed in the same T3 MRI scanner (Intera Achieva scanner; Philips, 
Eindhoven, the Netherlands) at the Newcastle Magnetic Resonance Centre, Newcastle 
University, UK.  
 
Images acquired included a T1-weighted volumetric sequence covering the whole brain 
(MPRAGE, sagittal acquisition, slice thickness = 1.2 mm, voxel size = 1.15 × 1.15 mm; 
repetition time = 9.6ms; echo time=4.6ms; flip angle = 8 degrees; SENSE factor = 2) 
and FLAIR (TR = 11,000ms; TE = 125ms; inversion time = 2,800ms; SENSE factor = 
1.5; voxel size = 1.02 × 1.02; 50 slice thickness = 3 mm).  
 
Volumetric estimates of global, periventricular, and regional WMHs were obtained for 
each subject. First, statistical parametric mapping was used to partition T1 scan of the 
subjects into grey, white, and cerebrospinal fluid images. From the segmentations, the 
total brain volume of each subject was calculated from grey matter plus white matter. 
Second, each subject’s FLAIR scan was co-registered to its corresponding T1 image in 
native space, and WMHs were identified using a validated automated segmentation 
method (Firbank et al., 2004).  
 
Each scan was visually checked for accuracy by two trained raters, blinded to the 
participants’ clinical characteristics. Total volume of white matter hyperintensities and 
volume of periventricular white matter hyperintensities were calculated. In addition, 
volumes of hyperintensities in each lobe were calculated.   
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 Summary of Study Time Table  2.12
The table below highlights the key stages of the study and the individuals responsible 
for data collection and analysis.  
Figure 2-2 Summary of Study Time Table and Personnel Responsible for 
Assessment and Analysis 
Year Assessment  Personnel  
2002-2004 Clinical Assessment Simon Kerr 
Autonomic Function Test 
and Test of NCVI 
Simon Kerr 
Cognitive Testing Michelle Widdrington  
Baseline Analysis  Simon Kerr 
 
2005 Follow-up Cognitive Testing Michelle Widdrington  
 
2007 Follow-up Cognitive Testing Michelle Widdrington 
 
2011 Follow-up Clinical Assessment Claire McDonald 
Cognitive Testing Claire McDonald 
Magnetic Resonance 
Imaging and Processing 
Newcastle Magnetic 
Resonance Centre 
Visual inspection of 
Magnetic resonance scans 
Claire McDonald 
Ieuan Lewis  
Follow-up Analysis  Claire McDonald  
 
 Statistical Methods  2.13
The long-term associations of NCVI and autonomic dysfunction are the focus of this 
thesis; consequently, only follow-up data from the year 10 assessments will be analysed 
here.  
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Statistical methods relevant to all results chapters are described here. More detailed 
descriptions of statistics relevant to individual chapters are given at the beginning of 
each chapter.  
 
All data was analysed using Statistical Package for Social Science (SPSS) version 19. 
For all tests the level of statistical significance was set at <0.05.  
 
 Responses to active stand, carotid sinus massage and autonomic function 2.13.1
tests have been classified as a categorical or continuous hemodynamic 
response. For example the response to active stand may be categorical if it 
is calcified according to the presence or  OH or absence OH defined 
according to standard criteria. The term continuous haemodynamic 
response is used when BP or HR respone to a stimulus has been used as a 
continuous variable in the analysis e.g. in the case of active stand where the 
size of the systolic BP response is used as an explanatory variable or 
covariate. All BP and HR measurments recorded in this study were 
recorded using beat to beat recordings. Distribution of Data 
Frequency distributions of continuous data were examined to assess if data were 
normally distributed. In addition the Kolmogorov Smirnov statistic and associated P 
value were used assess if data were normally distributed.  
 
Normally distributed data are described using the mean and standard deviation. Non-
parametric data are described using the median and inter quartile. In some rare cases 
data was skewed such that 25
th
, 50
th
 and 75
th
 percentile were identical, in these cases 
range has been used in place of interquartile range.  
 Comparison of Data between Samples 2.13.2
2.13.2.1 Categorical data 
Chi square test was used to test for differences in distribution of categorical 
observations between two groups. For small samples that violated the assumptions of 
the Chi square test Fisher’s exact test was used.   
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2.13.2.2 Continuous data from two independent groups 
Normally distributed data were analysed using the independent t-test 
Non-parametric data were assessed using Mann- Whitney U test.  
2.13.2.3 Continuous data from two related samples 
Normally distributed data were analysed using paired t-test 
Non-parametric data were assessed using Wilcoxon Signed Ranks test.  
2.13.2.4 Association between two continuous variables 
The associations between two continuous variables were initially assessed using 
correlation. Where data were normally distributed Pearson’s correlation co-efficient was 
used. If data were not normally distributed Spearman’s correlation co-efficient was used 
to assess the significance of the correlation.  
2.13.2.5 Association between categorical dependent variables and linear explanatory 
variable.  
Binary logistic regression was used to assess the association between linear explanatory 
variables and categorical dependent variables.  
2.13.2.6 Association between multiple explanatory variables and a dependent variable 
Where the dependent variable was continuous, multi-linear regression was used to 
assess the association between multiple linear and categorical explanatory variables and 
a single continuous dependent variable. Where the dependent variable was categorical 
binary logistic regression with multiple explanatory variables was used.   
 Ethical Approval 2.14
Ethical approval for the baseline study was provided by the County Durham and 
Darlington Local Research Ethics Committee in February 2002. Ethical Approval for 
the Follow-up study was granted by the Nation Research Ethics Service Committee 
North East- Newcastle and North Tyneside one in August 2011.   
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Chapter 3 Description of the Cohort Participating in Ten 
Year Follow-up 
 Recruitment to Ten Year Follow-up 3.1
Review of GP medical records in October 2011 revealed that of the 209 individuals who 
participated in five-follow-up, 27 had died and 16 were no longer registered with the 
general practice. Of the remaining 166 individuals, 54 declined to participate in this 
phase of the study and eight could not be contacted, despite two letters and three phone 
calls. Thus 104 individuals consented to participate in this follow-up phase (Figure 3-1 
Flow Chart of Patient Recruitment and Follow-up). Follow-up participants’ median age 
was 79 (range 74-92) and 55% were male.  
 
 
  
Baseline cohort = 352 
2 year follow-up = 278 
5 year follow-up = 209 
10 year follow-up 104 
Loss to follow-up = 74
• Died = 13 
• Withdrawn = 18 
• Left GP = 5 
• Loss to follow-up = 38 
Loss to follow-up = 105 
• Died = 27 
• Withdrawn = 54 
• Left GP = 16 
• No response  = 8 
Loss to follow up = 69 
• Died = 16 
• Withdrawn = 25 
• Left GP = 13 
• Loss to follow-up = 15 
Figure 3-1 Flow Chart of Patient Recruitment and Follow-up 
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 Comparison of Ten Year Follow-up Participants and Participants 3.2
Lost to Follow-up   
 Comparison of Demographics and Baseline Clinical Characteristics  3.2.1
Data from the baseline study was used to compare baseline characteristic of the 104 
individuals participating in this follow-up with the 248 individuals lost to follow-up. 
Follow-up participants were significantly younger than non-participants [median age at 
baseline 70 years (range 65, 83) versus 74 years (65, 93) respectively (P < 0.001)].  
 
Baseline clinical characteristics and cardiovascular risk factors for the two groups are 
shown in Table 3-1. The groups were well matched in terms of sex, smoking status and 
alcohol use. There were no significant differences in the proportion of participants 
reporting a past medical history of hypertension, diabetes, ischaemic heart disease 
(IHD), cerebrovascular disease (CVD), peripheral vascular disease and hyperlipidaemia 
at baseline. Use of antihypertensive medication, cardioactive medication and 
psychoactive medication were similar between the two groups at baseline.  
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Table 3-1 Baseline Characteristics for Individuals Participating in the Ten Year 
Follow-up and Non-participants.  
Variable Participants 
N = 104 
Non- participants 
N = 248 
P 
 Frequency (%) Frequency (%)  
Sex (male) 57 (55) 143 (58) 0.62 
Smoker at baseline 8 (7.7) 21 (8.4) 0.81 
Ex-smoker at baseline 65 (63) 147 (59) 0.57 
Alcohol use at baseline 73 (61) 164 (66) 0.40 
Past Medical History at Baseline 
Ischaemic heart disease 22 (21) 68 (27) 0.22 
Hypertension  33 (32) 89 (39) 0.46 
Diabetes  4 (3.8) 19 (7.6) 0.24 
Cerebrovascular disease  8 (7.6) 31 (13) 0.19 
Peripheral vascular disease  6 (5.7) 31 (13) 0.06 
Hyperlipidaemia  36 (34) 74 (30) 0.38 
Pacemaker 0 (0) 3 (1.2) 0.56 
Medication Use at Baseline 
Any antihypertensive medication 48 (46) 113 (46) 0.92 
Any cardioactive medication 51 (49) 134 (45) 0.39 
Any psychoactive medication 15 (14) 46 (19) 0.35 
 
 Comparison of Baseline Falls History  3.2.2
Baseline characteristics in terms of history of falls, recurrent falls and injurious falls did 
not significantly differ between year ten participants and participants lost to follow-up 
(Table 3-2).   
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Table 3-2: Prior Symptoms of Falls, Syncope and Dizziness at Baseline for Year 10 
Follow-up Participants and Non-Participants 
Variable Follow-up Participants 
N = 104 
Non- participants  
N = 248 
P 
 Frequency (%) Frequency (%)  
Faller 45 (43) 116 (47) 0.55 
Recurrent Falls 10 (9.6) 31 (13) 0.59 
Injurious Falls 20 (19) 50 (20) 0.89 
    
 Median (range) Median (range)  
Number of falls in 12 
months 
0 (0 -100) 0 (0-50) 0.96 
 Comparison of Baseline Tinetti Gait and Balance Scores 3.2.3
At baseline, compared to follow-up participants, participants lost to follow-up 
performed more poorly on Tinetti assessments of balance (Table 3-3). Although the 
median Tinetti gait scores at baseline for the two groups were similar the range of 
Tinetti scores was significantly wider for the group of individuals not participating in 
follow-up assessment.  
 
Table 3-3: Baseline Tinetti scores for Year 10 Participants and Non-Participants 
 Year 10 Participants 
N=104 
Non- participants 
N = 248 
P 
 Median (range) Median (range)  
Tinetti Balance 25 (12, 26) 24 (3, 26) 0.001 
Tinetti Gait 9 (6, 9) 9 (0, 9) 0.002 
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 Comparison of Baseline Activity of Daily Living Scores  3.2.4
Similarly, although the median ADL scores at baseline were similar for the two groups, 
individuals not participating in the follow-up examination had a significantly wider 
distribution of scores (Table 3-4 ).  
 
Table 3-4 Comparison of Baseline ADL scores for Year 10 Follow-up Participants 
and Non-Participants 
 Follow-up 
Participants N=104 
Non- participants 
N = 248 
P 
 Median (range) Median (range)  
Bristol ADL 0 (0, 6) 0 (0, 26) <0.001 
Nottingham ADL 22 (15, 22) 21 (8, 22) <0.001 
 Comparison of Baseline Cognitive Function 3.2.5
Three hundred and thirteen individuals underwent cognitive testing at baseline. All ten 
year follow-up study participants had undergone full cognitive testing at baseline. 
Median ages on leaving education and median years in education were the same for 
participants and non-participants; however, distribution of data differed significantly, 
with greater numbers of non-participants leaving school at an earlier age, with fewer 
years in education (Table 3-5). 
 
Compared with participants lost to follow-up, follow-up participants performed 
significantly better on MMSE and CAMCOG assessments at baseline. Comparing CDR 
results for follow-up participants and non-participants revealed that non-participants had 
significantly longer reaction times on the choice reaction time tests, digit vigilance 
reaction time test and tests of power of attention, indicating poorer cognition. Simple 
reaction times and cognitive reaction times at baseline did not differ significantly 
between follow-up participants and non-participants. Baseline Cornell depression scores 
did not differ between follow-up participants and non-participants (Table 3-5).  
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Table 3-5: Baseline Cognitive Function for Year 10 Follow-up Participants and 
Non-participants 
Variable Year 10 Participants 
N = 104 
Non- participants 
N = 209 
P 
 Median (range) Median (range)  
Age on leaving education 15 (14, 26) 15 (11, 25) <0.01 
Years in education 10 (9, 21) 10 (6, 20) <0.01 
     
MMSE 29 (25, 30) 28 (20, 30) <0.01 
CAMCOG Total Score 97 (92,103) 94 (64, 104) <0.01 
CAMCOG Memory Score 24 (18, 27) 23 (7, 27) <0.01 
CAMCOG Executive Score 22 (14, 28) 19 (8, 27) <0.01 
     
Simple Reaction Time (ms) 332 (219, 987) 351 (221, 1611) 0.05 
Choice Reaction Time (ms) 511 (371, 801) 537 (374, 1125) <0.01 
Digit Vigilance (ms) 446 (339, 707) 474 (357, 746) <0.01 
Power of attention (ms) 1298 (1046, 2270) 1367 (1020, 2786) <0.01 
Cognitive Reaction Time 
(ms) 
161 (-341, 348) 180 (-913, 629) 
0.14 
     
Cornell depression scale 2 (0, 26) 3 (0, 13) 0.74 
 Frequency (%) Frequency (%)   
Cornell depression scale >10 8 (8) 15 (7) 0.86 
MMSE ≤24 0  6 (3) 0.18 
CAMCOG ≤80 0 15 (7) <0.01 
 Comparison of Baseline Ambulatory Blood Pressure Recordings.  3.2.6
Three hundred and forty six participants underwent 24-hour ambulatory blood pressure 
monitoring (ABPM) at baseline. Of these, 338 had a minimum of 16 recordings over the 
24-hour period, 333 had ten or more daytime recordings, and 311 had five or more 
nocturnal recordings.  
 
Incidence of hypertension on ABPM, at baseline as defined by NICE (BP>135/85) did 
not significantly differ between follow-up participants and non-participant (45% versus 
48% respectively, P=0.51). Mean daytime systolic BP was lower for follow-up 
participants than non-participants, but this did not quite reach statistical significance 
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(P=0.07) (Table 3-6). Daytime systolic and diastolic variability however were 
significantly greater for non-participants than participants (Table 3-6). Mean nocturnal 
mean systolic BP was significantly lower for follow-up participants versus non-
participants (Table 3-7). Mean 24-hour mean systolic BP was lower in follow-up 
participants than non-participants (Table 3-8).  
 
Table 3-6: Baseline Daytime ABPM results for Ten Year Follow-up Participants 
and Non -participants 
Variable Follow-up 
Participants 
Non- 
participants 
P 
 Mean (SD)  Mean (SD)  
DAY N=101 N=231  
Mean SBP (mmHg) 132 (15.8) 135 (14.4) 0.07 
Mean DBP (mmHg) 76 (8.0) 76 (10) 0.60 
SD SBP (mmHg) 11 (3.4) 13 (4.2) 0.02 
SD DBP (mmHg) 7.8 (2.3) 8.4 (2.4) 0.04 
 
 
Table 3-7 Baseline nocturnal ABPM results for Ten Year Follow-up Participants 
and Non-participants 
Variable Follow-up 
Participants 
Non- 
participants 
P 
 Mean (SD)  Mean (SD)  
Night N=91 N=220  
Mean SBP (mmHg) 116 (13.1) 120 (16.3) 0.01 
Mean DBP (mmHg) 63 (8.2) 64 (8.4) 0.38 
SD SBP (mmHg) 9 (3.7) 9 (3.9) 0.68 
SD DBP (mmHg) 7 (2.9) 7 (3.0) 0.87 
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Table 3-8 Baseline 24-hour ABPM results for Ten Year Follow-up Participants 
and Non-participants  
Variable Follow-up 
Participants 
Non- 
participants 
P 
 Mean (SD)  Mean (SD)  
24-hour N = 103 N = 235  
Mean SBP (mmHg) 127 (14.1) 130 (14.1) 0.04 
Mean DBP (mmHg) 72 (8.9) 72 (7.5) 0.92 
SD SBP (mmHg) 13 (3.3) 14. (3.8) 0.08 
SD DBP(mmHg) 9.5 (2.3) 9.7 (2.3) 0.46 
 
Comparing participants with non-participants did not reveal any statistically significant 
differences in systolic or diastolic diurnal variation between groups (Table 3-9). 
 
Table 3-9 Diurnal Variation at Baseline for Year 10 Follow-up Participants and 
Non-Participants  
Variable Follow-up 
Participants 
Non- 
participants 
P 
 Mean (SD)  Mean (SD)  
Diurnal variation N=89 N=213  
Systolic % 0.11 (0.08) 0.11 (0.09) 0.93 
Diastolic % 0.16 (0.09) 0.15 (0.08) 0.48 
 Comparison of Response to Active Stand at Baseline  3.2.7
Active stand was performed in 318 participants at baseline. Of the 104 participants who 
underwent follow-up examination at ten years, 98 had results available from baseline 
active stand. Prevalence of OH as defined by the American Academy of Neurology and 
subtypes of OH did not significantly differ between those participating in the follow-up 
and those not participating. Similarly, systolic or diastolic; baseline blood pressure, 
nadir reached during stand or degree of vasodepression did not significantly differ 
between the groups (Table 3-10).  
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Table 3-10: Response to Active Stand at Baseline for Year 10 Participants versus 
Non-Participants 
Variable Follow-up 
Participants 
N = 98 
Non- participants 
N = 220 
P 
 Frequency (%) Frequency (%)  
OH Positive 80 (82) 181 (82) 0.89 
Systolic OH Positive 63 (64) 146 (66) 0.72 
Diastolic OH Positive 71 (72) 154 (70) 0.66 
 Mean (SD) Mean (SD)  
Systolic Nadir (mmHg) 113 (27.3) 118 (20.1) 0.12 
Diastolic Nadir (mmHg) 47 (14.1) 47 (13.0) 0.91 
Systolic Vasodepression (mmHg) 28 (18.0) 25 (17.4) 0.18 
Diastolic Vasodepression (mmHg) 15 (9.5) 28 (18.1) 0.93 
 Comparison of Response to Carotid Sinus Massage (CSM) at Baseline.  3.2.8
Two hundred and seventy two individuals consented to carotid sinus massage at 
baseline. Of the 104 assessed at ten year follow-up, 90 consented to CSM at baseline. 
There was no significant difference in incidence of CSH or CSH subtypes between 
follow-up participants and non-participants. Maximum RR interval post CSM and 
maximum delta RR were lower in follow-up participants than non-participants. 
Vasodepression and systolic nadir post CSM did not differ significantly between groups 
(Table 3-11).  
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Table 3-11: Comparison of Response to CSM at Baseline at Baseline for Ten Year 
Follow-up Participants and Non-participants 
Variable Year 10 
Participants 
N = 90 
Non- participants 
N = 182 
P 
 Frequency (%) Frequency (%)  
CSH 28 (31) 78 (43) 0.06 
Cardioinhibitory CSH 2 (2) 4 (2) 1 
Vasodepressive CSH 12 (13) 30 (16) 0.50 
Mixed CSH 14 (15) 44 (24) 0.10 
    
 Median  
(IQ range) 
Median  
(IQ range) 
 
Maximum RR  interval (ms)  1481 (1156, 2391) 1816 (1304, 3345) 0.03 
Maximum delta RR (ms) 549 (232, 1372) 866 (63, 2286) 0.04 
SBP Vasodepression 
(mmHg) 
43 (30, 53) 46 (32, 60) 0.13 
SBP Nadir (mmHg) 81 (68, 101) 79 (63, 98) 0.18 
 Comparison of Response to Autonomic Function Tests at Baseline 3.2.9
Ninety of the follow-up participants and 190 of the non-participants completed 
sufficient autonomic function tests to define autonomic function as normal or abnormal 
according to Modified Ewing criteria at baseline. There were no significant differences 
in the incidence of abnormal autonomic function between groups (non-participants 
=33.6% v follow-up participants =32.2%, P=0.89).   
 
Continuous response to individual autonomic function tests was compared for follow-up 
participants versus non participants. Non-participants had a significantly larger systolic 
BP overshoot in response to Valsalva manoeuvre. There was a trend towards greater 
heart response to deep breathing and greater Valsalva ratio in participants but this did 
not quite reach statistical significance (P=0.08 in both cases) (Table 3-12). 
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Table 3-12 Comparison of Response to Autonomic Function Tests at Baseline for 
Ten Year Follow-up Participants and Non-participants 
 Non-
Participants 
Participants P 
 Median (IQR) Median (IQR)  
30:15 ratio 1.34 (1.08, 1.20) 1.13 (1.05, 1.21) 0.64 
Diastolic BP response to 
Isometric exercise (mmHg) 
13.0 (4.00, 19.0) 12.0 (5.0, 19.8) 0.97 
Diastolic BP response to cold 
pressor test 
8.5 (3.0, 15.0) 9.0 (3.0, 15.0) 0.67 
Heart rate response to deep 
breathing 
6.6 (4.2, 9.9) 7.8 (5.0, 11.5) 0.08 
Systolic BP over shoot in 
response to Valsalva 
21.5 (6.8, 37.5) 25.5 (11.8, 53.0) 0.04 
Valsalva ratio 1.4 (1.3, 1.6) 1.5 (1.3, 1.7) 0.08 
 
 Comparison of Heart Rate Variability at Baseline 3.2.10
Two hundred and ninety five individuals had heart rate variability recordings performed 
at baseline. Of these 280 had studies where <10% of beats were interpolated or edited. 
Eighty-three individuals participated in the follow-up study and had baseline HRV 
recordings suitable for analysis.  Baseline HRV parameters did not differ significantly 
between individuals participating in the follow-up study and those lost to follow-up 
(Table 3-13).   
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Table 3-13: Baseline Heart Rate Variability for Ten Year Follow-up Participants 
and Non-participants  
Variable Year 10 Participants 
N = 83 
Non- participants 
N = 197 
P 
 Median (range) Median (range)  
RRSD 27.4 (19.2, 43.5) 25.7 (18.7, 35.5) 0.76 
Total power (mm
2
) 439 (250, 829) 388 (182, 873) 0.92 
VLF (ms
2
) 140 (83.7, 285) 160 (67.5, 347) 0.96 
LF (ms
2
) 173 (79.3, 292) 137 (60.2, 350) 0.62 
HF (ms
2
) 65.3 (28.4, 137) 65.5 (30.8, 157) 0.97 
HF/LF 0.39 (0.26, 0.81) 0.43 (0.23, 0.86) 0.66 
 
 Summary 3.3
In conclusion, individuals participating in the ten year follow-up study were younger 
than participants lost to follow-up and performed better on cognitive function tests at 
baseline than individuals lost to follow-up. Individuals lost to follow-up were less 
independent with activities of daily living at baseline and performed more poorly on 
assessments of gait and balance. In terms of past medical history and medication use at 
baseline the two groups did not significantly differ. Of the tests of NCVI only the RR 
interval post carotid sinus massage differed between follow-up participants and 
participants lost to follow-up. Finally, ambulatory blood pressure monitoring showed 
that ten year follow-up participants tended to have lower nocturnal and 24-hour systolic 
blood pressure than non-participants and had lower daytime blood pressure variability.   
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Chapter 4 The Long-term Associations between Autonomic 
Function, Neurocardiovascular Instability and Cognition 
 Introduction 4.1
Several studies have shown a relationship between impaired cognitive function and 
hypertension (Sharp et al., 2011, Nagai et al., 2010, Birns and Kalra, 2009, Eftekhari et 
al., 2007). Chronic hypotension, particularly among older people, has been associated 
with cognitive impairment and cognitive decline (Power et al., 2011, Guo et al., 1996, 
Morris et al., 2000, Hestad et al., 2005, Richmond et al., 2011). Disorders of 
neurocardiovascular instability (NCVI), notably orthostatic hypotension and carotid 
sinus hypersensitivity, have been shown to be more common among people with 
dementia, and NCVI has been associated with poorer performance on cognitive tests in 
community cohorts (Andersson et al., 2008, Mehrabian et al., 2010, Matsubayashi et al., 
1997, Kenny et al., 2004, Yap et al., 2008, Pearce, 2007). Similarly, abnormal 
autonomic function in the form of reduced heart rate variability and impaired response 
to autonomic function tests have been shown to be more evident in people with 
cognitive impairment and dementia (Allan et al., 2007, Algotsson et al., 1995, Allan et 
al., 2005, Elmstahl et al., 1992, Giubilei et al., 1998, Kim et al., 2006).    
 
The direction of the association between impaired neurocardiovascular function and 
cognition remains unclear (Rose et al., 2010, Britton et al., 2008).  It is hypothesised 
that failure of neurocardiovascular autoregulation to maintain peripheral blood pressure 
may result in recurrent cerebral hypoperfusion, in turn causing cerebral white matter 
disease resulting in among other symptoms cognitive impairment and cognitive decline.  
 Aim 4.2
To examine the long-term association between neurocardiovascular instability, 
autonomic function and cognition in community-dwelling older people.  
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  Methods 4.3
 Tests of Neurocardiovascular Function 4.3.1
Tests of neurocardiovascular function performed at baseline are described in detail in 
section 2.3, page 42.  
 Cognitive tests 4.3.2
Cognitive tests used included MMSE, CAMCOG total scores, CAMCOG memory and 
CAMCOG executive. Simple Reaction Time, Complex Reaction Time, Digit Vigilance 
Time, Power of Attention and Cognitive Reaction Time. These were described in 
section 2.6, page 48.  
 Defining Outcome Variables 4.3.3
Analysis of change in cognition is complex and presents a number of methodological 
challenges. Four methods have therefore been used to examine cognition at follow-up 
and change in cognition 
4.1.1.1 Cognitive Performance at Follow-up 
In each case, the association between baseline blood pressure or heart rate variable and 
raw cognitive score / reaction time at follow-up has been examined.  
4.1.1.2 Change in MMSE and CAMCOG Scores 
Change in cognitive score was calculated by subtracting follow-up score from baseline 
score. Negative integers therefore indicate an increase/improvement in cognitive 
function while positive integers indicate a decline/ worsening of cognitive function. 
4.1.1.3  Cognitive Decline 
Reliable change indices (RCI) aim to determine the amount of change in a cognitive test 
score that is necessary to be deemed statistically reliable. It estimates the probability 
that change in a test score between assessments is due to a change in an individual’s 
ability to perform the task, not due to measurement error, practice effect and / or 
regression to the mean. Two authors have published RCI for the MMSE in this age 
group ranging from 4-5 points (Stein et al., 2010, Hensel et al., 2007). Studies 
suggesting an RCI of five points have included patients who developed dementia,  
where as those reporting and RCI of 4 or less have included only “cognitively intact 
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older individuals” (Hensel et al., 2007). Baseline variables associated with a drop of 
four or more points in the MMSE was therefore examined in this study, as there were 
few participants with dementia.   
 
Published reliable change indices are not available for the total CAMCOG. Changes in 
total CAMCOG scores were reviewed. Several individuals had undergone a decline in 
total CAMCOG score of five or more points. None had increased by five or more 
points. Baseline variables associated with dropping five or more points on the 
CAMCOG over the follow-up period were therefore examined. 
4.1.1.4 Cognitive Impairment 
Finally, participants were defined as cognitively impaired or cognitively normal 
according to their MMSE and CAMCOG scores. A cut off of  <24 was chosen to 
indicate cognitive impairment for the MMSE and is associated with 87.0%  sensitivity 
and 82.4% specificity for dementia / delirium (Anthony et al., 1982). For the 
CAMCOG, a cut-off score of 80 was chosen. This has been associated with a 92% 
sensitivity and 96% specificity (Roth et al., 1986). Incident cognitive impairment was 
defined as having a CAMCOG>80 at baseline but CAMCOG ≤80 at follow-up or 
having an MMSE≥24 at baseline but <24 at follow. 
 Statistics  4.4
 Comparison between Baseline and Follow-up Cognition  4.4.1
Baseline and follow-up cognitive scores were compared using the Related Samples 
Wilcoxon Signed Rank Test. Incidence of cognitive impairment at baseline and follow-
up were compared using Chi square tests. Where one or more cells had an expected 
count of less than five, Fisher’s exact test was used. Correlation between baseline 
reaction times and follow-up reaction times were examined using Pearson’s Correlation 
Coefficient.  
 Association between baseline neurocardiovascular assessment and cognition 4.4.2
at follow-up 
Non-normally distributed data were compared between groups using the Mann-Whitney 
U test. Normally distributed data were compared using a T-test.  
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 Covariates  4.4.3
 Multivariable linear regression analysis and multiple logistic 4.5
regression adjusted for age, sex and risk factors known to be 
associated with cognitive function and blood pressure. They 
included:  number of years in education, smoking status, alcohol 
consumption, PMH of diabetes, PMH of cardiovascular or 
cerebrovascular disease, use of psychoactive medication, use of 
cardioactive medication, Cornell depression score and relevant 
cognitive score at baseline Results 
 Cognitive Function at Ten Year Follow-up 4.5.1
Of the 104 individuals participating in the follow-up assessment, two individuals 
withdrew prior to cognitive assessment, one died and one individual was registered 
blind and unable to complete the cognitive tests. Data from another individual with 
severe visual impairment were excluded from the analysis, as she was unable to 
complete the full battery of cognitive tests. Hence, 99 individuals completed the full 
battery of cognitive tests at baseline and ten years follow-up.  
 Comparison of CAMCOG and MMSE scores at Baseline and Follow-up 4.5.2
MMSE and CAMCOG scores at baseline and MMSE and CAMCOG scores at ten-year 
follow-up examination were compared for the 99 individuals who underwent cognitive 
testing at both assessments. MMSE, CAMCOG total, CAMCOG memory and 
CAMCOG executive scores were all significantly lower at ten year follow-up than at 
baseline (P<0.001 in all cases) (Table 4-1).  
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Table 4-1: CAMCOG and MMSE Scores at Baseline and Follow-up 
Variable Baseline scores 
N = 99 
Ten Year Follow-
up N = 99 
P 
 Median  
(IQR range) 
Median  
(IQR range) 
 
MMSE 29.0 (28.0, 30.0) 28.0 (26.0, 30.0) <0.001 
CAMCOG Total Score 98.0 (94.0, 100.0) 94.0 (90.0, 97.0) <0.001 
CAMCOG Memory Score 24.0 (22.0, 24.0) 23.0 (21.0, 24.0) <0.001 
CAMCOG Executive Score 22 (19.0, 24.0) 20.0 (17.0, 23.0) <0.001 
 
At baseline, all participants achieved a total CAMCOG score of 80 or more and MMSE 
score of 24 or more, indicating none had cognitive impairment. Four individuals were 
found to have a CAMCOG score of ≤80 at follow-up. This increase was not statistically 
significant. Similarly, four individuals were found to have MMSE score of <24 at ten 
years but this increase was not significant. As non of the ten year follow-up participants 
had an MMSE <24 or total CAMCOG ≤80 at baseline these individual were defined as 
having incident cognitive impairment. Only one individual had a total CAMCOG ≤80 
and an MMSE ≤23 (Table 4-2).  
 
Table 4-2: Cognitive Impairment at Baseline and Follow-up 
Variable Baseline scores 
N = 99 
Ten Year Follow-
up N = 99 
P 
 Frequency Frequency  
MMSE <24 0 4 0.12 
Total CAMCOG score ≤80 0 4 0.12 
 
 Change in CAMCOG and MMSE Over Ten Year Follow-up 4.5.3
The majority of subjects showed a decrease in MMSE score and in all domains of the 
CAMCOG. However, no change in cognitive scores or an improvement in cognitive 
scores was not uncommon (Table 4-3). Seven individuals showed an improvement on 
both the MMSE and CAMCOG total score. Median decrease in MMSE was one point. 
Median decrease total CAMCOG over follow-up was 4 points (Table 4-4).  
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Table 4-3 Number of Participants Showing a Decrease, No Change or an Increase 
in CAMCOG and MMSE Score over Ten year Follow-up 
 
Table 4-4 Change in MMSE and CAMCOG Score Over Follow-up  
 Change in cognition  
baseline score minus score at ten years 
Median ( IQ range) 
MMSE 1.0 (0, 2.0) 
CAMCOG total score 4.0 (1.0, 7.0) 
CAMCOG memory score 0 (0, 2.0) 
CAMCOG executive score 1.0 (-1.0, 3.0) 
 
Ten individuals showed a decrease of four or more points on the MMSE. Only one 
individual showed an increase of four or more points on MMSE (Figure 4-1). Forty-four 
participants showed a decline of five or more points on the total CAMCOG score. By 
contrast, only 17 participants showed an increase in total CAMCOG score. The 
maximum increase observed was 4 points (Figure 4-2).     
 
 Decrease in 
score of ≥ 1 
point 
 
No change in 
score 
Increase in 
score  of ≥ 1 
point 
 Frequency Frequency Frequency 
MMSE 60 22 17 
CAMCOG total score 79 3 17 
CAMCOG memory score 49 26 24 
CAMCOG executive score 58 14 27 
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Figure 4-1 Histogram Showing Change in MMSE Score (Negative results indicate 
an increase in score over ten year follow-up) 
 
 
Figure 4-2 Histogram Showing Change in Total CAMCOG Score (Negative results 
indicate an increase in score over ten year follow-up) 
 
 Reaction Times at Ten Year Follow-up  4.5.4
All ninety-nine individuals completing MMSE and CAMCOG also completed 
assessment of reaction times using Computerised Mental Performance Assessment 
System (COMPASS) (Table 4-5). All COMPASS scores at year 10 follow-up, except 
CRT, were correlated with equivalent baseline CDR score (r range from 0.32 – 0.59) 
(Table 4-6).  
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Table 4-5 COMPASS Results at Follow-up 
 Median (IQ range)  
Choice Reaction Time (ms) 622.4 (562.2, 671.5) 
Simple Reaction Time (ms) 445.3 (407.5, 522.8) 
Digit Vigilance Reaction Time (ms) 545.0 (515.1, 584.5) 
Cognitive Reaction Time (ms) 159.7 (113.1, 223.4) 
Power of Attention (ms) 1648.0 (1512.0, 1793.2) 
 
 
Table 4-6 Correlation between Baseline CDR Results and Equivalent COMPASS 
Result at Follow-up  
    Year 10 COMPASS results 
Baseline CDR results 
Simple 
Reaction 
Time 
(ms) 
Choice 
Reaction 
Time 
(ms) 
Digit 
Vigilance 
(ms) 
Cognitive 
Reaction 
Time (ms) 
Power of 
Attention 
(ms) 
Simple Reaction 
Time (ms) 
r 0.32         
P 0.002         
Choice Reaction 
Time (ms) 
r   0.42       
P   <0.001       
Digit Vigilance 
(ms) 
r     0.59     
P     <0.001     
Cognitive 
Reaction Time 
(ms) 
r       0.07   
P       0.50   
Power of 
Attention (ms) 
r         0.51 
P         <0.001 
 
 Ambulatory Blood Pressure Monitoring and Cognitive 4.6
Performance at Follow-up  
Of the 99 individuals who underwent cognitive testing at ten year follow-up, ninety-
eight had ambulatory BP monitored at baseline.  
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 Baseline Hypertension and Cognition at Follow-up  4.6.1
Ninety-six individuals had ten or more daytime recordings and therefore had sufficient 
data to calculate if they were hypertensive at baseline according to NICE guidelines 
(mean daytime BP > 135/85). There were no differences in cognitive function at ten 
years for individuals with mean daytime BP >135/85 on ABPM at baseline and those 
without (Table 4-7). Similarly, there were no associations between hypertension status 
and change in cognition over follow-up period (Table 4-8) 
 
Table 4-7 Cognitive Function at Follow-up by Baseline Hypertension Status (Mean 
Daytime BP ≥ 135/85)  
Variable No Hypertension  
N= 52 
 
Hypertension 
N= 44 
P 
 Median  
(IQ range) 
Median  
(IQ range) 
 
MMSE 29.0 (27.0, 29.0) 28.0 (25.0, 29.0) 0.60 
CAMCOG total  94.5 (90.0, 97.0) 93.0 (89.0, 97.0) 0.44 
CAMCOG memory  23.0 (21.3, 24.0) 23.0 (21.0, 24.0) 0.99 
CAMCOG executive  21.0 (17.3, 23.8) 19.0 (17.0, 22.8) 0.24 
CRT (ms) 622.2 (553.8, 679.6) 618.6 (562.2, 669.0) 0.64 
SRT (ms) 436.8 (398.0, 499.8) 455.8 (410.2, 544.9) 0.27 
VigRT (ms) 545.5 (516.0, 588.2) 537.4 (511.9, 537.4) 0.62 
CogRT (ms) 162.6 (126.4, 256.6) 155.2 (95.9, 189.5) 0.11 
POA (ms) 1650 (1508, 1753) 1638 (1486, 1850) 0.79 
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Table 4-8 Change in MMSE and CAMCOG Scores by Baseline Hypertension 
Status (Hypertension = Mean Daytime BP ≥ 135/85) 
Variable No Hypertension  
N= 52 
 
Hypertension 
N= 44 
P 
 Median  
(IQ range) 
Median  
(IQ range) 
 
Change in MMSE 1.0 (0.0, 2.0) 1.0 (0.0, 2.8) 0.37 
Change in CAMCOG 
total  
3.0 (1.0, 7.0) 5.0 (1.3, 7.8) 0.32 
Change in CAMCOG 
memory  
0.0 (-1.0, 2.0) 1.0 (0.0, 2.0) 0.73 
Change in CAMCOG 
executive  
1.0 (-1.0, 2.8) 2.0 (0.0, 5.0) 0.12 
 
Hypertension status at baseline was not associated with either an MMSE score <24 
points at follow-up or a CAMCOG total score of ≤80 at follow-up (Table 4-9).  
 
Table 4-9 Association between Hypertension at Baseline and Cognitive 
Impairment at Follow-up 
Variable No Hypertension  
N= 52 
Hypertension 
N= 44 
P 
 Number (%) Number (%)  
MMSE  <24 3 (5.7) 1 (2.2) 0.62 
CAMCOG ≤80 3 (5.7) 1 (2.2) 0.62 
 
Hypertension at baseline was associated with dropping five or more points on the total 
CAMCOG score (P= 0.03), but it was not associated with a drop in MMSE score of 
four or more points (Table 4-10). The association between baseline hypertension status 
and decline in CAMCOG total of ≥ 5 points remained after adjusting for covariates 
(Table 4-11).  
 
79 
 
Table 4-10 Association between Hypertension at Baseline and Cognitive Decline at 
Follow-up 
Variable No Hypertension  
N= 52 
Hypertension 
N= 44 
P 
 Number (%) Number (%)  
Drop in MMSE of  ≥4 points 5 (8.7) 5 (11.4) 1.00 
Drop in total CAMCOG ≥ 5 points 18 (31.5) 25 (56.8) 0.03 
 
Table 4-11 Logistic Regression Examining independent Association Between 
Hypertension at baseline and Fall of ≥ 5 Points on CAMCOG Total Score over 
Follow-up 
  
OR 
95% C.I. 
P Lower Upper 
Age 1.16 1.03 1.31 0.02 
Sex 1.04 0.38 2.85 0.94 
Diabetes 2.74 0.16 46.64 0.49 
Current smoker (Y/N) 0.62 0.11 3.51 0.59 
Cardioactive medication 1.75 0.61 5.01 0.30 
Years in education 1.00 0.84 1.18 0.96 
Any Cardiovascular or Cerebrovascular 
Disease 
0.56 0.19 1.67 0.30 
Any Psychoactive Medication 1.40 0.37 5.29 0.62 
Consumes Alcohol (Y/N) 1.85 0.60 5.77 0.29 
Cornell Depression Score 1.14 0.99 1.32 0.06 
Baseline Total CAMCOG Score 0.93 0.81 1.06 0.28 
Hypertension 3.01 1.16 7.81 0.02 
 
Because the NICE criteria are stricter than many definitions of hypertension these 
analyses were repeated with hypertension defined as a mean daytime BP greater than 
150/90. This did not reveal any additional significant associations between hypertension 
and cognitive function at year 10 or change in cognitive function. 
 Daytime Ambulatory Blood Pressure at Baseline and Cognition Follow-up 4.6.2
CAMCOG and MMSE scores at ten years were not associated with daytime mean BP or 
BP variability. Lower mean systolic BP was associated with longer cognitive reaction 
times and longer choice reaction times, indicating poorer cognition (Table 4-12). 
Greater daytime diastolic BP variability was associated with longer digit vigilance 
reaction time (Table 4-12). After adjusting for potential covariates, only the association 
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between mean daytime systolic BP and cognitive reaction time remained significant 
(Table 4-13).  
 
Table 4-12 Spearman Correlation between Daytime Ambulatory BP Results and 
Cognitive Scores at Follow-up 
 Day mean 
systolic 
pressure  
(mmHg) 
Day mean 
diastolic 
pressure  
(mmHg) 
Day time SD 
SBP (mmHg) 
Day time SD 
DBP (mmHg) 
MMSE r -0.05 -0.09 -0.05 -0.04 
P 0.61 0.38 0.66 0.70 
CAMCOG total 
score 
r -0.01 0.05 -0.14 -0.11 
P 0.93 0.64 0.19 0.28 
CAMCOG 
memory score 
r 0.00 0.07 -0.07 -0.05 
P 0.99 0.51 0.52 0.65 
CAMCOG 
executive score 
r -0.03 -0.02 -0.18 -0.20 
P 0.79 0.88 0.08 0.05 
CRT (ms) r -0.22 -0.10 0.03 0.13 
P 0.03 0.32 0.79 0.22 
SRT (ms) r 0.10 -0.08 0.05 0.03 
P 0.32 0.45 0.66 0.79 
VigRT (ms) r -0.11 -0.02 0.15 0.23 
P 0.28 0.82 0.15 0.03 
CogRT(ms) r -0.26 -0.04 -0.01 0.09 
P 0.01 0.69 0.95 0.36 
POA (ms) r -0.11 -0.10 0.07 0.15 
P 0.28 0.32 0.50 0.15 
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Table 4-13 Multiple Linear Regression Examining Independent Associations 
between Daytime Mean Systolic BP and Cognitive Reaction Time.  
 
B 
95.0% Confidence 
Interval for B P 
Age (years) -1.16 -9.40 7.08 0.78 
Sex -12.64 -96.40 71.13 0.76 
Hypertension 23.97 -62.63 110.56 0.58 
Cardioactive medication -73.43 -164.01 17.15 0.11 
Years in education 4.73 -7.70 17.16 0.45 
Psychotropic medication 30.79 -61.63 123.21 0.51 
Diabetes 17.81 -81.91 117.53 0.72 
Any cardiovascular or 
cerebrovascular disease 
4.48 -74.40 83.36 0.91 
Consumes alcohol -12.75 -53.46 27.96 0.53 
Cornell depression score -2.13 -11.86 7.60 0.66 
Smoking status  40.40 -23.19 104.00 0.21 
CogRT at baseline (ms) 0.13 -0.24 0.50 0.48 
Daytime mean systolic BP (mmHg) -2.36 -4.51 -0.20 0.03 
Dependent Variable: Cognitive Reaction Time at Follow-up 
Model Adjusted R
2
 = 0.12 
 
Greater decline in total CAMCOG score was associated with greater daytime diastolic 
BP variability [r=0.20 (P<0.05)] (Table 4-14). This was no longer significant after 
adjusting for potential covariates.  
 
Table 4-14: Spearman Correlation between Baseline Daytime Ambulatory BP 
Results and Change in Cognitive Scores at Follow-up. 
 Day mean 
systolic 
pressure  
(mmHg) 
Day mean 
diastolic 
pressure  
(mmHg) 
Day time SD 
SBP (mmHg) 
Day time SD 
DBP (mmHg) 
MMSE r 0.12 0.12 0.04 -0.01 
P 0.23 0.24 0.71 0.89 
total CAMCOG 
score 
r 0.07 0.07 0.19 0.20 
P 0.52 0.51 0.06 <0.05 
CAMCOG 
memory score 
r 0.06 0.09 0.17 0.16 
P 0.59 0.38 0.10 0.12 
CAMCOG 
executive score 
r 0.14 0.07 0.02 0.01 
P 0.19 0.52 0.83 0.96 
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 Night-time Ambulatory Blood Pressure at Baseline and Cognition at 4.6.3
Follow-up 
Eighty-four individuals had five or more baseline, night-time, ABPM readings and were 
therefore eligible to be included in the analysis of nocturnal data. Greater night-time 
diastolic BP variability was associated with poorer MMSE and total CAMCOG scores 
at year ten (Table 4-15). After adjusting for potential covariates, these associations 
remained of borderline significance, P=0.05 (Table 4-16 and Table 4-17). Further 
adjustment was made for mean night-time diastolic BP, but this did not significantly 
alter the models. COMPASS reaction times were not related to night-time ABPM 
results (Table 4-15).  
 
Table 4-15 Spearman Correlation between Night-time 24-hour Ambulatory BP 
Results and Cognitive Scores at Follow-up 
 Night-time 
mean systolic 
pressure  
(mmHg) 
Night-time 
mean diastolic 
pressure  
(mmHg) 
Night-time SD 
SBP  (mmHg) 
Night-time SD 
DBP  (mmHg) 
MMSE r 0.05 -0.04 -0.13 -0.25 
P 0.67 0.75 0.24 0.02 
CAMCOG total 
score 
r 0.01 0.01 -0.20 -0.26 
P 0.92 0.94 0.06 0.02 
CAMCOG memory 
score 
r 0.02 0.03 -0.14 -0.13 
P 0.87 0.76 0.20 0.24 
CAMCOG 
executive score 
r -0.05 0.02 -0.05 -0.08 
P 0.66 0.86 0.64 0.46 
CRT (ms) r -0.07 0.01 -0.11 -0.02 
P 0.52 0.95 0.30 0.83 
SRT (ms) r 0.13 -0.05 0.03 -0.15 
P 0.25 0.65 0.78 0.18 
VigRT (ms) r -0.03 -0.05 -0.12 -0.16 
P 0.80 0.66 0.30 0.14 
CogRT (ms) r -0.15 0.04 -0.12 0.08 
P 0.18 0.73 0.27 0.49 
POA (ms) r 0.00 -0.04 -0.08 -0.13 
P 0.97 0.75 0.45 0.26 
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Table 4-16 Linear Regression Examining Independent Predictors of MMSE at 
Follow-up 
 B 95% CI P 
Age -0.12 -0.22 -0.01 0.03 
Sex -0.42 -1.30 0.46 0.35 
Hypertension -0.23 -1.46 1.01 0.72 
Diabetes 0.43 -1.97 2.83 0.72 
Current smoker (Y/N) -0.07 -1.69 1.55 0.93 
Cardioactive medication 0.10 -1.00 1.21 0.85 
Years in education 0.18 0.03 0.33 0.02 
Any Cardiovascular or Cerebrovascular 
Disease 
0.26 -0.67 1.19 0.58 
Any Psychoactive Medication 0.67 -0.46 1.81 0.24 
Consumes Alcohol (Y/N) 0.13 -0.79 1.06 0.77 
Cornell Depression Score -0.05 -0.18 0.07 0.39 
Baseline MMSE 0.60 0.28 0.92 <0.01 
Night-time SD DBP (mmHg) -0.15 -0.31 0.00 0.05 
Dependent Variable: MMSE at Follow-up 
Model Adjusted R
2
 =0.27 
 
Table 4-17 Linear Regression Examining Independent Predictors of CAMCOG at 
Follow-up 
  B 95% CI P 
Age -0.28 -0.52 -0.04 0.02 
Sex -0.09 -2.12 1.95 0.93 
Hypertension -0.40 -3.26 2.46 0.78 
Diabetes -3.00 -8.53 2.52 0.28 
Current smoker (Y/N) 1.92 -1.82 5.67 0.31 
Cardioactive medication -0.82 -3.38 1.74 0.53 
Years in education 0.29 -0.08 0.66 0.12 
Any Cardiovascular or Cerebrovascular 
Disease 
0.87 -1.28 3.03 0.42 
Any Psychoactive Medication -0.63 -3.19 1.93 0.63 
Consumes Alcohol (Y/N) -1.54 -3.71 0.62 0.16 
Cornell Depression Score -0.27 -0.56 0.02 0.06 
Baseline Total CAMCOG 1.02 0.74 1.30 <0.01 
Night-time SD DBP (mmHg) -0.36 -0.72 0.00 0.05 
Dependent Variable: Total CAMCOG at Follow-up 
Model Adjusted R
2
 =0.52 
 
In univariate analysis, greater decline in MMSE and total CAMCOG score were also 
associated with increased night-time diastolic BP variability (Table 4-18). These 
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findings remained significant after adjusting for potential covariates (Table 4-19 and 
Table 4-20). Once again, adding mean nocturnal DBP into the model did not alter the 
model fit or variables significantly associated with change in total CAMCOG over 
follow-up. 
 
Table 4-18 Spearman Correlation between Night-time 24-hour Ambulatory BP 
Results and Change in Cognitive Scores at Follow-up 
 Night-time 
mean systolic 
pressure  
(mmHg) 
Night-time 
mean diastolic 
pressure  
(mmHg) 
Night-time SD 
SBP  (mmHg) 
Night-time SD 
DBP  (mmHg) 
Change in MMSE r -0.01 0.03 0.12 0.23 
P 0.91 0.75 0.26 0.03 
Total CAMCOG 
score 
r 0.01 0.09 0.20 0.26 
P 0.96 0.43 0.07 0.02 
CAMCOG memory 
score 
r 0.15 0.17 0.12 0.00 
P 0.17 0.11 0.26 1.00 
CAMCOG executive 
score 
r 0.11 0.03 0.02 0.08 
P 0.30 0.80 0.84 0.46 
 
Table 4-19 Multiple Linear Regression Examining Independent Predictors of 
Change in MMSE over Follow-up 
  B 95% CI P 
Age 0.12 0.01 0.22 0.03 
Sex 0.42 -0.46 1.30 0.35 
Hypertension 0.23 -1.01 1.46 0.72 
Diabetes -0.43 -2.83 1.97 0.72 
Current smoker (Y/N) 0.07 -1.55 1.69 0.93 
Cardioactive medication -0.10 -1.21 1.00 0.85 
Years in education -0.18 -0.33 -0.03 0.02 
Any Cardiovascular or Cerebrovascular 
Disease 
-0.26 -1.19 0.67 0.58 
Any Psychoactive Medication -0.67 -1.81 0.46 0.24 
Consumes Alcohol (Y/N) -0.13 -1.06 0.79 0.77 
Cornell Depression Score 0.05 -0.07 0.18 0.39 
Baseline MMSE 0.40 0.08 0.72 0.02 
Night-time SD DBP (mmHg) 0.15 0.00 0.31 <0.05 
Dependent Variable: Change in MMSE over Follow-up 
Model Adjusted R
2
 =0.12 
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Table 4-20 Multiple Linear Regression Examining Independent Predictors of 
Change in Total CAMCOG over Follow-up 
  B 95% CI P 
Age 0.28 0.04 0.52 0.02 
Sex 0.09 -1.95 2.12 0.93 
Hypertension 0.40 -2.46 3.26 0.78 
Diabetes 3.00 -2.52 8.53 0.28 
Current smoker (Y/N) -1.92 -5.67 1.82 0.31 
Cardioactive medication 0.82 -1.74 3.38 0.53 
Years in education -0.29 -0.66 0.08 0.12 
Any Cardiovascular or Cerebrovascular 
Disease 
-0.87 -3.03 1.28 0.42 
Any Psychoactive Medication 0.63 -1.93 3.19 0.63 
Consumes Alcohol (Y/N) 1.54 -0.62 3.71 0.16 
Cornell Depression Score 0.27 -0.02 0.56 0.06 
Baseline Total CAMCOG -0.02 -0.30 0.26 0.89 
Night-time SD DBP (mmHg) 0.36 0.00 0.72 <0.05 
Dependent Variable: Change in Total CAMCOG over Follow-up 
Model Adjusted R
2
 =0.13. 
 Twenty-four Hour Ambulatory Blood Pressure at Baseline and Cognition at 4.6.4
Follow-up  
All ninety-eight individuals who had undergone cognitive assessment at follow-up had a 
minimum of 16 BP recordings during the 24-hour period and met the criteria for 
analysis. MMSE and CAMCOG scores at ten years were not associated with baseline 
24-hour ambulatory BP variables (Table 4-21). Longer cognitive reaction times 
(indicating poorer cognition) were associated with lower mean systolic BP [r = - 0.24, 
(P = 0.02)]. This remained significant after adjusting for covariates [B -2.56 (P=0.04)] 
(Table 4-22). 
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Table 4-21: Spearman Correlation between Baseline 24-hour Ambulatory BP 
Results and Cognitive Scores at Follow-up.  
 
24hr mean 
systolic 
pressure 
(mmHg) 
24hr mean 
diastolic 
pressure 
(mmHg) 
 24hr SD 
SBP 
(mmHg) 
24hr  SD 
DBP 
(mmHg) 
MMSE r -0.03 -0.10 -0.09 -0.07 
P 0.77 0.33 0.39 0.51 
CAMCOG total 
score 
r -0.03 0.02 -0.16 -0.08 
P 0.75 0.82 0.11 0.45 
CAMCOG 
memory score 
r -0.03 0.02 -0.13 -0.06 
P 0.74 0.83 0.21 0.54 
CAMCOG exec 
score 
r -0.06 -0.02 -0.15 -0.16 
P 0.54 0.82 0.13 0.11 
CRT (ms) r -0.18 -0.08 -0.03 0.07 
 P 0.08 0.44 0.80 0.52 
SRT (ms) r 0.13 -0.08 0.06 0.07 
 P 0.22 0.41 0.58 0.50 
VigRT (ms) r -0.12 -0.04 0.09 0.20 
 P 0.26 0.68 0.37 0.06 
CogRT (ms) r -0.24 -0.01 -0.06 0.01 
 P 0.02 0.89 0.55 0.91 
POA (ms) r -0.08 -0.10 0.04 0.14 
 P 0.45 0.35 0.69 0.19 
 
 
87 
 
Table 4-22 Multiple Linear Regression Examining Independent Predictor of 
Cognitive Reaction Time at Follow-up  
  
B 
95.0% Confidence 
Interval for B P 
Age (years) -0.40 -8.62 7.82 0.92 
Sex -10.45 -94.15 73.25 0.80 
Hypertension 24.62 -62.29 111.54 0.57 
Cardioactive medication -72.66 -163.37 18.06 0.11 
Years in education 4.23 -8.19 16.66 0.50 
Psychotropic medication 34.07 -58.33 126.46 0.47 
Diabetes 19.22 -80.81 119.26 0.70 
Any cardiovascular or 
cerebrovascular disease 
1.76 -77.16 80.68 0.96 
Consumes alcohol -11.66 -52.57 29.24 0.57 
Cornell depression score -2.21 -11.96 7.53 0.65 
Current smoker  43.00 -21.00 106.99 0.18 
CogRT (ms) 0.13 -0.23 0.50 0.47 
24hr mean systolic pressure 
(mmHg) 
-2.56 -4.99 -0.14 0.04 
Dependent variable: Cognitive Reaction Time at Follow-up 
Model Adjusted R
2
 = 0.12 
 
Greater 24-hour systolic BP variability was significantly associated with greater decline 
in total CAMCOG score over follow-up period [r = 0.21 (P=0.04)] (Table 4-23). This 
association did not quite reach statistical significance after adjusting for relevant 
covariates [B= 0.26, (P=0.06)]. Change in MMSE and change in CAMCOG executive 
and memory subscores were not associated with 24-hour BP variables (Table 4-23).  
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Table 4-23 Spearman Correlation between Baseline 24-hour Ambulatory BP 
Results and Change in Cognitive Scores at Follow-up. 
Change in Score 
24hr mean 
systolic 
pressure 
(mmHg) 
24hr mean 
diastolic 
pressure 
(mmHg) 
 24hr SD 
SBP (mmHg) 
24hr  SD 
DBP 
(mmHg) 
MMSE r 0.09 0.12 0.17 0.08 
P 0.38 0.25 0.10 0.41 
CAMCOG 
total score 
r 0.08 0.08 0.21 0.13 
P 0.41 0.43 0.04 0.21 
CAMCOG 
memory score 
r 0.12 0.17 0.15 0.12 
P 0.25 0.10 0.14 0.23 
CAMCOG 
exec score 
r 0.15 0.05 0.07 0.03 
P 0.15 0.61 0.49 0.73 
 Diurnal Variation at Baseline and Cognition at Follow-up  4.6.5
Eighty-four individuals had 10 or more daytime ABPM recordings and five or more 
night-time recordings. These participants were included in the analysis of diurnal 
variation. Percentage diurnal variation was not associated with performance on 
cognitive tests at ten years or cognitive decline (Table 4-24 and Table 4-24).  
 
Table 4-24: Spearman Correlation between Ambulatory BP Diurnal Variation 
Results and Cognitive Scores at Follow-up. 
 
 Systolic Diurnal 
Variation (%) 
Diastolic Diurnal 
Variation (%) 
 r (P) r (P) 
MMSE -0.15 (0.16) -0.06 (0.58) 
CAMCOG total score -0.09 (0.44) -0.02 (0.87) 
CAMCOG memory score -0.01 (0.95) 0.05 (0.65) 
CAMCOG executive score -0.02 (0.85)  -0.06 (0.62) 
CRT (ms) -0.22 (0.05) -0.14 (0.22) 
SRT (ms) -0.12 (0.30) -0.06 (0.60) 
VigRT (ms) -0.13 (0.26) 0.01 (0.92) 
CogRT (ms) 0.03 (0.82) 0.04 (0.71) 
POA (ms) -0.16 (0.16) -0.06 (0.58) 
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Table 4-25 Spearman Correlation between Ambulatory BP Diurnal Variation 
Results and Change in Cognitive Scores at Follow-up 
 
 Dipping Status at Baseline and Cognition at Follow-up 4.6.6
Participants were classified according to dipping status (non-dipper; <10% diurnal 
variation, dipper; 10-20% diurnal variation and extreme dippers; >20% diurnal 
variation). Cognitive scores and reaction times at ten years were not significantly 
different for non-dippers, dippers and extreme dippers (Table 4-26). Similarly, cognitive 
decline was not significantly different between groups (Table 4-26). 
 
 Systolic Diurnal 
Variation (%) 
Diastolic Diurnal 
Variation (%) 
 R (P) R (P) 
Change in MMSE 0.19 (0.08) 0.08 (0.47) 
Change in total CAMCOG score 0.15 (0.18) 0.09 (0.43) 
Change in CAMCOG memory score -0.15 (0.17) -0.14 (0.22) 
Change in CAMCOG executive score 0.13 (0.25) 0.15 (0.17) 
90 
 
Table 4-26 Cognitive Function at Follow-up by Ambulatory BP Dipping Status  
 Non dipper  
N= 35  
Median (IQR) 
Dipper  
N = 38  
Median (IQR) 
Extreme dipper  
N= 11  
Median (IQR) 
P 
MMSE 29.0  
(27.0, 29.0) 
29.0  
(26.0, 30.0) 
28.0  
(26.5, 29.0 
0.23 
CAMCOG total  94.0 
(90.0, 96.5) 
94.5 
(90.0, 97.0) 
94.00  
(88.5, 95.0) 
0.33 
CAMCOG memory  23.0 
(21.0, 24.0) 
23.0  
(22.0, 25.0) 
22.0 
(16.0, 24.0) 
0.27 
CAMCOG executive  20.0  
(17.0, 23.0) 
20.0 
(17.0, 23.0) 
19.0 
(16.0, 24.0) 
0.85 
CRT (ms) 623.2 
(584.5, 688.8) 
637.3  
(596.8, 668.2) 
594.7 
(531.0, 605.3) 
0.05 
SRT (ms) 457.1 
(414.3, 559.3) 
443.1 
(395.6, 481.7) 
412.6 
(391.3, 589.8) 
0.84 
VigRT (ms) 558.7 
(528.0, 598.8) 
541.7 
(509.7, 570.2) 
532.0 
(532.0, 584.8) 
0.63 
CogRT (ms) 138.4  
(99.7, 213.7) 
171.8 
(142.9, 230.2) 
107.6 
(169.9, 184.9) 
0.68 
POA (ms) 1702.9 
(1536.4, 1812.7) 
1649.4 
(1499.1, 1695.4) 
1602.0  
(1441.3, 1973.1) 
0.98 
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Table 4-27 Change in Cognitive Function at Follow-up by Ambulatory BP Dipping 
Status. 
 Non dipper  
N= 35 
Median (IQR) 
Dipper  
N = 38 
Median (IQR) 
Extreme dipper  
N= 11 
Median (IQR) 
P 
MMSE 1.00 
(-0.05, 2.00) 
1.00 
(0, 3.00) 
2.00  
(1.00, 2.50) 
0.20 
Total CAMCOG  3.00 
(1.00, 7.00) 
3.5 
(2.00, 7.00) 
5.00 
(3.00, 7.50) 
0.35 
CAMCOG memory  1.00 
(0.00, 2.50) 
0 
(-1.00, 2.00) 
0 
(0, 1.00) 
0.90 
CAMCOG executive  1.00 
(-0.50, 2.50) 
1.50 
(-1.00, 5.00) 
1.00 
(-0.50, 4.50) 
0.85 
 
 Ambulatory Blood Pressure Monitoring at Baseline and Incident Cognitive 4.6.7
Impairment 
The association between ambulatory blood pressure parameters and scoring ≤80 on the 
CAMCOG or <24 on MMSE was examined to determine if ABPM recordings were 
associated with incident cognitive impairment at ten years.  
Daytime and 24-hour ambulatory BP parameters were not associated with CAMCOG 
total ≤80 or MMSE <24 at ten year follow-up. Lower night-time mean systolic BP was 
associated with reduced odds of scoring <24 on MMSE at follow-up (Table 4-28). This 
was no longer significant after adjusting for potential covariates.  
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Table 4-28 Logistic Regression Examining Association between Baseline 
Ambulatory BP Records and Cognitive Impairment  
 MMSE <24 CAMCOG ≤ 80 
 OR 95% CI P  OR 95% CI P 
DAY 
Mean SBP (mmHg) 0.96 0.88, 1.03 0.24 0.97 0.90, 1.05 0.45 
Mean DBP (mmHg) 0.95 0.85, 1.07 0.42 0.93 0.81, 1.06 0.26 
SD SBP (mmHg) 1.00 0.76, 1.32 1.00 0.99 0.75, 1.30 0.94 
SD DBP (mmHg) 1.07 0.71, 1.60 0.76 0.70 0.38, 1.27 0.24 
NIGHT 
Mean SBP (mmHg) 0.90 0.80, 0.99 0.04 0.96 0.87, 1.06 0.41 
Mean DBP (mmHg) 0.90 0.77, 1.05 0.18 0.99 0.86, 1.15 0.94 
SD SBP (mmHg) 0.96 0.72, 1.28 0.78 1.01 0.73, 1.40 0.94 
SD DBP (mmHg) 1.02 0.73, 1.42 0.92 1.06 0.75, 1.50 0.76 
24-hour 
Mean SBP (mmHg) 0.93 0.85, 1.02 0.12 0.97 0.89, 1.05 0.40 
Mean DBP (mmHg) 0.93 0.81, 1.06 0.28 0.92 0.80, 1.06 0.92 
SD SBP (mmHg) 1.02 0.76, 1.38 0.88 0.99 0.73, 1.34 0.95 
SD DBP (mmHg) 1.06 0.71, 1.58 0.78 0.59 0.32, 1.10 0.10 
 
 Ambulatory Blood Pressure Monitoring at Baseline and Cognitive Decline 4.6.8
ABPM parameters were not associated with a fall of four or more points on MMSE 
score. A fall of five or more points on total CAMCOG was associated with greater 
daytime systolic and diastolic BP variability, greater night-time diastolic BP variability, 
greater 24-hour mean systolic and diastolic pressures and greater SBP and DBP 
variability (Table 4-29). Multiple binary logistic regression was performed to determine 
if these findings were independent of potential covariates. All but the association with 
night-time mean diastolic BP remained significant.  
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Table 4-29 Logistic Regression Examining Association between Baseline 
Ambulatory BP Records and Cognitive Decline 
 Drop in MMSE of ≥ 4 points Drop in CAMCOG OF ≥ 5 
points  
 OR 95% CI P OR 95% CI P 
Daytime 
Mean SBP (mmHg) 1.01 0.97, 1.05 0.75 1.03 1.00, 1.06 0.06 
Mean DBP (mmHg) 1.00 0.94, 1.06 0.93 1.04 1.00, 1.08 0.06 
SD SBP (mmHg) 0.95 0.78, 1.16 0.62 1.13 1.00, 1.27 <0.05 
SD DBP (mmHg) 0.97 0.73, 1.30 0.85 1.31 1.07, 1.60 0.01 
Night-time 
Mean SBP (mmHg) 1.00 0.94, 1.05 0.88 1.02 0.98, 1.05 0.30 
Mean DBP (mmHg) 1.02 0.94, 1.10 0.62 1.05 0.99, 1.11 0.09 
SD SBP (mmHg) 0.99 0.82, 1.20 0.92 1.09 0.97, 1.23 0.16 
SD DBP (mmHg) 1.19 0.97, 1.47 0.97 1.19 1.02, 1.40 0.03 
24-hour 
Mean SBP (mmHg) 1.01 0.96, 1.06 0.70 1.03 1.00, 1.07 0.04 
Mean DBP (mmHg) 1.02 0.95, 1.09 0.69 1.05 1.00, 1.10 0.04 
SD SBP (mmHg) 0.87 0.69, 1.09 0.21 1.21 1.05, 1.39 0.01 
SD DBP (mmHg) 0.79 0.56, 1.13 0.20 1.22 1.01, 1.47 0.04 
 
 Response to Active Stand at Baseline and Cognitive Performance 4.7
at Follow-up 
4.7.1 Orthostatic Hypotension at Baseline and Cognition at Follow-up 
Ninety-four individuals had active stand at baseline and full cognitive testing at ten year 
follow-up. Of these 76 met the diagnostic criteria for OH described by the American 
Academy of Neurology. Of whom, 59 had systolic OH and 68 had diastolic OH.  
Presence or absence of OH as defined by AAN was not associated with cognitive 
performance at ten years or change in cognitive performance (Table 4-30). Nor were 
systolic or diastolic OH associated with cognitive function at follow-up when examined 
separately (Table 4-31 and Table 4-32).  
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Table 4-30 Cognitive Function at Ten Years by Presence or Absence of OH at 
Baseline 
 OH  
N=76 
No OH 
N=18 
 
 Median  (IQ range) Median (IQ range) P 
MMSE 28.0 (26.0, 29.0) 29.0 (27.0, 29.0) 0.98 
CAMCOG total  93.5 (89.5, 96.0) 95.0 (90.0, 98.0) 0.08 
CAMCOG memory  23.0 (21.0, 24.0) 23.0 (22.0, 25.0) 0.12 
CAMCOG executive  20.0 (17.0, 23.0) 20.5 (18.0, 22.0) 0.40 
CRT (ms) 627.6 (559.4, 669.8) 611.9 (565.0, 646.8) 0.63 
SRT (ms) 451.0 (405.8, 541.1) 431.1 (416.4, 455.6) 0.62 
VigRT (ms) 543.8 (516.3, 586.4) 558.7 (508.8, 584.8) 0.77 
CogRT (ms) 158.0 (108.1, 214.4) 155.7 (121.2, 216.7) 0.86 
POA (ms) 1654.0 (1512.0,1818.5) 1622.1 (1499.1, 1717.2) 0.50 
Change in Cognitive Scores 
MMSE 1.0 (0, 2.0) 1.0 (0, 2.0) 0.89 
CAMCOG total  4.0 (1.5, 8.8) 2.0 (-2.0, 7.0) 0.11 
CAMCOG memory  1.0 (0, 2.0) 0 (-1.0, 2.0) 0.22 
CAMCOG executive  2.0 (-0.5, 3.5) 0.0 (-1.0, 3.0) 0.51 
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Table 4-31 Cognitive Function at Ten Years by Presence or Absence of Systolic 
OH at Baseline 
 Systolic OH  
N=59 
No Systolic  OH  
N= 35 
 
 Median  (IQ range) Median (IQ range) P 
MMSE 28.0 (26.0, 29.0) 29.0 (27.0, 29.0) 0.67 
CAMCOG total  93.0 (90.0, 96.0) 95.0 (90.0, 97.5) 0.12 
CAMCOG memory  23.0 (21.0, 24.0) 23.0 (22.0, 25.0) 0.26 
CAMCOG executive  20.0 (17.0, 22.5) 20.0 (18.0, 22.5) 0.32 
CRT (ms) 627.7 (555.7, 669.3) 611.5 (565.0, 673.2) 0.94 
SRT (ms) 440.8 (400.2, 522.8) 449.3 (416.4, 545.7) 0.63 
VigRT (ms) 540.3 (511.8, 588.6) 549.2 (515.2, 584.7) 0.52 
CogRT (ms) 155.6 (113.1, 206.0) 158.5 (108.1, 230.2) 0.84 
POA (ms) 1638.4 (1504.4, 1817.7) 1652.6 (1499.1, 1785.8) 0.62 
Change in Cognitive Scores 
MMSE 1.0 (0, 2.5) 1 .0 (0, 2.0) 0.53 
CAMCOG total  4.0 (2.0, 8.0) 3.0 (0, 7.0) 0.16 
CAMCOG memory  1.0 (0, 2.0) 0 (-1.0, 2.0) 0.12 
CAMCOG executive  2.0 (-0.5. 4.0) 1.0 (-1.0, 2.5) 0.22 
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Table 4-32 Cognitive Function at Ten Years by Presence or Absence of Diastolic 
OH at Baseline 
 Diastolic OH  
N= 68 
No Diastolic  OH  
N= 26 
 
 Median  (IQ range) Median (IQ range) P  
MMSE 28.0 (26.0, 29.0) 28.5 (26.0, 29.0) 0.70 
CAMCOG total  94.0 (89.5, 96.0) 94.0 (90.0, 98.0) 0.40 
CAMCOG memory  23.0 (21.0, 24.0) 22.5 (21.0, 25.0) 0.76 
CAMCOG executive  20.0 (17.0, 23.0) 19.5 (18.0, 22.0) 0.87 
CRT (ms) 621.1 (552.0, 668.8) 623.2 (566.2, 673.2) 0.88 
SRT (ms) 451.0 (405.8, 523.0) 438.1 (412.6, 509.7) 0.67 
VigRT (ms) 544.4 (518.3, 586.4) 551.8 (508.3, 587.2) 0.67 
CogRT (ms) 150.2 (103.8, 214.4) 161.7 (127.2, 216.7) 0.62 
POA (ms) 1643.5 (1500.1, 1818.5) 1650.3 (1519.7, 1757.2) 0.92 
Change in Cognitive Scores 
MMSE 1.0 (0, 2.0) 1.0 (0, 3.0) 0.47 
CAMCOG total  4.0 (1.0, 7.5) 3.5 (-2.0, 7.0) 0.38 
CAMCOG memory  1.0 (0, 2.0) 0 (-1.0, 2.0) 0.33 
CAMCOG executive  1.0 (-1.0, 3.0) 1.5 (0, 5.0) 0.69 
 
4.7.2 Symptomatic Orthostatic Hypotension at Baseline and Cognition at Ten 
Year Follow-up  
Of the 76 participants meeting the AAN criteria for OH at baseline, 12 had symptoms of 
dizziness, pre-syncope or syncope. Symptomatic OH was associated with longer choice 
reaction times and greater decline in CAMCOG memory subscore (Table 4-33). After 
adjusting for potential covariates, these findings remained significant for change in 
CAMCOG memory score but not for Choice Reaction Time (Table 4-34).  
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Table 4-33 Cognitive Function at Ten Years by Presence or Absence of 
Symptomatic OH at Baseline 
 Asymptomatic  
N= 82 
Symptomatic  OH  
N= 12 
 
 Median  (IQ range) Median (IQ range) P  
MMSE 28.0 (26.0, 29.0) 28.5 (26.0, 29.8) 0.95 
CAMCOG total  94.0 (90.0, 97.0) 93.0 (86.3, 95.8) 0.29 
CAMCOG memory  23.0 (21.0, 24.0) 22.0 (18.0, 23.0) 0.08 
CAMCOG executive  20.0 (17.0, 23.0) 19.0 (17.3, 22.8) 0.87 
CRT (ms) 611.5 (551.8, 663.4) 668.4 (615.6, 704.6) 0.04 
SRT (ms) 442.3 (408.3, 527.3) 452.4 (393.8, 570.2) 0.73 
VigRT (ms) 544.4 (512.7, 518.8) 567.9 (540.0, 600.0) 0.18 
CogRT (ms) 154.0 (107.0, 208.8) 200.5 (123.7, 258.8) 0.20 
POA (ms) 1635 (1482, 1813) 1666 (1585, 1810) 0.28 
Change in Cognitive Scores 
MMSE 1.0 (0, 2.0) 1.0 (-0.75, 2.8) 0.66 
CAMCOG total  3.5 (1.0, 7.0) 5.0 (2.3, 8.8) 0.39 
CAMCOG memory  0 (-1.0, 2.0) 1.5 (1.0, 4.5) <0.01 
CAMCOG executive  1.5 (-1.0, 4.3) 1.0 (-0.8, 2.0) 0.56 
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Table 4-34 Multiple Linear Regression Examining the Independent Predictors of 
Change in CAMCOG memory score.  
 B 95% CI P 
Age 0.09 0.00, 0.18 0.06 
Sex 0.59 -0.30, 1.48 0.19 
High blood pressure 0.59 -0.36, 1.54 0.22 
Diabetes 0.61 -0.52, 1.74 0.29 
Smoker yes or no -0.52 -1.38, 0.34 0.23 
Any cardioactive drug 0.52 -0.49, 1.53 0.31 
Years in education -0.35 -1.23, 0.52 0.43 
Any cardiovascular or cerebrovascular 
disease 
-0.18 -0.32, -0.05 0.01 
Psychotropic Medication -0.03 -0.91, 0.84 0.94 
Consumes alcohol yes / no 0.09 -0.02, 0.19 0.11 
Cornell -0.17 -1.24, 0.90 0.75 
CAMCOG Memory Score 0.20 -0.02, 0.41 0.07 
Symptomatic OH 1.19 0.02, 2.35 <0.05 
Dependent variable: Change in CAMCOG memory subscore over Follow-up 
Adjusted Model R
2 = 
0.23 
     
4.7.3 Orthostatic Hypotension at Baseline and Cognitive Impairment 
Of the 94 participants who underwent active stand at baseline and cognitive testing at 
ten year follow-up, four had an MMSE score <24 at follow-up and 4 had a total 
CAMCOG score of ≤80 at follow-up. Neither of these outcomes was associated with the 
presence or absence of OH as defined by AAN, OH subtypes or symptomatic OH 
(Table 4-35).  
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Table 4-35 Association between Orthostatic Hypotension, Orthostatic Hypotension 
Subtypes and Cognitive Impairment  
 Frequency (%) Frequency (%) P 
 AAN OH  
N= 76 
No AAN OH N=18  
MMSE <24 2 (3) 2 (11) 0.16 
Total CAMCOG ≤80 0 (0) 4 (22) 1.00 
 Systolic OH  
N= 59 
No Systolic OH  
N= 35 
 
MMSE <24 4 (7) 0 (0) 0.29 
Total CAMCOG ≤80 4 (7) 0 (0) 0.29 
 Diastolic OH 
 N=65 
No Diastolic OH 
N=26 
 
MMSE <24 2 (31)  2 (8) 0.32 
Total CAMCOG ≤80 4 (6) 0 (0) 0.57 
 Symptomatic OH 
N=12 
Asymptomatic  
N=82 
 
MMSE <24 0 4 1.00 
Total CAMCOG ≤80 0 4 1.00 
 
4.7.4 Orthostatic Hypotension at Baseline and Cognitive Decline  
Similarly, OH status was not associated with cognitive decline (defined as a drop of 
four or more points in MMSE score or a drop of ≥5 points on CAMCOG total score) 
(Table 4-36).  
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Table 4-36 Orthostatic Hypotension, Orthostatic Hypotension Subtypes and 
Cognitive Decline 
 Frequency (%) Frequency (%) P 
 OH N= 76 No OH N=18  
Drop in MMSE of  ≥4 points 9 (12) 1 (6) 0.68 
Drop in total CAMCOG ≥5 points 37 (49) 6 (33) 0.24 
 Systolic OH  
N= 59 
No Systolic OH 
N= 35 
 
Drop in MMSE of  ≥4 points 8 (14) 2 (6) 0.31 
Drop in total CAMCOG ≥5 points 29 (49) 14 (40) 0.40 
 Diastolic OH 
 N=65 
No Diastolic OH 
N=26 
 
Drop in MMSE of  ≥4 points 8 (12) 2 (8) 0.72 
Drop in total CAMCOG ≥5 points 32 (49) 11 (42) 0.55 
 Symptomatic OH 
N=12 
Asymptomatic  
N=82 
 
Drop in MMSE of  ≥4 points 1 (8) 9 (11) 1.00 
Drop in total CAMCOG ≥5 points 7 (58) 36 (44) 0.35 
4.7.5 Continuous Response to Active Stand at Baseline and Cognition at Ten 
Year Follow-up  
There were no significant associations between continuous blood pressure response to 
active stand and cognitive scores at follow-up (Table 4-37). There was an association 
between diastolic nadir in response to active stand and change in CAMCOG executive 
subscore (Table 4-38). These data were no longer significant after adjusting for 
potential covariates.  
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Table 4-37 Spearman Correlation between Continuous Haemodynamic Response 
to Active Stand and Cognitive Function at Follow-up 
  
Systolic 
Nadir 
(mmHg) 
Diastolic 
Nadir 
(mmHg) 
Systolic 
Vasodepression 
(mmHg) 
Diastolic 
Vasodepression 
(mmHg) 
Year 10 MMSE 
r -0.05 -0.13 -0.04 0.15 
P 0.61 0.22 0.69 0.14 
Year 10 CAMCOG total 
score 
r -0.04 0.01 -0.11 0.01 
P 0.74 0.92 0.29 0.91 
Year 10 CAMCOG 
memory score 
r -0.04 0.03 -0.11 0.03 
P 0.68 0.80 0.28 0.81 
Year 10 CAMCOG 
executive score 
r -0.03 -0.05 -0.06 0.05 
P 0.75 0.66 0.57 0.63 
CRT (ms) 
r -0.19 -0.05 0.16 0.02 
P 0.06 0.64 0.13 0.89 
SRT (ms) 
r 0.11 0.01 -0.05 -0.02 
P 0.28 0.94 0.66 0.82 
VigRt (ms) 
r 0.05 -0.04 -0.08 0.06 
P 0.63 0.73 0.44 0.59 
CogRT (ms) 
r -0.25 -0.05 0.17 0.03 
P 0.02 0.64 0.10 0.78 
POA (ms) 
r -0.07 -0.04 0.06 0.01 
P 0.54 0.74 0.55 0.97 
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Table 4-38 Spearman Correlation between Continuous Haemodynamic Response 
to Active Stand and Change in Cognitive Function over Follow-up Period 
  
Systolic 
Nadir 
(mmHg) 
Diastolic 
Nadir 
(mmHg) 
Systolic 
Vasodepression 
(mmHg) 
Diastolic 
Vasodepression 
(mmHg) 
Change in MMSE 
r 0.02 0.05 0.08 -0.10 
P 0.82 0.65 0.46 0.35 
Change in total 
CAMCOG score 
r 0.04 0.05 0.10 0.00 
P 0.68 0.64 0.32 0.98 
Change in CAMCOG 
memory score 
r -0.06 -0.06 0.17 0.08 
P 0.59 0.56 0.10 0.47 
Change in CAMCOG 
executive score 
r 0.17 0.22 0.00 -0.16 
P 0.10 0.03 0.97 0.13 
 
4.7.6 Continuous Response to Active Stand at Baseline and Cognitive 
Impairment 
Continuous haemodynamic responseto active stand was not associated with incident 
cognitive impairment (Table 4-39). 
 
Table 4-39 Logistic Regression Examining the Association between Continuous 
Response to Active Stand and Cognitive Impairment  
Variable MMSE<24 CAMCOG ≤80 
  OR 95% CI P  OR 95% CI P 
Systolic Nadir  
(mmHg) 
1.01 0.97, 1.04 0.77 0.99 0.96, 1.03 0.72 
Diastolic Nadir (mmHg) 1.09 1.00, 1.20 0.08 0.98 0.92, 1.04 0.50 
Systolic vasodepression 
(mmHg) 
0.94 0.87, 1.02 0.13 1.01 0.96, 1.07 0.63 
Diastolic vasodepression 
(mmHg) 
0.85 0.75, 0.98 0.02 0.93 0.90, 1.11 0.93 
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4.7.7 Continuous Response to Active Stand at Baseline and Cognitive Decline 
Similarly, continuous haemodynamic response to active stand was not associated with a 
decline in MMSE of four or more points or a decline in total CAMCOG score of five or 
more points (Table 4-40) 
 
Table 4-40 Logistic Regression Examining the Association between Continuous 
Response to Active Stand and Cognitive Decline over Follow-up 
Variable OR 95% CI P 
 Drop in MMSE ≥ 4 Points 
Systolic Nadir (mmHg) 0.99 0.97, 1.02 0.42 
Diastolic Nadir (mmHg) 0.98 0.94, 1.03 0.46 
Systolic Vasodepression (mmHg) 1.02 0.99, 1.06 0.27 
Diastolic Vasodepression (mmHg) 1.04 0.97, 1.11 0.31 
 Drop in total CAMCOG ≥ 5Points 
Systolic Nadir (mmHg) 1.01 0.99, 1.03 0.25 
Diastolic Nadir (mmHg) 1.01 0.98, 1.04 0.51 
Systolic Vasodepression (mmHg) 1.01 0.99, 1.03 0.46 
Diastolic Vasodepression (mmHg) 1.01 0.97, 1.06 0.64 
 
 Response to Carotid Sinus Massage at Baseline and Cognitive 4.8
Performance at Follow-up 
 Carotid Sinus Hypersensitive at Baseline and Cognition at Follow-up 4.8.1
Eighty-eight participants underwent CSM at baseline and full cognitive testing at ten 
year follow-up. Twenty-eight participants were diagnosed with carotid sinus 
hypersensitivity at baseline. Neither cognitive scores at ten years or change in cognitive 
score over follow-up period were significantly influenced by CSH status at baseline 
(Table 4-41).  
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Table 4-41 Cognitive Function at Follow-up According to CSH Status at Baseline 
 CSH  
N=28 
No CSH  
N=60 
 
 Median  
(IQ range) 
Median 
 (IQ range) 
P  
Scores at Follow-up 
MMSE 27.0 (26.0, 29.0) 29.0 (27.0, 29.0) 0.08 
CAMCOG total  92.0 (87.0, 96.0) 94.5 (91.0, 98.0) 0.12 
CAMCOG memory  22.5 (21.0, 24.0) 23.0 (21.0, 24.0) 0.55 
CAMCOG executive  20.5 (16.5, 22.5) 20.5 (18.0, 22.0) 0.26 
CRT (ms) 600.7 (550.7, 654.6) 629.1 (566.2, 668.2) 0.24 
SRT (ms) 451.0 (411.7, 539.5) 440.8 (405.8, 509.8) 0.69 
VigRT (ms) 543.3 (416.3, 569.6) 545.5 (511.7, 587.2) 0.64 
Cog RT (ms) 150.2 (109.4, 194.0) 158.7 (114.9, 230.2) 0.55 
POA (ms) 1636.5 (1530.1, 1802.6) 1648.9  (1501.7, 1758.1) 0.90 
Change in Cognitive Function of Follow-up 
MMSE 1.0 (0, 2.5) 1.0 (0, 2.0) 0.42 
CAMCOG total  4.5 (1.0, 7.0) 3.0 (1.0, 7.0) 0.51 
CAMCOG memory  1.0 (0, 2.0) 0 (0, 2.0) 0.53 
CAMCOG executive  1.0 (-1.0, 3.0) 2.0 (-1.0, 3.0) 0.39 
 Symptomatic Carotid Sinus Hypersensitivity at Baseline and Cognitive 4.8.2
Impairment at Follow-up 
Twelve of the participants with CSH had symptoms during carotid sinus massage. 
Cognitive function at ten years did not differ between the symptomatic and 
asymptomatic groups. Similarly, cognitive decline over the follow-up did not differ 
according to presence of absence of symptoms during carotid sinus massage (Table 
4-42).   
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Table 4-42 Cognitive Function at Follow-up According to Symptomatic CSH 
Status at Baseline 
 Symptomatic CSH  
N=12 
Asymptomatic 
N=76 
 
 Median  
(IQ range) 
Median 
 (IQ range) 
P  
Scores at Follow-up 
MMSE 28.5 (27.0, 29.0) 28.0 (26.0, 29.0) 0.77 
CAMCOG total  91.5 (88.3, 95.0) 94.0 (90.0, 97.8) 0.29 
CAMCOG memory  23.0 (18.5, 24.0) 23.0 (21.0, 24.0) 0.51 
CAMCOG executive  19.0 (16.3, 20.8) 20.5 (18.0, 23.0) 0.56 
CRT (ms) 580.9 (539.3, 657.6) 627.6 (583.1, 668.2) 0.10 
SRT (ms) 419.9 (381.3, 581.4) 449.6 (412.6, 509.7) 0.52 
VigRT (ms) 544.6 (478.0, 597.3) 545.0 (515.1, 584.0) 0.96 
Cog RT (ms) 160.1 (97.5, 199.9) 154.7 (114.9, 230.2) 0.51 
POA (ms) 1587 (1388, 1808) 1649 (1525, 1774) 0.34 
Change in Cognitive Function of Follow-up 
MMSE 1.0 (-0.75, 2.0) 1.0 (0, 2.0) 0.88 
CAMCOG total  5.0 (1.5, 6.75) 3.0 (1.0, 7.0) 0.60 
CAMCOG memory  2.0 (-0.75, 3.0) 0 (0, 1.75) 0.24 
CAMCOG executive  1.5 (-1.5, 4.5) 2.0 (-1, 3.0) 0.71 
 
 Carotid Sinus Hypersensitivity at Baseline and Cognitive Impairment 4.8.3
Of those participants who had carotid sinus massage at baseline, 3 had total CAMCOG 
score of  ≤80 and 3 had and  MMSE <24. These outcomes were not associated with 
presence of carotid sinus hypersensitivity at baseline or presence or absence of 
symptomatic CSH at baseline (Table 4-43).  
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Table 4-43 Carotid Sinus Hypersensitivity and Cognitive Impairment 
 CSH N= 28 
Frequency (%) 
No CSH N= 60 
Frequency (%) 
P  
MMSE <24 1 (4) 2 (3) 1.00 
Total CAMCOG ≤80 1 (4) 2 (3) 1.00 
 Symptomatic CSH  
N= 12 
Frequency (%) 
Asymptomatic  
 N= 76 
Frequency (%) 
P  
MMSE <24 0 3 (5) 1.00 
Total CAMCOG ≤80 0 3 (5) 1.00 
 Carotid Sinus Hypersensitivity at Baseline and Cognitive Decline over 4.8.4
Follow-up 
Similarly, decline in MMSE, defined as a drop of four or more points on MMSE, was 
not associated with CSH at baseline or symptomatic CSH. Nor was decline in 
CAMCOG, when defined as a drop of ≥ 5 points (Table 4-44).  
 
Table 4-44 Carotid Sinus Hypersensitivity and Cognitive Decline 
 CSH N= 28 
Frequency (%) 
No CSH N= 60 
Frequency (%) 
P  
Drop in MMSE of  ≥4 points 4 (14) 5 (8) 0.46 
Drop in total CAMCOG ≥ 5 points 14 (50) 24 (40) 0.38 
 Symptomatic 
CSH N= 12 
Frequency (%) 
Asymptomatic  
N= 76 
Frequency (%) 
P  
Drop in MMSE of  ≥4 points 0  9 (11) 0.35 
Drop in total CAMCOG ≥ 5 points 7 (58) 31 (40) 0.25 
 Continuous Haemodynamic Response to CSM at Baseline and Cognition at 4.8.5
Follow-up 
Continuous haemodynamic response to CSM at baseline was not associated with 
performance on MMSE, CAMCOG or COMPASS at ten years or change in cognitive 
performance over follow-up period (Table 4-45 and Table 4-46)  
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Table 4-45: Spearman Correlation between Continuous Haemodynamic Response 
to CSM and Cognitive Function at Follow-up 
 Max RR 
interval  
Max Vaso-
depression 
Minimum 
Systolic Nadir 
Max delta RR 
MMSE r -0.08 -0.06 -0.08 -0.10 
P 0.46 0.57 0.46 0.34 
CAMCOG total  r -0.16 -0.10 -0.01 -0.17 
P 0.15 0.33 0.93 0.12 
CAMCOG memory  r -0.16 -0.14 -0.01 -0.17 
P 0.13 0.18 0.95 0.11 
CAMCOG executive  r -0.09 0.01 -0.02 -0.09 
P 0.41 0.95 0.89 0.41 
CRT (ms) r -0.08 -0.04 -0.09 -0.07 
P 0.44 0.68 0.43 0.50 
SRT (ms) r 0.00 0.06 -0.04 0.01 
P 0.97 0.59 0.74 0.94 
VigRT (ms) r -0.01 -0.05 -0.09 -0.01 
P 0.92 0.67 0.39 0.93 
CogRT (ms) r -0.08 -0.08 -0.05 -0.07 
P 0.49 0.48 0.64 0.53 
POA (ms) r -0.06 -0.02 -0.09 -0.05 
P 0.58 0.86 0.42 0.63 
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Table 4-46 Spearman Correlation between Continuous Haemodynamic Response 
to CSM and Change in Cognitive Function over Follow-up 
Change in Max RR 
interval  
Max Vaso-
depression 
Minimum 
Systolic Nadir 
Max delta RR 
MMSE r 0.13 0.07 0.08 0.15 
P 0.22 0.52 0.46 0.17 
CAMCOG total  r 0.10 0.02 0.07 0.12 
P 0.35 0.82 0.54 0.27 
CAMCOG 
memory  
r 0.12 0.07 0.02 0.13 
P 0.26 0.50 0.87 0.22 
CAMCOG 
executive  
r -0.07 -0.13 0.16 -0.06 
P 0.49 0.22 0.14 0.56 
 Continuous Haemodynamic Response to CSM at Baseline and Cognitive 4.8.6
Impairment 
No association was observed between haemodynamic response to CSM at baseline and 
scoring less than 24 points on MMSE at follow-up or ≤80 points on total CAMCOG at 
follow-up (Table 4-47).  
 Continuous Haemodynamic Response to CSM at Baseline and Cognitive 4.8.7
Decline 
Similarly decline in MMSE, defined as a drop of four or points on MMSE, was not 
associated with haemodynamic response to CSM at baseline (Table 4-48). Nor was 
decline in CAMCOG total score, defined as a drop of ≥ 5 points, associated with 
response to CSM at baseline (Table 4-48).  
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Table 4-47 Logistic Regression Examining Association between Continuous 
Response to CSM at baseline and Cognitive Impairment at Follow-up 
 MMSE<24 Total CAMCOG ≤ 80 
 OR 95% CI P OR 95% CI P 
Max RR interval (s) 0.83 0.34, 2.00 0.67 0.99 0.52, 1.91 0.99 
Max Vasodepression 
(mmHg) 
1.00 0.94, 1.07 0.99 0.99 0.92, 1.06 0.73 
Minimum Systolic Nadir 
(mmHg) 
1.00 0.95,1.07 0.90 0.97 0.90, 1.03 0.29 
Max Delta RR (s) 0.90 0.41, 2.0 0.80 1.02 0.53, 1.94 0.96 
 
Table 4-48 Logistic Regression Examining Association between Continuous 
Response to CSM at baseline and Cognitive Decline over Follow-up 
 OR 95% CI P 
Drop in MMSE of  ≥4 points    
Max RR interval (s) 0.89 0.57, 1.41 0.62 
Max Vasodepression (mmHg) 1.00 0.96, 1.04 0.82 
Minimum Systolic Nadir (mmHg) 0.68 0.98, 1.03 0.68 
Max Delta RR (s) 0.90 0.57, 1.43 0.66 
Drop in total CAMCOG ≥5 points    
Max RR interval (s) 1.13 0.89, 1.43 0.31 
Max Vasodepression (mmHg) 1.01 0.98, 1.03 0.61 
Minimum Systolic Nadir (mmHg) 1.01 0.99, 1.02 0.34 
Max Delta RR (s) 1.15 0.90, 1.47 0.27 
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 Response to Autonomic Function Tests at Baseline and Cognition 4.9
at Follow-up 
Data from one or more autonomic function test was available for 94 or the 99 
participants who underwent cognitive testing at follow-up. Numbers of participants 
completing each of the autonomic function tests at baseline and full cognitive testing at 
follow-up are shown below (Table 4-49). Eighty-six participants completed all five tests 
required for classification of autonomic function as normal or abnormal using modified 
Ewing criteria.  
Table 4-49 Number of participants completing individual autonomic function tests 
Autonomic Function Test Number of 
participants 
Blood pressure and heart rate response to standing 91 
Blood pressure response to isometric exercise 93 
Blood pressure and heart rate response Valsalva manoeuvre 94 
Blood pressure response to cold stimulation 91 
Heart rate response to deep breathing 89 
 
 Abnormal Autonomic Function at Baseline and Cognition  4.9.1
Comparing participants with abnormal autonomic function at baseline with those with 
normal baseline autonomic function as defined by modified Ewing criteria did not 
reveal any difference in cognitive scores or reaction times at follow-up (Table 4-50). 
Participants with abnormal autonomic function however did have significantly greater 
decline in total CAMCOG scores over the follow-up period (Table 4-50). This was no 
longer significant after adjusting for potential confounding variables.    
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Table 4-50 Comparison of Cognitive Performance at Follow-up and Change in 
Cognitive Performance for Participants with Normal and Abnormal Autonomic 
Function at Baseline by Ewing Classification  
 
Normal Autonomic 
function  
N=57 
Abnormal Autonomic 
function 
N =29 
P  
 Median (IQR) Median (IQR)  
Cognitive Function at Follow-up 
MMSE 29.0 (27.0, 29.0) 27.0 (26.0, 29.0) 0.36 
CAMCOG total  94.0 (90.0, 97.0) 94 (86.0, 97.0) 0.50 
CAMCOG memory  23.0 (21.0, 24.0) 23.0 (21.0, 24.0) 0.80 
CAMCOG executive 20.0 (18.0 22.0) 19.0 (17.0, 21.0) 0.43 
CRT (ms) 618.3 (566.1, 655.8) 659.3 (656.6, 732.0) 0.15 
SRT (ms) 440.6 (402.5, 541.1) 450.7 (428.8, 514.6) 0.46 
VigRT (ms) 545.0 (512.0, 584.8) 545.0 (524.2, 566.0) 0.88 
CogRT (ms) 49.4 (108.1, 230.2) 183.6 (121.8, 219.4) 0.27 
POA (ms) 1620.7  (1499.1, 1754.0) 1663.7  (1563.4, 
1818.5) 
0.30 
Change in Cognitive Function 
MMSE 1.0 (0, 2.0) 1.0 (0, 3.0) 0.11 
Total CAMCOG  3.0 (1.0, 7.0) 6.0 (2.0, 9.0) 0.04 
CAMCOG memory  0 (-1.0, 2.0) 1.0 (0, 2.0) 0.23 
CAMCOG executive  2.0 (-1.0, 5.0) 1.0 (0.0, 3.0) 0.66 
 
 Abnormal Autonomic Function at Baseline, Cognitive Impairment and 4.9.2
Cognitive Decline  
Presence of cognitive impairment as defined as MMSE<24 or total CAMCOG ≤80 was 
not associated with abnormal autonomic function at baseline. Similarly, a drop in 
MMSE score of four or more points or a decline in CAMCOG total score of ≥5 points 
was not associated with abnormal autonomic function at baseline (Table 4-51) 
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Table 4-51 Cognitive impairment and Cognitive Decline at Ten Years by 
Autonomic Function  
 Normal Autonomic 
Function 
N=57 
Abnormal 
Autonomic 
Function 
N=29 
P  
MMSE <24 3 (5%) 1 (3%) 1.00 
Total CAMCOG ≤80 2 (4%) 1 (3%) 1.00 
Drop in MMSE of  ≥4 points 3 (5%) 3 (27%) 1.00 
Drop in total CAMCOG ≥5 
points 
19 (33%) 16 (55%) 0.10 
 
 Continuous Response to Individual Autonomic Function Tests at Baseline 4.9.3
and Cognition at Follow-up 
Examining the association between cognitive function at ten years and haemodynamic 
response to individual autonomic function tests at baseline showed that greater BP 
response to placing a hand in cold water was associated with shorter digit vigilance 
reaction time;  greater systolic BP overshoot during Valsalva manoeuvre was associated 
with better CAMCOG executive score and shorter digit vigilance reaction time at ten 
years; greater heart rate response to Valsalva manoeuvre was associated with shorter 
simple reaction time, shorter digit vigilance reaction time and shorter power of 
attention; and, finally, that greater 30:15 ratio in response to standing was associated 
with shorter choice reaction time (Table 4-52).  None of these associations remained 
significant after adjusting for potential covariates.  
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Table 4-52 Spearman Correlation between Continuous Haemodynamic Response 
to Individual Autonomic Function and Cognitive Score at Follow-up  
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MMSE 
r -0.07 0.12 0.03 0.03 0.07 0.07 0.09 
P 0.51 0.24 0.75 0.77 0.47 0.47 0.41 
CAMCOG total score 
r -0.11 0.13 0.00 0.19 0.12 0.18 0.09 
P 0.29 0.23 0.99 0.07 0.27 0.09 0.40 
CAMCOG memory score 
r -0.10 0.12 -0.11 0.15 0.14 0.19 0.05 
P 0.35 0.27 0.28 0.14 0.17 0.06 0.62 
CAMCOG executive score 
r -0.05 0.00 -0.09 0.26 0.07 0.18 -0.11 
P 0.60 0.98 0.41 0.01 0.52 0.09 0.32 
CRT (ms) r 0.10 -0.18 -0.01 -0.12 -0.22 -0.10 -0.19 
 
P 0.35 0.09 0.92 0.26 0.04 0.35 0.08 
SRT (ms) r 0.01 -0.01 -0.16 -0.18 -0.05 -0.27 -0.17 
 
P 0.93 0.91 0.13 0.09 0.61 0.01 0.11 
VigRT (ms) r -0.09 -0.23 0.07 -0.20 -0.17 -0.25 -0.18 
 P 0.39 0.03 0.54 0.05 0.12 0.02 0.10 
CogRT (ms) r 0.15 -0.13 0.11 0.07 -0.11 0.15 0.00 
 P 0.17 0.24 0.30 0.50 0.30 0.16 0.98 
POA (ms) r 0.03 -0.12 -0.05 -0.17 -0.19 -0.23 -0.20 
 P 0.75 0.27 0.61 0.10 0.07 0.03 0.07 
 
Examination of the associations between continuous response to autonomic function 
tests and change in cognitive function over ten year follow-up showed that smaller 
active stand 30:15 ratio was associated with greater declines in CAMCOG total score 
and CAMCOG memory score. Smaller heart rate ratio in response to Valsalva were 
associated with greater decline in CAMCOG memory score and larger heart rate 
changes in response to deep breathing were associated with greater decline in 
CAMCOG executive score over ten years (Table 4-53). 
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Table 4-53 Spearman Correlation between Continuous Haemodynamic Response 
to Individual Autonomic Function and Change in Cognitive Score at Follow-up 
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Change in MMSE 
r 0.02 -0.05 0.02 0.06 -0.17 -0.04 0.00 
P 0.83 0.66 0.86 0.56 0.11 0.74 0.99 
Change in total 
CAMCOG score 
r 0.11 -0.04 -0.11 -0.08 -0.31 -0.17 -0.01 
P 0.27 0.70 0.30 0.45 <0.01 0.09 0.93 
Change in CAMCOG 
memory score 
r 0.16 -0.08 -0.02 -0.15 -0.28 -0.31 -0.02 
P 0.12 0.46 0.81 0.15 0.01 <0.01 0.86 
Change in CAMCOG 
executive score 
r 0.03 0.19 -0.02 -0.03 -0.06 0.07 0.23 
P 0.77 0.07 0.84 0.74 0.54 0.49 0.03 
 
After adjusting for covariates, only the associations between 30:15 ratio and change in 
total CAMCOG remained significant. Lower 30:15 ratio was associated with greater 
decline in total CAMCOG score over the follow-up period (Table 4-54). There was a 
borderline association between 30:15 ratio and change in CAMCOG memory score 
(Table 4-55).  
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Table 4-54 Linear Regression Examining the Independent Association Between 
30:15 Ratio and Change in CAMCOG Total Score 
 B 95% CI P 
Age 0.20 -0.05 0.45 0.12 
Sex 0.66 -1.41 2.73 0.53 
High blood pressure 1.12 -1.37 3.61 0.37 
Diabetes 1.37 -4.30 7.05 0.63 
Smoker (yes / no) -2.51 -6.67 1.64 0.23 
Any cardioactive drug 0.38 -2.16 2.91 0.77 
Years in education -0.18 -0.54 0.19 0.34 
Any cardiovascular or cerebrovascular 
disease 
-1.60 -3.84 0.65 0.16 
Psychotropic Medication 0.31 -2.35 2.96 0.82 
Consumes alcohol (yes / no) 1.92 -0.25 4.09 0.08 
Cornell 0.36 0.08 0.64 0.01 
CAMCOG Total Score at Baseline -0.15 -0.42 0.13 0.29 
30:15 ratio -13.41 -23.74 -3.08 0.01 
Dependent variable: Change in Total CAMCOG score over Follow-up 
Adjusted Model R
2 = 
0.14  
     
Table 4-55 Linear Regression Examining the Independent Association Between 
30:15 Ratio and Change in CAMCOG Memory Score 
  B 95% CI P 
Age 0.06 -0.04 0.16 0.25 
Sex 0.41 -0.45 1.27 0.34 
High blood pressure -0.15 -1.19 0.89 0.78 
Diabetes 1.72 -0.57 4.02 0.14 
Smoker (yes / no) -0.10 -1.79 1.58 0.90 
Any cardioactive drug 1.34 0.27 2.41 0.02 
Years in education -0.13 -0.27 0.01 0.07 
Any cardiovascular or cerebrovascular 
disease 
-0.82 -1.75 0.11 0.08 
Psychotropic Medication -0.27 -1.39 0.85 0.63 
Consumes alcohol (yes / no) 0.36 -0.52 1.23 0.42 
Cornell 0.06 -0.05 0.18 0.30 
CAMCOG Memory Score at Baseline -0.26 -0.49 -0.04 0.02 
30:15 ratio -4.09 -8.29 0.11 0.06 
Dependent variable: Change in CAMCOG Memory Score 
Adjusted Model R
2
= 0.25  
 
116 
 
 Continuous Response to Individual Autonomic Function Tests at Baseline 4.9.4
and Incident Cognitive Impairment 
Haemodynamic response to autonomic function tests was not associated with cognitive 
impairment defined as MMSE <24 or total CAMCOG ≤80 (Table 4-56) 
 
Table 4-56 Association between Haemodynamic Response to Autonomic Function 
Tests at Baseline and Cognitive Impairment at Follow-up 
 
 Continuous Response to Individual Autonomic Function Tests at Baseline 4.9.5
and Cognitive Decline 
Greater 30:15 ratio was associated with significantly lower odds ratio of a fall in MMSE 
of four or more points or fall in total CAMCOG of five or more points. Greater Valsalva 
overshoot was associated with increased OR of fall in MMSE of four or more points 
(Table 4-57). None of these associations was significant after adjusting for potential 
covariates.  
 MMSE <24 Total CAMCOG ≤80 
 OR 95% CI P  OR 95% CI P 
30:15 Ratio 7.21 0.01, 138573 0.70 0.01 0.00, 264 0.30 
Cold pressor DBP 
difference (mmHg) 
0.98 0.85, 1.13 0.78 1.02 0.89, 1.17 0.78 
Isometric Exercise  BP 
difference (mmHg) 
1.02 0.97, 1.08 0.48 0.95 0.88, 1.02 0.14 
Valsalva SBP overshoot 
(mmHg) 
1.03 0.99, 1.06 0.18 0.96 0.91, 1.01 0.13 
Valsalva ratio 0.22 0.00, 15.6 0.49 0.22 0.00, 29.1 0.55 
Heart rate response to 
deep breathing (B.P.M) 
0.98 0.84, 1.13 0.74 1.09 0.92, 1.28 0.32 
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Table 4-57 Logistic Regression Examining Association between Haemodynamic 
Response to Autonomic Function Tests and Cognitive Decline 
 
 Heart Rate Variability at Baseline and Cognition at Follow-up 4.10
Of the 99 individuals who underwent full cognitive testing at follow-up, 88 had heart 
rate variability assessed at baseline. Of these 80 had recordings where less than 10% of 
the beats were interpolated or ectopic beats and were therefore suitable for analysis.   
 Heart Rate Variability at Baseline and Cognition at Follow-up 4.10.1
Examining the association between heart rate variability and cognition at ten years did 
not show any associations between HRV parameters and MMSE or CAMCOG. An 
association was observed between the cognitive reaction time and HF/LF ratio (Table 
4-58). This was not significant after adjusting for covariates. There was no association 
between HRV parameters and change in cognitive scores (Table 4-59). 
 
 Drop in MMSE of ≥ 4 
points 
Drop in CAMCOG 
TOTAL of ≥ 5 points 
 OR 95% CI P OR 95% CI P 
30:15 Ratio 
 
0.01 0.00, 0.96 0.05 0.01 0.00, 0.98 0.05 
Cold pressor DBP 
difference (mmHg) 
0.92 0.82, 1.03 0.13 1.00 0.95, 1.06 0.96 
Isometric Exercise DBP 
difference (mmHg) 
0.98 0.93, 1.03 0.34 0.97 0.94, 1.01 0.97 
Valsalva SBP overshoot 
(mmHg) 
1.03 1.00, 1.05 0.04 1.00 0.99, 1.02 1.00 
Valsalva ratio 
 
6.25 0.61, 63.8 0.12 0.69 0.16, 3.04 0.62 
Heart rate response to 
deep breathing (B.P.M) 
0.99 0.88, 1.11 0.84 1.00 0.94, 1.06 0.88 
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Table 4-58 Spearman Correlation between Heart Rate Variability and Cognitive 
Function at Follow-up 
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MMSE  r -0.06 0.00 0.00 0.04 0.01 0.03 
P 0.61 0.97 1.00 0.74 0.92 0.80 
Total CAMCOG  r 0.01 0.07 0.13 0.12 -0.03 -0.21 
P 0.95 0.50 0.22 0.25 0.79 0.05 
CAMCOG m r -0.02 0.02 0.06 0.07 -0.09 -0.19 
P 0.86 0.88 0.61 0.53 0.38 0.08 
CAMCOG executive  r 0.04 0.08 0.07 0.16 0.03 -0.11 
P 0.73 0.45 0.54 0.14 0.77 0.31 
CRT (ms) r -0.02 -0.06 -0.06 -0.08 -0.01 0.09 
P 0.84 0.59 0.59 0.44 0.90 0.41 
SRT (ms) r -0.02 0.03 0.08 0.03 -0.07 -0.15 
P 0.85 0.79 0.44 0.76 0.53 0.15 
VigRt (ms) r -0.08 -0.03 -0.04 -0.01 -0.01 -0.03 
P 0.49 0.76 0.74 0.93 0.91 0.79 
CogRT (ms) r 0.02 -0.05 -0.09 -0.09 0.05 0.22 
P 0.87 0.64 0.40 0.40 0.66 0.04 
POA (ms) r -0.06 -0.04 -0.01 -0.04 -0.05 -0.04 
P 0.61 0.72 0.90 0.71 0.62 0.71 
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Table 4-59 Spearman Correlation between Heart Rate Variability and Cognitive 
Decline over Follow-up 
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Change in MMSE r 0.01 -0.03 -0.03 -0.08 -0.07 -0.06 
P 0.93 0.75 0.76 0.45 0.50 0.55 
Change in total 
CAMCOG score 
r -0.04 -0.10 -0.17 -0.12 -0.07 0.07 
P 0.73 0.35 0.12 0.27 0.51 0.55 
Change in CAMCOG 
memory score 
r 0.14 0.13 0.10 0.12 0.11 0.01 
P 0.19 0.21 0.34 0.25 0.31 0.91 
Change in CAMCOG 
executive score 
r -0.06 -0.08 -0.05 -0.08 -0.14 -0.13 
P 0.60 0.48 0.62 0.44 0.20 0.24 
 Heart Rate Variability at Baseline and Cognitive Impairment 4.10.2
Heart rate variability was not associated with an MMSE <24 at follow-up or a total 
CAMCOG of ≤ 80 (Table 4-60) 
 
Table 4-60 Logistic Regression Examining Association between Baseline Heart 
Rate Variability and Cognitive Impairment at Follow-up 
 MMSE <24 Total CAMCOG ≤80 
 OR 95% CI P  OR 95% CI P 
SDRR (ms) 0.96 0.83, 1.11 0.56 0.93 0.83, 1.05 0.24 
Total Power (ms
2
) 1.00 0.99, 1.01 0.84 1.00 0.99, 1.00 0.44 
VLF (ms
2
) 1.00 0.99, 1.01 0.63 1.00 0.99, 1.00 0.88 
LF (ms
2
) 1.00 0.99, 1.01 0.59 0.99 0.98, 1.01 0.28 
HF (ms
2
) 0.98 0.93, 1.02 0.32 0.99 0.96, 1.01 0.24 
HF/LF ratio 0.41 0.01, 24.8 0.67 2.24 0.89, 5.69 0.09 
 
 Heart Rate Variability at Baseline and Cognitive Decline 4.10.3
Similarly there were no significant associations between heart rate variability and 
decline in MMSE of ≥4 points or a decline in total CAMCOG score of ≥5 points.  
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Table 4-61 Logistic Regression Examining Association between Baseline Heart 
Rate Variability and Cognitive Decline Over Follow-up  
 
  Summary of Key Findings in Chapter 4. 4.11
To summarise the following associations were noted in this chapter.  
 Change in Cognition 4.11.1
Scores on the MMSE and CAMCOG were significantly lower at ten year follow-up 
than at baseline 
 Hypertension and Cognition 4.11.2
Among participants who were hypertensive at baseline a significantly higher proportion 
were found to have a drop in total CAMCOG score of ≥5 points indicating cognitive 
decline. This remained significant after adjusting for age, sex, cardiovascular risk 
factors and cardioactive medication including antihypertensive medication.  
 
 OR 95% CI P 
 Drop in MMSE of ≥ 4 points 
SDRR (ms) 1.03 0.97, 1.08 0.39 
Total Power (ms
2
) 1.00 0.99, 1.00 0.96 
VLF (ms
2
) 1.00 0.99, 1.00 0.78 
LF (ms
2
) 1.00 0.99, 1.00 0.52 
HF (ms
2
) 1.00 0.99, 1.00 0.41 
HF/LF ratio 2.14 0.92, 4.96 0.08 
 Drop in CAMCOG TOTAL of ≥ 5 points 
SDRR (ms) 0.99 0.96, 1.03 0.72 
Total Power (ms
2
) 1.00 0.99, 1.00 0.51 
VLF (ms
2
) 1.00 0.99, 1.00 0.41 
LF (ms
2
) 1.00 0.99, 1.00 0.21 
HF (ms
2
) 1.00 0.99, 1.00 0.57 
HF/LF ratio 1.95 0.84, 4.52 0.12 
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 Ambulatory Blood Pressure and Cognition 4.11.3
Lower daytime mean systolic BP was associated with longer cognitive reaction time a 
longer choice reaction time. After adjusting for covariates this only remained significant 
for the association between mean systolic BP and cognitive reaction time. Longer 
cognitive reaction times were also associated with lower 24 hour mean systolic BP.  
 
Greater nighttime BP variability at baseline was independently associated with poorer 
MMSE and total CAMCOG scores at follow-up. Greater decline in these scores was 
also indepently associated with greater nocturnal diastolic BP variability at baseline 
 
Decline in total CAMCOG of ≥5 points was independently associated with greater 
daytime systolic and diastolic BP variability, greater 24 hour mean systolic and diastolic 
BP and greater 24 hour systolic and diastolic BP variability.  
 Active Stand 4.11.4
Orthostatic hypotension was not associated with cognition at ten years. Symptomatic 
OH was associated greater change in CAMCOG memory. There were no significant 
associations between cognitive function at follow-up and degree of vasodepression or 
BP nadir during active stand.  
 Carotid Sinus Massage 4.11.5
CSH and CSS at baseline were not associated with cognitive function at follow-up. Nor 
were they associated with change in cognition, incident cognitive impairment or 
cognitive decline. Similarly, degree of vasodepression and / or RR interval post CSM 
were not associated with cognitive function at follow-up or change in cognitive function 
over the ten year follow-up interval.  
 Autonomic Function 4.11.6
Abnormal autonomic function at baseline was associated with a greater change in total 
CAMCOG score over the ten year follow-up interval but this did not remain significant 
after adjusting for covariates. When autonomic tests were examined individually longer 
30:15 ratio was independently associated with greater decline in CAMCOG total score. 
After adjusting for potential covariates, heart rate variability at baseline, was not 
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associated with cognition at follow-up or change in cognition over the follow-up 
interval.  
 
 Discussion 4.12
Comparison of baseline and follow-up scores showed that there had been a significant 
decline in MMSE scores, total CAMCOG scores and CAMCOG subscores over the ten 
year follow-up period. This is in keeping with other longitudinal studies which have 
consistently shown an age-related cognitive decline, particularly among people aged 60 
years and over (Salthouse, 2009, Park et al., 2003). None of the follow-up participants 
scored below 24 on the MMSE at baseline or below 80 on the total CAMCOG at 
baseline. At follow-up, 4% of participants were defined as cognitively impaired using 
these cut-offs. This is markedly lower than the reported prevalence of cognitive 
impairment in the MRC study,  that found 18.3% of a community-dwelling UK adults  
aged ≥75 years have an MMSE<24 and suggests that the sample in this study is not be 
fully representative of the wider general population (Rait et al., 2005). 
 
Individuals lost to follow-up prior to the year ten assessment scored significantly worse 
on cognitive tests at baseline compared to individuals participating in year ten follow-
up. Similarly, compared to the year ten follow-up cohort, the group lost to follow-up 
had significantly longer reaction times at baseline (indicating poorer cognition). None 
of the 15 individuals with cognitive impairment at baseline (total CAMCOG <80) 
participated in the ten year follow-up examination (eight had died, four no longer lived 
in the recruitment area and three declined to participate in the ten year follow-up). There 
was also a suggestion that, compared to individuals lost to follow-up, autonomic 
function among ten year follow-up participants may have been better preserved at 
baseline, but this did not reach statistical significance.  
 
These data suggest that the follow-up cohort was not representative of the baseline 
population from which participants were recruited. Every effort was made to make the 
study as accessible as possible to frail older people. All assessments, except the MRI 
scan, were conducted in participants’ homes and provision was made for a personal 
consultee. However, attrition appears to have been greatest in the people with cognitive 
impairment at baseline. This is a common challenge in longitudinal studies involving 
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older people and must to be borne in mind when interpreting the result of the ten year 
follow-up (Chatfield et al., 2005).  
 
Few associations were found between hypertension and either cognitive function at 
follow-up or change in cognitive function over the follow-up period. Hypertension at 
baseline was significantly associated with increased odds of finding that the total 
CAMCOG score had declined by ≥5 points but not with a decline of ≥4 points on 
MMSE. The failure to show an association between hypertension and decline in MMSE 
score may be a result of the ceiling effect observed with the MMSE. This is dealt with 
in further detail later in the discussion.  
 
Several points should be noted when examining associations between blood pressure 
and cognition. Firstly, the age of participants in this study at baseline ranged from 65-83 
years. It is possible that the relationship between blood pressure and cognition is not 
uniform across this age range. Studies suggest hypertension in midlife is associated 
impaired cognitive function in later life (Wolf et al., 2007, Knopman et al., 2009, Singh-
Manoux and Marmot, 2005). However hypertension in later life, particularly among 
individuals aged 80 and over, appears to be less strongly associated with cognitive 
impairment and may even be associated with superior cognitive function (Herbert et al., 
2004, Tervo et al., 2004, Solfrizzi et al., 2004). In this study, greater mean 24-hour BP 
and daytime mean BP at baseline were independently associated with shorter cognitive 
reaction time at ten year follow-up (indicating better cognitive function). Hypotension 
in later life has also been associated with impaired cognitive function and some authors 
suggest a U or J shaped relationship between BP and cognitive function in older people 
(Glynn et al., 1999, Bohannon et al., 2002, Ruitenberg et al., 2001, Morris et al., 
2001b). The small sample size in this study meant it was not possible to examine if 
there was an interaction between age, blood pressure and cognition.  
 
The relationship between hypertension and cognition may also be modified by the 
duration of hypertension. Recent studies have shown that cognition is affected only in 
individuals with long duration of hypertension, regardless of age (Power et al., 2013).  
Although hypertensive status at baseline was known, duration of hypertension prior to 
baseline assessment, and degree of BP control following baseline assessment was not 
known. It is likely that BP control has improved in this cohort since baseline 
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assessment. During the study follow-up period control of cardiovascular risk factors 
became a public health priority (Redwood, 2007).  Since 2005, general practitioners in 
England have been financially incentivised to identify patients with hypertension and 
optimise BP control. Examination of GP records and ambulatory BP recordings at 
baseline and follow-up revealed significantly fewer unrecognised hypertensive patients 
within the cohort at follow-up and that significantly more individuals were treated to 
target BP at follow-up compared with baseline (McDonald et al., 2013). These 
improvements in hypertension management may have weakened the association 
between hypertension and cognition. 
 
In an attempt to control for the effects of antihypertensive treatment on outcomes in this 
study, adjustment was made in multivariable models for “use of antihypertensive 
medication” or “use of cardioactive medication”. Controlling for use of antihypertensive 
medication makes no allowance for duration of treatment, degree of BP control attained 
or compliance with medication. Furthermore, it is increasingly recognised that 
antihypertensive agents, particularly ACE inhibitors and angiotensin receptor blockers 
have class specific neuroprotective properties (Macquin-Mavier et al., 2013). Because 
of the small sample size, adjustment could not be made for individual classes of 
antihypertensive agents. Class specific effects will therefore not have been accounted 
for in the analysis.  
 
Analysis of the association between BP variability and cognition also revealed mixed 
results. After adjusting for potential covariates, greater night-time diastolic BP 
variability was independently associated with poorer MMSE and total CAMCOG score 
at follow-up, and with greater decline in these scores over the follow-up period. 
Daytime and 24-hour BP variability were not associated with cognition at follow-up or 
change in cognition over the follow-up period.  Greater daytime and 24-hour systolic 
and diastolic BP variability were, however, both independently and significantly 
associated with increased odds of participants’ total CAMCOG score having fallen five 
or more points over the follow-up interval. These findings suggest greater BP variability 
maybe associated with subsequent cognitive decline.  
 
There are no other published studies examining the long-term association between 24-
hour blood pressure variability and cognition. Cross-sectional studies examining 24-
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hour BP variability have shown that increases in both systolic and diastolic BP 
variability are associated with poorer cognitive function (Sakakura et al., 2007, Kerr, 
2009). Sakakura showed that participants with greatest BP variability scored 
significantly less well on the MMSE and Kerr et al showed increased greater BP 
variability was associated with deficits in attention, processing speed and executive 
function (Sakakura et al., 2007, Kerr, 2009). Studies have also shown increased systolic 
and diastolic BP variability among patients with cognitive impairment (Bellelli et al., 
2002, Kanemaru et al., 2001, Marti-Fabregas et al., 2001). 
 
In addition to BP variability, 24 ABPM recordings also allow calculation of diurnal 
variation and nocturnal BP dipping pattern. In this study, percentage diurnal variation 
was not associated with cognition at follow-up or change in cognition over the follow-
up period. Similarly, dipping status was not associated with cognition at ten years, 
cognitive decline or incident cognitive impairment.  Only one other study has examined 
the longitudinal association between blood pressure diurnal variation and cognitive 
impairment. Yamamoto et al followed-up 177 older people who had presented with a 
first lacunar infarct and had undergone 24-hour ABPM (Yamamoto et al., 2005). 
Participants were defined as dippers or non-dippers. Twenty-six participants developed 
incident dementia over a mean follow-up period of 8.7 years. In contrast to the findings 
of this study non-dipping status was a significant, independent risk factor for incident 
dementia (RR, 7.1; 95% CI, 2.2 to 22.0) (Yamamoto et al., 2005).  
 
Most data regarding the association between BP diurnal variation and cognition come 
from cross-sectional studies. Several studies have shown an association between loss of 
normal dipping pattern and cognitive impairment or dementia (Bellelli et al., 2004, Guo 
et al., 2009, van Boxtel et al., 1998, Yamamoto et al., 2005). In addition, smaller 
percentage changes between daytime and nigh-time BP have been associated with 
poorer cognitive function, particularly executive function (Kerr, 2009, Ohya et al., 
2001). The low rate of incident cognitive impairment in this study and the small number 
of participants in each group (dippers N= 38, non-dipper N=35, extreme-dipper N=11) 
may have limited the power of the study to detect small differences in cognition 
between groups or an association with incident cognitive impairment.  
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This follow-up study did not show any statistically significant associations between the 
components of neurocardiovascular instability (OH and CSH) and cognitive function at 
follow-up, cognitive decline over the follow-up period or incident cognitive impairment 
at ten year follow-up. Similarly, the sizes of haemodynamic responses to the active 
stand or carotid sinus massage were not associated with cognitive performance at ten 
years.  
 
Abnormal autonomic function at baseline was not associated with cognition at follow-
up. Although univariate analysis revealed abnormal autonomic function was associated 
with a significantly greater decline in CAMCOG total score, this was not significant 
after adjusting for potential demographic and cardiovascular covariates. This suggests 
that the relationship between abnormal autonomic function and cognitive decline is 
secondary to age and other vascular risk factors.  Abnormal autonomic function was not 
significantly associated with incident cognitive impairment.  
 
Examining associations between the response to individual autonomic function tests and 
cognitive scores at follow-up did not reveal any significant independent associations 
with the tests of parasympathetic or sympathetic function. Lower 30:15 ratio at baseline 
was however independently associated with greater decline in total CAMCOG score 
over the follow-up period.  
 
Few associations were observed between heart rate variability at baseline and cognition 
at follow-up and these were not significant after adjusting for covariates, again 
suggesting that the observed association is secondary to age and cardiovascular risk 
factors. No associations were observed between HRV and cognitive decline over 
follow-up period or incident cognitive impairment.  
 
Overall, after adjusting for potential covariates, there were few associations between 
altered autonomic function and / or neurocardiovascular instability at baseline and 
cognitive impairment or cognitive decline at follow-up. These findings are in keeping 
with other longitudinal studies examining the association between autonomic function, 
NCVI and cognitive function (Viramo et al., 1999, Rose et al., 2010, Yap et al., 2008, 
Elmstahl and Rosen, 1997, Britton et al., 2008). 
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Viramo et al followed-up 651 community-dwelling people aged ≥70 years and found 
neither systolic or diastolic OH predicted cognitive decline at a 2.5 year follow-up 
(Viramo et al., 1999). Rose et al showed a weak association between OH and 
performance on Digital Symbol Subtraction Test and Word Fluency Test. However 
after adjusting for demographic and cardiovascular risk factor, this finding was no 
longer statistically significant(Rose et al., 2010). Yap et al followed up 2321 
community-dwelling Chinese older people. Despite finding a cross-sectional association 
between OH and cognitive impairment at baseline, they found no association between 
OH and cognitive decline over a one year follow-up period (Yap et al., 2008). Only one 
longitudinal study has found an association OH and cognition.  The study was small 
with just 33 healthy woman, but with a longer follow-up period (5 years). Women who 
developed cognitive decline had significantly greater orthostatic fall in BP at baseline 
(Elmstahl and Rosen, 1997).  
 
To my knowledge, there are no studies examining the long-term association between 
CSH and cognition and only one longitudinal study has examined the longitudinal 
association between HRV and cognition. Britton et al examined HRV in 5375 middle-
aged people. In keeping with the findings of this study, they found that there was no 
association between HRV and cognition at five and twelve years follow-up or decline in 
cognition during the intervening seven years between follow-up cognitive assessments 
(Britton et al., 2008).  
 
The lack of long-term association between NCVI, autonomic dysfunction and cognition 
found in longitudinal studies is in contrast to findings from cross-sectional studies.  
Several studies report a higher prevalence of OH among patients with dementia than 
among aged matched controls and poorer cognitive function has been observed among 
individuals with OH (Matsubayashi et al., 1997, Mehrabian et al., 2010, Allcock et al., 
2006, Andersson et al., 2008). Similarly, cross-sectional studies have shown CSH to be 
more common among people with dementia, and a greater degree of vasodepression in 
response to CSH has been associated with more severe white matter disease among 
patients with dementia (Ballard et al., 2000, Kenny et al., 2004). Several studies have 
compared HRV and response to autonomic function tests among healthy controls and 
patients with dementia (Allan et al., 2007, Algotsson et al., 1995, Allan et al., 2005, 
Elmstahl et al., 1992, Giubilei et al., 1998, Kim et al., 2006). Most have shown altered 
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response to autonomic function tests and reduced HRV in patients with dementia,  
particularly patients with Parkinson’s disease dementia and dementia of Lewy body 
(Allan et al., 2007, Algotsson et al., 1995, Allan et al., 2005, Elmstahl et al., 1992, 
Giubilei et al., 1998, Kim et al., 2006). Population studies have also shown cognitive 
impairment to be more common among those with reduced HRV, particularly 
parasympathetic activity (Kim et al., 2006).  
 
It was the initial hypothesis that episodic hypotension results in cognitive decline due to 
cerebral hypoperfusion and anoxic damage to cerebral white matter. However, the fact 
that this study and other longitudinal studies have not demonstrated an association 
between NCIV and cognitive impairment raises questions about the direction of the 
relationship, possibly indicating that the reported cross-sectional associations between 
NCVI and cognitive decline result from concurrent neurodegeneration of CNS 
structures integral for normal cognition and control of the autonomic nervous system.  
 
Several studies support the hypothesis that autonomic nervous system dysfunction is a 
consequence of dementing diseases rather than a precipitating risk factor. Patients with 
alpha synucleopathies such as Parkinson’s disease dementia and dementia of Lewy 
body frequently demonstrate both autonomic dysfunction and cognitive 
impairment(Jellinger, 2011). In both conditions, Lewy bodies are found throughout the 
autonomic nervous system. Lewy bodies are also found in the brain stem, including the 
dorsal vagus nerve nucleus, important in the autonomic control of the cardiovascular 
system (Korczyn and Gurevich, 2010, Allan et al., 2007). Cardiac MIBG-I uptake is 
severely reduced in PD and DLB indicating sympathetic nerve damage (Oka et al., 
2007). PD, DLB and AD have also all been associated with an underactive cholinergic 
system and in AD anti-cholinesterase inhibitors may normalise heart rate response to tilt 
testing (Allan et al., 2007). Alzheimer’s disease has been associated with early 
involvement of the insula. The insula has been implicated in autonomic control and 
insula pathology is associated with arrhythmia and autonomic dysfunction (Royall et al., 
2006). Cross-sectional associations between cognition and autonomic impairment may 
therefore be a feature of wider neurodegenerative processes associated with dementia, 
and the lack of longitudinal findings may indicate autonomic and cognitive dysfunction 
progress concurrently in these conditions.    
 
129 
 
Alternatively, features of the study may have precluded detection of a longitudinal 
association between episodic hypotension and cognition. The sample size was small, 
potentially limiting the power of the study to detect small differences in reaction times 
or changes in cognitive function between groups.  Review of the study’s power showed 
that when comparing the CSH and OH positive groups with “normal” individuals there 
was ≥80 percent power to detect differences between groups of; ≥1.5 point on MMSE 
and CAMCOG memory score, ≥2.5 points on CAMCOG executive score and ≥3 points 
on total CAMCOG score. When comparing COMPASS scores between these groups, 
the study had power to detect differences of 30 – 75 ms depending on reaction time. It 
could therefore be argued that the study has sufficient power to detect clinically 
significant changes in cognitive function. The surprisingly small number of participants 
with MMSE <24 in the cohort did, however, limit the study’s power to detect 
associations with incident cognitive impairment.  
 
The challenges in measuring cognitive decline should also be noted. In order to measure 
change it is important to administer the same cognitive tests. However, with repeated 
attempts ability to perform the test may improve. This practice effect can compensate 
for true deteriorations in cognitive function and may obscure associations with cognitive 
decline. Unsolicited comments from patients revealed they had checked the date, 
practiced serial sevens and reminded themselves who the Prime Minster was before the 
follow-up assessment. This was particularly problematic for the questions contained in 
the MMSE which many of participants had been routinely asked if admitted to hospital 
and were therefore very familiar with the test.  
 
The MMSE had a marked ceiling effect; 38% of participants had an MMSE score of 30 
at baseline and 19.2% had an MMSE score of 30 at follow-up. In order to detect change 
in cognitive performance accurately the test used must be able to measure cognitive 
performance at all levels of function. If the test has a ceiling effect, individuals who 
attain the highest cognitive scores at baseline and follow-up may have undergone 
cognitive decline not detected by the test. Persons with the highest scores on the MMSE 
could only change in one direction meaning random variation in test scores will not be 
evenly distributed around the initial score (Morris et al., 1999). Several variables in this 
study were associated with a decline in CAMCOG total score of >5 points but not with 
decline on MMSE >4. In contrast to the MMSE, the CAMCOG did not appear to have a 
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ceiling effect. This may account for some of the inconsistencies observed in this study. 
Statistical methods that allow inclusion of cognitive test results from additional time 
points may allow for better control of random variation in cognitive scores and 
regression towards the mean. Follow-up cognitive testing had also been conducted at 2 
and 5 years. Exploratory analysis was conducted to examine if random effects 
modelling or generalised estimating equations would allow inclusion of these data in the 
analysis. The data however did not meet the required model assumptions of random 
effects modelling, most notably the residuals were not normally distributed and despite 
attempts to transform the data this could not be rectified. Boththese statistical methods 
usually require attrition from the study to be random which was not the case in this 
sample. Attrition in this study was associated with poorer cognitive function and older 
age at baseline. Reaction times are continuous data without ceiling effect and may 
therefore allow better detection of change. Unfortunately, due to the differences in the 
way CDR and COMPASS handle data it was not possible to assess change in reaction 
times.  
 
The long-follow-up interval increased the likelihood of an individual dying before the 
final assessment. Individuals who developed cognitive impairment but died before the 
ten year follow-up assessment have not been accounted for in this analysis. As cognitive 
impairment is associated with increased mortality it possible that the individuals who 
have died were more likely to have developed cognitive impairment (Dewey and Saz, 
2001). Autonomic dysfunction and NCVI have also been associated with premature 
mortality (Fedorowski et al., 2010, Verwoert et al., 2008, Rose et al., 2006, Masaki et 
al., 1998, Maser et al., 2003). It is therefore possible that individuals with more severe 
autonomic disease at baseline have died before year 10 cognitive assessment could be 
completed. These issues are examined in detail in the Chapter 8, page 238.  
 
It should also be noted that testing of NCVI and autonomic function poses difficulties. 
Prevalence of neurocardiovascular and autonomic dysfunction increases with increasing 
age. Neurocardiovascular function was only measured at baseline. It is likely that some 
of the individuals without NCVI at baseline may have developed abnormalities of BP 
control over the follow-up period but these have not been accounted for. This may lead 
to an underestimate of the role of NCVI in subsequent cognitive decline or impairment.  
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Finally it may be that NCVI is only associated with cognitive impairment / decline in 
select subgroups. In order for systemic hypotension to cause cerebral hypoperfusion, BP 
must fall below the lower limit of cerebral autoregulation. Although many participants 
experienced large changes in systemic BP, it is not known if these changes caused BP to 
fall outside the limits of cerebral autoregulation. Symptoms of dizziness, presyncope 
and syncope are thought to be a potential clinical marker of cerebral hypoperfusion. The 
relatively low number of participants reporting symptoms during the active stand and 
carotid sinus massage may suggest that most individuals maintained cerebral perfusion 
through effective cerebral autoregulation. Interestingly, symptomatic orthostatic 
hypotension was independently associated with greater decline in CAMCOG memory. 
Other recently published studies also suggest that NCVI only threatens cognitive 
function in select patient groups. Frewen et al showed that OH was only associated with 
impaired cognition in individuals with supine hypertension (Frewen et al., 2013). 
Hypertension is known to alter the cerebral autoregulation such that the lower limit of 
autoregulation is elevated. It is possible that hypertension predisposes individual to 
cerebral hypoperfusion during episodes of OH.   
 
In conclusion, this study has not shown an association between NCVI and change in 
cognitive function over ten year follow-up in healthy community-dwelling people. 
Further, larger, studies are needed to examine if there are select subgroups for which 
CSH and OH are associated with future cognitive decline.  
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Chapter 5 The Long-term Association between 
Neurocardiovascular Function and Depression  
 Introduction 5.1
The vascular depression hypothesis posits that depression, at least in some older people, 
is a result of cerebrovascular disease(Taylor et al., 2013). Late-life depression is 
associated with white matter hyperintensities (WMH), believed to be a hallmark of 
small vessel cerebrovascular disease (Taylor et al., 2013, Alexopoulos, 2006, Chen et 
al., 2006, de Groot et al., 2000, Firbank et al., 2005, Godin et al., 2008, Firbank et al., 
2004). Community studies, however, have often failed to show an association between 
conventional vascular risk factors and depression in later life (Valkanova and Ebmeier, 
2013). It has been suggested that this may be because the cerebrovascular changes as 
evidenced by WMH result from atypical risk factors such as cerebral hypoperfusion 
secondary to age-related changes in autonomic function and neurocardiovascular 
instability (Vasudev et al., 2011, Richardson et al., 2009).  
 Aim 5.2
To establish the long-term associations between autonomic dysfunction, NCVI and 
depression in older community-dwelling adults.  
 Methods 5.3
 Tests of Neurocardiovascular Function 5.3.1
Tests of neurocardiovascular function performed at baseline are described in detail in 
section 2.3, page 42.  
 Examination of Depression 5.3.2
The Cornell depression scale was used at baseline and follow-up to assess depressive 
symptoms among participants. This 19-itemed semi-structured interview takes into 
account information obtained from the participant and a relative or carer(Alexopoulos et 
al., 1988a). The score was developed initially for use among older people with dementia 
but has since been validated in non-demented older people (Alexopoulos et al., 1988b).  
Scores of 10 or more are indicative of probable major depression. Cornell scores have 
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been associated with severity of depressive symptoms, higher scores indicating more 
severe depression (Alexopoulos et al., 1988a).  
 Outcome Variables 5.3.3
Initial analysis considered the associations between baseline neurocardiovascular 
function and three outcome variables. 
1. Cornell score obtained at follow-up assessment 
2. Change in Cornell score over the follow-up period. Follow-up score was 
subtracted from baseline score. Positive integers therefore indicate an 
improvement in depressive symptoms, while negative integers indicate a 
worsening of depressive symptoms.  
3. Cornell score ≥10 at follow-up, indicating probable severe depression at follow-
up 
 
To take account of medication, analyses were then repeated with two further dependent 
variables 
1. Cornell score ≥ 10 and /or use of antidepressant medication at follow-up.  
2. Incident depression: Cornell score ≥ 10 and /or use of antidepressant medication 
at follow-up, but no use of antidepressant medication at baseline and baseline 
Cornell score ≤10.  
 
 Results 5.4
 Depression Scores at Year 10 Follow-up 5.4.1
Of the 104 participants taking part in follow-up examination, one individual died and 
two participants withdrew from the study before assessment of depression was 
completed. Data were incomplete for three individuals as collateral history could not be 
obtained. Ninety-eight participants therefore had fully completed Cornell depression 
score.  
 
Median Cornell depression score was higher at follow-up than at baseline, (P=0.002) 
(Table 5-1). The number of individuals with Cornell scores ≥10 (indicative of probable 
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depression) however, had decreased from eight to six. This change was not significant 
(P=0.78).  
 
Table 5-1 Comparison of Cornell Depression Score at Baseline and Follow-up for 
the 98 Individuals Completing Depression Assessment at year 10  
Variable Baseline scores 
N = 98 
Ten year follow-
up N = 98 
P 
 Median (IQR) Median (IQR)  
Cornell depression scale 
score 
2.0 (1.0, 5.0) 4.0 (2.0, 6.0) 0.002 
 
 Ambulatory Blood Pressure Recordings at Baseline and 5.5
Depression at Follow-up 
Of the 98 participants for whom Cornell depression scores were available at ten years, 
97 had ambulatory BP monitoring at baseline. All had 16 or more BP recordings over 
the 24-hour period and were suitable for analysis.  
 Baseline Hypertension Status and Depression at Follow-up 5.5.1
Comparing individuals who were hypertensive at baseline, defined according to NICE 
guidelines (mean daytime BP >135/80 on baseline ABPM), with normotensive 
participants did not reveal any significant difference in Cornell score at ten years or 
change in Cornell scores (Table 5-2). There was no association between hypertension 
status and participants having a Cornell score of 10 or more at follow-up (Table 5-3).  
 
Table 5-2 Association between Hypertension Status at Baseline and Depression 
Scores at Follow-up 
 Hypertension N=44 No Hypertension 
N=53 
P 
 Median  
(IQ range) 
Median  
(IQ range) 
 
Cornell score at year ten 3.0 (2, 6) 4.0 (1.5, 6) 0.65 
Change in Cornell score -1 (-3.5, 0.5) -1 (-3.0, 1.0) 0.85 
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Table 5-3 Association between Hypertension Status and Frequency of Cornell 
Depression Scores ≥10 
 Hypertension N=43 No Hypertension 
N=52 
P 
 Frequency 
(percentage) 
Frequency 
(percentage) 
 
Cornell score ten or more at 
year ten  
2 (5%) 4 (8%) 0.69 
 
Because the NICE criteria are stricter than many definitions of hypertension, these 
analyses were repeated with hypertension defined as a mean daytime BP ≥150/90. This 
did not reveal any additional significant associations between BP ≥ 150/90 and Cornell 
depression score at follow-up, or change in Cornell depression score. Similarly, a 
Cornell score of ten or more was not associated with BP ≥ 150/90.  
 Ambulatory BP Results at Baseline and Cornell Depression Score at 5.5.2
Follow-up 
Examining the continuous relationship between Cornell scores at follow-up and 24-hour 
ABPM variables did not show any significant associations. Nor were any associations 
observed between daytime or night-time BP variables and Cornell scores at ten years 
(Table 5-4). Similarly, no associations were observed between change in Cornell scores 
over the follow-up interval and ABPM variables (Table 5-5). 
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Table 5-4 Spearman Association between 24-hour ABPM Variables and Cornell 
Score at Follow-up 
 
Mean 
systolic 
pressure 
(mmHg) 
Mean 
diastolic 
pressure 
(mmHg) SD SBP  SD DBP  
24-hour 
Cornell Score 
Year 10 
r 0.07 0.06 0.03 0.15 
P 0.47 0.55 0.74 0.14 
Daytime 
Cornell Score 
Year 10 
r 0.08 0.06 0.09 0.15 
P 0.42 0.54 0.38 0.15 
Night-time 
Cornell Score 
Year 10 
r 0.10 0.13 -0.01 0.13 
P 0.38 0.26 0.90 0.25 
 
 
Table 5-5 Association between 24-hour ABPM Variables and Change in Cornell 
Score over Follow-up 
 
Mean 
systolic 
pressure 
(mmHg) 
Mean 
diastolic 
pressure 
(mmHg) SD SBP SD DBP 
24-hour 
Change in 
Cornell Score 
r 0.01 -0.03 0.08 0.06 
P 0.92 0.77 0.43 0.55 
Daytime 
Change in 
Cornell Score 
r 0.01 -0.03 0.02 -0.03 
P 0.92 0.75 0.89 0.79 
Night-time 
Change in 
Cornell Score 
r -0.07 -0.14 -0.01 0.01 
P 0.53 0.20 0.93 0.93 
 
There was no association between ABPM recordings and incidence of Cornell 
depression score ≥10 (indicative of depression) at follow-up (Table 5-6).  
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Table 5-6 Logistic Regression Examining Association between ABPM Recordings 
and Cornell Score of ≥10 at Follow-up 
 OR 95% CI P 
Daytime    
Mean Systolic Pressure (mmHg) 1.01 0.96, 1.06 0.65 
Mean Diastolic Pressure (mmHg) 1.00 0.93, 1.09 0.95 
SD SBP (mmHg) 0.95 0.74, 1.22 0.70 
SD DBP (mmHg) 0.85 0.56, 1.28 0.44 
Night-time    
Mean Systolic Pressure (mmHg) 1.02 0.95, 1.09 0.60 
Mean Diastolic Pressure (mmHg) 1.00 0.90, 1.12 0.95 
SD SBP (mmHg) 0.94 0.72, 1.22 0.63 
SD DBP (mmHg) 1.00 0.74, 1.35 0.99 
24-hour    
Mean Systolic Pressure (mmHg) 1.01 0.95, 1.07 0.77 
Mean Diastolic Pressure (mmHg) 0.98 0.89, 1.08 0.71 
SD SBP (mmHg) 1.01 0.79, 1.29 0.93 
SD DBP (mmHg) 0.94 0.64, 1.37 0.74 
 Diurnal Variation at Baseline and Depression Scores at Ten years 5.5.3
Eighty-three patients had the 10 or more daytime ABPM recordings and the five or 
more night-time recordings required to calculate diurnal variation. Diurnal variation was 
not associated with year 10 Cornell score or change in Cornell score (Table 5-7). 
Participants were classified as dippers (n= 37), non-dippers (n= 36) and extreme dippers 
(n= 10). There was no significant difference in Cornell score at ten years or change in 
Cornell score between groups.  
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Table 5-7 Association between 24 ABPM Diurnal Variation, Cornell Depression 
Score at Follow-up and Change in Cornell Score over Follow-up 
 Systolic Diurnal 
Variation (%) 
Diastolic Diurnal 
Variation (%) 
 r (P) r (P) 
Cornell score at ten years -0.02 (0.84) 0.01 (0.97) 
Change in Cornell score 0.07 (0.52) 0.07 (0.55) 
 
 Response to Active Stand at Baseline and Depression Score at 5.6
Year 10 
Ninety-three participants underwent active stand at baseline and completed the Cornell 
depression scale at year 10.  
 Orthostatic Hypotension at Baseline and Depression Score at Follow-up 5.6.1
There was no association between presence or absence of OH as defined by AAN at 
baseline and Cornell depression score at year 10, or change in depression score (Table 
5-9). Neither Cornell depression score at ten years nor change in depression score were 
associated OH subtypes or symptomatic OH (Table 5-9).  
 
Table 5-8 Cornel Depression Score at Follow-up and Change in Depression Score 
over Follow-up Period by AAN OH Status 
 OH (AAN 
definition) 
N=75 
No OH  
(AAN definition) 
N=18 
P 
 Median  (IQ 
range) 
Median (IQ 
range) 
 
Cornell depression score at year 10 4.0 (2.0, 6.0) 3.0 (3.0, 6.3) 0.95 
Change in Cornell depression score.  -1.0 (-3.0, 0.0) -0.5 (-1.3, 1.3) 0.27 
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Table 5-9 Cornel Depression Score at Follow-up and Change in Depression Score 
over Follow-up Period by Systolic and Diastolic OH Status 
 Median  
(IQ range) 
Median 
 (IQ range) 
P 
 Systolic OH  
N=58 
No Systolic OH 
N= 35 
  
Cornell depression score at year 10 4.0 (2.0, 6.25) 3.0 (2.0, 6.0) 0.65 
Change in Cornell depression score.  -1.0 (-4.0, 0.3) -1.0 (-2.0, 1.0) 0.54 
 Diastolic OH  
N=67 
No Diastolic OH 
N=26 
 
Cornell depression score at year 10 4.0 (2.0, 6.0) 3.0 (2.0, 6.0) 0.89 
Change in Cornell depression score.  -1.0 (-4.0, 0) 0 (-1.0, 2.0) 0.10 
 Symptomatic OH  
N=12 
No Symptoms  
N=81 
 
Cornell depression score at year 10 5 (2.3, 7.8) 3.0 (2.0, 6.0) 0.42 
Change in Cornell depression score.  -1.0 (-3.0, 1.0) -1 (-3.0, 0.8) 0.91 
 Orthostatic Hypotension at Baseline and Cornell Depression Score ≥ 10 at 5.6.2
Follow-up 
Of the 93 participants who underwent active stand at baseline and completed the 
Cornell depression scale at year 10, six had Cornell depression scores of 10 or more at 
follow-up. Neither OH as defined by AAN or subtypes of OH, were associated with 
Cornell score of 10 or more at follow-up (Table 5-10).  
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Table 5-10 Association between OH (and OH subtypes) and a Cornell Score of 10 
or more at follow-up 
 Frequency (%) Frequency (%) P 
 OH N= 75 No OH N= 18  
Cornell score ≥ 10 5 (6) 1 (6) 1.00 
 Systolic OH N= 58  No Systolic OH  N=35  
Cornell score ≥ 10 5 (9) 1 (3) 0.40 
 Diastolic OH N= 67 No Diastolic OH N= 31   
Cornell score ≥ 10 4 (6) 2 (6) 1.00 
 Symptomatic OH= 12 No Symptoms = 81  
Cornell score ≥ 10 0  6 (7) 1.00 
 
 Continuous Response to Active Stand at Baseline and Depression Score at 5.6.3
Follow-up 
Continuous haemodynamic response to active stand was not associated with Cornell 
depression score at year 10, change in depression score over follow-up period or scoring 
≥10 on the Cornell depression scale (Table 5-11 and Table 5-12).  
 
Table 5-11 Spearman Correlation between Haemodynamic Response to Active 
Stand, Cornell Depression Score and Change in Depression Score over Follow-up  
  
Systolic 
Nadir 
(mmHg) 
Diastolic 
Nadir 
(mmHg) 
Systolic 
Vasodepression 
(mmHg) 
Diastolic 
Vasodepression 
(mmHg) 
Year 10 Cornell score 
r 0.09 0.06 0.02 -0.09 
P 0.39 0.60 0.82 0.37 
Change in Cornell 
score over ten years 
r 0.15 0.14 -0.11 -0.16 
P 0.16 0.19 0.32 0.14 
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Table 5-12 Logistic Regression Analysis Examining the Association between 
Continuous Response to Active Stand and Scoring ≥ 10 on Cornell Depression 
Scale 
 OR 95% CI P 
Systolic Nadir (mmHg) 1.02 0.99, 1.05 0.14 
Diastolic Nadir (mmHg) 1.02 0.96, 1.08 0.58 
Systolic Vasodepression (mmHg) 1.01 0.97, 1.05 0.69 
Diastolic Vasodepression  (mmHg) 0.98 0.89, 1.07 0.59 
 
 Response to Carotid Sinus Massage at Baseline and Depression 5.7
Score at Follow-up 
Eighty-seven participants underwent carotid sinus massage at baseline and completed 
the Cornell depression scale at follow-up.  
 Carotid Sinus Hypersensitivity at Baseline and Depression Score at Follow-5.7.1
up 
Comparing participants with CSH to those without CSH did not reveal any significant 
difference in Cornell depression scores at follow-up or any difference in change in 
Cornell scores over the follow-up period (Table 5-13).  
 
Table 5-13 Association between Carotid Sinus Hypersensitivity, Cornell 
Depression Score at Follow-up and Change in Depression Score 
 CSH  
N=28 
No CSH  
N=59 
 
 Median  
(IQ range) 
Median 
 (IQ range) 
P  
Cornell depression score at year 10 5.0 (2.0, 7.0) 3.0 (2.0, 6.0) 0.24 
Change in Cornell depression score  -1.0 (-4.0, 0.8) -1.0 (-3.0, 1.0) 0.76 
 Carotid Sinus Hypersensitivity at Baseline and Cornell Score ≥ 10 5.7.2
Seven per cent of participants with CSH had Cornell scores of 10 or more at follow-up 
versus 3% of participant without CSH at baseline. This was not significantly different 
(P= 0.66).  
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 Continuous Haemodynamic Response to Carotid Sinus Massage at Baseline 5.7.3
and Cornel Depression Score at Follow-up 
Continuous haemodynamic response to CSM at baseline was not associated with 
Cornell depression score at year 10 or change in depression score over follow-up period 
(Table 5-14). Greater, minimum systolic nadir was, however, associated with scoring 10 
or more on the Cornell depression scale (Table 5-15).  
 
Table 5-14 Spearman Correlation between Continuous Haemodynamic Response 
to CSM and Follow-up Cornell Depression Scores  
 Max RR 
interval (ms) 
Max Vaso-
depression 
(mmHg) 
Minimum 
Systolic Nadir 
(mmHg) 
Max delta RR 
(ms) 
Cornell at year 10 r 0.11 0.05 -0.15 0.13 
P 0.32 0.62 0.16 0.24 
Change in Cornell 
score.  
r -0.04 0.08 0.11 -0.04 
P 0.68 0.48 0.33 0.69 
 
Table 5-15 Logistic Regression Examining Association between Response to CSM 
and Cornell Score ≥ 10 
 OR 95% CI P 
Maximum RR interval (s) 1.23 0.83, 1.83 0.30 
Maximum Vasodepression (mmHg) 0.97 0.91, 1.03 0.26 
Minimum Systolic Nadir (mmHg) 1.03 1.00, 1.05 0.04 
Maximum delta RR interval (s) 1.27 0.86, 1.88 0.24 
 
 Response to Autonomic Function Tests at Baseline and 5.8
Depression Score at Follow-up 
Of the 98 participants who completed the Cornell depression scale at follow-up, 93 had 
results from one or more autonomic function test. The number of participants 
undergoing each of the tests is shown in Table 5-16. 
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Table 5-16 Number of Participants Completing Cornell Depression Score at Ten 
Years and Each Autonomic Function Test at Baseline  
Autonomic Function Test Number of 
participants 
Blood pressure and heart rate response to standing 93 
Blood pressure response to isometric exercise 92 
Blood pressure and heart rate response Valsalva manoeuvre 93 
Blood pressure response to cold stimulation 90 
Heart rate response to deep breathing 88 
 
Eighty-five participants had completed Cornell depression scale at follow-up and had 
results from sufficient tests at baseline to classify participants as having abnormal or 
normal autonomic function according to modified Ewing criteria.   
 Abnormal Autonomic Function at Baseline and Depression Score at Follow-5.8.1
up 
Abnormal versus normal autonomic function at baseline was not associated with 
Cornell score at ten years or change in Cornell score over follow-up period. Nor was it 
associated with a Cornell score or 10 or more at follow-up (Table 5-17).   
 
Table 5-17 Association between Abnormal Autonomic Function at Baseline and 
Cornell Score at Ten Years, Change in Cornell Scores and Cornell Score ≥10 at 
Ten Years.  
 
Normal 
Autonomic 
function  
N=57 
Abnormal 
Autonomic 
function 
N =29 
P  
 Median (IQR) Median (IQR)  
Year 10 Cornell Score 4.0 (1.5, 6.0) 3.5 (2.0, 6.6) 0.97 
Change in Cornell score -1.0 (-3.0, 1.0) -1.0 (-2.8, 0) 0.71 
 
 Frequency (%) Frequency (%) P 
Cornell score at year 10 ≥ 10 points 4 (7) 1 (3) 1.00 
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 Response to Individual Autonomic Function Tests at Baseline and 5.8.2
Depression Score at Follow-up 
Examining association between response to individual autonomic tests and depression 
scores as continuous variables did not show any associations (Table 5-18).  
 
Table 5-18 Association between Continuous Response to Individual Autonomic 
Function Tests and Cornell Score at Year 10 
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Year 10 Cornell Score 
r 
0.02 0.19 0.06 -0.04 -0.19 -0.11 0.12 
P 
0.82 0.07 0.57 0.73 0.07 0.31 0.26 
Change in Cornell Score 
r 
-0.10 -0.03 0.11 0.06 0.08 0.07 -0.07 
P 
0.32 0.76 0.32 0.54 0.47 0.52 0.54 
 
Similarly, there were no associations observed between continuous response to 
individual autonomic function tests and attaining a score of 10 or more on the Cornell 
scale at ten year follow-up.   
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Table 5-19 Results of Logistic Regression Examining Association between 
Continuous Response to Individual Autonomic Function Tests and Attaining a 
score of ≥10 on Cornell Depression Scale at Follow-up.  
Variable Cornell at Ten years ≥ 10 points 
  OR 95% CI P 
Stand SBP drop (mmHg) 1.01 0.97, 1.05 0.69 
Cold pressor DBP difference (mmHg) 1.12 0.99, 1.26 0.06 
Isometric Exercise DBP difference (mmHg) 0.99 0.93, 1.05 0.70 
Valsalva SBP overshoot (mmHg) 1.00 0.97, 1.03 0.98 
30:15 ratio 0.06 0.00, 442 0.54 
Valsalva ratio 0.83 0.04, 17.5 0.90 
Heart rate response to deep breathing 1.09 0.93, 1.29 0.30 
 
 Heart Rate Variability at Baseline and Depression Score at 5.9
Follow-up 
Eighty six participants had heart rate variability recorded at baseline and completed the 
Cornell depression scale at follow-up. Of these 78 had recordings where ≤ 10% of the 
beats were interpolated or edited and were suitable for analysis.   
 Heart Rate Variability at Baseline and Depression Score at Follow-up 5.9.1
Year 10 Cornell score was not associated with baseline heart rate variability parameters. 
Change in Cornell score over the follow-up period was however associated with high 
frequency power spectra and HR:LF ratio (Table 5-20). Examining the data further 
revealed one extreme outlier. With this individual removed, the association between HF 
HRV and change in Cornell score was no longer significant. However, greater HF:LF 
ratio remained associated with greater decline in Cornell. After adjusting for age, sex, 
years in education, diabetes, hypertension, cardiovascular disease and use of tobacco, 
alcohol, cardioactive medications and psychoactive medication HF power and HF/LF 
ratio were no longer independently associated with change in Cornell score over ten 
year follow-up.  
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Table 5-20 Association between baseline HRV parameters and Cornell score at 
year 10 
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Year 10 Cornell score 
r -0.11 -0.13 -0.13 -0.04 -0.18 -0.16 
P 0.33 0.24 0.27 0.70 0.12 0.16 
Change in Cornell Score 
r 0.06 0.10 0.06 0.00 0.24 0.23 
P 0.61 0.39 0.57 0.97 0.03 0.04 
 Heart Rate Variability at Baseline and Cornell Score of ≥ 10 at Follow-up 5.9.2
HRV parameters at baseline were not significantly associated with having a Cornell 
score of 10 or more points at follow-up (Table 5-21).  
 
Table 5-21 Association between Baseline HRV Parameters and a Cornell Score of 
10 or More Points at Follow-up.  
Variable Cornell at Ten years ≥ 10 points 
  OR 95% CI P 
SDRR (ms) 1.03 0.96, 1.10 0.42 
Total Power (ms
2
) 1.00 1.00, 1.01 0.25 
VLF (ms
2
) 1.00 1.00, 1.01 0.05 
LF (ms
2
) 1.00 1.00, 1.01 0.39 
HF (ms
2
) 1.00 0.99, 1.01 0.55 
HF/LF ratio 0.05 0.01, 5.28 0.20 
 
 Alternative Analyses  5.9.3
Few associations have been identified in this study between autonomic function, and / 
or neurocardiovascular function at baseline and depression at follow-up. To account for 
use of antidepressants further analyses were performed with two additional derived 
dependent variables 
1. Any indication of depression: Participants were classed as having “any 
indication of depression” if they reported taking antidepressants, or scored 10 or 
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more on the Cornell at follow-up assessment. Seventeen per cent of participants 
met these criteria  
2. Incident depression: participants were diagnosed with “incident depression” if 
they had any indication of depression at follow-up, but were not taking 
antidepressants at baseline and had scored less than 10 on Cornell assessment at 
baseline. Ten per cent of participants met this definition.  
 
The analyses presented in this chapter were repeated for these two new dependent 
variables. The only additional association identified that had not been apparent on the 
initial analysis was with response to CSM: a diagnosis of mixed CSH was associated 
and incident depression. Twenty-nine percent of participants with mixed CSH at 
baseline had incident depression at follow-up versus five percent of subjects without 
mixed CSH (P=0.02). Logistic regression showed this finding remained significant after 
adjusting for potential covariates [OR 13.5 (95% CI 1.87, 97.6) P=0.01].  
 
 Summary of Key Results in Chapter 5 5.10
Cornell Depression scores where higher at follow-up than at baseline but number of 
participants scoring ≥10 had decreased suggesting prevalence of severe depression had 
not increased.  
 Hypertension  5.10.1
Hypertension was not associated with cornell score at follow-up, depression or incident 
depression.  
 Ambulatory BP recordings 5.10.2
Neither mean BP nor BP variability were associated with depression, indecent 
depression or Cornell score at follow-up.  
 Active Stand and Carotid Sinus Massage.  5.10.3
OH, CSH or CSS were not associated with Cornell scores at follow-up or prevalence of 
depression. Similarly, degree of haemodynamic response to active stand or CSM was 
not associated with depression at ten years. Mixed CSH (but not pure cardioinhibitory 
or vasodepresser CSH)  was associated with incident depression. 
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 Autonomic Function 5.10.4
Abnormal autonomic function as defined by Ewing criteria was not associated with 
Cornell score or with the prevalence of severe depression or incident depression.  The 
response to individual autonomic function tests was not associated with depression at 
follow-up. Measures of heart rate variability were not independently associated with 
depression at follow-up or scoring ten or more on Cornell depression scale.  
 Discussion 5.11
In this study, no association was found between hypertension status at baseline and 
depression at follow-up or change in Cornell score over the follow-up period. This is 
interesting as hypertension is a strong risk factor for white matter hyperintensities which 
in turn have been associated with depression in later life (Chen et al., 2006, de Groot et 
al., 2000, Firbank et al., 2005, Godin et al., 2008, Firbank et al., 2004). A meta-analysis 
by Valkanov et al identified 14 studies comparing the prevalence or incidence of late-
life depression among people with hypertension. In total, the studies included over 
20,000 participants. In keeping with the findings of this study, there was no association 
between hypertension and depression (Valkanova and Ebmeier, 2013).  
 
This study was the first population-based study to examine the longitudinal associations 
between autonomic nervous system function, neurocardiovascular instability and 
depression. These data consistently showed no significant association between BP and 
HR control at baseline and performance on Cornell score at the follow-up examination. 
Similarly, it did not identify any independent associations between HR and BP control 
at baseline and change in Cornell score over the follow-up period.  
 
The findings of this study are in contrast to a number of cross-sectional studies 
examining the association between BP control and depression (Scuteri et al., 2009, Jun 
et al., 2012, Sunbul et al., 2013, Richardson et al., 2009, Vasudev et al., 2011, Pearce, 
2007, Kayano et al., 2012). Cross-sectional studies using 24-hour ambulatory BP 
monitoring have shown depression to be associated with increased 24-hour and daytime 
BP variability, non-dipping status and decreased diurnal variation  (Scuteri et al., 2009, 
Jun et al., 2012, Sunbul et al., 2013, Kayano et al., 2012). Similarly 2 cross-sectional 
studies using beat-to-beat monitoring to compare systolic BP response to standing 
among depressed older people and controls found systolic vasodepression was 
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significantly greater in depressed patient and systolic OH was significantly more 
common among individuals with depression than controls (Richardson et al., 2009, 
Vasudev et al., 2011). A more recent community study oscillometric measures of 
postural change in BP found that symptomatic OH but not asymptomatic OH was 
associated with higher Centre for Epidemiology Depression score among community 
dwelling older people (Regan et al., 2013). CSH has also been associated with higher 
Cornell depression scores and greater number of people scoring 10 or more points on 
the Cornell score in cross-sectional studies (Pearce, 2007).  
 
Several cross-sectional studies have examined the association between autonomic 
nervous system function and depression. These have been reviewed by two authors 
(Grippo and Johnson, 2009, Rottenberg, 2007). All used HRV as a measure of 
autonomic function, rather than cardiovascular autonomic function tests. Grippo et al 
and Rottenburg et al report mixed results, some studies have shown decreased HRV in 
patients with depression while others, in keeping with our findings, have shown no 
association (Grippo and Johnson, 2009, Rottenberg, 2007). Two studies have examined 
changes in HRV associated with changes in depressive symptoms among patients 
treated for depression (Voss et al., 2008, Antipova, 2011). Antipova et al found heart 
rate variability was significantly lower in depressed patients compared to controls. After 
six weeks treatment with serotonin selective reuptake inhibitor antidepressants mood 
improved but HRV was unchanged. At six months, HRV was normalising in 30% of 
participants (Antipova, 2011). Voss et al investigated HRV in controls and people with 
depression at three time points; T1 unmediated, T2 medicated and T3 after 18 month 
follow-up (Voss et al., 2008). They found non-medicated patients had significantly 
lower HRV than controls. At T2, after introduction of medication, these differences 
became more pronounced. However, at T3 HRV among depressed patients normalised, 
suggesting reduced HRV might be secondary to depression.  
 
There are several reasons why our longitudinal findings may be in contrast to previous 
cross-sectional studies.  Firstly, the direction of the association between depression and 
autonomic function / neurocardiovascular instability cannot be ascertained from cross-
sectional studies. It was our hypothesis that impaired autonomic nervous system 
function and NCVI would result in cerebral hypoperfusion, white matter damage and 
consequently vascular depression. However, depression may result directly or indirectly 
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in altered autonomic function. This could occur by several mechanisms. Firstly, 
depression is associated with altered behaviour that may result in changes to BP and 
autonomic function. Depressed patients have been shown to be less active than controls 
and decreased activity is associated with reduced resting heart rate and blood pressure 
variability (Volkers et al., 2003). Disturbed sleep patterns, commonly seen in 
depression, are associated with altered 24-hour BP variability and diurnal variation. 
Furthermore, patients with depression are often less responsive to emotional stimuli 
(Rottenberg, 2007). The observation that HRV normalised among depressed patients as 
mood improves supports the idea that depression itself may contribute to abnormal 
autonomic nervous system activity (Antipova, 2011, Voss et al., 2008).   
 
A further potential confounder in cross-sectional studies examining the association 
between autonomic function NCVI and depression is use of medication. 
Antidepressants, particularly tricyclic antidepressants, have been associated with altered 
BP regulation and orthostatic hypotension(Glassman and Bigger Jr, 1981). Both 
tricyclic and SSRI antidepressant medication has been associated with reductions in 
HRV (Voss et al., 2008, Delaney et al., 2010, Glassman and Bigger Jr, 1981). 
Conversely, antihypertensive and cardioactive medications are recognised to have class 
specific effect on mood. Renin-angiotensin-aldosterone affecting medications are 
believed to have antidepressant effects and have been associated with lower use of 
antidepressants while beta-blockers have been implicated in depression (Nasr et al., 
2011, Beers and Passman, 1990). It is therefore possible that the associations between 
depression and NCVI / autonomic dysfunction observed in cross-sectional studies is a 
result of the direct and indirect effects of depression on the autonomic nervous system, 
rather than a result of autonomic dysfunction leading to depression as was initially 
hypothesised.  
 
Alternatively, our study may have been underpowered to detect weak associations 
between NCVI and depression. The sample size was small and only 6% of participants 
in this study were depressed at the follow-up assessment. This is lower than reported 
rates of depression detected in similar populations using symptom assessment scales 
(Luppa et al., 2012). A meta-analysis of 12 studies using depressive symptom rating 
scales to estimate prevalence of depression among older people aged 75 years reported a 
pooled prevalence of depression of 17.1% (95% CI 9.7–26.1%) (Luppa et al., 2012). It 
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would therefore appear that this study sample is not typical of the general population in 
terms of prevalence of depression.  
 
Baseline rates of depression among follow-up participants and participants lost to 
follow-up were examined to determine if the low prevalence of depression in the cohort 
was a result of selection bias. Participants lost to follow-up did not significantly differ 
from follow-up participants in terms of Cornell scores at baseline or incidence of 
depression at baseline. However, participants who developed depression following 
baseline assessment may have disproportionately declined participation in the follow-up 
phase of the study. Depression has been shown to be associated with increased attrition 
from studies and the impact of depression on attrition appears to increase with age 
(Mirowsky and Reynolds, 2000).   
 
The small number of patients with depression in the study meant that it was difficult to 
separate participants with long-term depression from participants with late-life 
depression. It has been suggested that depression developing in middle age and 
persisting into later life has a different aetiology to depression starting in later life. It is 
possible that NCVI and autonomic dysfunction are risk factors only for late-life 
depression. In an attempt to increase the statistical power of the study and examine 
incident depression we widened the definition of depression by including participants 
taking antidepressants. This showed an association between mixed CSH and incident 
depression. However the model had poor fit and given the extensive multiple testing 
this finding should be interpreted with caution.  
 
None of the participants in this study were under the care of psychiatrists for depression 
and few were taking antidepressant medication. Most of the previous studies examining 
associations between NCVI and depression have recruited depressed participants from 
secondary care (Vasudev et al., 2012, Colloby et al., 2011). Depressed participants in 
this study may have had less severe depression than participants in studies that recruited 
patients from secondary care.  
 
In conclusion, this study does not support the hypothesis that episodic hypotension 
underlies depression in later life in unselected community-dwelling older people. Larger 
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studies may be needed to identify weak associations and to ensure an adequate number 
of individuals with severe depression are included.  
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Chapter 6 The Long-term Association between 
Neurocardiovascular Function and Falls, Gait and Balance  
 Introduction 6.1
Impaired blood pressure control and NCVI are frequently cited in guidelines as risk 
factors for falls in older people (NICE, 2013, Panel on Prevention of Falls in Older 
Persons and British Geriatrics, 2011, Beauchet et al., 2011).  
 
Falls may directly result from cerebral hypoperfusion resulting in unrecognised 
syncope; alternatively, they may result from impaired gait and balance secondary to 
cerebral white matter hyperintensities (Shaw and Kenny, 1997) (Frith and Davison, 
2013, Willey et al., 2013, Kreisel et al., 2013, Callisaya et al., 2013, Soumaré et al., 
2009, DeCarli, 2013).  
 
 Aims 6.2
- To examine the long-term association between autonomic function,  NCVI and 
falls among community-dwelling older people 
- To examine the long-term association between autonomic function, NCVI and 
gait and balance among community-dwelling older people in order to better 
understand the mechanism by which NCVI and falls may be associated  
 Methods  6.3
 Assessment of Neurocardiovascular Function  6.3.1
Autonomic function tests and tests of NCVI were conducted at baseline as described in 
section 2.3, page 42.  
 Assessment of Falls  6.3.2
All participants were interviewed by the same trained assessor. Participants were asked, 
“have you had a fall in the last 12 months?” The interviewer explained, “a fall is any 
time you have fallen or found yourself on the ground, a piece of furniture, stairs or a 
wall without meaning to.” Participants were asked how many falls they had had in the 
last 12 months, and if they had experienced any prodromal symptoms, loss of 
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consciousness or injuries in association with each reported fall. Finally, participants 
were asked if they had been given a diagnosis as to the cause of the fall and if they had 
been seen in A&E or been hospitalised because of the fall.  
 
Three categorical variables were derived from the falls history obtained during 
interview with participants.  
 Faller: Participants were defined as a faller if they had fallen one or more times 
during the 12 months prior to assessment. 
 Recurrent Faller: Participants were defined as a recurrent faller if they had 
fallen two or more times during the 12 months prior to the assessment. 
 Injurious fall: An injurious fall was any fall resulting in a fracture, head injury, 
strain, sprain, cut, bruise, persistent pain, a visit to an accident and emergency 
department or admission to hospital.  
 
 Assessment of Gait and Balance 6.3.3
Gait and balance were assessed in participants’ homes by a single trained observer using 
the Tinetti POAM assessment (Tinetti, 1986). Several versions of the Tinetti assessment 
have been developed (Kopke and Meyer, 2006). At both assessments, the same tools 
were used. The balance score can be scored from zero to 26 (higher scores indicating 
better balance) and the gait score is scored from 0-9 (again higher scores indicating 
better performance).  
 Statistics  6.4
Associations between two categorical variables were examined using Chi square tests. If 
more than 20% of cells had an expected count of five or less, Fisher’s exact test was 
used instead.  
 
Differences in Tinetti scores were compared between groups using Mann-Whitney U 
test. Spearman correlation was used to examine the association between Tinetti score 
and continuous response to tests of neurocardiovascular function. 
 
Logistic regression was used to examine associations between continuous explanatory 
variables and falls, recurrent falls and injurious falls . Odds ratio and 95% confidence 
intervals are reported.  
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Negative binomial regression (which is a form of linear regression more appropriate 
when analysing data that have a high frequency of negative counts) was used to 
examine variables associated with the number of falls in the year prior to follow-up 
examination. Incident rate ratios and 95% confidence intervals are reported. 
 
 Covariates 6.4.1
Covariates were determined by review of the literature. In addition to age and sex, the 
following recognised risk factors for falling were included: previous stroke, Parkinson’s 
disease, diabetes, use of psychoactive medication, use of cardioactive medication, 
history of one or more falls at baseline, cognition (measured using CAMCOG total 
score), Tinetti scores and BMI (Tinetti et al., 1988, Campbell et al., 1989, Nevitt et al., 
1989, Schwartz et al., 2002).  
 Results  6.5
 Prevalence of Falls at Follow-up  6.5.1
Of the 104 people consenting to participate in the follow-up study, all of them 
completed the falls history. Comparing baseline and follow-up falls histories showed 
that more individuals reported having had a fall in the 12 months prior to assessment at 
follow-up than at baseline, 32% versus 27%. These differences were not statistically 
significant (P=0.44). The number of participants reporting recurrent falls (defined as 2 
or more falls  in the 12 months prior to assessment) was, however, significantly greater 
at follow-up than at baseline, [15.4% and 9.6% respectively (P< 0.05)]. There was not a 
significant difference in the number of participants sustaining injuries because of a fall 
in the year prior to baseline assessment or the year prior to follow-up [19.2% v 20.2% 
respectively (P=0.23)]. 
 
For fallers, the median number of falls in the 12 months prior to assessment at baseline 
and at follow-up was 1 (IQ range 1, 2 in both cases). Table 6-1 shows the number of 
falls prior to assessment reported by participants at baseline and at follow-up.  
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Table 6-1: Number of Falls in Year Prior to Assessment  
Number of Falls Baseline 
N= 104 
Follow-up 
N =104 
0 76 71 
1 18 17 
2 7 9 
3 0 3 
4 0 3 
5 0 0 
6 1 1 
7 1 0 
≥8 1 0 
 
 Tinetti Gait and Balance Scores at Follow-up 6.6
Of the 104 participants taking part in the follow-up examination, 101 were able to 
complete Tinetti balance assessment and 100 completed Tinetti assessment of gait. 
Subjects performed more poorly on assessments of both gait and balance at follow-up 
compared to baseline, P≤0.001 (Table 6-2). 
  
Table 6-2 Tinetti Gait and Balance Scores at Baseline and Follow-up 
Variable Baseline 
Median (IQR) 
Follow-up 
Median (IQR) 
P 
Tinetti Balance 25 (23, 26) 24 (22, 25) <0.001 
Tinetti Gait 9 (8, 9) 8.5 (5, 9) <0.001 
 
 Baseline Ambulatory Blood Pressure Recordings and Falls, Gait 6.7
and Balance at Follow-up  
Of the 104 participants who underwent the falls assessment at the ten year follow-up, 
103 had undergone ambulatory blood pressure monitoring at baseline.  
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 Hypertension at Baseline and Falls at Follow-up  6.7.1
One hundred participants had 10 or more daytime recordings, and could be classified as 
hypertensive or normotensive at baseline. Hypertension at baseline was not associated 
with falling, recurrent falls or injurious falls in year prior to assessment (Table 6-3).  
 
Table 6-3 Association between Falls and Baseline Hypertension Status  
 No Hypertension, N= 55  Hypertension, N=54 P  
 Frequency (%) Frequency (%)  
Fall  16 (29) 17 (38) 0.33 
Recurrent Falls  11 (20) 5 (11) 0.24 
Injurious Fall  9 (16) 12 (27) 0.21 
 
Negative binomial regression failed to show an association between hypertensive status 
at baseline and number of falls in the 12 months prior to follow-up assessment [IRR 
0.73 (95% CI 0.38, 1.40), P=0.35].  
 Baseline Hypertension Status and Gait and Balance at Follow-up 6.7.2
Of the 100 participants who had sufficient daytime recordings to classify them as 
hypertensive or normotensive according to NICE guidelines, 98 had completed the 
Tinetti balance assessment and 97 had completed the Tinetti gait assessment at follow-
up. Comparing Tinetti scores for participants who had been normotensive with scores 
for participants who were hypertensive at baseline did not show any significant 
differences (Table 6-4).  
Table 6-4 Tinetti Scores at Follow-up by Baseline Hypertension Status 
 No Hypertension  Hypertension  P  
 Median (IQ range) Median (IQ range)  
Tinetti Balance Score 23.0 (21.0, 25.0) 24.0 (22.0, 25.0) 0.35 
Tinetti Gait Score 8.0 (4.0, 9.0) 8.5 (5.0, 9.0) 0.74 
 
 Twenty-four Hour Ambulatory BP Results at Baseline and Falls, Gait and 6.7.3
Balance at Follow-up  
All individuals had 16 or more recordings during the 24-hour period and were therefore 
suitable for analysis of 24-hour ABPM recordings.  
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Greater 24-hour systolic BP variability was associated with reporting a fall in the year 
prior to follow-up assessment (Table 6-5). This association was no longer significant 
after adjusting for age and other risk factors associated with falls.   
 
Logistic regression showed that twenty-four hour ABPM variables were not associated 
with recurrent falls or injurious falls. Similarly, negative binomial regression failed to 
show an association between 24-hour ambulatory BP monitor recordings and the 
number of falls reported in the year prior to follow-up assessment (Table 6-5).  
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Table 6-5 Unadjusted Logistic Regression Examining Association between 24-hour 
ABPM Results and Falls at Follow-up 
 OR 95% confidence interval P  
Falls *    
Mean SBP (mmHg) 1.03 1.00, 1.06 0.08 
Mean DBP (mmHg) 1.02 0.97, 1.06 0.53 
SD SBP (mmHg) 1.17 1.02, 1.33 0.02 
SD DBP (mmHg) 1.05 0.88, 1.25 0.61 
Recurrent Falls*    
Mean SBP (mmHg) 0.99 0.95, 1.03 0.62 
Mean DBP (mmHg) 0.97 0.91, 1.04 0.42 
SD SBP (mmHg) 1.03 0.87, 1.20 0.76 
SD DBP (mmHg) 0.97 0.77, 1.23 0.80 
Injurious Fall *    
Mean SBP (mmHg) 1.02 0.99, 1.06 0.17 
Mean DBP (mmHg) 1.02 0.96, 1.07 0.51 
SD SBP (mmHg) 1.03 0.89, 1.19 0.73 
SD DBP (mmHg) 0.96 0.77, 1.19 0.68 
    
Number of Falls
∞
 IRR 95% confidence interval P  
Mean SBP (mmHg) 0.99 0.97, 1.01 0.68 
Mean DBP (mmHg) 0.98 0.94, 1.02 0.27 
SD SBP (mmHg) 1.04 0.95, 1.15 0.41 
SD DBP (mmHg) 1.02 0.87, 1.18 0.85 
* Logistic Regression, 
∞
 Negative Binomial Regression 
 
 
160 
 
Spearman correlation did not show any significant associations between 24-hour ABPM 
results at baseline and Tinetti gait and balance scores at follow-up (Table 6-6).  
 
Table 6-6 Spearman Correlation between 24-hour ABPM Results and Tinetti 
Balance and Gait Scores 
 Tinetti Balance Score Tinetti Gait Score 
 r (P) r (P) 
Mean SBP (mmHg) 0.02 (0.85) -0.05 (0.66) 
Mean DBP (mmHg) 0.14 (0.17) -0.04 (0.69) 
SD SBP (mmHg) -0.08 (0.41) -0.03 (0.73) 
SD DBP (mmHg) 0.00 (0.96) 0.03 (0.76) 
 
 Daytime Ambulatory BP Results at Baseline and Falls, Gait and Balance at 6.7.4
Follow-up  
One hundred participants had 10 or more daytime recordings and could be included in 
the daytime analysis. No associations were observed between daytime ambulatory BP 
parameters and falls, recurrent falls or injurious falls (Table 6-7). Similarly, negative 
binomial regression failed to show an association between daytime ABPM recordings 
and number of falls in year prior to assessment (Table 6-7).  
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Table 6-7 Association between Daytime ABPM Results and Falls at Follow-up 
 Odds Ratio 95% CI P  
Falls *    
Mean SBP (mmHg) 1.03 1.00, 1.05 0.08 
Mean DBP (mmHg) 1.02 0.98, 1.06 0.46 
SD SBP (mmHg) 1.09 0.98, 1.22 0.13 
SD DBP (mmHg) 1.05 0.88, 1.26 0.58 
Recurrent falls*    
Mean SBP (mmHg) 0.99 0.95, 1.02 0.49 
Mean DBP (mmHg) 0.97 0.92, 1.03 0.35 
SD SBP (mmHg) 1.04 0.90, 1.19 0.61 
SD DBP (mmHg) 1.01 0.80, 1.27 0.95 
Injurious Fall *    
Mean SBP (mmHg) 1.02 0.99, 1.05 0.17 
Mean DBP (mmHg) 1.02 0.99, 1.06 0.52 
SD SBP (mmHg) 1.04 0.91, 1.18 0.59 
SD DBP (mmHg) 1.00 0.81, 1.2 0.98 
    
Number of Falls
 ∞
 IRR 95% CI P  
Mean SBP (mmHg) 0.99 0.97, 1.01 0.48 
Mean DBP (mmHg) 0.98 0.95, 1.02 0.33 
SD SBP (mmHg) 1.03 0.94, 1.13 0.49 
SD DBP (mmHg) 1.01 0.87, 1.18 0.87 
* Logistic Regression, 
∞
 Negative Binomial Regression 
  
Spearman correlation also failed to show any associations between daytime ABPM 
results at baseline and Tinetti Balance and Gait Scores at follow-up. 
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Table 6-8 Spearman Correlation between Daytime ABPM Results and Tinetti 
Balance and Gait Scores 
 Tinetti Balance Score Tinetti Gait Score 
 r (P) r (P) 
Mean SBP (mmHg) 0.09 (0.40) 0.02 (0.87) 
Mean DBP (mmHg) 0.18 (0.07) 0.02 (0.88)  
SD SBP (mmHg) -0.06 (0.55) 0.01 (0.91) 
SD DBP (mmHg) -0.02 (0.84) 0.00 (1.00) 
 
 Night-time Ambulatory BP at Baseline Results and Falls, Gait and Balance 6.7.5
at Follow-up 
Ninety-one participants had five or more nocturnal recordings and were included in the 
night-time analysis. No associations were observed between nocturnal ABPM 
parameter and falls, recurrent falls or injurious falls (Table 6-9). Similarly, no 
associations were observed for night-time ABPM recordings and the number of falls in 
the year prior to follow-up assessment (Table 6-9).   
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Table 6-9 Association between Night-time ABPM Results and Falls at Follow-up 
 Odds Ratio 95% CI P  
Falls*    
Mean SBP (mmHg) 1.02 0.98, 1.05 0.36 
Mean DBP (mmHg) 1.03 0.97, 1.08 0.32 
SD SBP (mmHg) 1.03 0.91, 1.16 0.64 
SD DBP (mmHg) 0.95 0.82, 1.11 0.53 
Recurrent Fall*    
Mean SBP (mmHg) 0.99 0.95, 1.04 0.81 
Mean DBP (mmHg) 1.01 0.95, 1.08 0.75 
SD SBP (mmHg) 1.03 0.88, 1.20 0.75 
SD DBP (mmHg) 0.99 0.81, 1.20 0.89 
Injurious Fall*    
Mean SBP (mmHg) 1.01 0.97, 1.05 0.80 
Mean DBP (mmHg) 1.01 0.95, 1.08 0.70 
SD SBP (mmHg) 0.96 0.83, 1.11 0.60 
SD DBP (mmHg) 0.87 0.70, 1.07 0.17 
    
Number of Falls
 ∞
 IRR 95% CI P 
Mean SBP (mmHg) 0.99 0.96, 1.01 0.28 
Mean DBP (mmHg) 0.99 0.95, 1.04 0.78 
SD SBP (mmHg) 0.99 0.90, 1.09 0.89 
SD DBP (mmHg) 0.97 0.86, 1.10 0.66 
* Logistic Regression, 
∞
 Negative Binomial Regression 
 
No associations were observed between night-time ABPM results at baseline and Tinetti 
Balance and Gait Scores at follow-up 
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Table 6-10 Spearman Correlation between Night-time ABPM Results and Tinetti 
Balance and Gait Scores 
 Tinetti Balance Score Tinetti Gait Score 
 r (P) r (P) 
Mean SBP (mmHg) -0.05 (0.67) -0.12 (0.26) 
Mean DBP (mmHg) 0.05 (0.06) -0.13 (0.22) 
SD SBP (mmHg) 0.06 (0.58) 0.11 (0.31) 
SD DBP (mmHg) 0.09 (0.41) 0.09 (0.42) 
 Baseline Diurnal Variation and Falls, Gait and Balance at Follow-up 6.7.6
Eighty-nine of the follow-up participants had 10 or more daytime recordings and five or 
more nocturnal recordings at baseline and were therefore suitable for analysis of diurnal 
variation. Percentage diurnal variation was not associated with falling, recurrent, or 
injurious falls, or number of falls in year prior to follow-up. 
  
Table 6-11 Diurnal Variation and Falls 
 OR 95% CI P  
Falls     
Systolic Diurnal variation (%) 1.04 0.98, 1.10 0.20 
Diastolic Diurnal variation (%) 1.03 0.98, 1.07 0.22 
Recurrent Falls    
Systolic Diurnal variation (%) 0.98 0.91, 1.05 0.54 
Diastolic Diurnal variation (%) 0.99 0.93, 1.05 0.68 
Injurious Fall     
Systolic Diurnal variation (%) 0.98 0.96, 1.10 0.48 
Diastolic Diurnal variation (%) 1.01 0.95, 1.07 0.76 
    
Number of Falls  IRR 95% CI P  
Systolic Diurnal variation (%) 1.01 0.97, 1.05 0.67 
Diastolic Diurnal variation (%) 1.01 0.97, 1.05 0.67 
* Logistic Regression, 
∞
 Negative Binomial Regression 
 
There was no association between diurnal variation in BP and Tinetti Gait and Balance 
Scores (Table 6-12).  
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Table 6-12 Spearman Correlation between ABPM Diurnal Variation and Gait and 
Balance Scores  
 Tinetti Balance 
Score 
Tinetti Gait Score 
 r (P) r (P) 
Systolic Diurnal Variation (%) 0.18 (0.10) 0.12 (0.29) 
Diastolic Diurnal Variation (%) 0.13 (0.24) 0.14 (0.20) 
 
 Orthostatic Hypotension at Baseline and Falls, Gait and Balance 6.8
at Follow-up  
Of the 104 participants who underwent falls assessment at ten years, 95 performed 
active stand at baseline. Presence of OH at baseline was not associated with falling in 
year prior to follow-up assessment or with reporting recurrent or injurious falls (Table 
6-13). Symptomatic orthostatic hypotension was associated with recurrent falls on 
univariate analysis but after adjusting for covariates this association was no longer 
significant.  
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Table 6-13 Association between Baseline Orthostatic Hypotension Status and Falls 
at Follow-up  
 No orthostatic 
Hypotension N= 18 
Orthostatic hypotension  
N= 77 
P  
 Frequency (%) Frequency (%)  
Falls 6 (33) 27 (35) 0.89 
Recurrent Falls 1 (6) 15 (20) 0.29 
Injurious Falls 2 (11) 19 (25) 0.34 
 No systolic OH  
N= 35 
Systolic OH  
N= 60  
P  
 Frequency (%) Frequency (%)  
Falls 11 (31) 22 (37) 0.61 
Recurrent Falls 3 (9) 13 (22) 0.10 
Injurious Falls 5 (14) 16 (27) 0.16 
 No diastolic OH  
N=  27 
Diastolic OH  
N= 68  
P  
 Frequency (%) Frequency (%)  
Falls 10 (37) 23 (34) 0.78 
Recurrent Falls 4 (15) 12 (18) 1.00 
Injurious Falls 4 (15) 17 (25) 0.28 
 Symptomatic OH  
N= 11 
No symptoms 
N= 84 
P  
 Frequency (%) Frequency (%)  
Falls 6 (55) 27 (32) 0.18 
Recurrent Falls 5 (45) 11 (13) 0.02 
Injurious Falls 5 (45) 16 0.06 
 
Negative binomial regression failed to show any association between OH, or subtypes 
of OH, and the reported number of falls in the year prior to follow-up assessments 
(Table 6-14). There was a borderline association between symptomatic OH and number 
of falls.  
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Table 6-14 Unadjusted Negative Binomial Regression Examining Associations 
between Number of Falls in Year Prior to Follow-up and OH as Defined by AAN 
and Components of OH  
 IRR 95% CI P  
AAN defined OH 1.84 0.72, 4.70 0.20 
Systolic OH 1.54 0.77, 3.10 0.22 
Diastolic OH 1.05 0.52, 2.15 0.89 
Symptomatic OH 2.23 0.97, 5.29 0.07 
 
 Continuous Response to Active Stand at Baseline and Falls at Follow-up 6.8.1
Logistic regression examining the association between continuous response to 
orthostasis at baseline and falls, recurrent falls and injurious falls in the year prior to ten 
year follow-up did not show any significant associations (Table 6-15). Similarly, there 
were no associations between continuous response to active stand and the reported 
number of falls in year prior to follow-up (Table 6-15).  
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Table 6-15 Association between Continuous Response to Orthostasis at Baseline 
and Falls at Follow-up 
 OR 95% CI P  
Falls*    
SBP Vasodepression (mmHg) 1.00 0.98, 1.03 0.79 
DBP Vasodepression (mmHg) 0.97 0.93, 1.02 0.25 
SBP Nadir (mmHg) 1.01 0.99, 1.02 0.47 
DBP Nadir (mmHg) 1.02 0.99, 1.06 0.18 
Recurrent Falls*    
SBP Vasodepression (mmHg) 1.02 0.99, 1.05 0.29 
DBP Vasodepression (mmHg) 0.98 0.92, 1.04 0.49 
SBP Nadir (mmHg) 1.00 0.98, 1.02 0.99 
DBP Nadir (mmHg) 1.01 099, 1.03 0.48 
Injurious Fall*    
SBP Vasodepression (mmHg) 1.01 0.98, 1.04 0.53 
DBP Vasodepression (mmHg) 0.99 0.94, 1.05 0.80 
SBP Nadir (mmHg) 0.99 0.98, 1.01 0.45 
DBP Nadir (mmHg) 1.02 0.98, 1.05 0.39 
    
Number of Falls
 ∞
 IRR 95% CI P 
SBP Vasodepression (mmHg) 1.01 0.99, 1.03 0.36 
DBP Vasodepression (mmHg) 0.98 0.95, 1.02 0.38 
SBP Nadir (mmHg) 1.00 0.99, 1.01 0.67 
DBP Nadir (mmHg) 1.01 0.99, 1.03 0.52 
* Logistic Regression, 
∞
 Negative Binomial Regression 
 
 Orthostatic Hypotension at Baseline and Tinetti Gait and Balance Scores at 6.8.2
Follow-up 
Of the 95 individuals who underwent active stand at baseline and participated in follow-
up study, 92 completed the Tinetti balance assessment and 91 completed the Tinetti gait 
assessment. Comparing participants who had OH as defined by AAN at baseline with 
those who did not, failed to show any significant differences in follow-up gait and 
balance scores (Table 6-16). The same was true when systolic OH was examined in 
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isolation (Table 6-16). Tinetti gait scores at follow-up were higher among participants 
who had had diastolic OH at baseline this observation reached borderline statistical 
significance (P=0.05) 
 
Table 6-16 Gait and Balance Scores at Follow-up by Presence or Absence of OH at 
Follow-up  
 Median (IQ range) Median (IQ range) P  
 No orthostatic 
Hypotension at baseline 
Orthostatic hypotension 
at baseline 
 
 N= 18 N= 74   
Tinetti Balance 24 (21.75, 26) 24 (20.75, 25) 0.47 
 N= 18 N= 73  
Tinetti Gait 7.5 (3.75, 9.00) 9 (5.5, 9) 0.30 
 No systolic OH at 
baseline  
Systolic OH at baseline 
 
 
 N=  35 N= 57  
Tinetti Balance 24 (21, 25) 24 (20, 25) 0.11 
 N= 35 N= 56  
Tinetti Gait 8 (4, 9) 8.5 (6, 9) 0.59 
 No diastolic OH at 
baseline  
Diastolic OH at baseline  
 N= 25 N= 67  
Tinetti Balance 23 (20, 25) 24 (22, 25) 0.40 
 N= 24 N= 67  
Tinetti Gait 6.5 (4, 9) 9 (6, 9) 0.05 
 
 Continuous Response to Active Stand at Baseline and Gait and Balance at 6.8.3
Follow-up 
Examining the association between continuous haemodynamic response to active stand 
at baseline and gait and balance scores at follow-up showed that greater diastolic 
vasodepression was associated with better Tinetti scores at follow-up (Table 6-17). This 
association was not evident after adjusting for covariates.  
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Table 6-17 Spearman Correlation between Continuous Response to Active Stand 
and Tinetti Scores at Follow-up  
  
Systolic 
vaso-
depression 
(mmHg) 
Diastolic 
vaso-
depression 
(mmHg) 
Systolic 
Nadir 
(mmHg) 
Diastolic 
Nadir 
(mmHg) 
Tinetti Balance r -0.15 0.13 0.13 0.08 
P 0.16 0.22 0.22 0.44 
Tinetti Gait  r 0.07 0.26 -0.07 -0.06 
P 0.50 0.01 0.52 0.59 
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 Response to Carotid Sinus Massage at Baseline and Falls, Gait 6.9
and Balance at Follow-up 
Of the 104 participants who gave a complete falls history at follow-up, 90 underwent 
carotid sinus massage at baseline. The number of these individuals with carotid sinus 
hypersensitivity and CSH subgroups are shown below (Table 6-18).  
 
Table 6-18 Number of Participants who Underwent CSM at Baseline and Falls 
Assessment at Follow-up with CSH and CSH subgroups.  
 Frequency 
Carotid Sinus Hypersensitivity 28 
Carotid Sinus Hypersensitivity Subgroups  
 Cardio inhibitory CSH 2 
 Vasodepressive CSH 12 
 Mixed CSH 14 
 
 Carotid Sinus Hypersensitivity at Baseline and Falls at Follow-up 6.9.1
Presence or absence of carotid sinus hypersensitivity at baseline was not associated with 
number of individuals reporting falls, recurrent falls, or injurious falls at follow-up. 
Analysing the CSH subtypes separately did not alter this finding (Table 6-19).  
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Table 6-19 Association between Carotid Sinus Hypersensitivity and Falls at 
Follow-up 
 No Carotid Sinus 
Hypersensitivity  
N= 61 
Carotid Sinus 
Hypersensitivity  
N=28 
P  
 Frequency (%) Frequency (%)  
Falls 18 (30) 9 (32) 0.77 
Recurrent Falls 9 (15) 5 (18) 0.76 
Injurious Falls 12 (20) 7 (25) 0.57 
    
 No Cardio inhibitory 
CSH N= 88 
Cardio inhibitory CSH 
N =2 
 
Falls 26 (29) 1 (50) 0.51 
Recurrent Falls 13 (15) 1 (50) 0.29 
Injurious Falls 18 (20) 1 (50) 0.38 
    
 No Vasodepressive CSH 
N=78 
Vasodepressive CSH 
N=12 
 
Falls 23 (29) 4 (33) 0.75 
Recurrent Falls 14 (18) 0  0.20 
Injurious Falls 10 (13) 2 (16) 1.00 
    
 No mixed CSH  
N=75 
Mixed CSH 
N=14 
 
Falls 23 (31) 4 (29) 1.00 
Recurrent Falls 10 (13) 4 (29) 0.22 
Injurious Falls 15 (20) 4 (29) 0.49 
 Symptomatic CSH 
N=12 
Asymptomatic 
N=78 
 
Falls 4 (33) 23 (29) 0.74 
Recurrent Falls 3 (25) 9 (12) 0.39 
Injurious Falls 2 (17) 19 (24) 1.00 
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There was no association between CSH status and reported number of falls in year prior 
to follow-up assessment. Similarly, CSH subtypes were not associated with number of 
falls (Table 6-20) 
 
Table 6-20 Negative Binomial Regression Examining Association between CSH 
and CSH Subtypes and Reported Number of Falls in Year Prior to Follow-up 
Assessment   
 IRR 95% CI P  
Carotid Sinus Hypersensitivity 1.53 0.74, 3.15 0.25 
Type of Carotid Sinus Hypersensitivity    
 Mixed CSH 1.83 0.75, 4.45 0.18 
 Vasodepressive CSH 0.71 0.21, 2.40 0.56 
 Cardioinhibitory CSH 4.28 0.74, 24.6 0.10 
 
To examine if symptoms during carotid sinus massage are an important predictor of 
falls, these analyses were repeated. There were no significant associations between 
symptoms during CSM and falls, recurrent fall and injurious falls (Table 6-19). 
Negative binomial regression did not show any association between symptoms during 
CSM and reported number of falls in year preceding the ten year follow-up assessment.  
 
Examining the relationship between continuous haemodynamic response to CSM and 
number of participants reporting falls at follow-up did not show any significant 
associations (Table 6-21). There was however a significant relationship between 
maximum RR interval and reporting recurrent falls and delta RR interval and reporting 
recurrent falls (Table 6-21). These associations were no longer significant after 
adjusting for covariates.  
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Table 6-21 Association between Continuous Response to CSM and Falls at Follow-
up  
 Odds Ratio 95% CI P  
Falls *    
SBP vasodepression (mmHg) 1.00 0.98, 1.03 0.76 
SBP nadir (mmHg) 1.00 0.98, 1.01 0.69 
Maximum RR interval (s) 1.04 0.81, 1.33 0.77 
Maximum delta RR (s) 1.05 0.81, 1.35 0.72 
Recurrent Falls*    
SBP vasodepression (mmHg) 1.01 0.98, 1.05 0.50 
SBP nadir (mmHg) 1.00 0.98, 1.02 0.79 
Maximum RR interval (s) 1.34 1.02, 1.75 0.03 
Maximum delta RR (s) 1.35 1.02, 1.77 0.03 
Injurious Fall *    
SBP vasodepression (mmHg) 1.00 0.97, 1.03 0.95 
SBP nadir (mmHg) 1.00 0.98, 1.02 0.88 
Maximum RR interval (s) 1.07 0.82, 1.40 0.63 
Maximum delta RR (s) 1.08 0.82, 1.42 0.60 
    
Number of Falls 
∞
 IRR 95% CI P  
SBP vasodepression (mmHg) 1.01 0.99, 1.03 0.29 
SBP nadir (mmHg) 0.99 0.98, 1.01 0.32 
Maximum RR interval (s) 1.18 0.99, 1.40 0.07 
Maximum delta RR (s) 1.18 0.99, 1.40 0.06 
* Binary logistic Regression, 
∞
 Negative Binomial Regression 
 
 Carotid Sinus Hypersensitivity at Baseline and Tinetti Scores at Follow-up  6.9.2
Of the 90 individuals who participated in follow-up examination and underwent carotid 
sinus massage at baseline, 89 completed the Tinetti balance assessment at follow-up and 
88 completed the Tinetti gait assessment. Comparing participants who had CSH at 
baseline with those who did not have CSH did not reveal any differences in follow-up 
Tinetti scores (Table 6-22).  
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Table 6-22 Tinetti Scores According to Baseline CSH Status 
 No Carotid Sinus 
Hypersensitivity  
Carotid Sinus 
Hypersensitivity  
P  
 Median (IQ range) Median (IQ range)  
 N= 61 N= 28  
Tinetti balance 24 (21.5, 25) 24 (21.0, 25.0) 0.77 
 N=60 N=28  
Tinetti gait 8.5 (5.0, 9.0) 9.0 (5.5, 9.0) 0.64 
 No Cardio inhibitory 
CSH 
Cardio inhibitory CSH 
 
 
 N=87 N=2  
Tinetti balance 24 (21, 25) 21.5 (17.0) 0.97 
 N=86 N=2  
Tinetti gait 9.0 (5.0, 9.0) 8.5 (8.0) 0.72 
 No Vasodepressive 
CSH  
Vasodepressive CSH   
 N=77 N=12  
Tinetti balance 24 (21.5, 25) 23 (21, 24.75) 0.55 
 N=76 N=12  
Tinetti gait 9.0 (5.25, 9.0) 8.5 (4.25, 9.0) 0.79 
 No mixed CSH  Mixed CSH  
 N=75 N=14  
Tinetti balance 24 (21, 25) 24 (21.25, 25) 0.87 
 N=74 N=14  
Tinetti gait 8.5 (5.0, 9.0) 9.0 (6.25, 9.0) 0.50 
 
There was no association between Tinetti gait and balance scores at ten year follow-up 
and continuous response to CSM at baseline (Table 6-23).  
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Table 6-23 Spearman Association between Continuous Haemodynamic Response 
to CSM and Tinetti Score at Follow-up 
 Tinetti Balance 
r (P) 
Tinetti Gait 
r (P) 
Maximum Vasodepression (mmHg) -0.01 (0.96) 0.03 (0.76) 
Minimum Systolic Nadir (mmHg) 0.11 (0.32) 0.11 (0.33) 
Max RR interval post CSM -0.08 (0.47) -0.02 (0.88) 
Max Delta RR -0.06 (0.55) -0.03 (0.79) 
 
 Autonomic Function at Baseline and Falls, Gait and Balance at 6.10
Follow-up 
Of the 104 participants who completed the falls history at follow-up, 81 had results 
from all five autonomic function tests at baseline. The number of participants with 
results available for each of the individual autonomic function tests is shown below 
(Table 6-24).  
 
Table 6-24 Number of Participants Completing Each Autonomic Function Test 
Autonomic Function Test Number of participants completing test 
Active stand 95 
Isometric exercise 96 
Valsalva manoeuvre 98 
Cold pressor  95 
Deep breathing 92 
  
Ninety participants had undergone sufficient autonomic function tests to classify 
autonomic function as normal or abnormal according to modified Ewing criteria. 
Abnormal autonomic function at baseline was not associated with falling, recurrent falls 
or injurious falls in the year preceding ten year follow-up assessment (Table 6-25). 
Similarly, negative binomial regression failed to show a significant association between 
abnormal autonomic function and reported number of falls in year preceding follow-up 
assessment [IRR 0.84 (95% CI 0.41, 1.74) P= 0.64].    
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Table 6-25 Association between Autonomic Function and Fall at Follow-up 
 Normal Autonomic 
Function N =61 
Abnormal Autonomic 
Function N=29 
P  
 Frequency (%) Frequency (%)  
Falls 21 (34) 9 (31) 0.75 
Recurrent Falls 10 (16) 5 (17) 1.00 
Injurious Falls 14 (23) 5 (17) 0.54 
 
 Continuous Response to Individual Autonomic Function Tests at Baseline 6.10.1
and Falls at Follow-up 
Examining the association between reported falls in the year preceding the ten year 
follow-up assessment and continuous response to individual autonomic function tests at 
baseline showed that increased Valsalva ratio at baseline was significantly associated 
with an increased number of subjects reporting one or more falls at the follow-up 
assessment (Table 6-26). These associations were not significant on multivariable 
analysis.  
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Table 6-26 Association between Continuous Haemodynamic Response to 
Autonomic Function Tests and Number of Individual Reporting Falls, Recurrent 
Falls or Injurious Falls at Follow-up 
 Odds Ratio 95% confidence 
interval 
P  
Falls     
Active sit DBP difference (mmHg) 1.00 0.97, 1.03 0.79 
Cold pressor DBP difference (mmHg) 0.99 0.94, 1.05 0.78 
Valsalva SBP overshoot (mmHg) 0.99 0.97, 1.01 0.21 
Valsalva ratio 0.15 0.03, 0.89 0.04 
30:15 ratio 0.14 0.01, 11.5 0.38 
Heart rate response to deep breathing 0.99 0.90, 1.08 0.74 
Recurrent Falls    
Active sit DBP difference (mmHg) 0.98 0.94, 1.02 0.38 
Cold pressor DBP difference (mmHg) 0.98 0.91, 1.06 0.62 
Valsalva SBP overshoot (mmHg) 0.98 0.96, 1.00 0.08 
Valsalva ratio 0.05 0.01, 0.74 0.03 
30:15 ratio 0.01 0.00, 2.25 0.09 
Heart rate response to deep breathing 1.03 0.92, 1.15 0.62 
Injurious Fall     
Active sit DBP difference (mmHg) 1.00 0.96, 1.03 0.79 
Cold pressor DBP difference (mmHg) 0.97 0.91, 1.04 0.42 
Valsalva SBP overshoot (mmHg) 1.00 0.98, 1.02 0.79 
Valsalva ratio 0.17 0.02, 1.37 0.10 
30:15 ratio 0.02 0.01, 4.23 0.15 
Heart rate response to deep breathing 0.97 0.87, 1.08 0.53 
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Negative Binomial regression showed that Valsalva ratio was significantly associated 
with reported number of falls in year prior to follow-up. One unit increase in Valsalva 
ratio was associated with an 81% reduction in falls count (Table 6-27). This association 
was no longer significant after adjusting for covariates.  
 
Table 6-27 Unadjusted Negative Binomial Regression Examining Association 
between Response to Individual Autonomic Function Tests and Reported Number 
of Falls in Year Preceding Follow-up Assessment  
 IRR 95% CI P  
Number of Falls    
Active sit DBP difference (mmHg) 0.99 0.97, 1.01 0.32 
Cold pressor DBP difference (mmHg) 0.99 0.94, 1.03 0.58 
Valsalva SBP overshoot (mmHg) 0.99 0.98, 1.00 0.06 
Valsalva ratio 0.19 0.05, 0.78 0.02 
30:15 ratio 0.04 0.01, 1.67 0.09 
Heart rate response to deep breathing 1.01 0.95, 1.08 0.75 
 
 Autonomic Function at Baseline and Tinetti Scores at Follow-up 6.10.2
Of the 90 participants who had undergone sufficient autonomic function tests to classify 
autonomic function as normal or abnormal according to modified Ewing criteria, 87 
underwent Tinetti balance assessment and 86 underwent Tinetti gait assessment.  
 
Participants with normal autonomic function at baseline had better Tinetti balance 
scores at ten year follow-up than individuals who had abnormal autonomic function at 
baseline, P=0.02 (Table 6-28). After adjusting for covariates, this association was no 
longer significant.  
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Table 6-28 Abnormal versus Normal Autonomic Function and Tinetti Scores at 
Follow-up 
 Normal Autonomic 
Function N =61 
Abnormal Autonomic 
Function N=29 
P  
 Median (IQ range) Median (IQ range)  
Tinetti balance score 24 (22, 25) 22 (18.5, 24) 0.02 
Tinetti gait score 8 (4.75, 9) 8.5 (5, 9) 0.98 
 
Examining the association between continuous response to autonomic function tests and 
Tinetti scores showed that: 
 greater change in diastolic BP in response to isometric exercise was associated 
with lower Tinetti gait score at follow-up 
 greater systolic overshoot and heart rate ratio in response to Valsalva manoeuvre 
was associated with better Tinetti balance scores  
 greater 30:15 ratio in response to active stand was associated with better Tinetti 
balance score (Table 6-29).  
 
These associations were no longer statistically significant after adjusting for covariates.  
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Table 6-29 Spearman Correlation between Continuous Response to AFT and 
Tinetti Scores 
  r P  
Isometric Exercise    
DBP change (mmHg) 
Tinetti balance score -0.08 0.48 
Tinetti gait score -0.23 0.03 
Cold Pressor    
DBP difference (mmHg) 
Tinetti balance score 0.15 0.16 
Tinetti gait score 0.13 0.24 
Valsalva Manoeuvre     
Valsalva SBP overshoot 
(mmHg) 
Tinetti balance score 0.24 0.02 
Tinetti gait score 0.18 0.09 
Valsalva ratio 
Tinetti balance score 0.31 <0.01 
Tinetti gait score 0.20 0.06 
Active stand    
30:15 ratio 
Tinetti balance score 0.22 0.03 
Tinetti gait score 0.08 0.47 
Deep breathing    
Heart rate response 
Tinetti balance score 0.06 0.55 
Tinetti gait score -0.07 0.54 
 
 Heart Rate Variability at Baseline and Falls, Gait and Balance at 6.11
Follow-up 
Of the 104 participants who gave a complete falls history at follow-up, 91 underwent 
assessment of heart rate variability at baseline. Of these, 83 participants had recordings 
where ≤10 percent of the beats were interpolated or ectopic.  
 Heart Rate Variability at Baseline and Falls at Follow-up 6.11.1
Heart rate variability at baseline was not associated with number of individuals 
reporting falls, recurrent falls or injurious falls in the year preceding follow-up 
assessment (Table 6-30). HF/LF ratio was however significantly associated with 
reported number of falls in year preceding follow-up [IRR 0.60 (95% CI 0.42, 0.86) 
P<0.01]. This was no longer the case after adjusting for covariates. 
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Table 6-30 Association between Heart Rate Variability and Falls  
 Odds Ratio 95% confidence interval P  
Falls *    
SDNN 0.97 0.93, 1.01 0.19 
Total Power 1.00 0.99, 1.01 0.90 
VLF 1.00 0.99, 1.02 0.57 
LF 1.00 0.99, 1.00 0.61 
HF 1.00 0.99, 1.00 0.88 
HF/LF 0.49 0.17, 1.39 0.18 
Recurrent Falls*    
SDNN 1.02 0.97, 1.07 0.56 
Total Power 1.001 1.000, 1.002 0.08 
VLF 1.002 1.000, 1.003 0.06 
LF 1.001 0.999, 1.003 0.48 
HF 1.001 0.999, 1.003 0.17 
HF/LF 1.04 0.42, 2.56 0.93 
Injurious Fall *    
SDNN 1.01 0.96, 1.05 0.83 
Total Power 1.00 1.00, 1.01 0.11 
VLF 1.00 1.00, 1.01 0.08 
LF 1.00 1.00, 1.01 0.49 
HF 1.00 1.00, 1.01 0.30 
HF/ LF 0.49 0.14, 1.73 0.27 
    
Number of Falls
∞
 IRR 95% confidence interval P  
SDNN 1.00 0.97, 1.03 0.93 
Total Power 1.00 1.00, 1.01 0.33 
VLF 1.00 1.00, 1.00 0.12 
LF 1.00 0.99, 1.00 0.98 
HF 1.00 1.00, 1.00 0.72 
HF/ LF 0.60 0.42, 0.86 <0.01 
* Logistic Regression, 
∞
 Negative Binomial Regression 
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 Heart Rate Variability at Baseline and Gait and Balance at Follow-up 6.11.2
Of the 83 follow-up participants with satisfactory heart rate variability recordings at 
baseline, 81 completed the balance assessment and 80 completed the gait assessment.  
Analysis of the association between heart rate variability and Tinetti scores revealed that 
greater SDNN, total power, very low frequency power and low frequency power were 
associated with better gait and balance scores ( 
 
Table 6-31). These associations were not significant after adjusting for covariates 
 
Table 6-31 Spearman Correlation between Heart Rate Variability and Tinetti Gait 
and Balance Scores 
 Tinetti Balance 
r (P) 
Tinetti Gait 
r (P) 
SDNN 0.28 (0.01) 0.30 (0.01) 
Total Power 0.29 (0.01) 0.27 (0.02) 
VLF 0.24 (0.03) 0.22 (0.05) 
Low Frequency 0.35 (<0.01) 0.31 (<0.01) 
High Frequency 0.18 (0.12) 0.20 (0.08) 
HF/LF -0.17 (0.13) -0.10 (0.36) 
 
 Summer y of Key Results From Chapter 6 6.12
The number of participants reporting falls had increased but not significantly where as 
the number of participants reporting recurrent falls had significantly increased. Median 
Tinetti scores for the cohort were significantly lower at follow-up than at baseline.  
 Hypertension 6.12.1
Hypertension at baseline was not associated with reports of falls or Tinetti scores at 
follow-up 
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 Ambulatory Blood Pressure Measurements 6.12.2
There were no independent associations between mean BP or BP variability and falls, 
recurrent falls or injurious falls. Similarly mean BP and BP variability were not 
associated with Tinetti Scores.  
 Orthostatic Hypotension 6.12.3
Orthostatic hypotension at baseline defined according to  AAN guidelines was not 
associated with falls, recurrent falls or injurious falls. Symptomatic OH was however 
associated with a greater number of participants reporting recurrent falls. This was no 
longer significant after adjusting for covariates including age, sex, cardiovascular risk 
factors and cardioactive medication. Degree of vasodepression in response to active 
stand was not associated with falls, recurrent fall, injurious falls or reported number of 
falls.  
 
OH was not associated with performance on Tinetti assessments of gait and balance.  
 Carotid Sinus Massage 6.12.4
Carotid sinus hypersensitivity at baseline was not associated with reported falls, 
recurrent falls or injurious falls. There was however an association between length or 
RR interval post CSM and reports or recurrent falls. With long RR interval being 
associated with greater odds of recurrent falls.  This association was no longer 
significant after adjusting for co-variates.  
 
CSH was not associated with performance on Tinetti assessment of gait and balance.  
 Autonomic Function 6.12.5
Abnormal autonomic function as defined by Ewing criteria was not associated with 
falls, recurrent falls or injurious falls. Of the individual autonomic function tests 
Valsalva ratio at baseline was associated with reports of falls, recurrent falls and number 
of falls at follow-up however these associations were not significant after adjusting for 
age, sex and cardiovascular risk factors.  
 
On univariate analysis an association was observed between abnormal autonomic 
function and poorer performance on the Tinetti balance score however after correcting 
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for covariates including age this was not long significant. Similarly associations 
observed between heart rate variability and Tinetti gait and balance scores were not 
significant after adjusting for covariates.    
 Discussion 6.13
 Hypertension and Falls, Gait and Balance 6.13.1
There were no associations between having hypertension on ambulatory BP monitoring 
at baseline and falling in the year prior to follow-up or with the reported number of falls 
in the year prior to follow-up. Review of the literature found there are few studies 
examining the association between hypertension and falls. McCarthy et al identified 4 
studies exploring the possible link between elevated blood pressure and falls (McCarthy 
et al., 2010). Three studies found that self-reported hypertension was a risk factor for 
falling, while the other found fallers were more likely to have hypertension than non-
fallers (Chan et al., 1997, Bergland et al., 2003, Assantachai et al., 2003, Davison et al., 
2005). None of these studies used objective measures of hypertension. Self-reported 
hypertension has been shown to underestimate the prevalence of hypertension. A further 
study published since McCarthy’s review examined the association between 
hypertension and frequent falls (three or more falls in the last 6 months). In keeping 
with the findings of this current study, no association was found between hypertension 
and frequent falls (Teh and Fisher, 2012).    
 
No association was seen between hypertension status at baseline and performance on 
the Tinetti gait and balance assessment at follow-up. A smaller study performed 
ambulatory BP monitoring in 72 older people (White et al., 2011). Gait and balance 
were assessed using the Tinetti score and time to walk 8 ft. and climb 3 stairs were 
recorded at baseline and at 2 years follow-up. Hypertension at baseline (defined as mean 
BP > 135/80) was associated with slower gait speed at follow-up, but not with 
performance on Tinetti assessment. Two other longitudinal studies have also reported 
the effect of hypertension on gait speed (Rosano et al., 2011, Dumurgier et al., 2010). 
Both found hypertension was associated with slower speed at baseline and faster 
declines in gait speed over follow-up. This was independent of demographic and 
selected comorbidities, but was attenuated by white matter disease. Shah et al developed 
a measure of lower limb function incorporating 2 measures of gait speed, 1 measure of 
chair rise capacity, and 2 measures of balance skills(Shah et al., 2006). No association 
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was found between systolic BP and performance on the assessment of lower limb 
function at baseline but greater systolic BP was associated with fast decline in function 
over the follow-up period. A small cross-sectional study, of 24 healthy community-
dwelling older people aged 65-90 compared several measures of gait and balance 
including the Tinetti scores among hypertensive and normotensive patients (Jeffrey M. 
Hausdorff and Tanya Gurevich, 2003). Again, the group found significantly poorer 
performance on the Timed Up-and-Go and Pull tests among the hypertensive group 
compared to the controls. However, there was no significant difference in the Tinetti 
gait and balance scores. These findings suggest that hypertension may be associated 
with gait speed but not performance on Tinetti assessment, possibly because the Tinetti 
score is not sensitive enough to detect small changes in gait associated with 
hypertension in fit older people.  
 Blood Pressure Variability and Falls, Gait and Balance  6.13.2
Twenty-four hour systolic BP variability was associated with increased odds of falling 
in the year prior to assessment. After adjusting for relevant covariates, however, this 
was no longer a significant predictor of falls. Few studies have examined the association 
between BP variability and falling. Puisieux et al compared BP variability in three 
groups of older people; fallers, people with syncope and a control group (Puisieux et al., 
2000). BP variability did not significantly differ between the groups. Jonsson et al 
examined BP variation in response to daily activities, e.g. eating, and response to nitro-
glycerine (GTN). They found older people with greater BP variability in response to 
these activities and GTN were at risk of falls (Jonsson et al., 1990). However, the study 
was conducted in older people living in nursing care and included BP variability 
induced by a pharmacological agent. Review of the literature did not reveal any studies 
examining the longitudinal association between BP variability and falls.  
 
No associations were observed in this study between BP variability and performance on 
Tinetti gait and balance assessment. Although increased BP variability has been 
associated with WMH, which in turn have been associated with gait abnormalities, no 
other studies were identified examining the direct association between BP variability 
and gait and balance in older people.  
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 NCVI and Falls Gait and Balance 6.13.3
Neither orthostatic hypotension nor carotid sinus hypersensitivity were associated with 
reports of falling in the year prior to assessment. This is in keeping with baseline 
findings and with studies examining the associations between OH and falls over shorter 
intervals (Kerr, 2009, Ganz et al., 2007, McCarthy et al., 2010). Prospective studies 
among community-dwelling older people have failed to show an association between 
OH and suffering a fall in the following 12 months (McCarthy et al., 2010, Ganz et al., 
2007). Some studies,  but not all, do suggest there may be an association between OH 
and recurrent  falls, most often defined as 2 or more falls in 12 months (McCarthy et al., 
2010, Ganz et al., 2007). There may have been a trend towards this finding in our study, 
22% of the systolic OH group reported recurrent falls compared to  9% of the group 
without systolic OH (P=0.10). The sample size in this study was small and the study 
may have lacked statistical power.  
 
To my knowledge there have been no prospective studies examining the association 
between CSH or CSS and falls. Several studies have however compared the prevalence 
of CSH among fallers and age-matched controls. Sachpekidis et al reported prevalence 
of CSH of 18.2%, 17.6% and 66.7% among controls, accidental fallers and individuals 
with and unexplained fall respectively (Sachpekidis et al., 2009). Tan et al reported 
finding CSH among 25% of individuals investigated for falls or syncope at a regional 
falls and syncope centre (Tan et al., 2009). Davies et al examined rates of CSH among 
older people presenting to A&E with non-accidental falls and among matched controls. 
The group found CSH in 46% of cases versus 13% of controls and CSS in 27% of cases 
versus 0% of controls (Davies et al., 2001). Rafanelli et al reported rates of carotid sinus 
syndrome of 10.5% and 14.3% among patients presenting with unexplained falls and 
syncope respectively (Rafanelli et al., 2013). It is interesting that most of these studies 
found rates of CSH and CSS among controls and fallers lower than observed in this 
unselected community-dwelling population. In this cohort CSH was present in 39% of 
participants at baseline and CSS was present in 16%(Kerr, 2009).  
 
Despite cross-sectional evidence supporting an association between CSH and falls, 
interventional studies examining the efficacy of permanent cardiac pacing for falls 
prevention in CSH have shown mixed results. These studies were recently reviewed by 
Parry and Mathews (Parry and Matthews, 2013). They found that un-blinded studies 
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among younger patients suggested pacing might reduce falls. However, studies among 
older people did not show a reduction in falls among the paced group, possibly because 
older patients are more likely to have multiple co-morbidities and falls are likely to be 
multifactorial. There is one published randomised double-blinded placebo controlled 
trial to examine pacing for CSS among older, recurrent fallers (Parry et al., 2009). This 
found a reduction in falls in both the placebo and the active arm of the trial, with no 
benefit in the pacing arm. The authors suggest that this study shows there is a clear 
anticipation effect associated with pacing resulting in reduced falls among both the 
placebo and pacing arms.  
 
It was hypothesised that WMH secondary to NCVI may lead to gait and balance 
impairment. No independent associations between OH at baseline and Tinetti gait and 
balance scores at follow-up were identified. Similarly, response to CSM at baseline was 
not associated with Tinetti gait and balance scores at follow-up. Few studies have 
examined the association between hypotensive syndromes and gait and balance among 
the general older population. Barret et al examined gait among three groups: elderly 
fallers without OH, elderly fallers with OH, and a control group (Barrett et al., 2008). 
They hypothesised that if elderly fallers with OH were falling purely due to BP 
abnormalities they would have similar gait patterns to age-matched controls. The OH 
group and the control group had similar gait variability, which was significantly less 
than observed in elderly fallers without OH. Barret et al concluded that this indicates 
that fallers with OH are falling purely because of their vascular abnormalities and are 
not falling due to gait impairment as seen in fallers without OH. Interestingly, the 
authors found that both fallers with and those without OH spent more time in the stance 
phase of gait; they suggested that this was due to fear of falling (Barrett et al., 2008). A 
study of the association between OH, gait and balance in 91 diabetic patients also found 
mixed results (Cordeiro et al., 2009). OH was negatively and independently associated 
with performance on the Berg Balance Scale, but not with performance on timed-up-
and-go. Similarly, a study among 120 patients with Parkinson’s disease found OH was 
associated with increased postural sway, but not with timed-up-and-go or walking speed 
(Matinolli et al., 2009).  
 Autonomic Function and Falls Gait and Balance 6.13.4
Of the autonomic function tests, only heart rate response to Valsalva manoeuvre was 
associated with falls risk and these associations were no longer significant adjusting for 
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covariates. From the heart rate variability variables only HF:LF ratio was associated 
with falls, but again this was not significant after adjusting for covariates, suggesting 
that the associations were due to confounding risk factors. There are a few other studies 
examining the association between autonomic function and falls. Isik et al have 
compared 24-hour heart rate variability among older people who had fallen in the last 
12 months and a control group who had never fallen. Time and frequency domains were 
examined. In keeping with our findings, heart rate variability parameters did not 
significantly differ between groups (Isik et al., 2012).  
 
After adjusting for covariates neither response to autonomic function tests nor measures 
of HRV were associated with Tinetti scores at follow-up. These findings are in keeping 
with those of  Aerts et al who examined the association between gait and heart rate 
variability among three groups: young healthy individuals, elderly healthy individuals, 
and people with Parkinson’s disease (Aerts et al., 2009). HRV was not significantly 
associated with gait speed, gait swing time or swing time variability.  
 
 Summary 6.13.5
These data have shown few associations between autonomic function or NCVI at 
baseline on the one hand, and falls, gait and balance on the other. Given the extensive 
multiple testing, those associations that have remained significant after adjusting for 
covariates should be interpreted with caution. It appears from these data that recurrent 
hypotensive episodes may not be a risk factor for falls over long follow-up periods. This 
is an interesting observation as assessment of autonomic function and NCVI is 
frequently advocated in guidelines on the assessment and management of falls (Panel on 
Prevention of Falls in Older Persons and British Geriatrics, 2011).  
 
This study has several potential limitations to. Firstly, this study relied on retrospective 
recall of falls. This method is widely used and was chosen at follow-up in order to 
reproduce baseline methods, and allow comparison of baseline and follow-up data. It 
should be acknowledged, however, that retrospective recall of falls is less accurate than 
prospective collection of falls data. Studies comparing retrospective and prospective 
reports of falls reported a sensitivity and specificity of 79.5 and 91.4% indicating 
potential for misclassification (Peel, 2000). To help maximise the accuracy of the falls 
histories obtained, the next of kin of participants with cognitive impairment were 
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interviewed to confirm the number of falls that had occurred during the 12 months prior 
to assessment. In all these cases, the study participants lived with their next of kin, 
making it more likely that the next of kin would be able to give an accurate history. In 
this study, 32% of participants reported falling in the twelve months prior to follow-up 
assessment. Reassuringly, this is in keeping with other community-based studies in 
similar aged populations, suggesting our sample was representative of the general 
population in respect to falls prevalence (Tinetti et al., 1988, Rubenstein, 2006).  
 
It should also be noted that autonomic function tests and tests of NCVI were only 
performed on one occasion at baseline. BP response varies by time of day and from 
day-to-day (Ward and Kenny, 1996). Best practice guidelines recommend that 
autonomic function should be tested in the morning and repeatedly (Ward and Kenny, 
1996). Although all tests were conducted in the morning, repeated testing may have 
identified a group for people with more persistent OH at greater risk of falling.  
 
Some participants may have developed OH or CSH over the follow-up period, while 
hypotensive syndromes may have improved or resolved in others. Diagnosing NCVI 
based on results of autonomic function tests from a single time point may have led to 
misclassification of participants. NCVI is often secondary to or exacerbated by 
antihypertensive medication. Review of medication and BP control at baseline and 
follow-up revealed increased use of  antihypertensive drugs at follow-up compared to 
baseline and tighter BP control (McDonald et al., 2013). This may have affected the 
prevalence of NCVI over the ten year follow-up  .  
 
Both OH and CSH were highly prevalent in the cohort at baseline. OH affected 81% of 
the follow-up cohort at baseline and CSH affected 31%. The high prevalence is likely 
due to the use of beat-to-beat monitoring. Beat-to-beat monitoring is likely to detect 
short-lived drops in BP that would be missed if change in BP was measured using a 
standard sphygmomanometer. The prevalence of OH found in our study was slightly 
less than that reported in other studies using beat-to-beat monitoring (Romero-Ortuno et 
al., 2011a).  
 
The failure to observe an association between NCVI and falls in this study may reflect 
the fact that the causes of falls, particularly in older people, are often multifactorial. In a 
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relatively small cohort, it may be difficult to identify the association between NCVI and 
falls as many of the falls occurring in the cohort may be due to other risk factors.  
 
It was hypothesised in this study that NCVI might be associated with falls due to gait 
and balance impairment secondary to white matter damage. Few associations were 
observed between NCVI or autonomic function on the one hand and performance on the 
Tinetti assessments of gait and balance on the other. Interestingly, studies that have used 
other measures of gait and balance such as gait speed, timed up-and-go and postography 
have suggested that there may be an association between OH and gait and balance. The 
failure to identify an association between NCVI and gait in this study may therefore be 
a consequence of the characteristics of the Tinetti scale. The Tinetti scale has a 
documented ceiling effect, particularly for the gait component (Hayes and Johnson, 
2003) At baseline 75% of participants had a Tinetti gait score of 9 (maximum attainable 
score). At follow-up, 50% of participants still had a score of nine. This ceiling effect 
may have meant that small differences in gait and balance associated with NCVI could 
not be detected, particularly among better performing members of the cohort.  
 
Although the sample size was small and the measures used in this study rather 
insensitive to small changes in gait and balance, these data suggest that autonomic 
dysfunction and NCVI are not a substantial risk factor for future falls and gait 
impairment in community-dwelling older people.  
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Chapter 7 Association between White Matter Hyperintensities 
Clinical Symptoms and Baseline Neurocardiovascular 
Function  
  Introduction 7.1
White matter hyperintensity volume has been associated with poorer cognition, 
particularly executive function, depressive symptoms, impaired gait and balance and 
falls(Frisoni et al., 2007, Pantoni et al., 2007, DeCarli, 2013, Culang-Reinlieb et al., 
2011, O'Brien, 2013, Zheng et al., 2011). Some studies have found WMH to be more 
severe in people with neurocardiovascular instability and a small number of studies 
have documented an association between greater WMH volume and altered autonomic 
function (Galluzzi et al., 2009, McLaren, 2004, Gottesman et al., 2011, Longstreth et 
al., 1996).  
 Aims 7.2
1. To examine if cognition, depressive symptoms and gait and balance are 
associated with WMH volume in this cohort at follow-up. 
2. To examine if WMH volume at follow-up is associated with control of blood 
pressure and heart rate at baseline 
 Methods 7.3
 Tests of Neurocardiovascular Function 7.3.1
Tests of neurocardiovascular function were described in 2.3, page 42. 
 Assessment of Clinical Symptoms  7.3.2
Assessment of cognition, depression, gait, balance, and falls was performed as 
described in sections 2.9 and 2.10, page 51.  
 Brain Magnetic Resonance Imaging  7.3.3
Magnetic resonance images were obtained on a 3T MRI scanner at Newcastle Magnetic 
Resonance Centre. The scanning protocol is described in section 2.11, page 52. An 
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automated volumetric method was used to calculate total, periventricular, and regional 
WMH volumes.  
 Statistics 7.4
White matter volumes were as expected highly skewed. In keeping with convention, 
WMH volume as a percentage of total brain volume was log transformed to normalise 
the distribution. White matter hyperintensity volume was then compared between two 
groups using the independent T test.  
 
White matter hyperintensity volume is highly correlated with age (Tiehuis et al., 2007). 
Associations between WMH volume and continuous variables were therefore examined 
using age-adjusted partial correlations.  
 
If significant associations were found on initial examination, analyses were repeated 
adjusting for covariates. Multi-linear regression was used to assess the association 
between multiple linear and categorical explanatory variables and white matter volume. 
 Covariates 7.4.1
A review of the literature revealed the following risk factors were consistently 
associated with greater WMH volume: age, hypertension, cerebrovascular disease 
(Chowdhury et al., 2011, Basile et al., 2006, Liao et al., 1997). These were entered as 
covariates into multivariate analysis. 
 Results: White Matter Hyperintensities and Cognition, 7.5
Depression and Motor Symptoms at Follow-up 
 Characteristics of MRI Cohort 7.5.1
Of the 104 individuals who participated in the ten year follow-up, two participants died 
before an MRI could be completed, two withdrew from the study, 34 declined (most 
often due to claustrophobia or feeling that they could not lie flat for the duration of the 
scan), nine had a recognised contraindication (this included pacemaker, a cardiac stent 
not compatible with 3T MRI, previous injury with shrapnel or recent eye surgery), one 
participant was housebound and two participants had known intracranial pathology that 
would make interpreting the scan difficult (this included a large previous subdural 
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haemorrhage and an acoustic neuroma). In total, 53 participants consented to MRI scan 
and were free from contraindication to magnetic resonance imaging.  
 
Table 7-1 compares the characteristics at year 10 follow-up of the participants who 
underwent MRI scan (N = 53) with those of the individuals who did not (N = 51). The 
groups were well matched in terms of age and sex, P=0.72 and P=0.71 respectively. 
Scores on cognitive tests at year 10 assessment tended to be higher among the group 
that underwent MRI, but these differences were not statistically significant. Rates of 
mild cognitive impairment and depression were similar in the two groups. Rates of 
cardiovascular and/or cerebrovascular disease were lower among the MRI cohort (P = 
0.05), however rates of hypertension and diabetes were similar between the two groups 
P=0.89 and P=0.93 respectively.  
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Table 7-1 Characteristics at Follow-up of Cohort Undergoing MRI and Those Not 
Undergoing MRI 
Characteristic at Follow-up No MRI (N= 51)  MRI (N= 53)  
 Median (IQR) Median (IQR) P  
Age (years) 80.0 (77.0, 83.0) 79.0 (76.0, 83.5) 0.72 
BMI (kg/m
2
) 27.4 (23.4, 30.8) 27.4 (24.4, 31.2) 0.71 
MMSE 28.0 (26.0, 29.0) 29.0 (26.0, 29.0) 0.96 
CAMCOG total score 94.0 (89.0, 96.0) 96.0 (90.3, 98.0) 0.12 
CAMCOG memory score 22.0 (21.0, 24.0) 23.0 (21.0, 25.0) 0.09 
CAMCOG executive score 20.0 (17.0, 23.0) 20.0 (18.0, 23.0) 0.70 
Cornell score 4.0 (2.0, 6.0) 4.0 (2.0, 6.0) 0.65 
    
 Frequency (%) Frequency (%)  
Sex (male) 27 (53) 30 (57) 0.71 
CVD 26 (51) 17 (32) 0.05 
Hypertension 29 (57) 29 (55) 0.83 
Diabetes 8 (16) 8 (15) 0.93 
Dementia 3 (6) 1 (2) 0.36 
MCI 2 (4) 0 0.15 
Depression 2 (4) 2 (4) 0.97 
Cardioactive medication 37 (73) 37 (70) 0.76 
Psychoactive medication 10 (20) 7 (13) 0.38 
 White Matter Hyperintensity Volume  7.5.2
Table 7-2 shows mean WMH volume in each region as percentage of brain volume. 
Volumes of white matter hyperintensities at all sites were significantly associated with 
age (Table 7-3).  
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Table 7-2 WMH Volume as Percentage of Total Brain Volume   
WMH Volume as Percentage of 
Total Brain Volume 
Mean Standard 
Deviation 
Total WMH 1.35 1.32 
Periventricular WMH 0.97 0.89 
Left Frontal WMH 0.34 0.33 
Right Frontal WMH 0.32 0.29 
Left Parietal WMH 0.19 0.28 
Right Parietal WMH 0.18 0.25 
Left Occipital WMH 0.08 0.08 
Right Occipital WMH 0.06 0.06 
Left Temporal WMH 0.06 0.07 
Right Temporal WMH 0.06 0.07 
 
Table 7-3 Association between Normalised White Matter Hyperintensity Volume 
and Age 
Log transformed white matter 
hyperintensity volume 
r  P  
Total WMH 0.45 0.001 
Periventricular WMH 0.48 <0.001 
Left Frontal WMH 0.40 0.003 
Right Frontal WMH 0.38 0.006 
Left Parietal WMH 0.43 0.001 
Right Parietal WMH 0.38 0.005 
Left Occipital WMH 0.32 0.018 
Right Occipital WMH 0.34 0.013 
Left Temporal WMH 0.39 0.004 
Right Temporal WMH 0.33 0.016 
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 White Matter Hyperintensity Volume and Cognitive Function  7.5.3
All 53 participants who underwent MRI also underwent cognitive testing. One patient, 
whose performance on the cognitive tests was affected by severe visual impairment, 
was excluded from the analysis. Age-adjusted partial correlations were used to examine 
the association between white matter hyperintensity volume and scores on MMSE and 
CAMCOG scores at year ten. There were no significant associations (Table 7-4). 
Similarly, there were no associations between WMH volume and reaction times scored 
on COMPASS battery (Table 7-5).  
 
To examine if there was a threshold effect between WMH volume and cognition, the 
population was divided into quintiles according to Log (total WMH volume / brain 
volume) and cognition in the lowest four quintiles and upper quintile of WMH volume 
compared. Participants with greater white matter volume performed more poorly on the 
MMSE, total CAMCOG and CAMCOG memory test but these differences were not 
statistically significant. Similarly, there were no statistically significant differences in 
reaction times (Table 7-6). The same procedure was repeated for the periventricular 
white matter load and the findings were similar (Table 7-7).   
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Table 7-4 Partial Correlation Adjusting for Age Examining the Association between WMH Volume and Cognitive Test Scores at  
Follow-up 
  
WMH PVWMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
MMSE Score at 
Year 10 
pr 0.03 0.02 0.00 -0.01 0.08 0.14 0.10 -0.02 0.04 0.11 
P 0.83 0.89 0.98 0.96 0.57 0.33 0.49 0.88 0.76 0.45 
Total CAMCOG 
at Year 10 
pr -0.08 -0.08 -0.10 -0.09 0.02 0.04 -0.11 -0.15 -0.10 0.01 
P 0.60 0.59 0.47 0.54 0.87 0.77 0.46 0.30 0.48 0.94 
CAMCOG 
memory score 
year 10 
pr -0.20 -0.18 -0.21 -0.15 -0.12 -0.13 -0.12 -0.16 -0.23 -0.12 
P 0.15 0.21 0.14 0.28 0.42 0.36 0.40 0.28 0.11 0.42 
CAMCOG 
executive score 
year 10 
pr -0.13 -0.16 -0.15 -0.13 -0.06 -0.01 -0.14 -0.10 -0.14 -0.05 
p 0.35 0.27 0.29 0.37 0.68 0.96 0.32 0.47 0.34 0.75 
(WMH volume expressed as percentage of total brain volume and log transformed for analysis) 
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Table 7-5 Partial Correlation Adjusting for Age Examining the Association between WMH Volume and Reaction Times at Follow-up 
  
WMH PVWMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Choice Reaction 
Time (ms) 
pr -0.14 -0.09 -0.14 -0.08 -0.09 -0.09 -0.14 -0.09 -0.08 -0.09 
P 0.31 0.52 0.33 0.60 0.52 0.54 0.31 0.53 0.60 0.52 
Simple Reaction 
Time (ms) 
pr -0.08 -0.09 0.00 -0.03 -0.16 -0.12 -0.20 -0.29 0.00 -0.05 
P 0.57 0.52 1.00 0.85 0.26 0.38 0.17 0.04 0.98 0.74 
Digit Vigilance 
Reaction Time (ms) 
pr -0.15 -0.15 -0.15 -0.11 -0.14 -0.02 -0.24 -0.22 -0.17 -0.06 
P 0.29 0.28 0.28 0.45 0.33 0.87 0.08 0.11 0.24 0.67 
Cognitive Reaction 
Time (ms) 
pr -0.05 0.00 -0.12 -0.04 0.06 0.03 0.04 0.16 -0.07 -0.04 
p 0.71 1.00 0.42 0.78 0.70 0.84 0.78 0.26 0.64 0.80 
Power of Attention 
(ms) 
pr -0.16 -0.13 -0.11 -0.08 -0.17 -0.13 -0.24 -0.26 -0.07 -0.09 
p 0.28 0.35 0.45 0.59 0.23 0.38 0.09 0.07 0.62 0.53 
(WMH volume expressed as percentage of total brain volume and log transformed for analysis) 
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Table 7-6 Comparison of the Cognitive Function at Ten Years for Participants in 
the Lowest 4 Quintiles and the Highest Quintile of total WMH volume.  
 Lower 4 quintiles 
of total white 
matter load N= 42 
Upper quintile of 
white matter load 
N=10 
P  
 Median (IQR) Median (IQR)  
MMSE 29 (26.8, 29.0) 27.5 (24.8, 29.3) 0.28 
Total CAMCOG 95 (91.8, 99.0) 93 (82.8, 96.5) 0.26 
CAMCOG memory 23.5 (21.8, 25.0) 22.5 (17.5, 24.5) 0.19 
CAMCOG executive function 20.0 (18.0, 23.0) 20.5 (16.0, 21.5) 0.50 
Choice reaction time (ms) 627 (576, 679) 563 (536, 701) 0.47 
Simple reaction time (ms) 446 (407, 542) 439 (403, 606) 0.23 
Digit vigilance time (ms)  543 (512, 596) 540 (522, 559) 0.91 
Cognitive reaction time (ms) 152 (113, 226) 143 (-70, 253) 0.73 
Power of attention (ms) 1643 (1502, 1810) 1662 (1491, 1796) 0.69 
 
Table 7-7 Comparison of the Cognitive Function at Ten Years for Participants in 
the Lowest 4 Quintiles and the Highest Quintile of periventricular WMH volume. 
 Lower 4 quintiles 
of peri-ventricular 
white matter load 
N= 42 
Upper quintile of 
peri-ventricular 
white matter load 
N=10 
P  
 Median (IQR) Median (IQR)  
MMSE 29.0 (26.0, 29.0) 28.0 (25.0, 30.0) 0.94 
Total CAMCOG 95.0 (91.0, 99.0) 94.0 (89.0, 96.0) 0.44 
CAMCOG memory 23.5 (21.0, 25.0) 23.0 (19.0, 24.0) 0.42 
CAMCOG executive function 20.0 (18.0, 23.0) 20.5 (17.0, 21.0) 0.86 
Choice reaction time (ms) 629 (583, 679) 563 (541, 669) 0.21 
Simple reaction time (ms) 446 (411, 523) 439 (409, 583) 0.48 
Digit vigilance time (ms)  541 (512, 592) 542 (526, 578) 0.25 
Cognitive reaction time (ms) 157 (151, 224) 120 (-42.6, 206) 0.85 
Power of attention (ms) 1643 (1502, 1797) 1682 (1519, 1819) 1.00 
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 White Matter Hyperintensity Volume and Depression 7.5.4
Of the 53 participants who underwent MRI 51 had complete data from the Cornell 
depression Score. Age-adjusted partial correlation failed to show an association between 
WMH volume and Cornell score at follow-up (Table 7-8)  
   
Table 7-8 Partial Correlation Examining Association between WMH volume and 
Performance on Cornell score at Follow-up 
WMH Volumes  Cornell Score at Follow-up 
 
r ( P ) 
Total WMH -0.13 (0.37) 
Periventricular WMH -0.09 (0.55) 
Left Frontal WMH -0.08 (0.56) 
Right Frontal WMH -0.16 (0.27) 
Left Parietal WMH -0.11 (0.45) 
Right Parietal WMH -0.23 (0.11) 
Left Occipital WMH -0.21 (0.15) 
Right Occipital WMH -0.20 (0.17) 
Left Temporal WMH 0.00 (1.00) 
Right Temporal WMH -0.14 (0.34) 
 
Four participants had a Cornell score of 10 or more at follow-up (indicative of probable 
depression). There was no association between Cornell depression score ≥ 10 and 
WMH volume (Table 7-9).  
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Table 7-9 Comparison of White Matter Volume for Participants with and without 
Probable Depression (depression defined as Cornell score ≥10) 
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
Cornell 
Score <10 
N =47 
Cornell 
score ≥10 
N=4 
P  
 Mean (SD) Mean (SD)  
Total WMH 1.37 (1.34) 1.29 (1.55) 0.86 
Periventricular WMH 0.96 (0.89) 1.09 (1.29) 0.90 
Left Frontal WMH 0.34 (0.33) 0.27 (0.33) 0.99 
Right Frontal WMH 0.32 (0.29) 0.27 (0.33) 0.65 
Left Parietal WMH 0.19 (0.29) 0.19 (0.31) 1.00 
Right Parietal WMH 0.19 (0.26) 0.13 (0.22) 0.41 
Left Occipital WMH 0.08 (0.08) 0.09 (0.07) 0.63 
Right Occipital WMH 0.06 (0.06) 0.06 (0.06) 0.48 
Left Temporal WMH 0.06 (0.07) 0.06 (0.07) 0.71 
Right Temporal WMH 0.06 (0.07) 0.06 (0.06) 0.83 
 
To examine if the use of antidepressants altered this finding we expanded the definition 
of depression to include participants taking any antidepressant medication or scoring 10 
or more on the Cornell score at follow-up. This showed an association between 
depression and decreased WMH in the right parietal lobe (P= 0.04). This association 
was not significant after adjusting for history of hypertension and cerebrovascular 
disease.  
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Table 7-10 Comparison of White Matter Volume for Participants with and without 
Probable Depression (depression defined as Cornell score ≥10 and or taking 
antidepressants) 
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but 
non transformed data shown here) 
Cornell Score 
<10 and not 
taking 
antidepressants  
N =43 
Cornell score 
≥10 or taking 
antidepressants 
N=8 
P  
 Mean (SD) Mean (SD)  
Total WMH 1.43 (1.38) 1.02 (1.09) 0.52 
Periventricular WMH 0.99 (0.92) 0.88 (0.91) 0.86 
Left Frontal WMH 0.35 (0.34) 0.28 (0.30) 0.83 
Right Frontal WMH 0.33 (0.30) 0.28 (0.24) 0.78 
Left Parietal WMH 0.21 (0.30) 0.12 (0.22) 0.19 
Right Parietal WMH 0.20 (0.27) 0.09 (0.16) 0.04 
Left Occipital WMH 0.09 (0.09) 0.07 (0.06) 0.54 
Right Occipital WMH 0.07 (0.06) 0.05 (0.05) 0.25 
Left Temporal WMH 0.07 (0.07) 0.04 (0.06) 0.63 
Right Temporal WMH 0.07 (0.07) 0.04 (0.05) 0.12 
 
 White Matter Hyperintensity Volume and Falls 7.5.5
Of the 53 participants who underwent MRI, 14 reported falling in the year prior to 
assessment, of which six had had more than 1 fall. Fallers had a greater volume of white 
matter hyperintensities in all regions, but these differences were not statistically 
significant (Table 7-11). Similarly, comparing recurrent fallers with those who had not 
fallen or had fallen only once did not reveal any significant differences in white matter 
hyperintensity volume.  
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Table 7-11 Comparison of WMH Volume for Fallers and Non-fallers  
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
No history of 
Falls 
N = 39 
History of 
≥ 1 Fall 
N= 14 
P  
Total WMH 1.25 (1.09) 1.63 (1.83) 0.92 
Periventricular WMH 0.90 (0.73) 1.15 (1.25) 0.91 
Left Frontal WMH 0.31 (0.27) 0.41 (0.47) 0.80 
Right Frontal WMH 0.32 (0.27) 0.33 (0.34) 0.67 
Left Parietal WMH 0.15 (0.22) 0.29 (0.41) 0.70 
Right Parietal WMH 0.16 (0.21) 0.23 (0.35) 0.75 
Left Occipital WMH 0.08 (0.06) 0.09 (0.12) 0.49 
Right Occipital WMH 0.06 (0.06) 0.06 (0.05) 0.10 
Left Temporal WMH 0.05 (0.06) 0.08 (0.10) 0.54 
Right Temporal WMH 0.06 (0.06) 0.07 (0.08) 0.96 
 
Negative binomial regression failed to show any significant associations between WMH 
volume and reported number of falls in year prior to follow-up assessment (Table 7-12) 
 
Table 7-12 Negative Binomial Regression Examining Association between WMH 
Volume and Reported Number of Falls in Year Prior to Follow-up 
Volume of WMH as percentage of brain 
volume  
IRR 95% CI P  
Total WMH 0.94 0.30, 2.89 0.91 
Periventricular WMH 1.10 0.34, 3.53 0.87 
Left Frontal WMH 0.72 0.24, 2.22 0.57 
Right Frontal WMH 0.57 0.18, 1.82 0.34 
Left Parietal WMH 1.32 0.68, 2.55 0.42 
Right Parietal WMH 0.84 0.44, 1.63 0.61 
Left Occipital WMH 0.89 0.37, 2.13 0.79 
Right Occipital WMH 0.57 0.25, 1.30 0.18 
Left Temporal WMH 1.14 0.55, 2.36 0.72 
Right Temporal WMH 1.29 0.55, 3.01 0.56 
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 White Matter Hyperintensity Volume and Gait and Balance 7.5.6
Fifty-two of the participants underwent MRI scan and completed the Tinetti assessment 
of gait and balance. Partial correlation adjusting for age showed a significant positive 
association between Tinetti gait score, total WMH, periventricular, frontal and parietal 
WMH. Greater WMH volume in these regions was associated with better performance 
on the assessment of gait (Table 7-13). After adjusting for history of hypertension and 
cerebrovascular disease these associations were no long statistically significant. No 
significant associations were observed between Tinetti balance score and white matter 
hyperintensity volume (Table 7-13)  
 
Table 7-13 Age-adjusted Partial Correlation between WMH Volume and Tinetti 
Scores.  
Volume of WMH  
 
Age-adjusted 
correlation with 
Tinetti Gait Score 
Age-adjusted 
correlation with 
Tinetti Balance 
score 
 Pr (P) Pr (P) 
Total WMH 0.30 (0.03) 0.17 (0.22) 
Periventricular WMH 0.30 (0.04) 0.15 (0.31) 
Left Frontal WMH 0.34 (0.01) 0.18 (0.20) 
Right Frontal WMH 0.30 (0.04) 0.15 (0.26) 
Left Parietal WMH 0.31 (0.03) 0.15 (0.29) 
Right Parietal WMH 0.28 (<0.05) 0.17 (0.24) 
Left Occipital WMH 0.08 (0.59) 0.24 (0.09) 
Right Occipital WMH -0.02 (0.91) 0.15 (0.29) 
Left Temporal WMH 0.22 (0.12) 0.13 (0.35) 
Right Temporal WMH 0.22 (0.07) 0.18 (0.22) 
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 Results Baseline Neurocardiovascular Function and White Matter 7.6
Hyperintensity Volume at Follow-up 
 Ambulatory Blood Pressure Variables at Baseline and White Matter 7.6.1
Hyperintensity Volume at Follow-up 
All 53 participants who underwent MRI at follow-up had ambulatory BP recordings 
with 16 readings or more readings at baseline. Of these, all had 10 or more daytime 
readings and 47 had five or more night-time readings. Fifty-three participants were 
therefore included in 24-hour and daytime analysis and 47 were included in night-time 
analysis and analysis of diurnal variation.  
 
Comparing participants who underwent MRI with those who did not, did not reveal any 
significant differences in 24-hour ambulatory BP parameters (Table 7-14).  
 
Table 7-14 Comparison of Baseline 24-hour Ambulatory BP Records for 
Participants Undergoing MRI and Those Who Did Not Undergo MRI 
 
Hypertension at baseline, defined according to NICE criteria, was not associated with 
WMH volumes at follow-up (Table 7-15). However, mean daytime systolic BP > 150 
on baseline ambulatory BP was associated with significantly greater total and 
periventricular white matter volumes (P= 0.019 and P= 0.035 respectively). Examining 
regions separately showed that the frontal regions had significantly greater volume of 
WMH in the systolic BP >150. The temporal, occipital and parietal lobes did not have 
significantly greater WMH volume (Table 7-16).  
 No MRI  
N= 51 
 MRI  
N=53 
 
 Median (IQR) Median (IQR) P  
Mean Systolic BP (mmHg) 129 (119, 136) 126 (115, 135) 0.72 
Mean Diastolic BP (mmHg) 723 (66, 76) 70 (67, 80) 0.95 
Systolic BP Variability 13 (11, 16) 13 (11. 14) 0.39 
Diastolic BP Variability  9 (8, 10.) 9 (8, 10) 0.20 
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Table 7-15 Comparison of WMH Volume for Hypertensive and Normotensive 
Groups 
Volume of WMH as percentage of 
brain volume  
(data log transformed for analysis but 
non transformed data shown here) 
No hypertension 
(NICE Criteria)   
(N= 30) 
Hypertension 
(NICE 
Criteria)   
 (N = 23) 
P  
 Mean (SD) Mean (SD)  
Total WMH 1.25 (1.10) 1.48 (1.57) 0.93 
Periventricular WMH 0.90 (0.72) 1.05 (1.09) 0.90 
Left Frontal WMH 0.32 (0.30) 0.36 (0.38) 0.95 
Right Frontal WMH 0.32 (0.29) 0.32 (0.30) 0.81 
Left Parietal WMH 0.16 (0.23) 0.22 (0.34) 0.84 
Right Parietal WMH 0.15 (0.20) 0.22 (0.30) 0.44 
Left Occipital WMH 0.07 (0.06) 0.10 (0.10) 0.86 
Right Occipital WMH 0.05 (0.04) 0.07 (0.07) 0.38 
Left Temporal WMH 0.05 (0.06) 0.06 (0.08) 0.94 
Right Temporal WMH 0.06 (0.06) 0.07 (0.07) 0.47 
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Table 7-16 Comparison of WMH Volume for Participants with Mean Daytime 
Systolic BP >150 and Participants with Mean Daytime Systolic BP <150  
Volume of WMH as percentage of 
brain volume  
(data log transformed for analysis but 
non transformed data shown here) 
Mean daytime 
systolic BP <150 
(N= 43) 
Mean daytime 
systolic BP 
>150  
(N = 10) 
P  
 
 Mean (SD) Mean (SD)  
Total WMH 1.10 (1.07) 2.42 (1.78) 0.02 
Periventricular WMH 0.81 (0.74) 1.61 (1.21) 0.04 
Left Frontal WMH 0.28 (0.28) 0.59 (0.44) 0.02 
Right Frontal WMH 0.27 (0.26) 0.53 (0.32) 0.04 
Left Parietal WMH 0.15 (0.23) 0.37 (0.42) 0.07 
Right Parietal WMH 0.13 (0.19) 0.38 (0.36) 0.08 
Left Occipital WMH 0.07 (0.06) 0.15 (0.13) 0.12 
Right Occipital WMH 0.05 (0.04) 0.11(0.08) 0.18 
Left Temporal WMH 0.05 (0.05) 0.11 (0.10) 0.08 
Right Temporal WMH 0.05 (0.06) 0.10 (0.07) 0.10 
 
Ambulatory blood pressure recordings for each time period was separately examined to 
determine if mean BP or BP variability were associated with WMH volume. No 
significant associations were identified (Table 7-17, Table 7-18 and Table 7-19). 
Similarly, percentage diurnal variation at baseline was not associated with WMH 
volume at follow-up (Table 7-20)  
  
 
2
0
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Table 7-17 Age-adjusted Partial Correlation Examining Association between 24 ABPM Recordings and WMH Volume  
 
WMH 
PV 
WMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
24-hour 
24hr mean systolic 
BP (mmHg) 
pr 0.18 0.15 0.23 0.17 0.10 0.06 0.12 -0.01 0.20 0.08 
P 0.20 0.30 0.11 0.23 0.47 0.69 0.38 0.97 0.16 0.60 
24hr mean 
diastolic BP 
(mmHg) 
pr 0.22 0.23 0.17 0.17 0.23 0.18 0.23 0.06 0.18 0.17 
P 
0.12 0.10 0.22 0.22 0.11 0.22 0.11 0.69 0.20 0.23 
24-hour systolic BP 
variability 
pr 0.00 -0.02 0.04 -0.03 0.03 0.09 0.02 -0.07 0.01 -0.01 
P 0.98 0.90 0.80 0.84 0.83 0.53 0.90 0.63 0.94 0.95 
24-hour systolic BP 
variability 
pr 0.15 0.17 0.13 0.07 0.15 0.17 0.14 0.12 0.20 0.20 
P 0.29 0.24 0.35 0.60 0.31 0.24 0.34 0.42 0.16 0.15 
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Table 7-18 Age-adjusted Partial Correlation Examining Association between Daytime ABPM Recordings and WMH Volume  
 
WMH 
PV 
WMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Daytime 
Day mean systolic 
BP  (mmHg) 
pr 0.16 0.13 0.20 0.13 0.08 0.03 0.13 0.01 0.17 0.08 
P 0.27 0.37 0.15 0.36 0.57 0.81 0.36 0.93 0.22 0.60 
Day mean diastolic 
BP (mmHg) 
pr 0.20 0.22 0.15 0.14 0.21 0.15 0.23 0.06 0.17 0.18 
P 0.15 0.12 0.28 0.32 0.14 0.28 0.10 0.66 0.24 0.21 
Day time SD SBP 
pr 0.02 -0.03 0.02 0.05 0.16 0.25 -0.01 -0.09 -0.03 0.05 
P 0.91 0.86 0.87 0.72 0.26 0.07 0.95 0.52 0.85 0.74 
Day time SD DBP 
pr 0.06 0.05 0.08 0.12 0.12 0.16 -0.06 -0.03 0.08 0.07 
P 0.69 0.75 0.58 0.39 0.39 0.25 0.68 0.85 0.58 0.61 
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Table 7-19 Age-adjusted Partial Correlation Examining Association between Nigh-time ABPM Recordings and WMH Volume. 
  
WMH VWMH 
L 
frontal 
WMH 
volume 
R 
frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Night mean systolic 
BP (mmHg) 
pr 0.09 0.06 0.11 0.11 0.07 0.03 0.02 -0.09 0.10 0.03 
P 0.56 0.68 0.45 0.45 0.66 0.86 0.90 0.57 0.49 0.87 
Night mean diastolic 
BP (mmHg) 
pr 0.10 0.10 0.05 0.12 0.18 0.15 0.07 -0.03 0.06 0.07 
P 0.51 0.53 0.74 0.44 0.25 0.31 0.62 0.86 0.72 0.65 
Night-time SD SBP pr -0.01 -0.02 0.08 0.09 -0.19 -0.21 -0.06 -0.07 -0.03 -0.18 
P 0.94 0.90 0.61 0.57 0.21 0.17 0.70 0.65 0.84 0.22 
Night-time SD DBP pr 0.03 0.04 0.11 0.08 -0.09 -0.13 0.03 -0.02 0.07 -0.10 
P 0.83 0.81 0.45 0.59 0.57 0.38 0.86 0.91 0.64 0.50 
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Table 7-20 Age-adjusted Partial Correlation Examining Association between Diurnal Variation and WMH Volume. 
  
WMH VWMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Systolic diurnal 
variation (mmHg) 
pr 0.02 0.03 0.08 -0.06 -0.03 -0.05 0.08 0.08 0.06 0.02 
P 0.89 0.84 0.60 0.71 0.84 0.77 0.58 0.62 0.69 0.89 
Diastolic diurnal 
variation (mmHg) 
pr 0.04 0.06 0.08 -0.03 -0.04 -0.08 0.06 0.02 0.07 0.07 
P 0.80 0.70 0.61 0.86 0.80 0.59 0.69 0.91 0.64 0.67 
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 Dipping Status and White Matter Hyperintensity Volume at Follow-up 7.6.2
Participants were divided according to dipping status (non-dipper, normal dipper, or 
extreme dipper) (Figure 7-1). Because of the small sample, size non-dippers and 
extreme dippers were combined to form an “abnormal dipping group”. White matter 
hyperintensity load for normal dippers and abnormal dippers were compared. Total 
white hyperintensities volume and white matter hyperintensity volume in the parietal 
lobes, left occipital lobe, and right temporal lobe were significantly greater in the 
abnormal dipper group than the normal dipper group. Periventricular white matter load 
was greater in the abnormal dipper group but this did not quite reach statistical 
significance (Table 7-21). As abnormal dippers were significantly older than normal 
dippers, [72.0 years versus 68.3 years respectively, P<0.01] these results were adjusted 
for age. WMH volume was no longer significantly associated with dipping status after 
adjusting for age.  
 
Figure 7-1 Mean Total WMH Volume by Dipping Status  
 
 
Non-dipper 
Dipper 
Extreme 
dipper 
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Table 7-21 Comparison of WMH Volume for Normal and Abnormal Dippers 
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
Normal 
Dipper  
(N = 24) 
Abnormal 
Dipper 
(N = 6) 
P  
 Mean (SD) Mean (SD)  
Total WMH 0.94 (0.90) 1.69 (1.56) 0.04 
Periventricular WMH 0.72 (0.67) 1.17 (1.02) 0.05 
Left Frontal WMH 0.26 (0.25) 0.41 (0.40) 0.21 
Right Frontal WMH 0.24 (0.22) 0.39 (0.35) 0.16 
Left Parietal WMH 0.10 (0.16) 0.26 (0.33) 0.02 
Right Parietal WMH 0.10 (0.17) 0.24 (0.29) 0.02 
Left Occipital WMH 0.05 (0.05) 0.10 (0.09) 0.01 
Right Occipital WMH 0.05 (0.07) 0.07 (0.04) 0.14 
Left Temporal WMH 0.04 (0.05) 0.07 (0.08) 0.11 
Right Temporal WMH 0.04 (0.05) 0.08 (0.07) 0.04 
 
 Response to Active Stand at Baseline and White Matter Hyperintensity 7.6.3
Volume at Follow-up 
Ninety-five follow-up participants had baseline active stand results suitable for analysis. 
Of these, 47 had an MRI scan. Comparing the MRI group with the group who did not 
undergo MRI showed identical rates of OH (81%). There were no statistically 
significant differences in baseline systolic or diastolic BP during active stand or degree 
of systolic or diastolic vasodepression between the groups (Table 7-22).  
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Table 7-22 Comparison of Response to Active Stand at Baseline for MRI group 
and Group not Undergoing MRI 
 No MRI N= 48  MRI N=47  
 Median (IQR) Median (IQR) P  
Baseline Systolic BP (mmHg) 141 (124, 162) 136 (123, 153) 0.43 
Baseline Diastolic BP (mmHg) 62 (54, 70) 60 (53, 71) 0.75 
Systolic vasodepression (mmHg) 28 (13, 41) 24 (13, 39) 0.41 
Diastolic vasodepression (mmHg) 12 (8, 19) 14 (8, 20) 0.50 
 Frequency (%) Frequency (%)   
ANN OH 39 (81) 38 (81) 0.96 
Systolic OH 33 (69) 27 (57) 0.25 
Diastolic OH  33 (69) 35 (79) 0.54 
 
Comparing total and regional white matter hyperintensity volume for the OH and no-
OH group showed that the OH group consistently had higher WMH volumes but that 
these differences were not significantly different (Table 7-23). Similarly, examining 
systolic and diastolic OH separately did not reveal any statistically significant 
differences in white matter hyperintensity volume (Table 7-24 and Table 7-25). Further 
analyses were performed to test if symptoms of cerebral hypoperfusion during active 
stand in conjunction with OH were associated with WMH volume in any region. No 
statistically significant differences in volume of WMH were found between the 
symptomatic and asymptomatic group.   
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Table 7-23 WMH Volume for OH Group and Group without OH (OH defined 
according to AAN definition).  
Volume of WMH as percentage of brain volume  
(data log transformed for analysis but non 
transformed data shown here) 
No OH = 9  OH = 38 P  
 Mean (SD) Mean (SD)  
Total WMH 0.91 (0.41) 1.49 (1.45) 0.59 
Periventricular WMH 0.67 (0.28) 1.04 (0.96) 0.66 
Left Frontal WMH 0.25 (0.12) 0.37 (0.38) 0.73 
Right Frontal WMH 0.27 (0.14) 0.35 (0.32) 0.97 
Left Parietal WMH 0.07 (0.06) 0.22 (0.30) 0.29 
Right Parietal WMH 0.09 (0.08) 0.20 (0.27) 0.42 
Left Occipital WMH 0.05 (0.03) 0.08 (0.08) 0.71 
Right Occipital WMH 0.05 (0.03) 0.06 (0.06) 0.24 
Left Temporal WMH 0.03 (0.03) 0.07 (0.08) 0.54 
Right Temporal WMH 0.03 (0.03) 0.07 (0.07) 0.13 
 
Table 7-24 WMH Volume for Systolic OH Group and Group without Systolic OH  
Volume of WMH as percentage of brain volume  
(data log transformed for analysis but non 
transformed data shown here) 
No  Systolic 
OH = 20 
 Systolic 
OH = 27 
P  
 Mean (SD) Mean (SD)  
Total WMH 1.27 (1.43) 1.45 (1.27) 0.43 
Periventricular WMH 0.91 (0.98) 1.01 (0.82) 0.44 
Left Frontal WMH 0.31 (0.30) 0.37 (0.37) 0.67 
Right Frontal WMH 0.29 (0.23) 0.37 (0.34) 0.54 
Left Parietal WMH 0.19 (0.35) 0.18 (0.22) 0.51 
Right Parietal WMH 0.19 (0.30) 0.18 (0.22) 0.68 
Left Occipital WMH 0.07 (0.10) 0.08 (0.06) 0.32 
Right Occipital WMH 0.06 (0.06) 0.06 (0.06) 0.92 
Left Temporal WMH 0.06 (0.08) 0.06 (0.06) 0.23 
Right Temporal WMH 0.05 (0.08) 0.07 (0.06) 0.11 
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Table 7-25 WMH Volume for Diastolic OH Group and Group without Diastolic 
OH  
Volume of WMH as percentage of brain volume  
(data log transformed for analysis but non 
transformed data shown here) 
No  
Diastolic 
OH = 12 
 Diastolic 
OH = 35 
P  
 Mean (SD) Mean (SD)  
Total WMH 0.93 (0.48) 1.53 (1.49) 0.64 
Periventricular WMH 0.66 (0.30) 1.07 (0.99) 0.61 
Left Frontal WMH 0.27 (0.16) 0.38 (0.38) 0.88 
Right Frontal WMH 0.28 (0.17) 0.35 (0.33) 0.98 
Left Parietal WMH 0.07 (0.05) 0.23 (0.31) 0.27 
Right Parietal WMH 0.08 (0.08) 0.21 (0.28) 0.31 
Left Occipital WMH 0.05 (0.04) 0.09 (0.09) 0.15 
Right Occipital WMH 0.04 (0.03) 0.06 (0.06) 0.09 
Left Temporal WMH 0.03 (0.02) 0.07 (0.08) 0.51 
Right Temporal WMH 0.03 (0.03) 0.07 (0.07) 0.17 
 
Examining relationship between continuous response to active stand and white matter 
volume showed that greater systolic vasodepression was associated with greater  
volume of white matter disease in the right temporal lobe (P=0.04). A trend towards an 
association between greater systolic vasodepression and greater left temporal WMH 
volume was also observed (P = 0.06) (Table 7-26).  
 
Multiple linear regression was performed to examine if the association between systolic 
vasodepression and temporal white matter volume was independent of other risk factors 
associated with WMH volume. After adjusting age, history of hypertension, history of 
cerebrovascular disease the association between systolic vasodepression was no longer 
an independent predictor of WMH volume in right temporal lobe (B=0.21, P=0.10).  
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Table 7-26 Partial Correlation between Response to Active Stand at Baseline and WMH Volume at Follow-up Adjusting for Age (WMH 
volume expressed as percentage of total brain volume and log transformed for analysis) 
  
WMH PVWMH 
L 
frontal 
WMH 
volume 
R 
frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Baseline Systolic 
BP (mmHg) 
pr 0.23 0.22 0.27 0.26 0.10 0.14 0.12 0.02 0.15 0.12 
P 0.12 0.14 0.07 0.08 0.51 0.34 0.42 0.91 0.33 0.43 
Baseline Diastolic 
BP (mmHg) 
pr 0.15 0.19 0.13 0.13 0.08 0.11 0.21 0.17 0.15 0.11 
P 0.31 0.22 0.38 0.37 0.60 0.46 0.17 0.27 0.33 0.48 
Systolic Nadir 
(mmHg) 
pr 0.07 0.06 0.12 0.12 -0.05 0.03 0.04 -0.04 -0.04 -0.08 
P 0.66 0.71 0.44 0.42 0.77 0.85 0.77 0.81 0.80 0.59 
Diastolic Nadir 
(mmHg) 
pr -0.04 -0.04 -0.04 -0.05 -0.03 0.00 0.05 0.00 -0.01 -0.09 
P 0.78 0.80 0.78 0.77 0.82 0.99 0.73 0.99 0.94 0.55 
Systolic 
vasodepression 
(mmHg) 
pr 0.23 0.23 0.20 0.18 0.22 0.16 0.11 0.08 0.27 0.31 
P 0.12 0.13 0.18 0.23 0.15 0.28 0.49 0.58 0.07 0.04 
diastolic 
vasodepression 
(mmHg) 
pr 0.23 0.26 0.21 0.22 0.14 0.13 0.16 0.19 0.18 0.25 
P 0.12 0.08 0.16 0.15 0.36 0.41 0.29 0.20 0.22 0.10 
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 Response to Carotid Sinus Massage at Baseline and White Matter 7.6.4
Hyperintensity Volume at Follow-up 
Forty-four participants had valid data from CSM at baseline and underwent MR 
imaging at follow-up. Comparing these individuals with follow-up participants who did 
not undergo MRI scan did not show any significant differences in response to CSM 
(Table 7-27).  
 
Table 7-27 Comparison of Response to CSM for Participants Who Underwent 
MRI Scan With Those who Did not Have an MRI scan  
 No MRI N= 46  MRI N=44  
 Median (IQR) Median (IQR) P  
Max RR interval post CSM (ms) 1568 (1168, 2423) 1460 (1131, 2298) 0.81 
Max Vasodepression (mmHg) 42.7 (27.9, 49.3) 42.2 (30.7, 59.1) 0.63 
Minimum Systolic Nadir 
(mmHg) 
80.0 (68.0, 104.0) 81.0 (67.8, 101.0) 0.99 
Max delta RR (ms) 628 (262, 1372) 484 (231, 1417) 0.59 
 Frequency (%) Frequency (%)   
CSH 11 (24) 17 (39) 0.13 
Mixed CSH 6 (13) 8 (18) 0.50 
Vasodepression CSH 4 (8.6) 8 (18) 0.19 
Cardio inhibitory CSH 1 (2.1) 1 (2.2) 0.98 
 
Participants with CSH had higher volumes of white matter disease than participants 
without CSH, but these differences were not statistically significant (Table 7-28). 
Comparing participants with symptomatic CSH with those without symptoms during 
CSM revealed that participants with symptomatic CSH had significantly greater 
volumes of WMH in all regions (Table 7-29).  
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Table 7-28 Comparison of WMH Volumes for CSH and no-CSH group  
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
No  CSH =27 
 
 
Mean (SD) 
 CSH = 17 
 
 
Mean (SD) 
P  
Total WMH 1.07 (1.03) 1.63 (1.66) 0.30 
Periventricular WMH 0.67 (0.47) 1.27 (1.23) 0.14 
Left Frontal WMH 0.29 (0.29) 0.37 (0.37) 0.53 
Right Frontal WMH 0.28 (0.29) 0.36 (0.30) 0.44 
Left Parietal WMH 0.12 (0.19) 0.26 (0.37) 0.25 
Right Parietal WMH 0.12 (0.16) 0.25 (0.33) 0.42 
Left Occipital WMH 0.07 (0.06) 0.10 (0.10) 0.22 
Right Occipital WMH 0.05 (0.04) 0.08 (0.07) 0.98 
Left Temporal WMH 0.05 (0.06) 0.07 (0.09) 0.61 
Right Temporal WMH 0.05 (0.06) 0.07 (0.07) 0.30 
 
Table 7-29 Comparison of WMH Volumes for Group With Symptoms During 
CSM and Group with No Symptoms During CSM 
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
Asymptomatic  
= 36  
 
Mean (SD 
Symptomatic 
CSH = 8  
 
Mean (SD) 
P  
Total WMH 1.00 (1.00) 2.59 (1.84) <0.01 
Periventricular WMH 0.66 (0.54) 1.99 (1.31) <0.01 
Left Frontal WMH 0.26 (0.26) 0.58 (0.43) 0.03 
Right Frontal WMH 0.26 (0.26) 0.55 (0.33) 0.04 
Left Parietal WMH 0.12 (0.20) 0.43 (0.45) 0.01 
Right Parietal WMH 0.11 (0.18) 0.42 (0.36) 0.01 
Left Occipital WMH 0.06 (0.06) 0.17 (0.12) <0.01 
Right Occipital WMH 0.05 (0.04) 0.13 (0.07) <0.01 
Left Temporal WMH 0.04 (0.05) 0.12 (0.11) 0.01 
Right Temporal WMH 0.05 (0.06) 0.11 (0.07) 0.01 
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Linear regression adjusting for age, sex, and history of hypertension showed that 
symptomatic CSH was significantly associated with WMH volume in all regions, 
independent of the included covariates.  
 
Table 7-30 Linear Regression Examining if Symptomatic CSH is an Independent 
Predictor of WMH Volume  
Dependent variable  
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
Adjusted 
Model R 
square 
B 95% CI P  
Total WMH 0.29 0.43 0.13, 0.73 0.01 
Periventricular WMH 0.34 0.46 0.18, 0.73  <0.01 
Left Frontal WMH 0.26 0.37 0.06, 0.68 0.02 
Right Frontal WMH 0.23 0.36 0.04,  0.68 0.03 
Left Parietal WMH 0.17 0.57 0.04, 1.10 0.04 
Right Parietal WMH 0.19 0.63 0.07, 1.18 0.03 
Left Occipital WMH 0.19 0.49 0.13, 0.85 0.01 
Right Occipital WMH 0.22 0.47 0.08,  0.86 0.02 
Left Temporal WMH 0.14 0.62 0.08,  1.15 0.03 
Right Temporal WMH 0.11 0.53 0.06, 0.98 0.03 
Each region examined separately. Co-variates age, sex, history of hypertension at 
baseline as detected by ambulatory BP and defined by NICE.   
 
Age-adjusted partial correlation was used to examine the association between white 
matter hyperintensity volume and continuous blood pressure and heart rate response to 
CSM. No significant associations were observed (Table 7-31). 
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Table 7-31 Partial Correlation between Continuous Response to CSM and WMH Volume 
  
WMH 
PV 
WMH 
L frontal 
WMH 
volume 
R 
frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
Max RR interval 
post CSM (ms) 
pr 0.04 0.10 0.03 0.10 0.02 0.01 0.06 -0.06 -0.07 0.03 
P 0.80 0.53 0.86 0.53 0.88 0.94 0.70 0.72 0.68 0.84 
Max Vaso-
depression (mmHg) 
pr 0.05 0.10 0.02 0.08 0.09 0.08 0.16 -0.04 -0.01 0.03 
P 0.75 0.51 0.90 0.60 0.57 0.63 0.30 0.82 0.93 0.86 
Minimum Systolic 
Nadir (mmHg) 
pr 0.03 0.01 0.08 0.06 -0.15 -0.15 -0.01 0.01 0.12 -0.12 
P 0.84 0.97 0.63 0.69 0.35 0.34 0.95 0.95 0.45 0.46 
Max delta RR 
(ms) 
pr 0.06 0.12 0.04 0.11 0.03 0.02 0.09 -0.04 -0.05 0.04 
P 0.72 0.46 0.80 0.48 0.83 0.89 0.59 0.79 0.76 0.80 
(WMH volume expressed as percentage of total brain volume and log transformed for analysis) 
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 Response to Autonomic Function Tests at Baseline and White Matter 7.6.5
Hyperintensity Volume at Follow-up 
There were no statistically significant differences in response to baseline autonomic 
function tests between follow-up participants who had an MRI scan and those who did 
not (Table 7-32).   
 
Table 7-32 Response to Autonomic Function Tests at Baseline for Those Who Had 
MRI Scan and Those Who did not.  
 No MRI N= 48  MRI N=47  
 Median (IQR) Median (IQR) P  
30:15 ratio 1.11 (1.06, 1.18) 1.14 (1.05, 1.23) 0.45 
Valsalva ratio  1.46 (1.28, 1.66) 1.48 (1.33, 1.73) 0.16 
Valsalva overshoot (mmHg) 22.5 (12.3, 51.3) 30.0 (10.8, 56.0) 0.68 
Response to cold pressor (mmHg) 8 .00 (4.00, 13.5) 10.0 (4.00, 17.0) 0.25 
Response to isometric exercise 
(mmHg) 
12.5 (6.00, 19.8) 12.0 (5.00, 19.8) 0.94 
Response to deep breathing (BPM) 7.98 (5.23, 12.9) 7.66 (4.06, 11.3) 0.53 
    
 Frequency (%) Frequency (%)  
Ewing and Clark Abnormal 13 16 0.49 
 
Age-adjusted partial correlation showed an association between 30:15 ratio in response 
to active stand and volume of white matter hyperintensities in all regions. There were no 
associations between heart rate response to Valsalva manoeuvre or deep breathing and 
white matter hyperintensity volume. Greater diastolic BP response to cold pressor test 
was significantly associated with greater volume of WMH in the right temporal lobe 
(Table 7-33). After adjusting for age, sex, history of hypertension and history of 
cerebrovascular disease, the association between 30:15 ratio and WMH volume in all 
regions remained significant but the association between BP response to cold pressor 
test and WMH volume in right temporal lobe did not (Table 7-34).   
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Table 7-33 Partial Correlation between Continuous Response to Autonomic Function Tests and WMH Volume  
  
WMH VWMH 
L frontal 
WMH 
volume 
R frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
30 15 ratio [N=47] pr -0.38 -0.38 -0.34 -0.30 -0.34 -0.31 -0.38 -0.26 -0.53 -0.39 
P 0.01 0.01 0.02 0.04 0.02 0.04 0.01 0.08 <0.01 0.01 
best Valsalva ratio 
[N=49] 
pr 0.06 0.05 0.03 0.09 -0.06 0.03 0.18 -0.02 0.00 0.07 
P 0.69 0.72 0.86 0.54 0.69 0.86 0.21 0.90 0.98 0.61 
Overshoot 
associated with best 
Valsalva ratio 
(N=49) 
pr 0.00 0.03 0.07 0.12 -0.05 -0.04 -0.07 -0.08 -0.13 -0.14 
P 
0.98 0.82 0.65 0.43 0.73 0.78 0.66 0.59 0.38 0.35 
Cold pressor 
Difference DP 
(mmHg) [N=45] 
pr 0.24 0.22 0.29 0.23 0.17 0.20 0.19 0.07 0.25 0.34 
P 0.12 0.14 0.06 0.13 0.26 0.19 0.21 0.65 0.09 0.02 
Deep breathing 
average heart rate 
difference [N=47] 
pr 0.05 0.04 -0.01 0.00 -0.04 0.03 0.23 0.18 0.16 0.09 
P 0.73 0.78 0.95 0.99 0.80 0.85 0.12 0.24 0.30 0.57 
Isometric Exercise  
BP difference (mmHg) 
[n=45] 
0.09 0.05 0.12 0.14 0.07 0.07 -0.06 -0.04 0.01 0.07 
0.56 0.74 0.42 0.37 0.65 0.66 0.70 0.76 0.93 0.63 
(WMH volume expressed as percentage of total brain volume and log transformed for analysis) 
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Table 7-34 Linear Regression Examining if 30:15 ratio is an Independent Predictor 
of WMH Volume 
Dependent variable  
Volume of WMH as percentage of brain 
volume  
(data log transformed for analysis but non 
transformed data shown here) 
Adjusted 
Model R 
square 
B 95% CI P  
Total WMH 0.31 -1.41 -2.42, -0.40 <0.01 
Periventricular WMH 0.30 -1.36 -2.33, -0.39 <0.01 
Left Frontal WMH 0.35 -1.29 -2.32, -0.27 0.02 
Right Frontal WMH 0.26 -1.02 -2.10, 0.06 0.06 
Left Parietal WMH 0.23 -2.17 -3.92, -0.42 0.02 
Right Parietal WMH 0.18 -2.00 -3.77, -0.23 0.03 
Left Occipital WMH 0.20 -1.80 -3.04, -0.56 <0.01 
Right Occipital WMH 0.21 -1.55 -3.06, -0.03 <0.05 
Left Temporal WMH 0.39 -3.27 -4.87, 1.69 <0.01 
Right Temporal WMH 0.18 -2.02 -3.37, -0.67 <0.01 
Each region examined separately. Co-variates age, sex, history of hypertension at 
baseline as detected by ambulatory BP and defined by NICE and history of 
cerebrovascular disease.  
 
 Heart rate variability at Baseline and White Matter Hyperintensity Volume 7.6.6
at Follow-up 
Forty individuals underwent MRI and had HRV data from baseline suitable for analysis. 
A greater HF/LF ratio was associated with larger volumes of WMH. This was true for 
total volume, periventricular volume and frontal lobe volumes. After adjusting for age, 
sex, history of hypertension and history of cerebrovascular disease, these associations 
were no longer significant. Other measures of HRV were not associated with volume of 
white matter hyperintensities.  
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Figure 7-2 Age-adjusted Partial Correlation Examining Association between Heart Rate Variability and WMH Volume 
  
WMH 
PV 
WMH 
L 
 frontal 
WMH 
volume 
R 
frontal 
WMH 
volume 
L 
parietal 
WMH 
volume 
R 
parietal 
WMH 
volume 
L 
occipital 
WMH 
volume 
R 
occipital 
WMH 
volume 
L 
temporal 
WMH 
volume 
R 
temporal 
WMH 
volume 
SDNN pr -0.02 0.04 -0.07 -0.07 -0.03 -0.05 -0.10 -0.09 0.00 0.03 
P 0.89 0.81 0.64 0.66 0.83 0.77 0.55 0.58 0.99 0.84 
Total Power pr -0.05 -0.01 -0.06 -0.05 -0.07 -0.10 -0.23 -0.12 -0.06 -0.03 
P 0.76 0.95 0.69 0.73 0.65 0.51 0.15 0.45 0.70 0.84 
Very low 
frequency 
pr -0.08 -0.04 -0.06 -0.06 -0.06 -0.14 -0.30 -0.19 -0.11 -0.11 
P 0.64 0.81 0.72 0.70 0.70 0.37 0.05 0.23 0.47 0.49 
low frequency pr -0.11 -0.07 -0.17 -0.14 -0.11 -0.12 -0.19 -0.08 -0.06 -0.02 
P 0.48 0.64 0.29 0.37 0.48 0.47 0.24 0.63 0.71 0.91 
high 
frequency 
pr 0.17 0.20 0.15 0.17 0.02 0.09 0.04 0.07 0.12 0.16 
P 0.29 0.22 0.33 0.29 0.89 0.58 0.83 0.66 0.46 0.31 
HF/LF Ratio pr 0.30 0.28 0.39 0.37 0.12 0.15 0.08 -0.04 0.23 0.24 
P 0.05 0.08 0.01 0.02 0.45 0.35 0.61 0.82 0.14 0.12 
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 Summary of Key Results from Chapter 7 7.7
Fifty-three individuals (51%) underwent MRI scan. Greater WMH volume was 
significantly associated with increasing age.  
 
 Clinical Association with WMH Volume 7.7.1
In this small cohort WMH volume was not associated with performance on any of the 
cognitive tests or cornell depression scale. WMH volume did not significantly differ 
between fallers and non-fallers. Surprisingly greater WMH volume was associated with 
better performance on Tinetti assessment of gait and balance.  
 Ambulatory Blood Pressure 7.7.2
WMH volume was greater in participants with mean systolic daytime BP>  150mmHg 
but there was no continous association between mean BP or BP variability and WMH 
volume.  
 
On univariate analysis abnormal diurnal variation was associated with increased total 
and parietal WMH volume but this was no longer significant after adjusting for age.  
 Active Stand 7.7.3
No associations were observed between WMH volume at follow-up and response to 
active stand at baseline.  
 Carotid Sinus Massage 7.7.4
CSH was not associated with increased WMH volume. However symptomatic CSH was 
associated with increased WMH volume. This was independent of age, sex and history 
of hypertension. 
 Autonomic Function 7.7.5
Lower 30:15 ratio in response to standing was associated with greater volume of WMH 
on MRI independent of age, sex and history of cardiovascular disease. None of the other 
tests of cardiovascular autonomic function were independently associated with WMH 
volume.  
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 Discussion 7.8
Fifty-one per cent of year ten follow-up participants agreed to undergo an MRI brain 
scan and did not have any contraindications to MRI. The cohorts undergoing imaging 
and not undergoing imaging were well matched in terms of performance on cognitive 
tests and similar in terms of past medical history. Prevalence of NCVI at baseline and 
response to autonomic function tests and carotid sinus massage were similar for the 
group who underwent MRI and those who did not.   
 
It was the initial hypothesis that episodic systemic hypotension would cause impaired 
cognition, depression, gait and balance abnormalities and falls in later life as a result of 
cerebral hypoperfusion and resulting white matter lesion. The first half of this chapter 
examined if white matter hyperintensities were associated with cognition, depression, 
and/ or motor symptoms in this cohort at follow-up. The second half of the chapter 
examined if autonomic function and NCVI at baseline were associated with WMH 
volume at follow-up.  
 
Age and hypertension are well-recognised risk factors for WMHs. In keeping with other 
studies, WMH volume in this cohort was significantly and positively associated with 
age and WMH volume, particularly in frontal areas, was significantly greater among 
individuals with systolic BP >150 mmHg at baseline.    
 White Matter Hyperintensity Volume and Clinical Symptoms at Follow-up 7.8.1
7.8.1.1 White Matter Hyperintensity Volume and Cognition 
WMH volume was not associated with cognitive function in this study. Reviews of 
large population-based studies examining the association between WMH volume and 
cognition have concluded that greater WMH volume is associated with poorer cognitive 
function  but that the clinical effect of WMH on cognition is small, particularly on 
measures of global cognition in community cohorts (Frisoni et al., 2007, Pantoni et al., 
2007). The Framingham Offspring Study measured white matter volume in 1820 
dementia-free, stroke-free older people. Participants with little or no WMH were 
compared with participants with large WMH volume (WMH volumes more than1 SD 
above the age-predicted mean). MMSE score was 0.1 point lower in the large WMH 
volume group than in the no / little WMH group. This difference was not statistically 
significant (Au et al., 2006). The authors did find that participants with large WMH 
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volume performed more poorly on tests of attention, concentration and executive 
function, which was not the case in this current study.  
 
The lack of association between cognition and WMH in this study probably reflects the 
small sample size undergoing MRI, which was insufficient to detect small differences in 
performances on cognitive tests. This study had 80% power to detect a difference 2 or 
more points on the MMSE between the lower 4 quintiles of WMH volume and the 
upper quintile. Similarly this sample size allowed a difference of 6 points to be detected 
on the total CAMCOG with 80% power and differences of 40 -150 ms to be detected on 
the COMPASS scores. Given the apparently small effect of WMH on cognition in 
older, non-demented individuals, it must be acknowledged that this population size may 
be insufficient to detect changes in cognition resulting from WMH.    
 
It has been suggested that there is a threshold effect between white matter 
hyperintensities and cognition. Many studies have shown that there is a level of WMH 
volume beyond which white matter disease is associated with cognitive decline, but that 
this threshold can vary depending on host factors (e.g. age, ethnicity, education) , and 
concomitant brain changes (e.g. cortical atrophy lacunar infarcts and micro bleeds) 
(Frisoni et al., 2007, Pantoni et al., 2007). A threshold effect was not evident in this 
study but this may reflect some of the population characteristics. The cohort was well 
educated, physically healthier than the general population and had surprisingly low rates 
of dementia, depression and neurodegenerative disease (Kerr, 2009, Rait et al., 2005). It 
is possible that these features have led to greater cognitive reserve in this study 
population than in the general population. Higher rates of education have been 
associated with cognitive reserve and have been shown to delay decline in 
cognition(Muniz-Terrera et al., 2011). Similarly lower rates of hypertension and 
diabetes were observed in the study sample compared to the population from which they 
were recruited from (Kerr, 2009). This may have resulted in a lower burden of WMH in 
this cohort than might be expected among the general population.  
 
7.8.1.2 White Matter Hyperintensity Volume and Depression 
As with cognition, this study did not show an association between depression scores and 
WMH volume. This is in contrast to several, larger, cross-sectional studies which have 
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shown an associations between depressive symptoms and WMH volume (Geerlings et 
al., 2012, Ikram et al., 2010, Murray et al., 2013, Firbank et al., 2012b). 
 
Results from longitudinal studies examining the association between WMH volume and 
depression have been mixed (Verluis et al., 2006, Firbank et al., 2012b, Ikram et al., 
2010). Follow-up of the LADIS cohort found progression of WMH volume to be 
associated with incident depression (Firbank et al., 2012b). However,  the Prosper 
study, which examined 572 non-demented older people, found that presence of WMHs 
was not related to baseline depressive symptoms or to the development of depressive 
symptoms during follow-up (Verluis et al., 2006). Ikram et al found that although 
WMH volume was associated with the presence of depressive symptoms at baseline, 
there was no association between WMH grade and incident depression at follow-up 
(Ikram et al., 2010).  
 
There are several reasons why this study may not have found the association between 
WMH and depression seen in other cross-sectional studies. Firstly this study had a small 
sample size and a fewer individuals than anticipated had depression. Only 8% of 
participants in the MRI cohort had depression. The small numbers of depressed patients 
in this cohort resulted in a lack of statistical power to detect small differences between 
depressed and non-depressed participants. The low rates of depression in this cohort 
may indicate sampling bias. The severity of depression suffered by participants may 
also account for the differences observed between our study and the LADIS study 
(Firbank et al., 2012b). None of the participants with a Cornell score >10 were taking 
antidepressants or under the care of a psychiatrist for depression, suggesting that 
depressive symptoms were mild in this cohort. This is in contrast to the LADIS study 
where only participants receiving treatment for depression (medication, psychotherapy 
or hospitalisation) were classed as having incident depression (Firbank et al., 2012b).  
 
7.8.1.3 White Matter Hyperintensity Volume and Gait  
Significant associations were observed between better gait and greater total, 
periventricular and frontal white matter hyperintensity volume in this study. However, 
after adjusting for covariates this was no longer significant. No associations were 
observed between balance and WMH volume.  
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Our findings are in contrast to the published literature. A systematic review of papers 
examining the association between WMH and gait showed that studies have 
consistently found greater volumes of WMH  to be associated with impaired gait, 
specifically: decreased gait speed, shorter step length, increased double support time, 
and slowed gait initiation in cross-sectional studies (Zheng et al., 2011). Longitudinal 
studies have shown that progression of WMH volume is associated with slowing of gait 
speed, decreases in step length and worsening of lower limb physical function(Zheng et 
al., 2011, Willey et al., 2013, Kreisel et al., 2013, Callisaya et al., 2013, Moscufo et al., 
2012). Three studies were identified that used the Tinetti score to assess gait, as done in 
this study. In the first, study poorer Tinetti gait score was associated with greater 
volume of periventricular but not deep WMH. In the latter two studies, greater total 
WMH volume was associated with poorer Tinetti score (Wakefield et al., 2010, De Laat 
et al., 2010, Soumaré et al., 2009). 
 
The failure of our study to identify an association between gait and WMH may again 
reflect sample size. Although our sample was similar in size to the Wakefield study, 
their study used a balance 3x3 matrix to ensure inclusion of frailer participants 
(Wakefield et al., 2010). The De Latt and Soumare studies were larger than this study 
including 431 and 1402 participants respectively (De Laat et al., 2010, Soumaré et al., 
2009). There are several versions of the Tinetti gait assessment(Kopke and Meyer, 
2006) The 9 item scale (possible score 0-9)  was used in this study. De Latt et al and 
Wakefield et al used an eight item scale, with possible score 0-12, and Soumare et al 
used a modified five item score. Given the similarity in the content of the scores 
however it seems unlikely that this accounts for the contradictory findings between our 
study and the published literature (Wakefield et al., 2010, De Laat et al., 2010, Soumaré 
et al., 2009).  
7.8.1.4 White Matter Hyperintensity Volume and Balance 
No association was observed between WMH volume in this study and performance on 
Tinetti assessment of balance. This is in keeping with the large study by Soumare that 
also used the Tinetti scale to measure balance (Soumaré et al., 2009). However, studies 
using more sensitive measures of balance have shown associations between balance and 
WMH volume. Using a stabilometer, Mizuta et al showed that older people with severe 
white matter hyperintensities were significantly more unstable (Mizuta et al., 2007) and 
Start et al showed that individuals unable to stand on one leg for five seconds had 
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significantly greater WMH volume compared to those who could complete the task 
(Starr et al., 2003). This suggests that, in healthy cohorts, the Tinetti balance scale may 
be an insensitive measure of balance.  
7.8.1.5 White Matter Hyperintensity Volume and Falls  
In the current study, no association was observed between WMH volume and falls, 
recurrent falls or number of falls in the year prior to the MRI scan. Our findings are in 
contrast to other studies which have found associations between severe WMH and 
incident falls and  incident recurrent falls (Zheng et al., 2011, Srikanth et al., 2009, 
Blahak et al., 2009). The association between WMH and falls is thought to be mediated 
through impaired cognition, gait and balance. Given that WMH were not associated 
with cognition, gait or balance in this study it is perhaps not surprising that an 
association between WMH and falls was not identified in this study. 
 White Matter Hyperintensity Volume and Baseline Measure of Heart Rate 7.8.2
and Blood Pressure Control, Autonomic Function and NCVI 
7.8.2.1 White Matter Hyperintensity Volume and Hypertension 
In this study, hypertension (defined as systolic BP ≥150mmHg) was associated with 
increased total, periventricular and frontal WMH volume. Systolic BP on ABPM, 
however, did not correlate with volume of white matter disease suggesting a threshold 
effect. While hypertension has consistently been found to be a risk factor for WMH, 
results from studies examining the continuous association between BP and WMH have 
been mixed (Sierra, 2011, Henskens et al., 2009, Goldstein et al., 2005, Yamamoto et 
al., 2005, Schwartz et al., 2007). A recent review showed that, several authors have, in 
accordance with our results, found an association between hypertension and WMH but 
not between continuous BP and WMH, suggesting a threshold effect rather than a “dose 
response” (Sierra, 2011). In contrast, Henskens et al found 24-hour, daytime and night-
time BP were positively and significantly correlated with WMH volume(Henskens et 
al., 2009). While Yamoto et al and Goldstein et al found that higher night-time and 
daytime systolic and diastolic BP were associated with increased odds ratio of more 
severe WMH(Goldstein et al., 2005, Yamamoto et al., 2005). These differences may to 
some extent be explained by different populations. Schwartz et al showed that the 
association between ABPM results and WMH volume differs between white and black 
American adults (Schwartz et al., 2007). In black adults, ambulatory blood pressure 
measures associated with greater WMH were higher awake, asleep, and 24-hour systolic 
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and diastolic levels. In white adults, only higher asleep diastolic levels trended toward 
association with greater WMH load.  
7.8.2.2 White Matter Hyperintensity Volume and Blood Pressure Variability 
Greater BP variability on 24-hour ABPM has been associated with increased end organ 
damage (Parati et al., 2006). In this cohort we did not find an association between BP 
variability and WMH volume. Few studies have examined the association between 24-
hour BP variability and WMH on MRI. One retrospective study examined the 
association between BP variability and WMH for 79 elderly patients who had 
undergone 24 ABPM and a CT head scan. Greater blood pressure variability was 
associated with greater WMH volume (Puisieux et al., 2001). Goldstein et al found 
increased daytime SBP variability was associated with more severe white matter disease 
5 years later (Goldstein et al., 2005). BP variability increases with mean SBP and age 
(Parati et al., 2006). Studies examining the association between BP variability should 
therefore be adjusted for age and mean BP. Gómez-Angelat et al found that after 
adjusting for mean BP,  systolic BP variability was not associated with WMH volume 
(Gomez-Angelats et al., 2004) suggesting the association was due to elevated BP rather 
than BP variability.  
7.8.2.3 White Matter Hyperintensity Volume and Diurnal Variation 
Abnormal dipping pattern (non-dipping or extreme dipping) was associated with greater 
white matter hyperintensity volume in this study. After adjusting for age however, 
dipping status at baseline was no longer associated with WMH volume at follow-up. 
Findings from cross-sectional studies examining the association between dipping status 
and white matter hyperintensities have been mixed. In keeping with the findings of this 
study, Van Boxtel et  al and Henskens et al failed to show an association between 
dipping status and WMH volume in age-adjusted models(van Boxtel et al., 2006, 
Henskens et al., 2009). Schwartz et al found greater dips in BP were associated with 
fewer white matter lesions in white adults, but not in black adults. While Birns et al 
found greater nocturnal dips in BP were associated with greater white matter lesions. 
Finally, Yamamoto et al found non-dipping and reverse dipping (a rise in BP at night) 
were associated with increased odds of periventricular WMH (Yamamoto et al., 2005). 
These differences probably reflect differences in study populations. Studies failing to 
show an association between dipping and WMH or showing an adverse association 
between dipping and WMH have tended to include predominantly hypertensive patients 
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or patient groups at greater risk of hypertension (older patients /black adults). In 
hypertensive individuals, nocturnal falls in BP may cause BP to drop below limits of 
cerebral autoregulation potentially causing cerebral hypoperfusion and WMH.  
7.8.2.4 White Matter Hyperintensity Volume and Orthostatic Hypotension 
Volume of WMH in all regions was consistently higher in the OH groups but this was 
not statistically significant. After adjusting for covariates no association was found 
between degree of vasodepression and WMH volume. The association between OH and 
WMH has been examined in three previous community based studies (Longstreth et al., 
1996, Gottesman et al., 2011, Havlik et al., 2002). All measured postural drop using 
sphygmomanometer rather than beat-to-beat monitoring. In the cardiovascular health 
study (n=3301), OH was associated with increased WMH grade in models adjusted for 
age, sex and systolic BP but not after adjusting for presence of silent cerebral infarcts 
(Longstreth et al., 1996). The Honolulu heart study recorded postural drop in 3734 men 
in 1991. MRI scans were performed in a subset of 575 men between1993–1996. OH 
status was not associated with white matter load (Havlik et al., 2002).  In a recently 
published abstract regarding the Atherosclerosis Risk in Communities study (N= 983) 
OH was not associated with progression of WMH, but OH severity (ie the degree of 
vasodepression) was associated with WMH progression (OR 1.21 (95% CI 1.02-1.42) 
per 10 mm Hg SBP decrease) (Gottesman et al., 2011). Smaller studies have used to 
beat-to-beat monitoring to detect change in BP in response to standing. Colloby et al 
found that systolic vasodepression was significantly associated with WMH volume in 
bilateral temporal regions and left parietal region among patients with late-life 
depression, but not in age-matched controls (Colloby et al., 2011). Ballard et al found a 
systolic vasodepression >30 mmHg in response to CSM or active stand was associated 
with more severe WMH (Ballard et al., 2000).   
 
 
In this study, WMH volume was greater in the CSH group for all regions, but these 
differences were not statistically significant. Comparing participants who had been 
symptomatic during CSH with those who did not report symptoms, showed 
significantly greater white matter hyperintensity volume in the symptomatic group than 
the asymptomatic group. Symptoms suggest cerebral hypoperfusion and may indicte a 
failure of cerebral autoregulation. Parry et al examined cerebral autoregulation response 
to lower body negative pressure-induced hypotension in patients with carotid sinus 
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syncope (CSS) and asymptomatic case controls(Parry et al., 2006). CSS patients had 
abnormal cerebral autoregulation. Middle cerebral artery blood flow was significantly 
slower in the CSS group compared to controls. Interestingly, there was a paradoxical 
increase in cerebrovascular resistance among the CSS group. The authors noted cerebral 
autoregulation at rest prior to LBNP was significantly altered in the CSS patients 
compared to the controls and suggested the intriguing possibility that patients with CSS 
are prone to relative (and paradoxical) tonic intracerebral vasoconstriction, which 
predisposes them to further inappropriate vasoconstriction during CSS mediated 
vasodepression and asystole, when vasodilatation should otherwise supervene.  
 
Leftheriotis et al examined cerebral autoregulation in response to CSM among 11 
patients with carotid sinus syndrome with a pacemaker in the OOO mode and compared 
to this response to CSM among 6  CSS patients with pacemakers in the DDD 
mode(Leftheriotis et al., 1998). In non-paced patients, CSM was associated with a 50% 
decrease in mean cerebral blood flow velocity. In keeping with Parry et al’s findings the 
group also noted a transient increase in cerebrovascular resistance during CSM 
(although this did not reach significance). In the paced group systemic haemodynamic 
change and consequently cerebral haemodynamic change was reduced. The mean 
cerebral blood flow velocity decreased by only 30%. The authors argue that this 
remained above the ischemic threshold as none of the paced patients reported syncope 
or presyncope. Interestingly, only three patients reported symptoms when pacemaker 
was in the OOO mode.  These studies suggest that people with symptomatic carotid 
sinus hypersensitivity have abnormal cerebral autoregulation in response to systemic 
hypotension. None of the studies compared cerebral autoregulation among the 
symptomatic and asymptomatic individuals with CSH.  
 
It is interesting that degree of haemodynamic change in response to CSM was not 
associated with WMH volume in this study. Two other studies have examined the 
association between CSH and white matter hyperintensities (Kenny et al., 2004).. 
Kenny et al examined the association between CSH and white matter hyperintensity 
severity in patients with neurodegenerative dementia (43 Alzheimer’s disease (AD) 
patients and 42 patients with dementia of Lewy body (DLB))(Kenny et al., 2004, 
Ballard et al., 2000).  . In contrast to our findings, there was a significant association 
between fall in systolic blood pressure and severity of deep WMH in DLB patients. No 
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association between WMH and vasodepression was observed in the AD group. 
Dementia of Lewy body is associated with autonomic dysfunction and these patients 
had particularly large falls in BP in response to CSM. The authors suggested the 
absence of an association between vasodepression and WMH volume in AD patients 
reflected the less dramatic fall in systolic BP observed in these patients. Kenny et al did 
not record presence or absence of symptoms during CSM. Ballard et al also examined 
whether CSH and orthostatic hypotension were associated with WMH volume in 
patients with 17 AD and 13 DLB(Ballard et al., 2000).  WMH were classified as present 
or absent. Blood pressure drop >30 mmHg (either postural hypotension on active 
standing or BP drop during CSM) was significantly associated with presence of basal 
ganglia WMH, deep WMH but not periventricular WMH. Again significance of 
symptoms was not evaluated in this study.  
 
7.8.2.5 White Matter Hyperintensity Volume and Autonomic Function 
In this study, decreased 30:15 ratio in response to active stand was associated with 
greater WMH volume. The 30:15 ratio is a measure of parasympathetic function. It 
decreases with age and in conditions associated with impaired autonomic function such 
as diabetes. In normal controls, atropine causes a decrease in 30:15 ratio indicating that 
it is under vagal control. It would appear that decreased vagal activity at baseline is 
associated with greater white matter load at follow-up. However, other autonomic 
function tests of vagal activity (heart rate response to Valsalva manoeuvre and heart rate 
response to deep breathing) were not associated with white matter volume, nor were 
HRV indicators of parasympathetic function.  
 
There are few studies examining the association between autonomic function and 
WMH. In patients with mild cognitive impairment, reduced HRV indices of 
parasympathetic and sympathetic function have been associated with increased WMH 
severity (McLaren, 2004). Among 63 post-stroke patients, autonomic function, 
measured by HRV and the Ewing and Clarke autonomic battery, was not associated 
with WMH volume measured using the Schelten’s rating scale or as a percentage of 
intracranial volume (McLaren, 2004).  
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 Summary 7.8.3
It was the hypothesis of this study that episodic systemic hypotension would cause 
white matter damage and an increased prevalence of the clinical symptoms associated 
with white matter hyperintensities. Few associations however were identified between 
WMH volume and cognitive function, mood, gait, balance or falls at follow-up. 
Similarly, few significant correlations were identified between baseline 
neurocardiovascular function and WMH volume at follow-up.  
 
There are several reasons why our findings are not as initially hypothesised. Firstly, as 
previously discussed, the sample size undergoing MRI was small. Secondly, it is 
recognised that repeated assessment of autonomic function at baseline of the follow-up 
would have been desirable. Repeated assessment of NCVI would have lead to more 
accurate classification of participants as normal or abnormal and would have identified 
participants who developed NCVI over the follow-up period and have thus been 
exposed to recurrent hypotensive episodes for a proportion of the intervening ten years. 
Finally, we were unable to account for the integrity of cerebral autoregulation in this 
study. It is possible that hypotensive episodes are only associated with white matter 
damage in a subgroup of individuals in whom cerebral autoregulation fails to 
adequately compensate for changes in systemic blood pressure. Future studies could 
compare white matter hyperintensity volume in patients with NCVI and impaired 
cerebral autoregulation with WMH volume among participants with NCVI and normal 
cerebral autoregulation.  
 
 
   
238 
 
Chapter 8 Neurocardiovascular Function and Ten Year All-
Cause Mortality 
 Introduction 8.1
Autonomic dysfunction and orthostatic hypotension have been associated with 
increased mortality. Four large population-based studies have shown an association 
between orthostatic hypotension and reduced survival (Fedorowski et al., 2010, 
Verwoert et al., 2008, Rose et al., 2006, Masaki et al., 1998). Decreased heart rate 
variability has been associated with increased mortality in most community cohorts 
(Dekker et al., 1997, de Bruyne et al., 1999, Tsuji et al., 1994, Huikuri et al., 1998). And 
abnormal autonomic function, measured using bedside autonomic function tests, has 
been associated with increased mortality in diabetic patients (May and Arildsen, 2012, 
Maser et al., 2003).  
 
In contrast to the initial hypothesis, chapters 4-7 have shown few significant 
associations between NCVI at baseline and cognition, depression, falls and WMH 
volume at ten year follow-up. One explanation for the lack of significant findings could 
be that NCVI is associated with increased mortality and that the individuals most 
severely affected at baseline have been disproportionately lost to follow-up. In this 
chapter, the association between response to baseline tests of neurocardiovascular 
function and mortality is examined.  
 Methods 8.2
 Tests of Neurocardiovascular Function 8.2.1
Baseline test of autonomic function and NCVI have been previously described in 
section 2.3, page 42.  
 Survival Data 8.2.2
Participants’ General Practice electronic medical records were reviewed in September 
2012 to identify if participants were alive or their date of death if they had died. If 
participants were no longer registered with the general practice, the National Register of 
Births Deaths and Marriages up to the end of September 2012 was reviewed to confirm 
if they had died and verify participant’s date of death.  
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 Statistics 8.2.3
Time to event is defined as time between date of assessment of neurocardiovascular 
function and date of death or end of the study, 1
st
 October 2012. Risk factors associated 
with mortality were analysed using Cox’s regression analysis initially controlling only 
for age and sex. Subsequent models adjusted for relevant covariates. Model 2 adjusted 
for cardiovascular risk factors associated with increased ten year mortality and 
cardioactive medication. In order to adjust for baseline function, model 3 adjusted for 
the baseline Bristol ADL score. Finally, model 4 adjusted for baseline total CAMCOG 
score. Cognitive impairment is associated with increased mortality and CAMCOG score 
has been shown to be a strong predictor of survival (Firbank et al., 2012a, Dewey and 
Saz, 2001).  
 Results 8.3
 Characteristics of Subjects Alive at Follow-up versus Characteristics of 8.3.1
Deceased Participants 
Three hundred and fifty one participants completed one or more test of 
neurocardiovascular function between 29.4.2002 and 7.10.2003. Of whom, 106 
participants died, mean follow-up 99.9 months (SD 29.5).  
 
Participants who died were significantly older at baseline, had significantly lower BMI, 
and significantly higher mean systolic BP. They were more likely to have diabetes, 
cardiovascular disease and be taking cardioactive medication at baseline. Participants 
who died had significantly lower MMSE and total CAMCOG scores at baseline (Table 
8-1).  
 
   
240 
 
Table 8-1 Baseline Characteristics for Participants Who Were Alive at Follow-up 
versus Those Who Had Died 
 Alive N=245 Dead = 106 P 
 Mean (SD) Mean (SD)  
Age (years) 72.0 (5.1) 77.3 (6.9) <0.01 
BMI (kg/m
2
) 27.1 (4.0) 25.7 (3.5) <0.01 
Mean Systolic BP (mmHg) 133.2 (14.6) 136.7 (15.2) <0.05 
 Frequency (%) Frequency (%)  
Sex 132 (55) 67 (63) 0.11 
Diabetes 11 (4.5) 12 (11) 0.02 
Cardiovascular disease 126 (51) 70 (66) 0.01 
Cardiovascular medication 115 (47) 70 (66) <0.01 
Ever smoked 144 (59) 67 (63) 0.44 
Smoking at baseline 
assessment 
16 (6.5) 13 (12) 0.07 
 Median (IQR) Median (IQR)  
Pack years 3 (0 , 20) 8 (0 , 37.5) 0.10 
MMSE 29 (27,  30) 28 (26.3, 29) <0.01 
Total CAMCOG 96 (92, 99) 93 (86, 97) <0.01 
Bristol ADL Score 0 (0, 1) 0 (0, 2) 0.02 
 
 Survival and Ambulatory Blood Pressure Recordings 8.3.2
8.3.2.1 24-hour recordings 
Three hundred and thirty eight participants had ambulatory blood pressure recordings 
performed with 16 or more readings in 24-hours. Mean systolic BP was significantly 
higher among participants who died during the ten year follow-up. Systolic and 
Diastolic BP variability were also greater among participants who died during the 
follow-up period (Table 8-2). 
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Table 8-2 Comparison of 24-hour BP Variables for Participants who Died During 
Follow-up versus those who were Alive at the End of the Study 
 Alive Dead P 
 Mean (SD) Mean (SD)  
24-hour N= 238 N= 100  
Mean SBP (mmHg) 128.1 (13.6) 132.7 (14.9) 0.01 
Mean DBP (mmHg) 71.9 (8.2) 72.4 (7.2) 0.60 
SD SBP 13.3 (3.3) 14.7 (4.3) <0.01 
SD DBP 9.4 (2.2) 10.2 (2.4) <0.01 
 
8.3.2.2 Daytime  
Three hundred and thirty people had daytime recordings with 10 or more readings. 
Mean systolic BP was higher among participants who died, but this did not quite reach 
significance. Systolic and diastolic BP variability were higher among participants who 
died during follow-up (Table 8-3).  
 
Table 8-3 Comparison of Daytime BP Variables for Participants Who Died During 
Follow-up versus Those Who Were Alive at the End of the Study 
 Alive Dead P 
 Mean (SD) Mean (SD)  
Daytime  N=232 N=98  
Mean SBP (mmHg) 133 (14.6) 136.6 (15.4) 0.05 
Mean DBP (mmHg) 75.9 (9.0) 76.0 (8.1) 0.91 
SD SBP (mmHg) 11.7 (3.8) 13.4 (4.5) <0.01 
SD DBP (mmHg) 7.9 (2.3) 8.9 (2.5) <0.01 
 
8.3.2.3 Night-time 
Three hundred and ten individuals had night-time recordings with five or more readings. 
Mean systolic BP was significantly higher among people who died during follow-up. 
Blood pressure variability did not differ between groups (Table 8-4) 
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Table 8-4 Comparison of Night-time BP Variables for Participants Who Died 
during Follow-up versus Those Who Were Alive at the End of the Study 
 Alive Dead P 
 Mean (SD) Mean (SD)  
Night-time N= 220 N= 90   
Mean SBP (mmHg) 117.6 (14.5) 122.9 (17.3) 0.01 
Mean DBP (mmHg) 64.1 (8.5) 64.3 (8.1) 0.87 
SD SBP (mmHg) 8.9 (3.7) 9.6 (4.2) 0.18 
SD DBP (mmHg) 7.0 (2.9) 7.1 (3.2) 0.78 
 
8.3.2.4 24-hour BP  
In the model adjusting for age and sex, there was a borderline association between mean 
24-hour systolic BP and survival (HR 1.01 [95% CI 1.00, 1.03], P=0.06). Adjusting for 
other cardiovascular risk factors decreased the significance of this association. 
However, when baseline Bristol ADL score was added to the model there was a 
significant association between mean 24-hour systolic BP and survival (HR 1.02 [95% 
CI 1.00, 1.02], P=0.02) (Table 8-5). 
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Table 8-5 Cox Regression Models. Hazard Ratio of All-Cause Mortality Associated 
with 24-hour Mean Systolic BP 
Model 1 
B HR 
95% CI for HR 
P Lower Upper 
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.55 1.73 1.14 2.61 0.01 
24-hour Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.06 
 Model 2           
Age (years) 0.09 1.10 1.06 1.13 <0.01 
Sex 0.44 1.55 1.02 2.37 0.04 
24-hour Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.11 
Cardiovascular Disease -0.25 0.78 0.38 1.59 0.50 
Diabetes 0.25 1.28 0.68 2.43 0.44 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.69 2.00 0.97 4.14 0.06 
BMI (kg/m
2
) -0.07 0.93 0.88 0.99 0.02 
 Model 3           
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex 0.33 1.39 0.86 2.25 0.18 
24-hour Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Cardiovascular Disease 0.04 1.04 0.43 2.50 0.93 
Diabetes 0.63 1.88 0.93 3.81 0.08 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.50 1.64 0.70 3.85 0.25 
BMI (kg/m
2
) -0.13 0.88 0.82 0.95 <0.01 
Bristol ADL Score 0.07 1.07 0.93 1.24 0.34 
 Model 4           
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.34 1.40 0.86 2.27 0.17 
24-hour Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Cardiovascular Disease 0.01 1.01 0.43 2.39 0.98 
Diabetes 0.59 1.80 0.88 3.66 0.11 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.48 1.61 0.70 3.73 0.27 
BMI (kg/m
2
) -0.12 0.88 0.82 0.95 <0.01 
Bristol ADL Score 0.04 1.04 0.89 1.22 0.61 
Total CAMCOG Score -0.02 0.98 0.94 1.01 0.22 
 
Twenty-four hour mean diastolic BP was not associated with survival in the age and sex 
adjusted model or in models adjusting for baseline cardiovascular risk factors, 
functional status or cognitive function (Table 8-6) 
.  
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Table 8-6 Cox Regression Models. Hazard Ratio of All-Cause Mortality Associated 
with 24-hour Mean Diastolic BP 
Model 1 
B HR 
95% CI for HR 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.16 <0.01 
Sex 0.45 1.56 1.03 2.36 0.04 
24-hour Mean DBP (mmHg) 0.02 1.02 0.99 1.04 0.13 
Model 2       
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.37 1.45 0.95 2.20 0.08 
24-hour Mean DBP (mmHg) 0.01 1.01 0.99 1.04 0.25 
Cardiovascular Disease -0.29 0.75 0.37 1.51 0.42 
Diabetes 0.32 1.38 0.74 2.59 0.32 
Pack years 0.01 1.01 1.00 1.01 0.06 
Cardioactive medication 0.68 1.97 0.96 4.04 0.06 
Model 3       
Age (years) 0.12 1.12 1.08 1.17 <0.01 
Sex 0.29 1.34 0.83 2.17 0.23 
24-hour Mean DBP (mmHg) 0.02 1.02 0.99 1.05 0.12 
Cardiovascular Disease -0.14 0.87 0.37 2.03 0.74 
Diabetes 0.70 2.01 1.03 3.89 0.04 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive medication 0.54 1.71 0.74 3.96 0.21 
Bristol ADL Score 0.10 1.11 0.97 1.27 0.13 
Model 4       
Age (years) 0.11 1.12 1.08 1.16 <0.01 
Sex 0.28 1.33 0.82 2.15 0.25 
24-hour Mean DBP (mmHg) 0.02 1.02 0.99 1.05 0.11 
Cardiovascular Disease -0.16 0.86 0.37 1.98 0.72 
Diabetes 0.67 1.95 1.00 3.78 0.05 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive medication 0.50 1.64 0.72 3.78 0.24 
Bristol ADL Score 0.08 1.08 0.94 1.25 0.29 
Total CAMCOG Score -0.02 0.98 0.94 1.02 0.26 
 
In age and sex adjusted models, 24-hour SBP variability was not significantly 
associated with survival. Adjusting for cardiovascular risk factors did not reveal a 
significant association between BP variability and survival. However, models adjusting 
for baseline functional status, as measured by Bristol ADL and baseline cognitive 
function,  did show a significant association between 24-hour SBP variability and 
survival such that increased BP variability was associated with increased risk of death. 
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For every one SD increase in BP variability there was a 5% increase in risk of mortality 
(Table 8-7). 
  
Table 8-7 Cox Regression Models. Hazard Ratio of All-Cause Mortality Associated 
with 24-hour Systolic BP Variability 
Model 1 
B HR 
95% CI for HR 
P Lower Upper 
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.49 1.63 1.08 2.45 0.02 
24-hour SBP Variability (mmHg) 0.02 1.02 0.98 1.07 0.27 
Model 2 
     Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.38 1.46 0.96 2.20 0.07 
24-hour SBP Variability (mmHg) 0.02 1.02 0.98 1.07 0.37 
Cardiovascular Disease -0.24 0.79 0.39 1.60 0.51 
Diabetes 0.35 1.42 0.76 2.65 0.27 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.69 2.00 0.97 4.13 0.06 
BMI (kg/m
2
) -0.07 0.94 0.88 0.99 0.02 
Model 3 
     Age (years) 0.09 1.09 1.05 1.14 <0.01 
Sex 0.23 1.26 0.78 2.05 0.34 
24-hour SBP Variability (mmHg) 0.05 1.05 1.00 1.11 0.04 
Cardiovascular Disease 0.06 1.06 0.44 2.55 0.89 
Diabetes 0.79 2.19 1.12 4.28 0.02 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.43 1.53 0.65 3.60 0.33 
BMI (kg/m
2
) -0.12 0.89 0.83 0.95 <0.01 
Bristol ADL Score 0.11 1.11 0.96 1.29 0.15 
Model 4      
Age (years) 0.09 1.09 1.05 1.13 <0.01 
Sex 0.23 1.26 0.78 2.04 0.34 
24-hour SBP Variability (mmHg) 0.05 1.05 1.00 1.11 <0.05 
Cardiovascular Disease 0.04 1.04 0.44 2.47 0.93 
Diabetes 0.77 2.15 1.10 4.20 0.03 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.42 1.52 0.65 3.53 0.33 
BMI (kg/m
2
) -0.12 0.89 0.83 0.95 <0.01 
Bristol ADL Score 0.09 1.09 0.94 1.27 0.26 
Total CAMCOG Score -0.02 0.98 0.95 1.02 0.44 
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Similarly, 24-hour diastolic BP variability was not significantly associated with survival 
in models adjusting for age and sex or cardiovascular risk factors. However, in models 
adjusting for Bristol ADL score or total CAMCOG score, there was a significant 
association between diastolic BP variability and survival with greater BP variability 
being associated with increased risk of mortality (Table 8-8).  
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Table 8-8 Cox Regression Models. Hazard Ratio of All-Cause Mortality Associated 
with 24-hour Diastolic BP Variability 
Model 1 
B HR 
95% CI for HR 
P Lower Upper 
Age (years) 0.11 1.11 1.08 1.15 <0.01 
Sex 0.46 1.58 1.05 2.38 0.03 
24-hour DBP Variability (mmHg) 0.07 1.07 0.99 1.15 0.08 
Model 2 
    
  
Age (years) 0.09 1.10 1.06 1.13 <0.01 
Sex 0.34 1.41 0.93 2.13 0.11 
24-hour DBP Variability (mmHg) 0.07 1.07 0.99 1.16 0.07 
Cardiovascular Disease -0.25 0.78 0.38 1.57 0.48 
Diabetes 0.33 1.38 0.74 2.59 0.31 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.72 2.06 1.01 4.22 0.05 
BMI (kg/m
2
) -0.07 0.93 0.88 0.99 0.02 
Model 3 
    
  
Age (years) 0.09 1.09 1.05 1.13 <0.01 
Sex 0.18 1.20 0.74 1.94 0.47 
24-hour DBP Variability (mmHg) 0.12 1.13 1.04 1.23 0.01 
Cardiovascular Disease -0.01 0.99 0.42 2.31 0.98 
Diabetes 0.80 2.22 1.15 4.30 0.02 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.53 1.71 0.75 3.88 0.20 
BMI (kg/m
2
) -0.13 0.88 0.82 0.94 <0.01 
Bristol ADL Score 0.13 1.14 0.99 1.32 0.08 
Model 4 
    
  
Age (years) 0.08 1.09 1.05 1.13 <0.01 
Sex 0.18 1.20 0.74 1.94 0.47 
24-hour DBP Variability (mmHg) 0.12 1.13 1.03 1.23 0.01 
Cardiovascular Disease -0.04 0.96 0.41 2.22 0.92 
Diabetes 0.77 2.17 1.12 4.19 0.02 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.53 1.70 0.76 3.83 0.20 
BMI (kg/m
2
) -0.13 0.88 0.82 0.94 <0.01 
Bristol ADL Score 0.11 1.12 0.96 1.30 0.15 
Total CAMCOG Score -0.02 0.98 0.95 1.02 0.43 
 
8.3.2.5 Daytime 
Mean daytime SBP and DBP were not associated with survival in age and sex adjusted 
models. Adding cardiovascular risk factors to the model did not reveal any significant 
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associations between mean daytime blood pressures and survival. Adding Bristol ADL 
score to the model (in order to adjust for baseline functional status) did reveal 
significant association between both daytime mean SBP and mean DBP and survival, 
with greater mean BP being associated with increased risk of death due to all causes. 
The same was true for models including baseline CAMCOG score (Table 8-9 Table 
8-10).  
 
Both systolic and diastolic BP variability were associated with survival in age and sex 
adjusted models. After adjusting for cardiovascular risk factors, the association between 
systolic BP variability and survival was no longer significant; however, greater diastolic 
daytime BP variability remained associated with poorer outcome. In addition to 
adjusting for cardiovascular risk factors, baseline Bristol ADL score and baseline total 
CAMCOG score were entered into the models. Systolic BP variability was significantly 
associated with survival in models adjusting for baseline Bristol ADL score, but not in 
the model adjusting for cognition (Table 8-11). Diastolic BPV was associated with 
survival in all models (Table 8-12).  
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Table 8-9 Cox Regression Models. Hazard Ratio of All-Cause Mortality Associated 
with Daytime Mean Systolic BP 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.49 1.64 1.08 2.48 0.02 
daytime Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.22 
Model 2 
    
  
Age (years) 0.09 1.10 1.06 1.13 <0.01 
Sex 0.39 1.47 0.96 2.24 0.07 
daytime Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.18 
Cardiovascular Disease -0.27 0.77 0.38 1.57 0.47 
Diabetes 0.32 1.38 0.74 2.59 0.31 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.71 2.03 0.98 4.20 0.06 
BMI (kg/m
2
) -0.06 0.94 0.89 1.00 0.04 
Model 3 
    
  
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.27 1.31 0.80 2.13 0.28 
daytime Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.01 
Cardiovascular Disease 0.03 1.03 0.43 2.47 0.95 
Diabetes 0.69 2.00 0.99 4.04 0.05 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.51 1.67 0.71 3.92 0.24 
BMI (kg/m
2
) -0.12 0.89 0.82 0.95 <0.01 
Bristol ADL Score 0.08 1.09 0.93 1.27 0.28 
Model 4 
    
  
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.27 1.31 0.80 2.13 0.28 
daytime Mean SBP (mmHg) 0.02 1.02 1.01 1.03 0.01 
Cardiovascular Disease 0.00 1.00 0.42 2.37 1.00 
Diabetes 0.66 1.94 0.96 3.91 0.07 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.49 1.63 0.70 3.79 0.26 
BMI (kg/m
2
) -0.12 0.89 0.83 0.95 <0.01 
Bristol ADL Score 0.05 1.05 0.89 1.24 0.54 
Total CAMCOG Score -0.02 0.98 0.94 1.01 0.22 
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Table 8-10 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Daytime Mean Diastolic BP 
Model 1 
B HR 
95% CI  
P Lower Upper 
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex 0.43 1.53 1.01 2.33 0.05 
Daytime Mean DBP (mmHg) 0.01 1.01 0.99 1.04 0.23 
Model 2 
    
  
Age (years) 0.10 1.11 1.07 1.14 <0.01 
Sex 0.31 1.36 0.89 2.07 0.16 
Daytime Mean DBP (mmHg) 0.02 1.02 0.99 1.04 0.13 
Cardiovascular Disease -0.24 0.79 0.39 1.59 0.51 
Diabetes 0.33 1.39 0.74 2.60 0.31 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive medication 0.74 2.09 1.02 4.28 0.05 
BMI (kg/m
2
) -0.06 0.94 0.88 0.99 0.03 
Model 3 
    
  
Age (years) 0.11 1.11 1.07 1.15 <0.01 
Sex 0.10 1.11 0.67 1.82 0.68 
Daytime Mean DBP (mmHg) 0.03 1.03 1.01 1.06 0.01 
Cardiovascular Disease 0.02 1.02 0.43 2.44 0.96 
Diabetes 0.81 2.25 1.14 4.43 0.02 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.61 1.84 0.79 4.29 0.16 
BMI (kg/m
2
) -0.13 0.88 0.82 0.94 <0.01 
Bristol ADL Score 0.11 1.12 0.96 1.30 0.15 
Model 4 
    
  
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex 0.10 1.11 0.68 1.82 0.69 
Daytime Mean DBP (mmHg) 0.03 1.03 1.01 1.06 0.01 
Cardiovascular Disease -0.01 0.99 0.42 2.33 0.98 
Diabetes 0.78 2.18 1.11 4.30 0.02 
Pack years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive medication 0.59 1.81 0.79 4.17 0.16 
BMI (kg/m
2
) -0.13 0.88 0.82 0.94 <0.01 
Bristol ADL Score 0.08 1.09 0.93 1.28 0.30 
Total CAMCOG Score -0.02 0.98 0.94 1.02 0.27 
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Table 8-11 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Daytime Systolic BP Variability 
Model 1 
B HR 
95% CI  
P Lower Upper 
Age (years) 0.11 1.11 1.08 1.15 <0.01 
Sex 0.49 1.64 1.08 2.47 0.02 
Daytime SBP Variability (mmHg) 0.05 1.05 1.00 1.10 0.04 
Model 2 
     Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex 0.37 1.45 0.96 2.20 0.08 
Daytime SBP Variability (mmHg) 0.04 1.04 0.99 1.09 0.09 
Cardiovascular Disease -0.25 0.78 0.38 1.60 0.50 
Diabetes 0.40 1.50 0.80 2.80 0.21 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.62 1.85 0.89 3.87 0.10 
BMI (kg/m
2
) -0.05 0.95 0.89 1.00 0.07 
Model 3 
     Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.21 1.23 0.75 2.01 0.41 
Daytime SBP Variability (mmHg) 0.06 1.06 1.00 1.11 0.04 
Cardiovascular Disease 0.05 1.05 0.43 2.54 0.92 
Diabetes 0.87 2.40 1.23 4.67 0.01 
Pack years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive medication 0.36 1.43 0.60 3.42 0.42 
BMI (kg/m
2
) -0.10 0.90 0.84 0.97 <0.01 
Bristol ADL Score 0.08 1.08 0.93 1.26 0.33 
Model 4 
     Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.20 1.22 0.75 2.00 0.42 
Daytime SBP Variability (mmHg) 0.05 1.05 1.00 1.11 0.07 
Cardiovascular Disease 0.03 1.03 0.43 2.48 0.94 
Diabetes 0.86 2.36 1.21 4.61 0.01 
Pack years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive medication 0.36 1.43 0.60 3.39 0.42 
BMI (kg/m
2
) -0.10 0.90 0.84 0.97 <0.01 
Bristol ADL Score 0.06 1.07 0.91 1.25 0.44 
Total CAMCOG Score -0.01 0.99 0.95 1.03 0.57 
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Table 8-12 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Daytime Diastolic BP Variability 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.11 1.11 1.08 1.15 <0.01 
Sex 0.47 1.60 1.06 2.42 0.03 
Daytime DBP Variability (mmHg) 0.10 1.11 1.02 1.20 0.02 
Model 2 
    
  
Age (years) 0.09 1.10 1.06 1.13 <0.01 
Sex 0.37 1.44 0.95 2.19 0.08 
Daytime DBP Variability (mmHg) 0.09 1.09 1.01 1.19 0.03 
Cardiovascular Disease -0.28 0.76 0.38 1.52 0.43 
Diabetes 0.29 1.33 0.71 2.50 0.37 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.70 2.02 1.00 4.08 0.05 
BMI (kg/m
2
) -0.06 0.94 0.89 1.00 0.05 
Model 3 
    
  
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.16 1.18 0.72 1.92 0.51 
Daytime DBP Variability (mmHg) 0.12 1.13 1.03 1.23 0.01 
Cardiovascular Disease -0.01 0.99 0.42 2.32 0.98 
Diabetes 0.84 2.31 1.20 4.47 0.01 
Pack years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive medication 0.52 1.69 0.74 3.82 0.21 
BMI (kg/m
2
) -0.12 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.09 1.09 0.94 1.27 0.26 
Model 4 
    
  
Age (years) 0.10 1.11 1.07 1.15 <0.01 
Sex 0.31 1.36 0.84 2.20 0.21 
Daytime DBP Variability (mmHg) 0.11 1.12 1.02 1.23 0.02 
Cardiovascular Disease -0.19 0.82 0.36 1.89 0.65 
Diabetes 0.80 2.23 1.17 4.26 0.02 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.46 1.58 0.70 3.53 0.27 
Bristol ADL Score 0.08 1.08 0.92 1.27 0.35 
Total CAMCOG Score -0.02 0.98 0.95 1.02 0.42 
 
8.3.2.6 Night-time  
Night-time mean SBP was associated with survival in age and sex adjusted models but 
not in models adjusting for cardiovascular risk factors, baseline functional status, or 
baseline cognitive function (Table 8-13). Night-time mean DBP and SBP variability 
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were not associated with survival in any model (Table 8-14 and Table 8-15). Nocturnal 
DBP variability showed a significant association with survival in the age and sex 
adjusted model (Table 8-16). The association between DBP variability and survival was 
not quite significant in models adjusting for cardiovascular risk factors, but did reach 
statistical significance in models adjusting for Bristol ADL score and CAMCOG total 
score  
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Table 8-13 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Nocturnal Mean Systolic BP 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.56 1.76 1.13 2.73 0.01 
Nocturnal Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.04 
Model 2 
     Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex 0.46 1.58 1.01 2.47 0.05 
Nocturnal Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.18 
Cardiovascular Disease -0.33 0.72 0.35 1.49 0.38 
Diabetes 0.25 1.28 0.65 2.54 0.48 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication 0.77 2.15 1.02 4.54 0.05 
BMI (kg/m
2
) -0.07 0.94 0.88 0.99 0.03 
Model 3 
     Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex 0.38 1.46 0.88 2.41 0.14 
Nocturnal Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.19 
Cardiovascular Disease 0.01 1.01 0.42 2.42 0.98 
Diabetes 0.74 2.09 1.02 4.29 0.05 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.41 1.51 0.64 3.54 0.34 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.09 1.09 0.93 1.28 0.29 
Model 4 
     Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex 0.37 1.45 0.88 2.40 0.15 
Nocturnal Mean SBP (mmHg) 0.01 1.01 1.00 1.02 0.16 
Cardiovascular Disease -0.02 0.98 0.41 2.32 0.96 
Diabetes 0.70 2.02 0.98 4.16 0.06 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.40 1.49 0.64 3.46 0.35 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.06 1.06 0.90 1.26 0.50 
Total CAMCOG Score -0.02 0.98 0.94 1.02 0.33 
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Table 8-14 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Nocturnal Mean Diastolic BP 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex 0.49 1.63 1.06 2.52 0.03 
Nocturnal Mean DBP (mmHg) 0.01 1.01 0.99 1.04 0.26 
Model 2 
    
  
Age (years) 0.10 1.11 1.07 1.14 <0.01 
Sex 0.40 1.49 0.96 2.32 0.07 
Nocturnal Mean DBP (mmHg) 0.01 1.01 0.99 1.03 0.44 
Cardiovascular Disease -0.30 0.74 0.36 1.52 0.41 
Diabetes 0.32 1.37 0.71 2.68 0.35 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication 0.79 2.20 1.05 4.61 0.04 
BMI (kg/m
2
) -0.07 0.94 0.88 0.99 0.03 
Model 3 
    
  
Age (years) 0.10 1.11 1.07 1.16 <0.01 
Sex 0.31 1.36 0.82 2.27 0.23 
Nocturnal Mean DBP (mmHg) 0.01 1.01 0.99 1.04 0.32 
Cardiovascular Disease 0.02 1.02 0.43 2.43 0.97 
Diabetes 0.80 2.24 1.11 4.52 0.03 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.45 1.57 0.68 3.65 0.29 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.10 1.11 0.95 1.29 0.18 
Model 4 
    
  
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex 0.30 1.35 0.81 2.25 0.25 
Nocturnal Mean DBP (mmHg) 0.02 1.02 0.99 1.04 0.29 
Cardiovascular Disease -0.01 0.99 0.42 2.34 0.98 
Diabetes 0.78 2.18 1.08 4.41 0.03 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.44 1.55 0.68 3.57 0.30 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.08 1.08 0.92 1.28 0.33 
Total CAMCOG Score -0.02 0.98 0.94 1.02 0.36 
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Table 8-15 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Nocturnal Systolic BP Variability 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.11 1.12 1.09 1.15 <0.01 
Sex 0.52 1.68 1.09 2.60 0.02 
Nocturnal SBP Variability (mmHg) 0.02 1.02 0.97 1.07 0.51 
Model 2 
    
  
Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex 0.40 1.49 0.96 2.32 0.07 
Nocturnal SBP Variability (mmHg) 0.00 1.00 0.95 1.05 0.89 
Cardiovascular Disease -0.33 0.72 0.35 1.48 0.38 
Diabetes 0.36 1.44 0.74 2.81 0.29 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive medication 0.81 2.25 1.07 4.72 0.03 
BMI (kg/m
2
) -0.07 0.93 0.88 0.99 0.03 
Model 3 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex 0.37 1.45 0.87 2.41 0.15 
Nocturnal SBP Variability (mmHg) 0.02 1.02 0.97 1.08 0.41 
Cardiovascular Disease -0.01 0.99 0.42 2.34 0.97 
Diabetes 0.77 2.15 1.06 4.38 0.03 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.44 1.55 0.67 3.57 0.31 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.13 1.14 0.98 1.32 0.09 
Model 4 
    
  
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.36 1.44 0.86 2.38 0.16 
Nocturnal SBP Variability (mmHg) 0.02 1.02 0.97 1.08 0.46 
Cardiovascular Disease -0.04 0.96 0.41 2.26 0.92 
Diabetes 0.75 2.11 1.04 4.30 0.04 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.43 1.54 0.67 3.52 0.31 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.11 1.12 0.96 1.30 0.17 
Total CAMCOG Score -0.02 0.98 0.95 1.02 0.45 
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Table 8-16 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Nocturnal Diastolic BP Variability 
Model 1 
B HR 
95.0% CI  
P Lower Upper 
Age (years) 0.11 1.12 1.08 1.15 <0.01 
Sex 0.51 1.67 1.09 2.57 0.02 
Daytime DBP Variability (mmHg) 0.09 1.09 1.00 1.19 0.05 
Model 2 
    
  
Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex 0.41 1.51 0.98 2.34 0.06 
Daytime DBP Variability (mmHg) 0.07 1.08 0.99 1.17 0.09 
Cardiovascular Disease -0.34 0.71 0.35 1.46 0.36 
Diabetes 0.28 1.32 0.68 2.57 0.42 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive medication 0.81 2.25 1.09 4.67 0.03 
BMI (kg/m
2
) -0.07 0.94 0.88 0.99 0.03 
Model 3 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex 0.31 1.37 0.82 2.26 0.23 
Daytime DBP Variability (mmHg) 0.10 1.10 1.01 1.21 0.04 
Cardiovascular Disease -0.06 0.94 0.40 2.20 0.89 
Diabetes 0.78 2.18 1.09 4.36 0.03 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.50 1.65 0.73 3.75 0.23 
BMI (kg/m
2
) -0.11 0.90 0.83 0.96 <0.01 
Bristol ADL Score 0.12 1.13 0.98 1.31 0.10 
Model 4 
    
  
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex 0.31 1.36 0.82 2.25 0.23 
Daytime DBP Variability (mmHg) 0.09 1.10 1.00 1.21 0.05 
Cardiovascular Disease -0.08 0.93 0.40 2.15 0.86 
Diabetes 0.77 2.16 1.08 4.31 0.03 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive medication 0.50 1.65 0.73 3.72 0.23 
BMI (kg/m
2
) -0.11 0.90 0.84 0.96 <0.01 
Bristol ADL Score 0.11 1.12 0.96 1.31 0.16 
Total CAMCOG Score -0.01 0.99 0.95 1.03 0.64 
8.3.2.7 Hypertension 
Cox regression analysis was also used to establish if hypertension on baseline 
ambulatory blood pressure (defined according to NICE criteria) was associated with 
survival. Hypertension was not associated in the model adjusting only for age and sex or 
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cardiovascular factors. However, after adjusting for baseline functional and cognitive 
status, hypertension was associated with increased mortality (Table 8-17).  
 
Table 8-17 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Hypertension 
Model 1 
B HR 
95.0% CI  
P Lower Upper 
Age (years) 0.11 1.12 1.09 1.53 <0.01 
Sex 0.02 1.652 1.08 2.45 0.02 
Hypertension on ambulatory BP 0.30 1.36 0.91 2.02 0.14 
Model 2      
Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex 0.37 1.44 0.95 2.19 0.09 
Hypertension on ambulatory BP 0.29 1.34 0.89 2.10 0.16 
Cardiovascular Disease -0.28 0.76 0.37 1.55 0.45 
Diabetes 0.30 1.35 0.72 2.54 0.35 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive medication 0.68 1.98 0.96 4.11 0.07 
BMI (kg/m
2
) -0.06 0.94 0.89 1.00 0.06 
Model 3      
Age (years) 0.10 1.11 1.07 1.15 <0.01 
Sex 0.24 1.27 0.78 2.07 0.33 
Hypertension on ambulatory BP 0.66 1.94 1.22 3.09 0.01 
Cardiovascular Disease 0.01 1.01 0.42 2.43 0.98 
Diabetes 0.78 2.18 1.08 4.38 0.03 
Pack years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive medication 0.43 1.54 0.65 3.65 0.32 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.08 1.08 0.93 1.26 0.30 
Model 4      
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.24 1.27 0.78 2.06 0.34 
Hypertension on ambulatory BP 0.67 1.96 1.23 3.12 <0.01 
Cardiovascular Disease -0.02 0.98 0.41 2.32 0.96 
Diabetes 0.75 2.13 1.06 4.27 0.03 
Pack years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive medication 0.42 1.52 0.65 3.54 0.33 
BMI (kg/m
2
) -0.11 0.89 0.83 0.96 <0.01 
Bristol ADL Score 0.05 1.05 0.89 1.23 0.58 
Total CAMCOG Score -0.03 0.97 0.94 1.01 0.18 
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 Survival and Blood Pressure Response to Active Stand 8.3.3
Baseline active stand results were available for 297 participants. Of these, 74 
participants had died during the follow-up period. Comparing participants who were 
alive at the end of the follow-up period with those who had died did not reveal any 
significant difference in rates of orthostatic hypotension as defined by AAN, or systolic 
or diastolic OH examined separately. Similarly, there were no significant differences in 
terms of nadir reached during stand. Systolic vasodepression was greater in participants 
who died compared to those who were alive at end of follow-up, but this did not quite 
reach statistical significance (P=0.07). Degree of diastolic vasodepression did not differ 
between the groups (Table 8-18).   
 
Table 8-18 Response to Active Stand for Participants Who Were Alive at End of 
Follow-up versus Those Who Had Died  
 Alive N= 223 Dead N = 74 P  
 Frequency (%) Frequency (%)  
Orthostatic Hypotension 182  (81.6) 30 (40.5) 0.92 
Systolic Hypotension 147 (65.9) 45 (60.8) 0.43 
Diastolic Hypotension 161 (72.2) 49 (66.2) 0.33 
 Mean (SD) Mean (SD)   
Systolic Vasodepression (mmHg) 26.5 (16.4) 23.9 (19.4) 0.25 
Diastolic Vasodepression (mmHg) 14.5 (8.7) 15.1 (12.2) 0.65 
Systolic Nadir (mmHg) 115.2 (26.7) 121.7 (25.0) 0.07 
Diastolic Nadir (mmHg) 46.9 (13.1) 48.0 (13.9) 0.54 
 
Cox regression models were used to determine if OH was associated with survival. OH 
defined by the AAN was not associated with survival in models adjusting for age at 
baseline and sex. Further models adjusting for cardiovascular risk factors, baseline 
functional status and baseline cognitive function also failed to show an association 
between OH and survival (Table 8-19). Analysis was repeated to explore if examining 
systolic and diastolic OH separately showed any associations with survival. None were 
observed in the age and sex adjusted model, or in subsequent models adjusting for 
cardiovascular risks, functional ability and cognitive function (Table 8-20 & Table 
8-21). Finally, Cox regression models were repeated to examine if symptomatic 
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orthostatic hypotension was associated with survival. Symptomatic OH was not a 
significant predictor of survival in any of the models.  
Table 8-19 Cox Regression Models. Relative of All-Cause Mortality According 
Associated With Orthostatic Hypotension as Defined by ANN.  
Model 1 B HR 95% CI P 
   Lower Upper  
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.48 0.62 0.38 1.00 0.05 
OH (AAN definition) 0.03 1.03 0.57 1.84 0.93 
Model 2       
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.43 0.65 0.40 1.06 0.08 
OH (AAN definition) 0.12 1.13 0.61 2.11 0.70 
CVD 0.37 1.45 0.60 3.51 0.41 
Diabetes -0.36 0.70 0.32 1.50 0.35 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.67 0.51 0.21 1.26 0.15 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.10 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Model 3       
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.19 0.83 0.49 1.41 0.49 
OH (AAN definition) -0.13 0.88 0.42 1.84 0.74 
CVD 0.04 1.04 0.38 2.86 0.94 
Diabetes -0.74 0.48 0.20 1.14 0.09 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.50 0.61 0.22 1.64 0.32 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.26 0.54 
Model 4       
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.22 0.80 0.47 1.36 0.42 
OH (AAN definition) -0.19 0.82 0.39 1.73 0.61 
CVD 0.04 1.04 0.39 2.80 0.93 
Diabetes -0.72 0.49 0.20 1.17 0.11 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.44 0.65 0.24 1.72 0.38 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.00 1.00 0.82 1.21 0.97 
CAMCOG total score -0.04 0.96 0.92 1.00 0.05 
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Table 8-20 Cox Regression Models. Relative of All-Cause Mortality Associated 
with Systolic Orthostatic Hypotension. 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.12 1.13 1.09 1.16 <0.01 
Sex -0.47 0.62 0.39 1.00 0.05 
Systolic OH -0.29 0.75 0.47 1.19 0.22 
Model 2       
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.44 0.64 0.40 1.05 0.08 
Systolic OH -0.29 0.75 0.46 1.21 0.23 
CVD 0.33 1.39 0.57 3.38 0.46 
Diabetes -0.36 0.70 0.32 1.52 0.37 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.65 0.52 0.21 1.29 0.16 
BMI (kg/m
2
) -0.06 0.94 0.87 1.01 0.09 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Model 3       
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.19 0.83 0.49 1.41 0.49 
Systolic OH -0.05 0.95 0.55 1.64 0.86 
CVD 0.02 1.02 0.37 2.81 0.98 
Diabetes -0.74 0.48 0.20 1.14 0.10 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.49 0.62 0.23 1.67 0.34 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.27 0.52 
Model 4       
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.21 0.81 0.47 1.37 0.43 
Systolic OH -0.03 0.97 0.56 1.67 0.90 
CVD 0.02 1.02 0.38 2.77 0.96 
Diabetes -0.72 0.49 0.20 1.17 0.11 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.42 0.66 0.24 1.76 0.40 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.00 1.00 0.82 1.21 0.99 
CAMCOG total score -0.04 0.96 0.92 1.00 0.06 
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Table 8-21 Cox Regression Models. Relative of All-Cause Mortality Associated 
with Diastolic Orthostatic Hypotension. 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.46 0.63 0.39 1.01 0.06 
Diastolic OH -0.18 0.83 0.51 1.36 0.46 
Model 2      
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.42 0.66 0.40 1.07 0.09 
Diastolic OH -0.20 0.82 0.50 1.35 0.43 
CVD 0.39 1.48 0.61 3.60 0.39 
Diabetes -0.39 0.67 0.31 1.46 0.32 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.66 0.52 0.21 1.27 0.15 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.10 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Model 3      
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.17 0.84 0.50 1.42 0.52 
Diastolic OH -0.10 0.91 0.52 1.58 0.73 
CVD 0.03 1.03 0.38 2.84 0.95 
Diabetes -0.76 0.47 0.20 1.12 0.09 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.48 0.62 0.23 1.68 0.35 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.27 0.51 
Model 4      
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.21 0.81 0.48 1.38 0.45 
Diastolic OH -0.09 0.91 0.52 1.60 0.75 
CVD 0.04 1.04 0.38 2.81 0.94 
Diabetes -0.74 0.48 0.20 1.15 0.10 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.42 0.66 0.24 1.77 0.41 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.00 1.00 0.83 1.22 0.98 
CAMCOG total score -0.04 0.96 0.92 1.00 0.06 
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To explore if degree of vasodepression or BP nadir reached during stand were 
associated with survival, BP responses as a continuous variable were entered into the 
models. Systolic vasodepression, diastolic vasodepression, systolic nadir, and diastolic 
nadir were entered into separate models controlling for age and sex. None of these 
variables were associated with survival (Table 8-22, Table 8-23, Table 8-24 & Table 
8-25). The models were then adjusted for cardiovascular risk factors, baseline physical 
function, and baseline cognitive function. There were no associations between survival 
and any of the continuous BP responses to active stand in these models (Table 8-22, 
Table 8-23, Table 8-24 and Table 8-25).  
.  
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Table 8-22 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to Systolic Vasodepression 
 B HR 95% CI P  
   Lower Upper  
Model 1 
Age (years) (years) 0.12 1.13 1.09 1.16 <0.01 
Sex -0.46 0.63 0.39 1.01 0.06 
Systolic Vasodepression (mmHg) -0.01 0.99 0.97 1.00 0.14 
Model 2 
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.43 0.65 0.40 1.06 0.08 
Systolic Vasodepression (mmHg) -0.01 0.99 0.97 1.00 0.10 
CVD 0.32 1.38 0.57 3.34 0.47 
Diabetes -0.35 0.71 0.33 1.53 0.38 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.66 0.52 0.21 1.27 0.15 
BMI (kg /m
2
) -0.07 0.93 0.87 1.00 0.07 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.02 
Model 3 
Age (years) 0.11 1.11 1.07 1.16 <0.01 
Sex -0.21 0.81 0.48 1.38 0.43 
Systolic Vasodepression (mmHg) -0.01 0.99 0.98 1.01 0.29 
CVD 0.00 1.00 0.36 2.73 1.00 
Diabetes -0.69 0.50 0.21 1.21 0.13 
Pack years 0.01 1.01 1.00 1.02 0.03 
Cardioactive Medication -0.48 0.62 0.23 1.67 0.34 
BMI (kg /m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.07 1.07 0.89 1.28 0.47 
Model 4      
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.23 0.79 0.47 1.35 0.39 
Systolic Vasodepression (mmHg) -0.01 0.99 0.98 1.01 0.31 
CVD 0.02 1.02 0.38 2.74 0.97 
Diabetes -0.68 0.51 0.21 1.23 0.13 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.42 0.66 0.25 1.77 0.41 
BMI (kg /m
2
) -0.11 0.90 0.83 0.97 <0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.01 1.01 0.83 1.22 0.95 
CAMCOG total score -0.04 0.96 0.92 1.00 0.06 
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Table 8-23 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to Diastolic Vasodepression 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.49 0.62 0.38 0.99 0.05 
Diastolic Vasodepression (mmHg) 0.00 1.00 0.98 1.03 0.80 
Model 2      
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.44 0.65 0.40 1.05 0.08 
Diastolic Vasodepression (mmHg) 0.00 1.00 0.98 1.02 0.97 
CVD 0.38 1.46 0.60 3.56 0.40 
Diabetes -0.36 0.70 0.33 1.51 0.36 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.67 0.51 0.21 1.26 0.14 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.11 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Model 3      
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.17 0.84 0.50 1.43 0.53 
Diastolic Vasodepression (mmHg) 0.01 1.01 0.98 1.04 0.46 
CVD -0.03 0.97 0.35 2.69 0.96 
Diabetes -0.76 0.47 0.20 1.12 0.09 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.48 0.62 0.23 1.66 0.34 
BMI (kg/m
2
) -0.10 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.05 1.05 0.88 1.26 0.58 
Model 4      
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex -0.20 0.82 0.48 1.39 0.46 
Diastolic Vasodepression (mmHg) 0.01 1.01 0.98 1.04 0.47 
CVD -0.04 0.96 0.35 2.61 0.93 
Diabetes -0.74 0.48 0.20 1.14 0.10 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.40 0.67 0.25 1.79 0.43 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score -0.01 0.99 0.82 1.20 0.94 
CAMCOG total score -0.04 0.96 0.92 1.00 0.06 
 
   
266 
 
Table 8-24 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to Systolic Nadir 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.11 1.12 1.08 1.16 <0.01 
Sex -0.50 0.61 0.38 0.97 0.04 
Systolic nadir (mmHg) 0.01 1.01 1.00 1.01 0.21 
Model 2      
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.44 0.64 0.40 1.05 0.08 
Systolic nadir (mmHg) 0.00 1.00 0.99 1.01 0.71 
CVD 0.37 1.45 0.60 3.52 0.41 
Diabetes -0.35 0.70 0.33 1.51 0.37 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.67 0.51 0.21 1.26 0.15 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.11 
Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.06 
Model 3      
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.18 0.83 0.49 1.41 0.50 
Systolic nadir (mmHg) 0.00 1.00 0.99 1.01 0.97 
CVD 0.03 1.03 0.37 2.82 0.96 
Diabetes -0.74 0.48 0.20 1.15 0.10 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.49 0.61 0.22 1.66 0.33 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.27 0.53 
Model 4      
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex -0.20 0.81 0.48 1.38 0.45 
Systolic nadir (mmHg) 0.00 1.00 0.99 1.01 0.69 
CVD 0.04 1.04 0.39 2.77 0.94 
Diabetes -0.75 0.47 0.20 1.14 0.10 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.43 0.65 0.24 1.73 0.39 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL Score -0.01 0.99 0.82 1.21 0.94 
CAMCOG total score -0.04 0.96 0.92 1.00 0.05 
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Table 8-25 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to Diastolic Nadir 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.48 0.62 0.38 0.99 0.05 
Diastolic nadir (mmHg) 0.01 1.01 0.99 1.03 0.34 
Model 2      
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.43 0.65 0.40 1.05 0.08 
Diastolic nadir (mmHg) 0.01 1.01 0.99 1.02 0.47 
CVD 0.35 1.42 0.58 3.47 0.44 
Diabetes -0.40 0.67 0.31 1.45 0.31 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.65 0.52 0.21 1.30 0.16 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.10 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.04 
Model 3      
Age (years) 0.11 1.12 1.07 1.16 <0.01 
Sex -0.18 0.84 0.49 1.41 0.51 
Diastolic nadir (mmHg) 0.01 1.01 0.99 1.03 0.54 
CVD 0.01 1.01 0.36 2.79 0.99 
Diabetes -0.74 0.48 0.20 1.13 0.09 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.47 0.62 0.23 1.71 0.36 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.07 0.89 1.28 0.49 
Model 4      
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex -0.21 0.81 0.48 1.38 0.44 
Diastolic nadir (mmHg) 0.00 1.00 0.98 1.02 0.79 
CVD 0.02 1.02 0.38 2.77 0.97 
Diabetes -0.72 0.49 0.20 1.16 0.10 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.42 0.66 0.24 1.78 0.41 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.00 1.00 0.83 1.22 0.97 
CAMCOG total score -0.04 0.96 0.92 1.00 0.07 
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As previously discussed orthostatic hypotension, diagnosed using a sphygmomanometer 
has been associated with increased mortality. To establish if the AAN criteria for OH 
are too sensitive when using beat-to-beat monitoring, new thresholds for OH were 
defined based on haemodynamic response observed in a subgroup that had no history of 
falls syncope or dizziness and had an MMSE≥24 at baseline. The 95th percentiles for 
systolic and diastolic vasodepression were 49mmHg and 33mmHg respectively. 
Twenty-six participants had orthostatic hypotension using these thresholds.    
 
In age and sex adjusted models there was a borderline association between OH defined 
by modified criteria and survival. After adjusting for cardiovascular risk factors and 
medication OH defined according to modified criteria was no longer a significant 
predictor of survival (Table 8-26).   
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Table 8-26 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According Modified Criteria for OH 
Model 1 B HR 95% CI P  
   Lower Upper  
Age (years) 0.13 1.13 1.09 1.17 <0.01 
Sex 0.42 1.53 0.95 2.45 0.08 
Modified OH criteria 0.58 1.79 0.91 3.49 0.09 
Model 2      
Age (years) 0.10 1.11 1.07 1.15 <0.01 
Sex 0.29 1.34 0.83 2.18 0.24 
Modified OH criteria 0.47 1.60 0.81 3.18 0.18 
CVD 0.52 1.68 0.79 3.60 0.18 
Diabetes -0.20 0.82 0.38 1.80 0.62 
Pack years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication -0.80 0.45 0.21 0.96 0.04 
BMI (kg/m
2
) -0.07 0.94 0.87 1.01 0.07 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.01 
Model 3      
Age (years) 0.12 1.12 1.08 1.17 <0.01 
Sex 0.14 1.15 0.68 1.95 0.60 
Modified OH criteria 0.58 1.79 0.86 3.71 0.12 
CVD 0.23 1.26 0.54 2.94 0.60 
Diabetes -0.76 0.47 0.20 1.10 0.08 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.62 0.54 0.24 1.21 0.14 
BMI (kg/m
2
) -0.10 0.90 0.83 0.98 0.02 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.26 0.49 
Model 4      
Age (years) 0.11 1.11 1.07 1.16 <0.01 
Sex 0.17 1.19 0.70 2.02 0.52 
Modified OH criteria 0.56 1.75 0.85 3.64 0.13 
CVD 0.24 1.27 0.55 2.92 0.58 
Diabetes -0.72 0.49 0.20 1.15 0.10 
Pack years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.58 0.56 0.25 1.25 0.16 
BMI (kg/m
2
) -0.10 0.90 0.83 0.98 0.02 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.01 1.01 0.84 1.22 0.88 
CAMCOG total score -0.04 0.96 0.93 1.00 0.07 
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 Survival and Response to Carotid Sinus Massage 8.3.4
To assess if CSH was more common among participants who had died before October 
2012 than in those who were alive at the end of follow-up, prevalence of CSH between 
the two groups in 2002 was compared. Mixed CSH was significantly more common 
among participants who died before October 2012 (Table 8-27).  
 
Continuous response to CSM was compared for the two groups. Systolic 
vasodepression post carotid sinus massage was significantly greater, and systolic nadir 
was significantly lower among participants who died prior to end of follow-up. Delta 
RR post CSM was longer for participants who died, but this did not quite reach 
statistical significance (Table 8-27).  
 
Table 8-27 Response to CSM among Participants who Died During Follow-up with 
Prevalence among Participants alive in October 2012  
 Alive 
N=201 
Dead 
N=71 
P  
    
CSH (any) 72 (38.5) 34 (47.9) 0.07 
Cardio inhibitory 5 (2.5) 1 (1.4) 0.51 
Vasodepressor 31 (15.4) 11 (15.5) 0.99 
Mixed 37 (18.4) 21 (29.6) 0.05 
 Median (IQR) Median (IQR)   
RR post CSM (ms) 1670 (1215, 2728) 1815(1316, 3882) 0.17 
Max Delta RR (ms) 693 (284, 1762) 1012 (338, 3018) 0.08 
Systolic Nadir (mmHg) 82.0 (66.5, 101.5) 73.0 (62.0, 94.0) 0.03 
Max systolic vasodepression 
(mmHg) 
42.1 (30.7, 57.7) 48.7 (35.2, 66.4) 
0.01 
 
Carotid sinus hypersensitivity was not associated with survival in age and sex adjusted 
Cox regression models or in models adjusted for cardiovascular risk factors, baseline 
functional status, or baseline cognitive function (Table 8-28).  
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Table 8-28 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Carotid Sinus Hypersensitivity. 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex -0.63 0.53 0.32 0.88 0.01 
CSH 0.28 1.32 0.83 2.11 0.24 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.56 0.57 0.34 0.97 0.04 
CSH 0.20 1.22 0.76 1.98 0.41 
CVD -0.42 0.65 0.29 1.49 0.31 
Diabetes 0.35 1.41 0.63 3.17 0.40 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.63 1.88 0.82 4.30 0.14 
BMI (kg/m
2
) -0.08 0.93 0.86 0.99 0.03 
Mean SBP (mmHg) 0.00 1.00 0.99 1.02 0.56 
Model 3 
    
  
Age (years) 0.13 1.14 1.09 1.19 <0.01 
Sex -0.40 0.67 0.37 1.20 0.18 
CSH 0.25 1.28 0.76 2.18 0.35 
CVD -0.04 0.96 0.39 2.38 0.94 
Diabetes 0.95 2.57 1.11 5.95 0.03 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.42 1.52 0.62 3.76 0.36 
BMI (kg/m
2
) -0.12 0.89 0.82 0.96 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.00 1.04 0.02 
Bristol ADL score -0.01 0.99 0.91 1.08 0.86 
Model 4 
    
  
Age (years) 0.11 1.12 1.07 1.18 <0.01 
Sex -0.42 0.66 0.37 1.17 0.15 
CSH 0.28 1.32 0.78 2.24 0.31 
CVD -0.05 0.95 0.40 2.29 0.91 
Diabetes 0.91 2.49 1.08 5.76 0.03 
Pack years 0.01 1.01 1.00 1.03 0.03 
Cardioactive medication 0.34 1.41 0.58 3.44 0.45 
BMI (kg/m
2
) -0.12 0.88 0.82 0.96 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL score -0.06 0.94 0.85 1.05 0.27 
CAMCOG total score -0.04 0.96 0.92 1.00 0.05 
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To establish if the different subgroups of CSH were associated with survival, the 
models were run with mixed, vasodepressor and cardioinhibitory CSH entered 
separately. No associations were seen between CSH group and survival in either age 
and sex adjusted models, or in the models adjusting for cardiovascular risk factors, 
baseline functional status, or baseline cognitive function (Table 8-29). 
  
To examine if continuous BP or HR response to CSM were better predictors of survival 
than categorical variables, Cox regression models were run with HR and BP response 
entered into the model. Heart rate and BP response to CSM were not associated with 
survival in either age and sex adjusted models, or in models adjusting for cardiovascular 
risk factors, baseline functional status or baseline cognitive function (Table 8-30, Table 
8-31). 
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Table 8-29 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to CSH group 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex -0.61 0.54 0.33 0.89 0.02 
CSH group 0.13 1.13 0.95 1.35 0.16 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.54 0.58 0.34 0.99 0.05 
CSH group 0.10 1.11 0.93 1.33 0.26 
CVD -0.42 0.66 0.29 1.50 0.32 
Diabetes 0.35 1.42 0.63 3.16 0.40 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.63 1.87 0.82 4.29 0.14 
BMI (kg/m
2
) -0.08 0.93 0.86 0.99 0.03 
Mean SBP (mmHg) 0.00 1.00 0.99 1.02 0.54 
Model 3 
    
  
Age (years) 0.13 1.14 1.09 1.19 <0.01 
Sex -0.37 0.69 0.38 1.23 0.21 
CSH group 0.14 1.15 0.94 1.41 0.17 
CVD -0.05 0.95 0.38 2.37 0.92 
Diabetes 0.93 2.54 1.10 5.86 0.03 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.43 1.54 0.62 3.84 0.35 
BMI (kg/m
2
) -0.12 0.89 0.82 0.96 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.00 1.04 0.02 
Bristol ADL score -0.01 0.99 0.91 1.08 0.80 
Model 4 
    
  
Age (years) 0.12 1.12 1.07 1.18 <0.01 
Sex -0.40 0.67 0.38 1.20 0.18 
CSH group 0.16 1.17 0.95 1.43 0.13 
CVD -0.05 0.95 0.39 2.31 0.91 
Diabetes 0.90 2.45 1.06 5.67 0.04 
Pack years 0.01 1.01 1.00 1.03 0.03 
Cardioactive medication 0.35 1.42 0.58 3.49 0.44 
BMI (kg/m
2
) -0.13 0.88 0.82 0.95 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL score -0.06 0.94 0.85 1.04 0.23 
CAMCOG total score -0.04 0.96 0.92 1.00 0.04 
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Table 8-30 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Maximum RR response to CSM 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex -0.58 0.56 0.33 0.93 0.03 
Maximum RR (ms) 0.00 1.00 1.00 1.00 0.27 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.53 0.59 0.34 1.01 0.05 
Maximum RR (ms) 0.00 1.00 1.00 1.00 0.32 
CVD -0.43 0.65 0.29 1.47 0.30 
Diabetes 0.31 1.37 0.61 3.06 0.45 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication 0.64 1.89 0.83 4.31 0.13 
BMI (kg/m
2
) -0.08 0.92 0.86 0.99 0.02 
Mean SBP 0.01 1.01 0.99 1.02 0.41 
Model 3 
    
  
Age (years) 0.13 1.14 1.09 1.19 <0.01 
Sex -0.34 0.71 0.39 1.29 0.27 
Maximum RR (ms) 0.00 1.00 1.00 1.00 0.10 
CVD -0.05 0.95 0.39 2.34 0.92 
Diabetes 0.92 2.51 1.08 5.82 0.03 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication 0.43 1.53 0.62 3.77 0.35 
BMI (kg/m
2
) -0.13 0.88 0.81 0.95 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL score 0.00 1.00 0.92 1.08 0.93 
Model 4 
    
  
Age (years) 0.12 1.12 1.07 1.18 <0.01 
Sex -0.37 0.69 0.39 1.25 0.22 
Maximum RR (ms) 0.00 1.00 1.00 1.00 0.07 
CVD -0.05 0.95 0.40 2.27 0.90 
Diabetes 0.90 2.45 1.06 5.69 0.04 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication 0.36 1.43 0.59 3.48 0.43 
BMI (kg/m
2
) -0.14 0.87 0.81 0.95 <0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL score -0.06 0.95 0.85 1.05 0.29 
CAMCOG total score -0.04 0.96 0.92 1.00 0.04 
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Table 8-31 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Maximum Vasodepression Response to CSM. 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.12 1.08 1.16 <0.01 
Sex -0.61 0.54 0.33 0.89 0.02 
Maximum vasodepression (mmHg) 0.01 1.01 0.99 1.02 0.30 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex -0.55 0.57 0.34 0.98 0.04 
Maximum vasodepression (mmHg) 0.00 1.00 0.99 1.02 0.50 
CVD -0.44 0.64 0.28 1.45 0.29 
Diabetes 0.35 1.42 0.63 3.19 0.40 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.64 1.89 0.83 4.30 0.13 
BMI (kg/m
2
) -0.08 0.92 0.86 0.99 0.03 
Mean SBP 0.00 1.00 0.99 1.02 0.57 
Model 3 
    
  
Age (years) 0.13 1.13 1.08 1.19 <0.01 
Sex -0.35 0.70 0.39 1.27 0.24 
Maximum vasodepression (mmHg) 0.01 1.01 1.00 1.02 0.19 
CVD -0.08 0.92 0.37 2.28 0.86 
Diabetes 0.96 2.62 1.14 6.05 0.02 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.43 1.54 0.63 3.80 0.35 
BMI (kg/m
2
) -0.12 0.89 0.82 0.96 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.00 1.04 0.02 
Bristol ADL score -0.01 0.99 0.91 1.08 0.82 
Model 4 
    
  
Age (years) 0.11 1.12 1.07 1.17 <0.01 
Sex -0.38 0.68 0.38 1.23 0.20 
Maximum vasodepression (mmHg) 0.01 1.01 1.00 1.02 0.18 
CVD -0.10 0.91 0.38 2.19 0.83 
Diabetes 0.95 2.57 1.11 5.94 0.03 
Pack years 0.01 1.01 1.00 1.03 0.03 
Cardioactive medication 0.36 1.44 0.59 3.50 0.42 
BMI (kg/m
2
) -0.13 0.88 0.81 0.95 <0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL score -0.06 0.94 0.85 1.04 0.26 
CAMCOG total score -0.04 0.96 0.92 1.00 0.05 
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The criteria for CSH were arbitrarily defined in young men. To establish if the criteria 
for CSH are too sensitive when using beat-to-beat monitoring, new thresholds for CSH 
were defined based on haemodynamic response observed in a subgroup that had no 
history of falls syncope or dizziness at baseline and had an MMSE≥24 at baseline. The 
95
th
 percentile for systolic vasodepression was 76.6 mmHg and the 95
th
 percentile for 
RR interval post CSM was 7.3 seconds. These thresholds were used to define CSH 
modified criteria.  
 
Twenty-three individuals had CSH defined according to modified criteria. In age and 
sex adjusted models there was a significant association between CSH defined according 
to modified criteria and mortality [HR 2.37, P=0.02] (Figure 8-1). This remained 
significant after adjusting for baseline cardiovascular risk factors and functional status 
(Table 8-32).  
 
Figure 8-1 Survival Curve Comparing Survival Among Participants With and 
Without CSH Defined According to Modified Criteria. Graph Shows Data 
Adjusted for Age and Sex.  
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Table 8-32 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with CSH Defined According to Modified Criteria 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.13 1.14 1.10 1.19 <0.01 
Sex 0.56 1.75 1.02 3.00 0.04 
CSH defined by modified criteria 0.86 2.37 1.16 4.87 0.02 
Model 2 
    
  
Age (years) 0.11 1.12 1.07 1.17 <0.01 
Sex 0.51 1.66 0.94 2.92 0.08 
CSH defined by modified criteria 0.82 2.26 1.09 4.70 0.03 
CVD -0.44 0.65 0.30 1.41 0.27 
Diabetes 0.12 1.13 0.46 2.78 0.79 
Pack years 0.01 1.01 1.00 1.02 0.13 
Cardioactive medication 0.64 1.89 0.86 4.16 0.11 
BMI (kg/m
2
) -0.10 0.91 0.84 0.98 0.01 
Mean SBP 0.01 1.01 1.00 1.03 0.13 
Model 3      
Age (years) 0.15 1.16 1.10 1.22 <0.01 
Sex 0.32 1.38 0.73 2.60 0.32 
CSH defined by modified criteria 1.02 2.78 1.18 6.52 0.02 
CVD 0.04 1.04 0.42 2.55 0.93 
Diabetes 1.10 3.01 1.16 7.78 0.02 
Pack years 0.01 1.01 1.00 1.03 0.09 
Cardioactive medication 0.31 1.37 0.58 3.25 0.48 
BMI (kg/m
2
) -0.14 0.87 0.79 0.95 <0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL score -0.14 0.87 0.67 1.13 0.30 
Model 4      
Age (years) 0.13 1.14 1.08 1.20 <0.01 
Sex 0.40 1.50 0.80 2.82 0.21 
CSH defined by modified criteria 1.01 2.76 1.18 6.43 0.02 
CVD 0.05 1.05 0.43 2.59 0.91 
Diabetes 1.14 3.13 1.20 8.14 0.02 
Pack years 0.01 1.01 1.00 1.03 0.06 
Cardioactive medication 0.23 1.25 0.53 2.99 0.61 
BMI (kg/m
2
) -0.16 0.85 0.78 0.94 <0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL score -0.26 0.77 0.58 1.04 0.09 
CAMCOG total score -0.06 0.94 0.90 0.99 <0.01 
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 Survival and Response to Autonomic Function Tests  8.3.5
Three hundred and twenty-one had data from at least one autonomic function test (AFT) 
suitable for analysis. Of these, 231 had adequate data from all five AFT. Comparing 
participants who died during follow-up with those who were alive at the end of follow-
up showed that the Valsalva ratio was significantly smaller in the group who had died. 
Statistically significant differences were not seen in response to the other AFT.  
Response to Autonomic Function tests among Participants who died During 
Follow-up versus those who were Alive at the End of the Study  
 Alive  
N=223 
Dead  
N= 74 
P 
 Mean (SD) Mean (SD)  
Best Valsalva Ratio 1.51 (0.29) 1.39 (0.24) <0.01 
Heart rate response to deep breathing 7.86 (4.45) 8.48 (6.36) 0.37 
30: 15 Ratio 1.15 (0.09) 1.15 (0.29) 0.90 
Active sit difference in DBP (mmHg) 12.4 (13.1) 13.1 (12.3) 0.70 
Valsalva BP overshoot (mmHg) 27.3 (24.7) 21.2 (24.9) 0.12 
DBP rise with cold pressor (mmHg) 9.82 (9.1) 8.4 (11.3) 0.30 
 
8.3.5.1 Normal v. Abnormal Autonomic Function 
Two hundred and fifty two individuals had sufficient tests to classify their function as 
normal or abnormal by modified Ewing criteria. Cox regression was used to establish if 
abnormal autonomic function at baseline was associated with survival.  
 
After adjusting for age and sex, abnormal autonomic function was not associated with 
survival. Further models adjusting in turn for cardiovascular risk factors, baseline 
functional status and baseline cognitive function did not show any association between 
abnormal autonomic function and survival (Table 8-33).  
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Table 8-33 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According Associated with Abnormal Autonomic Function at Baseline. 
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.05 1.06 1.02 1.09 <0.01 
Sex -0.35 0.71 0.44 1.15 0.16 
Abnormal autonomic function -0.15 0.86 0.53 1.41 0.56 
Model 2 
    
  
Age (years) 0.05 1.05 1.02 1.09 <0.01 
Sex -0.35 0.71 0.42 1.18 0.19 
Abnormal autonomic function -0.06 0.94 0.56 1.59 0.83 
CVD -0.46 0.63 0.25 1.55 0.31 
Diabetes 0.23 1.25 0.58 2.71 0.57 
Pack Years 0.01 1.01 1.00 1.02 0.04 
Cardioactive Medication 0.14 1.15 0.46 2.86 0.76 
BMI (kg/m
2
) -0.03 0.97 0.90 1.04 0.38 
Mean SBP (mmHg) 0.01 1.01 0.99 1.02 0.22 
Model 3 
    
  
Age (years) 0.07 1.07 1.03 1.12 <0.01 
Sex -0.27 0.77 0.44 1.35 0.36 
Abnormal autonomic function -0.33 0.72 0.41 1.25 0.25 
CVD -0.39 0.68 0.20 2.25 0.52 
Diabetes 0.14 1.15 0.48 2.78 0.75 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.05 1.05 0.33 3.34 0.93 
BMI (kg/m
2
) -0.06 0.94 0.86 1.02 0.15 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score 0.02 1.02 0.87 1.20 0.80 
Model 4 
    
  
Age (years) 0.06 1.06 1.02 1.11 <0.01 
Sex -0.29 0.75 0.42 1.31 0.31 
Abnormal autonomic function -0.42 0.66 0.37 1.15 0.14 
CVD -0.45 0.64 0.19 2.11 0.46 
Diabetes 0.11 1.12 0.46 2.71 0.80 
Pack Years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication -0.01 0.99 0.31 3.15 0.99 
BMI (kg/m
2
) -0.07 0.94 0.86 1.02 0.14 
Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL Score -0.04 0.96 0.80 1.15 0.65 
CAMCOG total score -0.04 0.96 0.92 1.01 0.11 
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Cox regression models were formulated to examine if responses to individual 
autonomic function tests were associated with survival at ten years. 
8.3.5.2 Stand 30:15 ratio 
Two-hundred participants underwent active stand and had heart rate recordings 
adequate for analysis. The 30:15 ratio was not associated with survival in the age and 
sex adjusted model. Adjusting for cardiovascular risk factors, functional status at 
baseline or baseline cognition did not reveal any association between 30:15 ratio and 
survival (Table 8-34).  
8.3.5.3 Active sit 
Adequate BP recordings in response to isometric exercise were available for 297 
participants. Rise in diastolic BP in response to isometric exercise was not associated 
with survival in age and sex adjusted models or subsequent models (Table 8-35).  
8.3.5.4 Heart Rate and BP response to Valsalva Manoeuvre  
Three hundred participants had results from one or more Valsalva manoeuvres suitable 
for analysis. There was a borderline association between Valsalva ratio and survival in 
the age and sex adjusted model P= 0.07 (Table 8-36). In models adjusted for 
cardiovascular risk factors, functional status at baseline and baseline cognitive function, 
this relationship was not apparent (Table 8-36).  
 
Cox regression did not reveal a significant association between Valsalva phase four 
systolic BP overshoot and survival in any of the models (Table 8-37).  
8.3.5.5 Cold Pressor Test 
Two hundred and eighty three participants completed the cold pressor test and had 
recordings suitable for analysis. Diastolic BP rise with cold pressor was not associated 
with survival in age and sex adjusted models or subsequent models (Table 8-38). 
8.3.5.6 Deep Breathing 
Recordings suitable to determine heart rate response to deep breathing were available 
for 289 participants. Heart rate response to deep breathing was not associated with 
survival in any of the models (Table 8-39).  
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Table 8-34 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
According to Active Stand 30:15 ratio 
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.48 0.62 0.39 1.00 0.05 
30:15 ratio 0.36 1.43 0.39 5.26 0.59 
Model 2 
     Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.43 0.65 0.40 1.06 0.08 
30:15 ratio 0.28 1.33 0.46 3.85 0.61 
CVD -0.38 0.68 0.28 1.65 0.40 
Diabetes 0.38 1.47 0.68 3.18 0.33 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.67 1.96 0.80 4.80 0.14 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.11 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Model 3 
     Age (years) 0.11 1.12 1.07 1.17 <0.01 
Sex -0.17 0.84 0.50 1.43 0.53 
30:15 ratio 0.46 1.59 0.55 4.56 0.39 
CVD -0.04 0.96 0.35 2.64 0.94 
Diabetes 0.78 2.17 0.91 5.21 0.08 
Pack Years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication 0.49 1.63 0.60 4.43 0.34 
BMI (kg/m
2
) -0.11 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.02 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.06 1.06 0.89 1.27 0.49 
Model 4 
     Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex -0.20 0.82 0.48 1.39 0.45 
30:15 ratio 0.39 1.47 0.49 4.44 0.49 
CVD -0.04 0.96 0.36 2.60 0.94 
Diabetes 0.75 2.11 0.88 5.09 0.10 
Pack Years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication 0.42 1.53 0.57 4.10 0.40 
BMI (kg/m
2
) -0.10 0.90 0.83 0.98 0.01 
Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.01 1.01 0.83 1.22 0.96 
CAMCOG total score -0.04 0.96 0.92 1.00 0.07 
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Table 8-35 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Response to Active Sit. 
Model 1 
B HR 
95% CI P 
Lower Upper 
Age (years) 0.12 1.12 1.09 1.16 <0.01 
Sex -0.44 0.64 0.40 1.03 0.07 
DBP rise with isometric exercise (mmHg) 0.01 1.01 0.99 1.02 0.43 
Model 2 
   
  
Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex -0.38 0.69 0.42 1.11 0.13 
DBP rise with isometric exercise (mmHg) 0.01 1.01 0.99 1.02 0.43 
CVD -0.28 0.76 0.31 1.84 0.54 
Diabetes 0.05 1.05 0.44 2.50 0.92 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.66 1.93 0.79 4.72 0.15 
BMI (kg/m
2
) -0.06 0.95 0.88 1.01 0.12 
Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.14 
Model 3 
   
  
Age (years) 0.11 1.12 1.08 1.17 <0.01 
Sex -0.14 0.87 0.52 1.48 0.61 
DBP rise with isometric exercise (mmHg) 0.00 1.00 0.98 1.02 0.98 
CVD 0.23 1.26 0.47 3.39 0.64 
Diabetes 0.53 1.70 0.68 4.23 0.26 
Pack Years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive Medication 0.44 1.55 0.59 4.08 0.38 
BMI (kg/m
2
) -0.11 0.90 0.82 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Bristol ADL Score 0.03 1.03 0.96 1.11 0.45 
Model 4 
   
  
Age (years) 0.11 1.11 1.07 1.16 <0.01 
Sex -0.16 0.85 0.50 1.45 0.56 
DBP rise with isometric exercise (mmHg) 0.00 1.00 0.98 1.02 0.82 
CVD 0.19 1.22 0.45 3.26 0.70 
Diabetes 0.49 1.63 0.65 4.08 0.29 
Pack Years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive Medication 0.42 1.52 0.58 4.03 0.40 
BMI (kg/m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Bristol ADL Score 0.00 1.00 0.92 1.10 0.96 
CAMCOG total score -0.02 0.98 0.93 1.02 0.28 
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Table 8-36 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Response to Valsalva Manoeuvre (Valsalva Ratio). 
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.10 1.10 1.07 1.14 <0.01 
Sex -0.46 0.63 0.40 1.01 0.05 
Valsalva ratio -0.90 0.41 0.16 1.06 0.07 
Model 2 
     Age (years) 0.09 1.09 1.05 1.13 <0.01 
Sex -0.40 0.67 0.42 1.08 0.10 
Valsalva ratio -0.79 0.45 0.16 1.27 0.13 
CVD -0.50 0.61 0.24 1.52 0.29 
Diabetes 0.13 1.14 0.50 2.58 0.75 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.57 1.77 0.71 4.41 0.22 
BMI (kg/m
2
) -0.05 0.95 0.89 1.02 0.15 
Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.06 
Model 3 
     Age (years) 0.09 1.10 1.05 1.14 <0.01 
Sex -0.19 0.83 0.50 1.39 0.48 
Valsalva ratio -0.85 0.43 0.13 1.35 0.15 
CVD -0.01 0.99 0.38 2.64 0.99 
Diabetes 0.53 1.70 0.73 4.01 0.22 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.29 1.33 0.51 3.47 0.56 
BMI (kg/m
2
) -0.10 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.02 1.02 0.94 1.10 0.66 
Model 4 
     Age (years) 0.09 1.09 1.04 1.13 <0.01 
Sex -0.20 0.82 0.49 1.37 0.45 
Valsalva ratio -0.79 0.45 0.14 1.42 0.17 
CVD -0.05 0.95 0.36 2.51 0.92 
Diabetes 0.49 1.64 0.69 3.87 0.26 
Pack Years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive Medication 0.28 1.32 0.51 3.42 0.57 
BMI (kg/m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score -0.02 0.98 0.90 1.08 0.73 
CAMCOG total score -0.03 0.97 0.93 1.01 0.17 
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Table 8-37 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Response to Valsalva Manoeuvre (Valsalva Overshoot) 
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.11 1.11 1.08 1.15 <0.01 
Sex -0.43 0.65 0.41 1.04 0.07 
Valsalva overshoot (mmHg) 0.00 1.00 0.99 1.01 0.98 
Model 2 
    
  
Age (years) 0.09 1.10 1.06 1.14 <0.01 
Sex -0.38 0.69 0.42 1.11 0.12 
Valsalva overshoot (mmHg) 0.00 1.00 0.99 1.01 0.69 
CVD -0.36 0.70 0.29 1.70 0.43 
Diabetes 0.26 1.30 0.57 2.93 0.53 
Pack Years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive Medication 0.61 1.84 0.76 4.48 0.18 
BMI (kg/m
2
) -0.05 0.95 0.89 1.02 0.14 
Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.09 
Model 3 
    
  
Age (years) 0.10 1.11 1.06 1.15 <0.01 
Sex -0.19 0.83 0.50 1.38 0.47 
Valsalva overshoot (mmHg) 0.00 1.00 0.99 1.02 0.57 
CVD 0.12 1.12 0.43 2.91 0.81 
Diabetes 0.68 1.97 0.84 4.61 0.12 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.38 1.46 0.57 3.78 0.43 
BMI (kg/m
2
) -0.10 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score 0.03 1.03 0.96 1.11 0.40 
Model 4 
    
  
Age (years) 0.09 1.10 1.05 1.14 <0.01 
Sex -0.21 0.81 0.48 1.36 0.43 
Valsalva overshoot (mmHg) 0.00 1.00 0.99 1.02 0.54 
CVD 0.07 1.07 0.41 2.77 0.89 
Diabetes 0.64 1.89 0.80 4.45 0.15 
Pack Years 0.01 1.01 1.00 1.02 <0.01 
Cardioactive Medication 0.36 1.43 0.55 3.69 0.46 
BMI (kg/m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 <0.01 
Bristol ADL Score 0.00 1.00 0.91 1.09 0.92 
CAMCOG total score -0.03 0.97 0.93 1.01 0.13 
      
   
285 
 
 
Table 8-38 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Response to Cold Pressor Test 
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.12 1.12 1.08 1.16 <0.01 
Sex -0.42 0.66 0.41 1.06 0.09 
DBP rise with cold pressor (mmHg) -0.01 0.99 0.96 1.01 0.31 
Model 2 
     Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex -0.33 0.72 0.44 1.17 0.19 
DBP rise with cold pressor -0.02 0.98 0.96 1.01 0.15 
CVD 0.00 1.00 0.41 2.45 0.99 
Diabetes 0.62 1.86 0.82 4.21 0.14 
Pack Years 0.01 1.01 1.00 1.02 0.02 
Cardioactive Medication 0.41 1.51 0.61 3.72 0.37 
BMI (kg/m
2
) -0.07 0.93 0.87 1.00 0.04 
Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.13 
Model 3 
     Age (years) 0.11 1.11 1.07 1.16 <0.01 
Sex -0.14 0.87 0.51 1.46 0.59 
DBP rise with cold pressor (mmHg) -0.01 0.99 0.96 1.02 0.42 
CVD 0.20 1.23 0.47 3.21 0.68 
Diabetes 0.60 1.82 0.77 4.28 0.17 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.32 1.38 0.53 3.58 0.51 
BMI (kg/m
2
) -0.10 0.91 0.84 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score 0.02 1.02 0.94 1.10 0.64 
Model 3 
     Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.17 0.85 0.50 1.43 0.54 
DBP rise with cold pressor -0.01 0.99 0.96 1.01 0.37 
CVD 0.16 1.17 0.45 3.05 0.74 
Diabetes 0.55 1.74 0.74 4.12 0.21 
Pack Years 0.01 1.01 1.00 1.02 0.01 
Cardioactive Medication 0.32 1.37 0.53 3.55 0.51 
BMI (kg/m
2
) -0.10 0.90 0.84 0.98 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score -0.01 0.99 0.90 1.09 0.85 
CAMCOG total score -0.03 0.98 0.93 1.02 0.26 
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Table 8-39 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Heart Rate Response to Deep Breathing.  
Model 1 
B HR 
95% CI 
P  Lower Upper 
Age (years) 0.11 1.12 1.08 1.16 <0.01 
Sex -0.37 0.69 0.43 1.11 0.13 
Heart rate response to deep breathing 0.02 1.02 0.99 1.06 0.22 
Model 2 
     Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex -0.34 0.71 0.44 1.17 0.18 
Heart rate response to deep breathing 0.03 1.03 0.99 1.07 0.18 
CVD -0.28 0.76 0.30 1.89 0.55 
Diabetes 0.31 1.37 0.61 3.08 0.45 
Pack Years 0.01 1.01 1.01 1.02 <0.01 
Cardioactive Medication 0.48 1.62 0.66 3.95 0.29 
BMI (kg/m
2
) -0.06 0.94 0.87 1.01 0.09 
Mean SBP(mmHg) 0.01 1.01 1.00 1.03 0.16 
Model 3 
     Age (years) 0.11 1.11 1.07 1.16 <0.01 
Sex -0.10 0.90 0.53 1.54 0.71 
Heart rate response to deep breathing 0.02 1.02 0.97 1.07 0.38 
CVD 0.20 1.22 0.45 3.31 0.70 
Diabetes 0.78 2.18 0.92 5.19 0.08 
Pack Years 0.02 1.02 1.01 1.03 <0.01 
Cardioactive Medication 0.20 1.22 0.47 3.19 0.68 
BMI (kg/m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score 0.02 1.03 0.95 1.10 0.50 
Model 4 
     Age (years) 0.10 1.11 1.06 1.16 <0.01 
Sex -0.12 0.89 0.52 1.52 0.67 
Heart rate response to deep breathing 0.02 1.02 0.97 1.06 0.52 
CVD 0.17 1.19 0.44 3.25 0.73 
Diabetes 0.75 2.13 0.89 5.07 0.09 
Pack Years 0.02 1.02 1.01 1.03 <0.01 
Cardioactive Medication 0.16 1.18 0.45 3.11 0.74 
BMI (kg/m
2
) -0.11 0.90 0.83 0.97 0.01 
Mean SBP (mmHg) 0.02 1.02 1.01 1.04 0.01 
Bristol ADL Score 0.00 1.00 0.91 1.09 0.94 
CAMCOG total score -0.03 0.97 0.93 1.02 0.24 
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 Survival and Heart Rate Variability 8.3.6
Two hundred and eighty participants underwent heart rate variability recordings and had 
recordings with less than 10% interpolated or ectopic beats. Of these participants, 72 
died during follow-up. Participants who died had significantly lower total power and LF 
HRV at baseline. Other measures of HRV did not significantly differ between those 
alive at end of follow-up and those who had died.  
Table 8-40 Heart Rate Variability among Participants who Died During Follow-up 
versus Participants alive in October 2012 
 Alive Dead P 
 208 72  
 Median (IQR) Median (IQR)  
SDNN 27.4 (19.1, 36.3) 24.2 (17.9, 31.9) 0.10 
Total Power 438.9 (218.3, 972.5) 330.0 (134.9, 698.7) <0.05 
VLF 152.0 (83.7, 343.0) 120.7 (58.6, 319.4) 0.10 
Low frequency 172.3 (73.2, 350.0) 107.3 (49.4, 274.3) 0.03 
High frequency 72.5 (32.7, 155.3) 50.3 (19.3, 150.8) 0.09 
HF/ LF 0.39 (0.23, 0.77) 0.48 (0.24, 0.96) 0.49 
 
None of the markers of heart rate variability were related to survival in age and sex 
adjusted models (Table 8-41, Table 8-42, Table 8-43, Table 8-44 and Table 8-45). 
Further adjusting models for cardiovascular risk factors, baseline functional status and 
cognitive function did not reveal any significant relationships between heart rate 
variability and survival (Table 8-41, Table 8-42, Table 8-43, Table 8-44 and Table 
8-45). 
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Table 8-41 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Total Power 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex 0.45 1.57 0.97 2.55 0.07 
Total power 0.00 1.00 1.00 1.00 0.42 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.43 1.53 0.92 2.55 0.10 
Total power 0.00 1.00 1.00 1.00 0.28 
Cardiovascular Disease -0.67 0.51 0.22 1.19 0.12 
Diabetes 0.21 1.24 0.57 2.69 0.59 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication 0.92 2.52 1.06 5.96 0.04 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.09 
daytime Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Model 3 
    
  
Age (years) 0.12 1.13 1.08 1.19 <0.01 
Sex 0.23 1.26 0.73 2.18 0.40 
Total power 0.00 1.00 1.00 1.00 0.09 
Cardiovascular Disease -0.15 0.86 0.33 2.26 0.76 
Diabetes 0.63 1.87 0.80 4.35 0.15 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication 0.66 1.94 0.72 5.21 0.19 
BMI (kg/m
2
) -0.12 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.02 1.02 0.94 1.10 0.65 
Model 4 
    
  
Age (years) 0.11 1.12 1.06 1.17 <0.01 
Sex 0.27 1.31 0.76 2.27 0.33 
Total power 0.00 1.00 1.00 1.00 0.09 
Cardiovascular Disease -0.14 0.87 0.34 2.20 0.76 
Diabetes 0.60 1.82 0.78 4.22 0.16 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.61 1.84 0.71 4.80 0.21 
BMI (kg/m
2
) -0.12 0.89 0.82 0.96 <0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score -0.02 0.98 0.90 1.07 0.71 
Total CAMCOG Score -0.03 0.97 0.93 1.01 0.14 
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Table 8-42 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Very Low Frequency 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex 0.44 1.55 0.95 2.52 0.08 
Very Low Frequency 0.00 1.00 1.00 1.00 0.70 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.41 1.51 0.90 2.52 0.12 
Very Low Frequency 0.00 1.00 1.00 1.00 0.54 
Cardiovascular Disease -0.66 0.52 0.22 1.20 0.12 
Diabetes 0.23 1.26 0.58 2.73 0.56 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.93 2.52 1.07 5.97 0.04 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.10 
daytime Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Model 3 
    
  
Age (years) 0.12 1.13 1.08 1.19 <0.01 
Sex 0.24 1.27 0.73 2.20 0.39 
Very Low Frequency 0.00 1.00 1.00 1.00 0.20 
Cardiovascular Disease -0.15 0.86 0.33 2.26 0.76 
Diabetes 0.61 1.84 0.79 4.25 0.16 
Pack years 0.01 1.01 1.00 1.02 0.07 
Cardioactive medication 0.67 1.95 0.73 5.23 0.19 
BMI (kg/m
2
) -0.11 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.02 1.02 0.95 1.10 0.62 
Model 4 
    
  
Age (years) 0.11 1.12 1.07 1.18 <0.01 
Sex 0.28 1.33 0.76 2.30 0.32 
Very Low Frequency 0.00 1.00 1.00 1.00 0.18 
Cardiovascular Disease -0.14 0.87 0.34 2.19 0.76 
Diabetes 0.58 1.78 0.77 4.12 0.18 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication 0.62 1.86 0.71 4.83 0.21 
BMI (kg/m
2
) -0.12 0.89 0.82 0.97 0.01 
daytime Mean SBP 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score -0.02 0.98 0.90 1.07 0.72 
Total CAMCOG Score -0.03 0.97 0.93 1.01 0.12 
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Table 8-43 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with Low Frequency HRV 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex 0.47 1.59 0.98 2.58 0.06 
Low Frequency 0.00 1.00 1.00 1.00 0.29 
Model 2           
Age (years) 0.10 1.10 1.06 1.14 <0.01 
Sex 0.44 1.55 0.93 2.56 0.09 
Low Frequency 0.00 1.00 1.00 1.00 0.20 
Cardiovascular Disease -0.65 0.52 0.23 1.20 0.13 
Diabetes 0.20 1.22 0.56 2.66 0.61 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.91 2.48 1.05 5.87 0.04 
BMI (kg/m
2
) -0.06 0.94 0.88 1.01 0.08 
daytime Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.03 
Model 3           
Age (years) 0.12 1.13 1.08 1.18 <0.01 
Sex 0.23 1.26 0.73 2.17 0.40 
Low Frequency 0.00 1.00 1.00 1.00 0.12 
Cardiovascular Disease -0.16 0.85 0.32 2.26 0.75 
Diabetes 0.61 1.84 0.79 4.26 0.16 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication 0.66 1.94 0.72 5.26 0.19 
BMI (kg/m
2
) -0.11 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.02 1.02 0.95 1.10 0.62 
Model 4           
Age (years) 0.11 1.12 1.06 1.17 <0.01 
Sex 0.27 1.32 0.76 2.28 0.33 
Low Frequency 0.00 1.00 1.00 1.00 0.11 
Cardiovascular Disease -0.16 0.86 0.34 2.18 0.74 
Diabetes 0.58 1.78 0.77 4.12 0.18 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication 0.61 1.83 0.70 4.81 0.22 
BMI (kg/m
2
) -0.12 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score -0.02 0.98 0.90 1.08 0.71 
Total CAMCOG Score -0.03 0.97 0.93 1.01 0.12 
 
   
291 
 
Table 8-44 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with High Frequency Heart Rate Variability 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex -0.42 0.66 0.41 1.06 0.09 
High Frequency 0.00 1.00 1.00 1.00 0.54 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.38 0.68 0.41 1.13 0.14 
High Frequency 0.00 1.00 1.00 1.00 0.38 
Cardiovascular Disease -0.67 0.51 0.22 1.19 0.12 
Diabetes 0.24 1.27 0.58 2.76 0.55 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication 0.92 2.51 1.06 5.93 0.04 
BMI (kg/m
2
) -0.06 0.95 0.88 1.01 0.11 
daytime Mean SBP (mmHg) 0.02 1.02 1.00 1.03 0.04 
Model 3 
    
  
Age (years) 0.13 1.13 1.08 1.19 <0.01 
Sex -0.15 0.86 0.50 1.48 0.59 
High Frequency 0.00 1.00 1.00 1.00 0.17 
Cardiovascular Disease 0.16 1.17 0.44 3.08 0.75 
Diabetes -0.70 0.50 0.21 1.18 0.11 
Pack years 0.01 1.01 1.00 1.02 0.06 
Cardioactive medication -0.69 0.50 0.19 1.35 0.17 
BMI (kg/m
2
) -0.11 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.04 <0.01 
Bristol ADL Score 0.02 1.02 0.95 1.09 0.63 
Model 4 
    
  
Age (years) 0.11 1.12 1.07 1.18 <0.01 
Sex -0.18 0.83 0.48 1.44 0.51 
High Frequency 0.00 1.00 1.00 1.00 0.19 
Cardiovascular Disease 0.16 1.17 0.46 2.99 0.74 
Diabetes -0.68 0.51 0.21 1.19 0.12 
Pack years 0.01 1.01 1.00 1.02 0.05 
Cardioactive medication -0.63 0.53 0.20 1.39 0.20 
BMI (kg/m
2
) -0.12 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL Score -0.01 0.99 0.90 1.08 0.77 
Total CAMCOG Score -0.03 0.97 0.93 1.01 0.18 
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Table 8-45 Cox Regression Models. Hazard Ratio of All-Cause Mortality 
Associated with HFLF ratio 
Model 1 
B HR 
95% CI 
P Lower Upper 
Age (years) 0.12 1.13 1.09 1.17 <0.01 
Sex -0.40 0.67 0.41 1.08 0.10 
HF:LF -0.10 0.91 0.70 1.18 0.48 
Model 2 
    
  
Age (years) 0.10 1.10 1.06 1.15 <0.01 
Sex -0.35 0.70 0.43 1.17 0.17 
HF:LF -0.13 0.87 0.67 1.14 0.33 
Cardiovascular Disease 0.73 2.08 0.88 4.94 0.10 
Diabetes -0.24 0.79 0.36 1.71 0.54 
Pack years 0.01 1.01 1.00 1.02 0.04 
Cardioactive medication -1.02 0.36 0.15 0.88 0.03 
BMI (kg/m
2
) -0.05 0.95 0.89 1.02 0.13 
daytime Mean SBP (mmHg) 0.01 1.01 1.00 1.03 0.04 
Model 3 
    
  
Age (years) 0.13 1.14 1.08 1.19 <0.01 
Sex -0.08 0.92 0.53 1.60 0.77 
HF:LF -0.33 0.72 0.50 1.04 0.08 
Cardiovascular Disease 0.26 1.29 0.47 3.58 0.62 
Diabetes -0.75 0.47 0.20 1.11 0.09 
Pack years 0.01 1.01 1.00 1.02 0.10 
Cardioactive medication -0.90 0.41 0.14 1.16 0.09 
BMI (kg/m
2
) -0.11 0.90 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL Score 0.02 1.02 0.95 1.10 0.53 
Model 4 
    
  
Age (years) 0.12 1.12 1.07 1.18 <0.01 
Sex -0.12 0.89 0.51 1.55 0.68 
HF:LF -0.33 0.72 0.49 1.05 0.08 
Cardiovascular Disease 0.25 1.29 0.48 3.46 0.62 
Diabetes -0.75 0.47 0.20 1.11 0.09 
Pack years 0.01 1.01 1.00 1.02 0.10 
Cardioactive medication -0.84 0.43 0.16 1.21 0.11 
BMI (kg/m
2
) -0.11 0.89 0.82 0.97 0.01 
daytime Mean SBP (mmHg) 0.03 1.03 1.01 1.05 <0.01 
Bristol ADL Score -0.01 0.99 0.91 1.08 0.83 
Total CAMCOG Score -0.03 0.97 0.93 1.01 0.15 
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 Discussion 8.4
 Hypertension 8.4.1
Hypertension is considered a risk factor for all-cause mortality in all age groups 
(Lewington et al., 2002). In this cohort, hypertension was not associated with mortality 
in age and sex adjusted models, or in models adjusting for cardiovascular risk factors. 
The addition of a term controlling for baseline functional status however did reveal a 
significant association between hypertension and increased mortality. Similar results 
were found when 24-hour and daytime mean systolic BP and mean daytime diastolic BP 
were entered into the models as a continuous variable.  
 
Two studies by Oden et al have also shown an interaction between functional status, 
hypertension, and mortality among older individual (Odden et al., 2012a, Odden et al., 
2012b). The first study accessed functional status by self-reported walking speed. The 
relationship between systolic BP and mortality varied according to reported walking 
speed. In high-functioning older adults, elevated systolic BP was a risk factor for all-
cause mortality but not in adults with slower walking speed(Odden et al., 2012a). In the 
second study, time to walk 20m was recorded in 2097 adults aged 65 years and older. 
Among fast walkers, elevated systolic BP >140 mmHg was associated with increased 
mortality (Odden et al., 2012b). Among slow walkers, neither systolic nor diastolic BP 
were associated with mortality. Further analysis stratified participants by age (above 75 
years and below 75 years). Elevated systolic BP remained associated with increased 
mortality among fast walkers aged 75 years and older, but not among fast walkers less 
than 75 years, suggesting that the interaction between functional status and hypertension 
may increase with age. Finally, the group examined the association between BP and 
mortality among the 243 older people unable to complete the 20m walk due to frailty. In 
this group, higher systolic BP was associated with reduced mortality, supporting the 
hypothesis that in frail older people hypertension may be beneficial. Although 
hypertension is generally considered a risk factor for all-cause mortality in all ages these 
data suggest that frailty may play an important role in modifying the relationship.  
 
Further evidence to suggest that hypertension is associated with all-cause mortality 
among fitter very elderly patients comes from the HYVETT study which showed 
antihypertensive treatment is associated with reduced all-cause mortality in the 
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elderly(Beckett et al., 2012). However, owing to the inclusion criteria, participants in 
these trials were healthier than the general older population and it remains unclear if 
antihypertensive treatment reduces mortality in frail older people.  
 Blood Pressure variability 8.4.2
In this study, 24-hour systolic and diastolic BP variability and daytime systolic BP 
variability were not associated with mortality in models adjusting for age, sex, and 
cardiovascular risk factors. However, as occurred with hypertension, they were 
associated with mortality when baseline functional status was added to the model. 
Greater daytime diastolic BP variability was associated with increased mortality in all 
models. Night-time blood pressure variability was not associated with mortality.   
 
A recently published study from the International Database on Ambulatory Blood 
Pressure in Relation to Cardiovascular Outcome examined the association between BP 
variability and mortality in 8938 participants from 11 countries across 3 continents 
(Hansen et al., 2010). Mean age of participants was 53 years, median follow-up 11.3 
years. Measures of variability included SD24 (BP variability over 24-hour), SDdn (SD 
day night - the mean of day and night SD) and the average real 24-hour variability (24 
ARV - the average of the absolute differences of consecutive measurements). In fully 
adjusted models, greater systolic SDdn and 24 ARV were associated with increased all-
cause mortality, as were diastolic SD24, SDdn and 24 ARV. In keeping with the 
findings of the current study, Hansen et al found Diastolic BP variability tended to be a 
stronger predictor of outcome than systolic BP variability (Hansen et al., 2010). In the 
PAMELA study, systolic BP variability was not associated with mortality in adjusted 
models, whereas daytime and night-time diastolic BP variability were associated with 
mortality in adjusted models (Sega et al., 2005). 
 Orthostatic hypotension 8.4.3
In this study, orthostatic hypotension defined according to standard criteria was not 
associated with ten year mortality. Nor were systolic or diastolic OH when examined 
separately. Similarly, systolic and diastolic vasodepression in response to standing were 
not associated with mortality.  
 
These results are in contrast to several large population-based studies examining the 
association between OH and all-cause mortality. The Malmo, Rotterdam, ARIC and 
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Honolulu heart studies have between them included over 50 000 middle aged and 
elderly participants (Fedorowski et al., 2010, Verwoert et al., 2008, Rose et al., 2006, 
Masaki et al., 1998). Follow-up periods ranged from 4 – 24 years. In each case, these 
studies showed an association between OH defined according to AAN criteria and 
increased adjusted all-cause mortality. Furthermore, the Malmo and Honolulu studies 
showed an association between degree of vasodepression and mortality (Fedorowski et 
al., 2010, Masaki et al., 1998).  
 
It is important to note that all these studies used a sphygmomanometer to record BP in 
the lying and standing position at predefined interval (number of recordings and interval 
between recordings differed between studies). There are no studies reporting mortality 
in association with OH diagnosed using beat-to-beat BP. As has been previously 
discussed, beat-to-beat monitoring is a more sensitive way of diagnosing OH. Methods 
using a sphygmomanometer to record BP intermittently risk overlooking short-lived 
drops in BP or missing the BP nadir and therefore underestimate the prevalence of OH. 
As a result, these methods are only likely to detect more severe, prolonged drops in BP. 
In this study, prevalence of OH according to AAN criteria was 71%. This is in keeping 
with other population-based studies that have found a high prevalence of OH using 
beat-to-beat monitoring and the AAN definition (Romero-Ortuno et al., 2011b). Using 
intermittent sphygmomanometer recordings, the Malmo, Rotterdam, ARIC and 
Honolulu studies have reported the prevalence of OH to be 6.2%, 17.8%, 5.0%, and 
6.9% respectively. It is likely that when using beat-to-beat monitoring the AAN criteria 
are too sensitive. OH, defined according modified criteria derived using beat-to-beat 
responses from baseline normal subsample was not associated with survival. Further 
analysis examining if symptomatic OH was associated with increased mortality also 
failed to reveal any significant association between symptomatic OH and survival in 
this cohort 
 CSH 8.4.4
In this study, CSH defined according to standard criteria was not associated with 
mortality. Similarly, mortality was not associated with Maximum RR interval post CSM 
or maximum vasodepression post CSM. Our findings are in keeping with two other 
studies reporting an association between CSH and mortality. Hampton et al examined 
mortality among1504 patients with CSH identified from a single syncope centre. 
Standardised mortality rates (SMRs) were compared with regional age-matched SMR 
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data from the Office of National Statistics. There was no difference between CSH 
patients and the general population in SMRs for all causes (Hampton et al., 2011). 
Comparable results were reported in a similar smaller study by Brignole et al (Brignole 
et al., 1992). CSH defined according to modified criteria, derived from the 
asymptomatic baseline population, was, however, associated with increased risk or 
mortality. This finding remained significant after adjusting for cardiovascular risk 
factors and use of cardioactive medication and suggests that the current criteria used to 
define CSH may be too sensitive to predict mortality in this age groups when using 
beat-to-beat monitoring. This study is the first to assess the association between 
asymptomatic CSH and mortality within a community population in which the 
prevalence of asymptomatic CSH is accurately documented.  
 Response to Autonomic Function Tests 8.4.5
Response to autonomic function tests was not associated with survival in this study 
when examined as composite variable “abnormal” or “normal”. Nor were there any 
associations between continuous response to each individual test and survival. There are 
no population-based studies examining the association between responses to Ewing’s 
battery of autonomic function tests and survival. A meta-analysis examining the 
association between performance on autonomic function tests and mortality in diabetic 
patients found that cardiovascular autonomic neuropathy is associated with increased 
mortality in patients with diabetes. Stronger associations were observed when 2 or more 
tests were used to define autonomic neuropathy(Maser et al., 2003). A recent study 
showed that, among 136 diabetic patients, autonomic function tests are a better 
predictor of mortality than heart rate variability(May and Arildsen, 2012).  
 Heart Rate Variability 8.4.6
None of the markers of heart rate variability recorded in this study were related to 
mortality at ten years. The Rotterdam, Zutphen, Bronx Ageing Heart and Leiden 85+ 
studies calculated time domain HRV measures from 12 lead ECG (de Bruyne et al., 
1999, Dekker et al., 1997, Bernstein et al., 1997, van Bemmel et al., 2006). Participants 
were followed-up for between 4 and 5 years in these studies. The Zutphen study found 
that low HRV was associated with increased mortality (Dekker et al., 1997). The 
Rotterdam study divided participants into quartiles according to HRV(de Bruyne et al., 
1999). Membership of the lowest and highest quartile was associated with increased 
mortality compared to participants in quartile 3. In contrast, the Leiden 85+ and Bronx 
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Ageing Heart studies showed no association between HRV and mortality (Bernstein et 
al., 1997, van Bemmel et al., 2006). Participants were older in the later studies 
(Bernstein et al., 1997, van Bemmel et al., 2006).  
 
In the ARIC study, time domain measures of HRV were made from a 2 minute ECG 
recording(Dekker et al., 2000). Participants in the lowest tertile of HRV had the highest 
mortality. Reduced HRV, calculated from longer recordings made using ambulatory 
heart rate monitors, has also been associated with increased mortality (Tsuji et al., 1994, 
Huikuri et al., 1998). The Framingham study recorded HRV for 2 hours. Reduced 
SDNN, total power, HF, LF and VLF were all associated with increased mortality, 
while Huikuri et al found SDNN <120ms is associated with increased mortality (Tsuji et 
al., 1994, Huikuri et al., 1998).  
 Summary 8.4.7
Using conventional definitions of OH and CSH, NCVI was not associated with 
increased risk of death. However, a modified definition of CSH, possibly more 
appropriate to older populations, and the use of beat-to-beat monitoring did show an 
association between severe CSH and increased risk of mortality. Neither autonomic 
function measured using Ewing and Clark’s battery nor heart rate variability were 
associated with survival in this population. This is in contrast to several previous studies 
(Tsuji et al., 1994, Huikuri et al., 1998, Dekker et al., 1997, de Bruyne et al., 1999). 
Data on cause of death were not available. Examination of cause specific mortality may 
have revealed associations between autonomic dysfunction and death due to specific 
conditions that have been overlooked in this study. Previous studies have shown 
associations between altered autonomic function and cardiovascular mortality, fatal 
stroke and neurological mortality but not with deaths due to cancer.  
 
The association between autonomic function, NCVI, and risk of mortality in this study 
was examined to establish if individuals with more severe NCVI had been lost to 
follow-up due to excess mortality. With the exception of severe CSH, baseline NCVI 
and autonomic dysfunction do not appear to have been associated with reduced survival 
in this cohort.  
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Chapter 9 Concluding Remarks and Areas for Future 
Research 
The current study has shown few longitudinal associations between neurocardiovascular 
or autonomic function at baseline and cognitive function, depression, gait, balance and 
falls at ten years follow-up. These findings are in contrast to our hypothesis and cross-
sectional studies but are in keeping with the small body of literature examining the 
longitudinal associations between blood pressure control, cognition, depression, and 
falls.  
 
The study’s findings raise questions about the direction of the relationship between 
NCVI, cognitive impairment, depression, and motor function; raising the possibility that 
NCVI may be a symptom of progressive neurodegenerative disease rather than a 
precipitating or exacerbating factor. Histopathological studies have shown involvement 
of the autonomic nervous system in a number of neurodegenerative disease associated 
with impaired cognition, depression and motor decline (Jellinger, 2011, Korczyn and 
Gurevich, 2010, Allan et al., 2007). Furthermore areas of the central nervous system 
influential in the control of autonomic nervous system are affected early in a number of 
dementing diseases (Korczyn and Gurevich, 2010, Allan et al., 2007). It is therefore 
possible that the associations between NCVI, cognition, and mood that have been 
observed in cross-sectional studies are a feature of simultaneous neurodegeneration of 
the autonomic and central nervous systems. All participants taking part in this study 
have been approached by the Newcastle Brain Tissue Resource. Consenting participants 
have agreed to post-mortem, whole brain donation, and donation of samples of cardiac 
tissue, peripheral nervous system tissue and tissue from the spinal column. In time, 
these samples may help to identify underlying pathological changes responsible for 
observed cross-sectional clinical associations of NCVI.  Alternatively, the lack of 
association between NCVI and cognition, mood or gait at ten years may reflect 
diagnostic criteria used to define CSH and OH. At baseline, 82% of participants met the 
AAN criteria for OH and 39% met the criteria for CSH (Kerr, 2009). The criteria for 
OH and CSH were developed prior to the widespread use of beat-to-beat monitoring 
and the diagnostic cut-offs were arbitrarily defined based on studies in young men 
(Krediet et al., 2011). Use of modified criteria for CSH, defined according to age-
specific normal ranges, did show an adverse association between CSH at baseline and 
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survival at ten years. Further studies are needed to examine if these modified criteria are 
associated with adverse outcome in other populations.  
 
Since this follow-up study began, the criteria for the diagnosis of OH have been 
modified (Freeman et al., 2011). Both initial OH and late OH are now described in the 
AAN 2011 criteria. Initial OH is defined as a 40 mmHg decrease in systolic blood 
pressure and/or a 20 mmHg decrease in diastolic blood pressure within 15 seconds of 
standing accompanied by symptoms of cerebral hypoperfusion. In this cohort 76.5% of 
participants reached systolic nadir within 15 seconds of standing, of these 24% had a 
decrease in systolic BP of ≥ 40mmHg. Similarly, 92% of participants reached diastolic 
nadir within 15 seconds of standing of which 20% had a decrease in diastolic BP of ≥ 
20mmHg. In contrast to the definition of classical OH, the guidelines suggest, 
symptoms indicative of cerebral hypoperfusion are required to make the diagnosis of in 
initial OH. There were some indications in this study that symptomatic NCVI may be 
important. Symptomatic orthostatic hypotension was associated with longer choice 
reaction time, greater decline in CAMCOG memory score and recurrent falls. 
Symptomatic CSH was associated with greater white matter hyperintensity volume. 
Although these associations did not always stand-up to multivariable analysis, and 
should be interpreted with caution given the extent of multiple testing, there are good 
reasons why symptoms may be important in identifying individuals at greater risk of 
adverse effects from NCVI.  
 
Symptoms in conjunction with NCVI are thought to indicate cerebral hypoperfusion. In 
order for cerebral hypoperfusion to occur there must be a drop in systemic BP below the 
lower limit of cerebral autoregulation and / or a failure of cerebral autoregulation. As 
haemodynamic response to CSM and active stand did not significantly differ between 
symptomatic and asymptomatic individuals, failure of cerebral autoregulation may play 
a greater role in determining presence of symptoms than degree of vasodepression 
(Kerr, 2009). One small study has shown greater decline in cerebral blood flow among 
symptomatic patients with OH compared to asymptomatic individuals with similar 
changes in systolic blood pressure during head-up-tilt (Khandelwal et al., 2011). 
Cerebral autoregulation in response to syncope is poorly understood. Although systemic 
hypoperfusion may be expected to cause a reduction in cerebral vascular resistance, 
several studies have shown a paradoxical increase in cerebral vascular resistance just 
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before syncope (Franco Folino, 2007). Some authors suggest this increased 
cerebrovascular resistance is secondary to hypercapnea induced by hyperventilation, 
while others have suggested the autonomic nervous system innervating the cerebral 
arterioles may play a role (Lagi et al., 2001). Ideally, future studies should establish 
cerebral autoregulation in participants and compare outcomes across four groups; 
1. Peripheral haemodynamic response diagnostic of NCVI with normal cerebral 
perfusion maintained. 
2. Peripheral haemodynamic response diagnostic of NCVI with impaired cerebral 
autoregulation 
3. Peripheral haemodynamic response not diagnostic of NCVI with normal 
cerebral perfusion maintained. 
4. Peripheral haemodynamic response not diagnostic of NCVI with impaired 
cerebral autoregulation 
 
 Limitations and Areas for Furture Research  9.1
It must be acknowledged that the study sample size was small. This study relied on the 
use of an existing well characterised cohort and there were therefore limited 
opportunities to expand the number of individuals participating in the study. In an 
attempt to make the study as accessible as possible to frailer individuals, all follow-up 
assessments (except MRI scan) were conducted in participants’ homes. Participants 
living in residential or nursing care at follow-up were also invited to take part.  
 
Nevertheless, participants recruited to follow-up were younger, more independent with 
activities of daily living and scored better on assessments of gait, balance, and cognitive 
function at baseline than participants lost to follow-up, suggesting that frailer 
individuals elected not to participate in the follow-up study. Similar difficulties were 
encountered at baseline where participants were more likely to be younger than non-
participants, were more likely to be male, and were less likely to have ischaemic heart 
disease or be using cardioactive, and psychoactive medication. As frailer older 
individuals were lost to follow-up in larger numbers at each stage, individuals studied 
here are the fitter survivors. Furthermore most individuals in this cohort had 
asymptomatic NCVI and the findings from this study cannot be assumed to apply to 
older frailer individual, individuals presenting to clinical services with symptomatic 
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NCVI. Notably, comparison with other cohort studies conducted in populations of a 
similar age showed rates of cognitive impairment and depression were considerably 
lower in this study than in other similar UK studies suggesting selection bias has been a 
problem in this study. (Luppa et al., 2012, Rait et al., 2005). 
 
Added to this there has been significant attrition. Only a third of participants enrolled in 
the study in 2001 took part in the ten year follow-up study. This meant only 99 
individuals underwent full cognitive assessment at follow-up and only 53 were able to 
undergo MRI. This was particularly problematic when analysing the impact of NCVI on 
incident cognitive impairment and depression as only very small numbers incident 
cognitive impairment or depression over the follow-up period and the study lacked 
power to examine the assocations with incident disease.  
 
The statistically significant associations found in this study should be interpreted with 
caution given the extensive statistical calculations performed. One possible option to 
reduce potential Type 1 error would have been to perform a Bonferroni correction. A 
decision was made not to use this or similar methods because it was felt that in this 
small sample the power would have become unacceptably low and there would have 
been serious risk of Type 2 error. It was therefore decided that a narrative approach 
would be taken where all data were presented at P value <0.05 and the overall data 
examined for patterns that may suggest an association between hypotension and the 
potential sequel examined here including cognitive decline, falls and WMH. This study 
can therefore support hypothesis generation for future studies and identify areas for 
focus for upcoming larger studies such as the Tilda Study.Tilda is a larger, longitudinal, 
study that aims to establish the long-term associations between NCVI, cognition, mood, 
gait and balance is now under way in Ireland (Cronin et al., 2013). Over 8000 
participants have completed the baseline assessment of the TILDA study. The large 
sample size of TILDA means that it will have greater statistical power to detect small 
differences in outcomes between groups and it will be interesting to see in what way the 
results of the current study and TILDA differ.  
 
Finally, much of the support for the hypothesis that hypotension causes cognitive 
decline, motor impairment and depression comes from cross sectional magnetic 
resonance imaging studies. Unfortunately MRI was only included in the final  phase of 
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this study. It was therefore not possible to examine the association between NCVI and 
WMH progression. To truly understand the direction of the relationship between 
hypotensive syndromes, white matter hyperintensities and related clinical symptoms, 
studies are needed that make repeated contemporaneous measures of 
neurocardiovascular function, WMH volume and clinical outcome. Such studies should 
include measures of cerebral auto regulation.  
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